0001213900-25-01218910-Q Pluri Inc. 20250211202502111600491600501600500 0 0001213900-25-012189 10-Q 47 20241231 20250211 20250211 Pluri Inc. 0001158780 2836 980351734 NV 0630 10-Q 34 001-31392 25609664 MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA L3 3508409 972-74-710-7171 MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA L3 3508409 PLURISTEM THERAPEUTICS INC 20071228 PLURISTEM LIFE SYSTEMS INC 20030701 AI SOFTWARE INC 20010906 10-Q 1 ea0229816-10q_pluri.htm QUARTERLY REPORT Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â Form 10-Q Â (Mark One) â˜'Â QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period endedÂ December 31, 2024 Â â˜Â TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT Â For the transition period from __________ to __________ Â Commission file numberÂ 001-31392 Â PLURI INC. (Exact name of registrant as specified in its charter) Â Nevada Â 98-0351734 (State or other jurisdiction of incorporation or organization) Â (I.R.S. Employer Identification No.) Â MATAM Advanced Technology Park, Building No. 5, Haifa, Israel Â 3508409 (Address of principal executive offices) Â (Zip Code) Â Registrantâ€™s telephone numberÂ 011-972-74-7108600 Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â Trading Symbol Â Name of each exchange on which registered Common Shares, par value $0.00001 Â PLUR Â The Nasdaq Capital Market Â Securities registered pursuant to Section 12(g) of the Act: Â None. (Title of class) Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesÂ â˜'Â Â Â Â Â NoÂ â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit files). Yes â˜'Â Â Â Â Â No â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. (Check one): Â Large accelerated filer â˜ Accelerated filer â˜Â Non-accelerated filer â˜'Â Smaller reporting companyÂ â˜' Emerging growth company â˜ Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Â Yes â˜Â Â Â Â Â No â˜' Â State the number of shares outstanding of each of the issuerâ€™s classes of common shares as of the latest practicable date: 6,997,140 common shares issued and outstanding as of February 10, 2025. Â Â Â Â Â PART I â€" FINANCIAL INFORMATION Â Item 1. Financial Statements Â Â PLURI INC. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Â As of December 31, 2024 Â U.S. DOLLARS IN THOUSANDS Â (Unaudited) Â INDEX Â Â PageÂ Â Â Â Interim Condensed Consolidated Balance Sheets (Unaudited) Â 2 Â Â Interim Condensed Consolidated Statements of Operations (Unaudited) Â 4 Â Â Â Interim Condensed Consolidated Statements of Changes in Shareholdersâ€™ Equity (Deficit) (Unaudited) Â 5 Â Â Interim Condensed Consolidated Statements of Cash Flows (Unaudited) Â 7 Â Â Notes to Interim Condensed Consolidated Financial Statements (Unaudited) Â 8 Â 1 Â Â PLURI INC. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) U.S. Dollars in thousands (except share and per share data) Â Â Â NoteÂ Â DecemberÂ 31, 2024Â Â June 30, 2024Â ASSETSÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CURRENT ASSETS:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash and cash equivalentsÂ Â Â Â $7,229Â Â $6,783Â Short-term bank depositsÂ Â Â Â Â Â Â Â Â Â Â 14,084Â Â 23,202Â Restricted cashÂ Â Â Â Â 261Â Â Â 254Â Customer receivablesÂ Â Â Â Â 140Â Â Â 34Â Prepaid expenses and other current assetsÂ Â Â Â Â 656Â Â Â 834Â Total current assetsÂ Â Â Â Â 22,370Â Â Â 31,107Â Â Â Â Â Â Â Â Â Â Â Â Â LONG-TERM ASSETS:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Restricted bank depositsÂ Â Â Â Â 800Â Â Â 634Â Severance pay fundÂ Â Â Â Â 527Â Â Â 470Â Property and equipment, netÂ Â Â Â Â 911Â Â Â 688Â Operating lease right-of-use assetÂ Â Â Â Â 6,236Â Â Â 6,558Â Other long-term assetsÂ Â Â Â Â 17Â Â Â 70Â Total long-term assetsÂ Â Â Â Â 8,491Â Â Â 8,420Â Â Â Â Â Â Â Â Â Â Â Â Â Total assetsÂ Â Â Â $30,861Â Â $39,527Â Â The accompanying notes are an integral part of these unaudited condensed consolidatedÂ financial statements. Â 2 Â Â PLURI INC. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) U.S. Dollars in thousands (except share and per share data) Â Â Â NoteÂ Â DecemberÂ 31, 2024Â Â June 30, 2024Â LIABILITIES AND SHAREHOLDERSâ€™ EQUITY (DEFICIT)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CURRENT LIABILITIESÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Trade payablesÂ Â Â Â $1,165Â Â $964Â Accrued expensesÂ Â Â Â Â 841Â Â Â 1,223Â Operating lease liabilityÂ Â Â Â Â 595Â Â Â 559Â Accrued vacation and recuperationÂ Â Â Â Â 730Â Â Â 702Â Other accounts payableÂ Â Â Â Â 1,109Â Â Â 1,006Â Total current liabilitiesÂ Â Â Â Â 4,440Â Â Â 4,454Â Â Â Â Â Â Â Â Â Â Â Â Â LONG-TERM LIABILITIESÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Accrued severance payÂ Â Â Â Â 637Â Â Â 605Â Operating lease liabilityÂ Â Â Â Â 4,903Â Â Â 5,026Â Loan from the European Investment Bank, or EIBÂ 4Â Â Â 23,798Â Â Â 24,027Â Total long-term liabilitiesÂ Â Â Â Â 29,338Â Â Â 29,658Â Â Â Â Â Â Â Â Â Â Â Â Â COMMITMENTS AND CONTINGENCIESÂ 3Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â SHAREHOLDERSâ€™ EQUITY (DEFICIT)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share capital:Â 5Â Â Â Â Â Â Â Â Â Common shares, $0.00001 par value per share: Authorized: 37,500,000 as of December 31, 2024, and June 30, 2024; Issued and outstanding: 5,565,449 and 5,408,212 shares as ofÂ December 31, 2024, and June 30, 2024, respectivelyÂ Â Â Â Â *Â Â Â *Â Additional paid-in capitalÂ Â Â Â Â 421,282Â Â Â 420,568Â Accumulated deficitÂ Â Â Â Â (429,310)Â Â (420,472) Total shareholdersâ€™ equity (deficit)Â Â Â Â Â (8,028)Â Â 96Â Non-controlling interestsÂ Â Â Â Â 5,111Â Â Â 5,319Â Total equity (deficit)Â Â Â Â Â (2,917)Â Â 5,415Â Total liabilities and equityÂ Â Â Â $30,861Â Â $39,527Â Â (*) Less than $1 Â The accompanying notes are an integral part of these unaudited condensed consolidatedÂ financial statements. Â 3 Â Â PLURI INC. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) U.S. Dollars in thousands (except share and per share data) Â Â Â Â Â Â Six months ended December 31Â Â Three months ended December 31,Â Â Â NoteÂ Â 2024Â Â 2023Â Â 2024Â Â 2023Â RevenuesÂ Â Â Â $511Â Â $159Â Â $185Â Â $105Â Cost of revenuesÂ Â Â Â Â (200)Â Â -Â Â Â (74)Â Â -Â Gross profitÂ Â Â Â Â 311Â Â Â 159Â Â Â 111Â Â Â 105Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development expensesÂ Â Â Â $(6,562)Â $(6,704)Â $(3,170)Â $(3,338) Less: participation by the National Institute of Allergy and Infectious Diseases, or NIAID, the Israeli Innovation Authority, or IIA, Horizon Europe and other partiesÂ Â Â Â Â 748Â Â Â 747Â Â Â 245Â Â Â 374Â Research and development expenses, netÂ Â Â Â Â (5,814)Â Â (5,957)Â Â (2,925)Â Â (2,964) General and administrative expensesÂ Â Â Â Â (4,652)Â Â (4,792)Â Â (2,143)Â Â (2,354) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating lossÂ Â Â Â Â (10,155)Â Â (10,590)Â Â (4,957)Â Â (5,213) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other financial income, netÂ 6Â Â Â 1,437Â Â Â 928Â Â Â 2,058Â Â Â 435Â Interest expensesÂ Â Â Â Â (428)Â Â (430)Â Â (211)Â Â (216) Total financial income, netÂ Â Â Â Â 1,009Â Â Â 498Â Â Â 1,847Â Â Â 219Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net lossÂ Â Â Â $(9,146)Â $(10,092)Â $(3,110)Â $(4,994) Net loss attributed to non-controlling interestÂ Â Â Â $(308)Â $(226)Â $(154)Â $(89) Net loss attributed to shareholdersÂ Â Â Â $(8,838)Â $(9,866)Â $(2,956)Â $(4,905) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Loss per share:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted net loss per shareÂ Â Â Â $(1.61)Â $(1.92)Â $(0.53)Â $(0.96) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average number of shares used in computing basic and diluted net loss per share (**)Â Â Â Â Â 5,505,915Â Â Â 5,178,555Â Â Â 5,552,931Â Â Â 5,190,853Â Â (**) See note 5(1) regarding reverse share split Â The accompanying notes are an integral part of these unaudited condensed consolidatedÂ financial statements. Â 4 Â Â PLURI INC. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERSâ€™Â EQUITY (DEFICIT) (UNAUDITED) U.S. Dollars in thousands (except share and per share data) Â Â Â Shareholdersâ€™ EquityÂ Â Â Â Â Â Â Â Â Common SharesÂ Â Additional Paid-inÂ Â AccumulatedÂ Â Total Shareholdersâ€™Â Â Non- controllingÂ Â TotalÂ Â Â SharesÂ (**)Â Â AmountÂ Â CapitalÂ Â DeficitÂ Â EquityÂ Â InterestsÂ Â EquityÂ Balance as of July 1, 2023Â Â 5,155,687Â Â $(*)Â $412,939Â Â $(399,584)Â $13,355Â Â $1,945Â Â $15,300Â Share-based compensation to employees, directors, and non-employee consultantsÂ Â 54,316Â Â Â (*)Â Â 910Â Â Â -Â Â Â 910Â Â Â 499Â Â Â 1,409Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (9,866)Â Â (9,866)Â Â (226)Â Â (10,092) Balance as of December 31, 2023Â Â 5,210,003Â Â $(*)Â $413,849Â Â $(409,450)Â $4,399Â Â $2,218Â Â $6,617Â Â Â Shareholdersâ€™ EquityÂ Â Â Â Â Â Â Â Â Common SharesÂ Â Additional Paid-inÂ Â AccumulatedÂ Â Total Shareholdersâ€™Â Â Non- controllingÂ Â TotalÂ Â Â SharesÂ (**)Â Â AmountÂ Â CapitalÂ Â DeficitÂ Â EquityÂ Â InterestsÂ Â EquityÂ Balance as of October 1, 2023Â Â 5,181,066Â Â $(*)Â $413,446Â Â $(404,545)Â $8,901Â Â $2,137Â Â $11,038Â Share-based compensation to employees, directors, and non-employee consultantsÂ Â 28,937Â Â Â (*)Â Â 403Â Â Â -Â Â Â 403Â Â Â 170Â Â Â 573Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (4,905)Â Â (4,905)Â Â (89)Â Â (4,994) Balance as of December 31, 2023Â Â 5,210,003Â Â $(*)Â $413,849Â Â $(409,450)Â $4,399Â Â $2,218Â Â $6,617Â Â (*) Less than $1 (**) See note 5(1) regarding reverse share split Â The accompanying notes are an integral part of these unaudited condensed consolidatedÂ financial statements. Â 5 Â Â PLURI INC. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERSâ€™Â EQUITY (DEFICIT) (UNAUDITED) U.S. Dollars in thousands (except share and per share data) Â Â Â Shareholdersâ€™ Equity (Deficit)Â Â Â Â Â Â Â Â Â Common SharesÂ Â Additional Paid-inÂ Â AccumulatedÂ Â Total Shareholdersâ€™Â Â Non- controllingÂ Â TotalÂ Â Â SharesÂ Â AmountÂ Â CapitalÂ Â DeficitÂ Â EquityÂ (Deficit)Â Â InterestsÂ Â EquityÂ Balance as of July 1, 2024Â Â 5,408,212Â Â $(*)Â $420,568Â Â $(420,472)Â $96Â Â $5,319Â Â $5,415Â Share-based compensation to employees, directors, and non-employee consultantsÂ Â 157,237Â Â Â (*)Â Â 714Â Â Â -Â Â Â 714Â Â Â 100Â Â Â 814Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (8,838)Â Â (8,838)Â Â (308)Â Â (9,146) Balance as of December 31, 2024Â Â 5,565,449Â Â $(*)Â $421,282Â Â $(429,310)Â $(8,028)Â $5,111Â Â $(2,917) Â Â Â Shareholdersâ€™ Equity (Deficit)Â Â Â Â Â Â Â Â Â Common SharesÂ Â Additional Paid-inÂ Â AccumulatedÂ Â Total Shareholdersâ€™Â Â Non- controllingÂ Â TotalÂ Â Â SharesÂ Â AmountÂ Â CapitalÂ Â DeficitÂ Â EquityÂ (Deficit)Â Â InterestsÂ Â EquityÂ Balance as of October 1, 2024Â Â 5,507,304Â Â $(*)Â $421,071Â Â $(426,354)Â $(5,283)Â $5,220Â Â $(63) Share-based compensation to employees, directors, and non-employee consultantsÂ Â 58,145Â Â Â (*)Â Â 211Â Â Â -Â Â Â 211Â Â Â 45Â Â Â 256Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (2,956)Â Â (2,956)Â Â (154)Â Â (3,110) Balance as of December 31, 2024Â Â 5,565,449Â Â $(*)Â $421,282Â Â $(429,310)Â $(8,028)Â $5,111Â Â $(2,917) Â (*) Less than $1 Â The accompanying notes are an integral part of these unaudited condensed consolidatedÂ financial statements. Â 6 Â Â PLURI INC. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) U.S. Dollars in thousands (except share and per share amounts) Â Â Â Six months ended December 31,Â Â Â 2024Â Â 2023Â CASH FLOWS FROM OPERATING ACTIVITIES:Â Â Â Â Â Â Net lossÂ $(9,146)Â $(10,092) Adjustments to reconcile loss to net cash used in operating activities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â DepreciationÂ Â 133Â Â Â 131Â Share-based compensation to employees, directors and non-employee consultantsÂ Â 814Â Â Â 1,409Â Decrease (increase) in customer receivableÂ Â (106)Â Â 94Â Decrease (increase) in prepaid expenses and other current assets and other long-term assetsÂ Â 231Â Â Â (393) Increase (decrease) in trade payablesÂ Â 164Â Â Â (713) Decrease in other accounts payable, accrued vacation and recuperation and accrued expensesÂ Â (251)Â Â (410) Decrease (increase) in operating lease right-of-use asset and liability, netÂ Â 235Â Â Â (25) Increase in interest receivable on short-term depositsÂ Â (71)Â Â 3Â Effect of exchange rate changes on cash, cash equivalents, deposits and restricted cashÂ Â (441)Â Â (373) Increase (decrease) in long-term interest payable and exchange rate differences related to the EIB loan, netÂ Â (229)Â Â 869Â Accrued severance pay, netÂ Â (25)Â Â (6) Net cash used for operating activitiesÂ $(8,692)Â $(9,506) Â Â Â Â Â Â Â Â Â CASH FLOWS FROM INVESTING ACTIVITIES:Â Â Â Â Â Â Â Â Purchase of property and equipmentÂ $(320)Â $(224) Proceeds from withdrawal of short-term deposits, netÂ Â 9,550Â Â Â 9,945Â Net cash provided by investing activitiesÂ $9,230Â Â $9,721Â Â Â Â Â Â Â Â Â Â EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS and restricted cashÂ Â 81Â Â Â 15Â Increase in cash, cash equivalents, restricted cash and restricted bank depositsÂ Â 619Â Â Â 230Â Cash, cash equivalents, restricted cash and restricted bank deposits at the beginning of the periodÂ Â 7,671Â Â Â 6,256Â Cash, cash equivalents, restricted cash and restricted bank deposits at the end of the periodÂ $8,290Â Â $6,486Â Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:Â Â Â Â Â Â Â Â Cash and cash equivalentsÂ Â 7,229Â Â Â 5,468Â Restricted cashÂ Â 261Â Â Â 373Â Long-term restricted bank depositsÂ Â 800Â Â Â 645Â Total cash, cash equivalents, restricted cash and restricted bank depositsÂ $8,290Â Â $6,486Â (a) Supplemental disclosure of non-cash activities:Â Â Â Â Â Â Â Â Purchase of property and equipment on creditÂ $41Â Â $80Â Lease liabilities arising from obtaining right-of-use assetsÂ $32Â Â $78Â Â The accompanying notes are an integral part of these unaudited condensed consolidatedÂ financial statements. Â 7 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) U.S. Dollars in thousands (except share and per share amounts) Â NOTE 1: - GENERAL Â Â a. Pluri Inc. (formally known as Pluristem Therapeutics Inc.), a Nevada corporation, was incorporated on May 11, 2001. Pluri Inc.â€™s common shares trade on the Nasdaq Capital Market and Tel-Aviv Stock Exchange under the symbol â€œPLURâ€. Pluri Inc. has a wholly owned subsidiary, Pluri-Biotech Ltd. (formerly known as Pluristem Ltd.), or the Subsidiary, which is incorporated under the laws of the State of Israel. In January 2020, the Subsidiary established a wholly owned German Subsidiary, Pluristem GmbH, or the German Subsidiary which is incorporated under the laws of Germany. In January 2022, the Subsidiary established a new subsidiary, Ever After Foods Ltd., or Ever After Foods (formerly known as Plurinuva Ltd.). Ever After Foods is incorporated under the laws of Israel, which followed the execution of the collaboration agreement with Tnuva Food Industries â€" Agricultural Co-Operative in Israel Ltd., through its fully owned subsidiary, Tnuva Food-Tech Incubator (2019), Limited Partnership, or Tnuva. In March 2024, the Subsidiary established a new wholly owned subsidiary, Coffeesai Ltd., or Coffeesai which is incorporated under the laws of Israel, to develop cultivated coffee. Pluri Inc., the Subsidiary, the German Subsidiary, Ever After Foods and Coffeesai are referred to as the â€œCompanyâ€ or â€œPluri.â€ The Subsidiary, the German Subsidiary, Coffeesai and Ever After Foods are referred to as the â€œSubsidiaries.â€ Â Â b. The Company is a bio-technology company with an advanced cell-based technology platform, which operates in one operating segment. The Company has developed a unique three-dimensional technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice cell manufacturing facility. Pluri currently uses its technology in the field of regenerative medicine, food technology and agricultural technology and launched a Contract Development and Manufacturing Organization, or CDMO, business and plans to utilize its technology in industries and verticals that have a need for a mass scale and cost-effective cell expansion platform. Pluri is focused on the research, development and manufacturing of cell-based products and the business development of cell therapeutics and cell-based technologies providing potential solutions for various industries. Â Â c. The Company has incurred an accumulated deficit of approximately $429,310 and incurred recurring operating losses and negative cash flows from operating activities since inception. As of December 31, 2024, the Companyâ€™s total shareholdersâ€™ deficit amounted to $8,028. During the six-month period ended December 31, 2024, the Company incurred losses of $9,146 and its negative cash flow from operating activities was $8,692. Â As of December 31, 2024, the Companyâ€™s cash balances (cash and cash equivalents, short-term bank deposits, restricted cash and restricted bank deposits) totaled $22,374. Â The Company plans to continue to finance its operations from its current resources, by entering into licensing or other commercial, partnerships and collaboration agreements, by providing CDMO services to clients, from grants and contracts to support its research and development activities and from sales of its equity securities (see note 7). Â The Companyâ€™s management believes that its current resources together with its existing operating plan are sufficient for the Company to meet its obligations as they come due at least for a period of twelve months from the date of the issuance of these interim unaudited condensed consolidated financial statements. During 2024, the Company also implemented a cost reduction and efficiency plan. There is no assurance, however, that the Company will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of its products. In the case the Company is unable to obtain the required level of financing, operations may need to be scaled down or discontinued. Â On April 30, 2020, the German Subsidiary entered into a finance contract, or the Finance Contract, with the EIB, pursuant to which the German Subsidiary obtained a loan in an amount of â‚¬20Â million, or the Loan. The amount received is due on June 1, 2026 and bears an annual interest ofÂ 4% to be paid with the principal of the Loan. The Company is currently in discussions with the EIB regarding a potential restructuring of the terms of the loan, however there is no certainty that such restructuring will be achieved. As of December 31, 2024, the linked principal and interest accrued balance was of $23,798 and is presented among long-term liabilities (see note 4). Â 8 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) U.S. Dollars in thousands (except share and per share amounts) Â NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES Â Â a. Unaudited Interim Financial Information Â The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to FormÂ 10-Q and ArticleÂ 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair statement have been included (consisting only of normal recurring adjustments). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Companyâ€™s Annual Report on FormÂ 10-K for the year ended June 30, 2024. The year-endÂ balance sheet data was derived from the audited consolidated financial statements as of June 30, 2024, but not all disclosures required by GAAP are included. Â Operating results for the six-month period ended December 31, 2024, are not necessarily indicative of the results that may be expected for the year ending JuneÂ 30, 2025. Â Â b. Significant Accounting Policies Â The significant accounting policies followed in the preparation of these interim unaudited condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements. Â Â c. Use of estimates Â The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments and assumptions that are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Â Â d. Fair value of financial instruments Â The carrying amounts of the Companyâ€™s financial instruments, including cash and cash equivalents, restricted cash, short-term bank deposits and restricted bank deposits and other current assets, trade payable and other accounts payable and accrued expenses, approximate their fair value because of their generally short-term maturities. Â The Company measures its derivative instruments at fair value under Accounting Standards Codification, or ASC 820; â€œFair Value Measurements and Disclosuresâ€, or ASC 820. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Â As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Â Â Levelâ€¯ 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities; Â Â Levelâ€¯ 2 - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and Â Â Level â€¯3 - Unobservable inputs for the asset or liability. Â The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy. Â The Company measures its liability pursuant to the Finance Contract based on the aggregate outstanding amount of the combined principal and accrued interest thereunder. As of December 31, 2024, the Company does not reflect its liability for future royalty payments pursuant to the Finance Contract with the EIB since the royalty payments are to be paid as a percentage of the Companyâ€™s future consolidated revenues, pro-rated to the amount disbursed, beginning in fiscal year 2024 and until fiscal year 2030 (see note 4). Â 9 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) U.S. Dollars in thousands (except share and per share amounts) Â NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (CONT.) Â Â e. Recently issued accounting pronouncements, not yet adopted Â ASU No. 2023-07 - â€œSegment Reporting (Topic 280): Improvements to reportable segment disclosuresâ€, or ASU 2023-07: Â In November 2023, the Financial Accounting Standards Board, or FASB, issued ASU 2023-07. This guidance expands public entitiesâ€™ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reported measure of segment profit or loss, an amount and description of its composition of other segment items, and interim disclosures of a reportable segmentâ€™s profit or loss and assets. The guidance is effective for the fiscal year beginning after December 15, 2023, and interim periods within the fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â ASU No. 2023-09 - â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€, or ASU 2023-09: Â In December 2023, the FASB issued ASU 2023-09. This guidance is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investorsâ€™ requests for enhanced income tax information primarily through changes to the tax rate reconciliation and regarding income tax paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, on a prospective basis. Early adoption and retroactive application are permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â ASU 2024-03 - â€œIncome Statement: Reporting Comprehensive Income - Expense Disaggregation Disclosuresâ€, or ASU 2024-03: Â In November 2024, the FASB issued ASU 2024-03 - which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion), which are included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â 10 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) U.S. Dollars in thousands (except share and per share amounts) Â NOTE 3: - COMMITMENTS AND CONTINGENCIES Â Â a. As of December 31, 2024, an amount of $1,061 of cash and deposits was pledged by the Subsidiary and Ever After Foods to secure its credit line, lease agreement, derivative and hedging and bank guarantees. Â Â b. Under the Law for the Encouragement of Industrial Research and Development, 1984, or the Research Law, research and development programs that meet specified criteria and are approved by the IIA are eligible for grants of up toÂ 50% of the projectâ€™s expenditures, as determined by the research committee, in exchange for the payment of royalties from the sale of products developed under the program. Regulations under the Research Law generally provide for the payment of royalties to the IIA ofÂ 3% on sales of products and services derived from a technology developed using these grants untilÂ 100% of the U.S. dollar-linked grant is repaid. The Companyâ€™s obligation to pay these royalties is contingent on its actual sale of such products and services. In the absence of such sales, no payment is required. The outstanding balance of the grants will be subject to interest at a rate equal to the 12-month Secured Overnight Financing Rate, or SOFRÂ (before January 1, 2024, to the 12-month London Interbank Offered Rate, or LIBOR) applicable to U.S. dollar deposits that is published on the first business day of each calendar year. Following the full repayment of the grant, there is no further liability for royalties. Â As of December 31, 2024, the Companyâ€™s contingent liability in respect to royalties to the IIA amounted to $27,565, not including LIBOR (from January 1, 2024, SOFR) interest as described above. Â Â c. In April 2017, the Company was awarded a Smart Money grant of approximately $229Â from Israelâ€™s Ministry of Economy and Industry to facilitate certain marketing and business development activities with respect to its advanced cell therapy products in the Chinese market, including Hong Kong. The Israeli government granted the Company budget resources that are intended to be used to advance the Companyâ€™s product candidate towards marketing in the China-Hong Kong markets. The Company will also receive support from Israelâ€™s trade representatives stationed in China, including Hong Kong, along with experts appointed by the Smart Money program. As part of the program, the Company will repay royalties ofÂ 5% from the Companyâ€™s revenues in the region for a five-year period, beginning the year in which the Company will not be entitled to reimbursement of expenses under the program and will be spread for a period of up toÂ 5Â years or until the amount of the grant is fully paid. As of August 4, 2022, the grant from this Smart Money program received was approximately $180Â and the program has ended. To date, no royalties were paid or accrued. Â Â d. In September 2017, the Company signed an agreement with the Tel-Aviv Sourasky Medical Center, or Ichilov Hospital, to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease, or GVHD. As part of the agreement with Ichilov Hospital, the Company will pay royalties ofÂ 1% from its net sales of the PLX-PAD product relating to GVHD, with a maximum aggregate royalty amount of approximately $500. Â Â e. In October 2024, Ever After Foods signed a facility operating lease agreement with a lessor. The lease period, which has not yet begun, is expected for a term of five years. In addition, Ever After Foods has the option to terminate the lease after a period of 36 months and to extend the term of the lease for an additional period of five years, or the Extension Option. The average monthly lease payment for the first five years is approximately NIS 50,192 or $14, which is linked to the consumer price index. The monthly lease payments will increase by 5% in the event that Ever After Foods exercises its Extension Option. Â Â f. As to potential royalties to the EIB, see note 4. Â 11 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) U.S. Dollars in thousands (except share and per share amounts) Â NOTE 4: - LOAN FROM THE EIB Â On April 30, 2020, the German Subsidiary entered into the Finance Contract with the EIB, pursuant to which the German Subsidiary can obtain a loan in the amount of up to â‚¬50 million, subject to certain milestones being reached, receivable in three tranches, with the first tranche consisting of â‚¬20 million, second tranche consisting of â‚¬18 million and third tranche consisting of â‚¬12 million for a period of 36 months from the signing of the Finance Contract. Â The tranches were treated independently, each with its own interest rate and maturity period. The annual interest rate is 4% (consisting of a 4% deferred interest rate payable upon maturity); for the first tranche, 4% (consisting of a 1% fixed interest rate and a 3% deferred interest rate payable upon maturity) for the second tranche and 3% (consisting of a 1% fixed interest rate and a 2% deferred interest rate payable upon maturity) for the third tranche. Â In addition to any interest payable on the loan, the EIB is entitled to receive royalties from future revenues for a period of seven years starting at the beginning of fiscal year 2024 and continuing up to and including its fiscal year 2030 in an amount equal to between 0.2% to 2.3% of the Companyâ€™s consolidated revenues, pro-rated to the amount disbursed from the Loan. As of December 31, 2024, Pluri had an accrued royalty in the amount of $5. Â During June 2021, Pluri received the first tranche in an amount of â‚¬20 million of the Finance Contract. The amount received is due on June 1, 2026, and bears annual interest of 4% to be paid with the principal of the Loan. As of December 31, 2024, the linked principal balance in the amount of $20,819 and the interest accrued in the amount of $2,979 are presented among long-term liabilities. Since the project period ended on December 31, 2022, the Company does not expect to receive additional funds pursuant to the Finance Contract. Â The Finance Contract also contains certain limitations such as the use of proceeds received from the EIB, limitations related to disposal of assets, substantive changes in the nature of the Companyâ€™s business, changes in holding structure, distributions of future potential dividends and engaging with other banks and financing entities for other loans. Â 12 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) U.S. Dollars in thousands (except share and per share amounts) Â NOTE 5: - SHAREHOLDERSâ€™ EQUITY Â (1) Reverse share split Â In March 2024, the Companyâ€™s Board of Directors, or the Board, approved a 1-for-8 reverse share split of the Companyâ€™s (a) authorized common shares; and (b) issued and outstanding common shares. The reverse share split became effective on April 1, 2024. All common shares, options, warrants and securities convertible or exercisable into common shares, as well as loss per share, have been adjusted to give retroactive effect to this reverse share split for all periods presented. As a result of rounding-up fractional shares into whole shares as a result of the reverse share split, an additional 67,836 common shares were included in the Companyâ€™s issued and outstanding shares. Â (2) Pursuant to a registration statement on Form S-3 (File No. 333-273347), declared effective by the U.S Securities and Exchange Commission on September 21, 2023, on February 13, 2024 the Company entered into an Open Market Sales Agreement, or Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P., which provides that upon the terms and subject to the conditions and limitations in the Sales Agreement, the Company may elect, from time to time, to offer and sell common shares having an aggregate offering price of up to $10,000Â through A.G.P. acting as sales agent. As of December 31, 2024, the Company soldÂ 42,729Â common shares under the Sales Agreement at an average price of $5.93Â per share. Â (3) Share options and restricted share units, or RSUs to employees, directors and consultants: Â a. Options to non-employee consultants: Â A summary of the share options granted to non-employee consultants under its equity incentive plans, or the Plans, by Pluri Inc. and its Subsidiary is as follows: Â Â Â Six months ended December 31, 2024Â Â Â NumberÂ Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Â Aggregate intrinsic valueÂ priceÂ Share options outstanding at the beginning of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.87Â Â $42Â Share options outstanding at end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.37Â Â $19Â Share options exercisable at the end of the periodÂ Â 8,100Â Â $7.41Â Â Â 4.74Â Â $19Â Share options unvestedÂ Â 9,375Â Â $4.40Â Â Â 4.05Â Â $-Â Share options vested and expected to vest at the end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.37Â Â $19Â Â Unamortized compensation expenses related to options granted to non-employee consultants by Pluri Inc. and its Subsidiary are approximately $11 to be recognized by the end of March 2027. Â 13 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) U.S. Dollars in thousands (except share and per share amounts) Â NOTE 5: - SHAREHOLDERSâ€™ EQUITY (CONT.) Â b. Options to the Chief Executive Officer, or CEO, and Director: Â A summary of the share options granted to the CEO and director under the Plans by Pluri Inc. and its Subsidiary is as follows: Â Â Â Six months ended December 31, 2024Â Â Â NumberÂ Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Share options outstanding at the beginning of the periodÂ Â 240,291Â Â $14.82Â Â Â 2.42Â Share options outstanding at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 1.91Â Share options vested and exercisable at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 1.91Â As of December 31, 2024, the aggregate intrinsic value of these options was $0. Â c. RSUs to employees and directors: Â Â The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and its Subsidiary, for the six-month period ended December 31, 2024: Â Â Â Six months ended DecemberÂ 31, 2024Â Â Â NumberÂ Unvested at the beginning of the periodÂ Â 353,134Â GrantedÂ Â 48,653Â ForfeitedÂ Â (13,938) VestedÂ Â (143,243) Unvested at the end of the periodÂ Â 244,606Â Expected to vest after the end of the periodÂ Â 223,496Â Â The fair value of all RSUs was determined based on the closing trading price of the Companyâ€™s shares known at the grant date. The weighted average grant date fair value of RSUs granted during the six-month period ended December 31, 2024 granted to employees and directors was $5.20Â per share. Â Unamortized compensation expenses related to RSUs granted to employees and directors by Pluri Inc. and its Subsidiary are approximately $439 to be recognized by the end of September 2027. Â 14 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) U.S. Dollars in thousands (except share and per share amounts) Â NOTE 5: - SHAREHOLDERSâ€™ EQUITY (CONT.) Â Â d. RSUs and restricted shares, or RS to consultants: Â The following table summarizes the activity related to unvested RSUs and RS granted to non-employee consultants by Pluri Inc. and its Subsidiary for the six-month period ended December 31, 2024: Â Â Â Six months ended DecemberÂ 31,Â Â Â 2024Â Â Â NumberÂ Unvested at the beginning of the periodÂ Â 4,802Â GrantedÂ Â 12,138Â VestedÂ Â (13,994) Unvested at the end of the periodÂ Â 2,946Â Â The fair value of all RSUs was determined based on the closing trading price of the Companyâ€™s shares known at the grant date. The weighted average grant date fair value of RSUs granted during the six-month period ended December 31, 2024 granted to non-employee consultants was $5.47Â per share. Â Unamortized compensation expenses related to RSUs and RS granted consultants by Pluri Inc. and its Subsidiary are approximately $6 to be recognized by the end of June 2025. Â Compensation expenses related to RSUs granted by Pluri Inc. and its Subsidiary were recorded as follows: Â Â Â Six months ended December 31,Â Â Three months ended December 31,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Research and development expensesÂ $136Â Â $62Â Â $48Â Â $31Â General and administrative expensesÂ Â 570Â Â Â 634Â Â Â 159Â Â Â 278Â Â Â $706Â Â $696Â Â $207Â Â $309Â Â 15 Â Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) U.S. Dollars in thousands (except share and per share amounts) Â NOTE 5: - SHAREHOLDERSâ€™ EQUITY (CONT.) Â (4) Nasdaq Deficiency Letter: Â On November 25, 2024, the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500Â in shareholdersâ€™ equity for continued listing on The Nasdaq Capital Market, or the Shareholdersâ€™ Equity Requirement, nor was it in compliance with either of the alternative listing standards, market value of listed securities of at least $35,000Â or net income of $500Â from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. Â On January 6, 2025, the Company submitted a plan to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq has determined to grant the Company an extension of time to regain compliance with the Shareholdersâ€™ Equity Requirement until May 24, 2025. If the Company fails to evidence compliance by the required deadline, the Company may be subject to delisting. At that time, the Company may appeal Staffâ€™s determination to a Hearings Panel. Â The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance the Company will ultimately regain compliance with all applicable requirements for continued listing. Â Neither the Nasdaq Letter nor the Companyâ€™s noncompliance have an immediate effect on the listing or trading of the Companyâ€™s common shares, which will continue to trade on The Nasdaq Capital Market under the symbol â€œPLURâ€. Â NOTE 6: - TOTAL FINANCIAL INCOME, NET Â Â Â Six months ended December 31,Â Â Three months ended December 31,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Foreign currency translation differences, netÂ $762Â Â $(68)Â $1,754Â Â $(128) Interest income on deposits and restricted bank depositsÂ Â 572Â Â Â 792Â Â Â 251Â Â Â 356Â Income from hedging derivativesÂ Â 103Â Â Â 204Â Â Â 53Â Â Â 207Â Other Financial income, netÂ

Â 1,437Â Â Â 928Â Â Â 2,058Â Â Â 435Â EIB loan interest expensesÂ Â (428)Â Â (430)Â Â (211)Â Â (216) Â Â $1,009Â Â $498Â Â $1,847Â Â $219Â Â 16 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) U.S. Dollars in thousands (except share and per share amounts) Â NOTE 7: - SUBSEQUENT EVENTS Â On January 23, 2025, the Company entered into a Securities Purchase Agreement, or the Securities Purchase Agreement, with Mr. Alejandro Weinstein, or the Investor, relating to a private placement offering, or the Offering, of: (i) 1,383,948 common shares of the Company, (ii) pre-funded warrants, or the Pre-Funded Warrants, to purchase up to 26,030 common shares, and (iii) warrants, or the Common Warrants, to purchase up to 84,599 common shares. The Offering price per share and accompanying warrant is $4.61. The Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable at any time following the receipt of certain approvals from the Companyâ€™s shareholders, or the Shareholder Approval, and until exercised in full. The Common Warrants have an exercise price of $5.568 per share, which will not be exercisable until the Company receives Shareholder Approval and will be exercisable for three years following the date of receipt of the Shareholder Approval. The Pre-Funded Warrants and Common Warrants contain customary anti-dilution provisions and are subject to a 19.99% beneficial ownership limitation until the Shareholder Approval is obtained. The Securities Purchase Agreement contains customary representations and warranties and agreements of the Company and the Investor and customary indemnification rights and obligations of the parties. Â Under the terms of the Securities Purchase Agreement, the Company appointed Mr. Weinstein, to the Board of Directors of the Company, or the Board, effective upon the closing of the Offering, and agreed to continue to recommend his election to its shareholders provided the Investor continues to hold at least 10% of the Companyâ€™s issued and outstanding Common Shares. Â The Offering closed on February 5, 2025, and the gross proceeds to the Company were $6.5 million. Â Concurrently with the Offering, on January 23, 2025, the Company and the Investor entered into a binding term sheet, or the Term Sheet, for the purchase of certain shares representing approximately 71% (on a fully diluted basis) of Kokomodo Ltd., or Kokomodo, for an aggregate purchase price of $4.5 million, payable in common shares, or the Kokomodo Transaction. The Kokomodo Transaction will be subject to, among other conditions, the approval by the Companyâ€™s shareholders. The Kokomodo Transaction is expected to close during the second quarter of 2025, (calendar year) following the approval of the Companyâ€™s shareholders. As of the date of this report, there is no guarantee when or if the Kokomodo Transaction will be completed. Â Pursuant to the Term Sheet, in case that the Kokomodo Transaction does not close, for any reason other than due to Investorâ€™s failure to perform its material undertakings and/or covenants as agreed under the definitive agreement, or due to any due diligence finding which the we are not currently aware of and that is likely to result in liabilities to us exceeding $0.5 million, then we shall: (a) purchase a certain portion of Investorâ€™s shares in Kokomodo for a purchase amount of $1 million (based on a $6 million pre-money valuation of Kokomodo, calculated prior to the investment described in (b)), and (b) invest an additional $0.5 million in Kokomodo under a under a Simple Agreement for Future Equity, or SAFE, providing a 20% discount of the price per share set in connection with a trigger event for conversion of the SAFE into equity of Kokomodo and a pre-money valuation cap of $5.5 million in connection with such round. Â On February 3, 2025, the Company entered into an additional securities purchase agreement, or the Additional Securities Purchase Agreement, with Merchant Adventure Fund L.P., an existing investor, of the Company, relating to a private placement offering, or the Second Offering, of: (i) 759,219 of the Companyâ€™s common shares, and (ii) warrants to purchase up to 45,553 common shares. The Second Offering price per share and accompanying warrant is $4.61. The Second Offering warrants have an exercise price of $5.568 per share and a term of three years, commencing on the date of issuance. The gross proceeds to the Company from the Second Offering are expected to be approximately $3.5 million. Â 17 Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. Â Â Forward-Looking Statements Â This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws, and is subject to the safe-harbor created by such Act and laws. Forward-looking statements may include statements regarding our goals, beliefs, strategies, objectives, plans, including product and technology developments, future financial conditions, results or projections or current expectations. In some cases, you can identify forward-looking statements by terminology such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œexpect,â€ â€œintend,â€ â€œplan,â€ â€œanticipate,â€ â€œbelieve,â€ â€œestimate,â€ â€œpredict,â€ â€œpotentialâ€ or â€œcontinue,â€ the negative of such terms, or other variations thereon or comparable terminology. These statements are merely predictions and therefore inherently subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause actual results, performance levels of activity, or our achievements, or industry results to be materially different from those contemplated by the forward-looking statements. Such forward-looking statements appear in Item 2 â€“ â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ and may appear elsewhere in this Quarterly Report on Form 10-Q and include, but are not limited to, statements regarding the following:Â Â Â â— the expected development, time-to-market and potential benefits from our products and ventures, based on our cell-based technology platform in regenerative medicine, immunotherapy, food technology, or food tech, agriculture technology, or agtech, and our Contract Development and Manufacturing Organization, or CDMO, business, as well as potentially in other industries and verticals that have a need for our mass scale and cost-effective cell expansion platform; Â Â â— our expectations of market and industry growth; Â Â â— the prospects of entering into additional license agreements, joint ventures, partnerships or other forms of cooperation with other companies, government institutes, research organizations and medical institutions; Â Â â— our ability to attract clients for our CDMO business; Â Â â— our pre-clinical and clinical study plans, including timing of initiation, expansion, enrollment, results, and conclusion of trials; Â Â â— achieving regulatory approvals; Â Â â— receipt of future funding from the Israel Innovation Authority, or IIA, the European Unionâ€™s Horizon programs, the National Institutes of Health, or NIH, as well as grants from other independent third parties; Â Â â— the capabilities of our placenta expanded, or PLX, cells, including future collaborations to further advance the development of our PLX- PAD and PLX-R18 cell therapy as a potential novel treatment; Â Â â— the expected clinical development of a new allogeneic Placental Mucosal Associated Invariant T, or MAIT, and the potential benefits it can produce for advanced cell-based therapies for immune disorders and neurodegenerative diseases; Â Â â— our expectation to solve medicineâ€™s unmet needs and demonstrate a real-world impact and value from our pipeline, technology platform and commercial-scale manufacturing capacity; Â Â â— the possible impacts of cybersecurity incidents on our business and operations; Â Â â— our expectations regarding our short and long-term capital requirements; Â Â â— our outlook for the coming months and future periods, including but not limited to our expectations regarding future revenue and expenses; Â Â Â Â â— our expectation to receive approval from our shareholders relating to a private placement offering, or the Offering, pursuant to a securities purchase agreement, or the Securities Purchase Agreement, and a binding term sheet, or the Term Sheet, each entered into on January 23, 2025; Â Â â— information with respect to any other plans and strategies for our business; Â Â â— general market, political and economic conditions in the countries in which we operate including those related to recent unrest in the Middle East and armed conflict between Israel and Hamas, Hezbollah and other terrorist organizations; and Â Â â— our ability to regain compliance with Nasdaq Listing Rule 5550(b)(1), which requires us to maintain a minimum of $2.5 million in stockholdersâ€™ equity, or the Stockholdersâ€™ Equity Requirement, for continued listing on the Nasdaq Capital Market. Â 18 Â Â Our business and operations are subject to substantial risks, which increase the uncertainty inherent in the forward-looking statements contained in this report. Â In addition, historic results of scientific research and development, or R&D, clinical and preclinical trials do not guarantee that the conclusions of future R&D or trials would not suggest different conclusions. Also, historic results referred to in this periodic report would be interpreted differently in light of additional research, development, clinical and preclinical trials results. Except as required by law, we undertake no obligation to release publicly the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Further information on potential factors that could affect our business is described under the heading â€œRisk Factorsâ€ in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2024, or the 2024 Annual Report, as well as in Part II, Item 1A of this Quarterly Report. Readers are also urged to carefully review and consider the various disclosures we have made in that report. Â As used in this Quarterly Report on Form 10-Q, the terms â€œweâ€, â€œusâ€, â€œourâ€, the â€œCompanyâ€ and â€œPluriâ€ mean Pluri Inc., our wholly owned subsidiaries, Pluri Biotech Ltd., Pluristem GmbH, and Coffeesai Ltd., and our subsidiary Ever After Foods Ltd., or Ever After Foods, unless otherwise indicated or as otherwise required by the context. Â All references to common shares, or price per common share, in this Quarterly Report on Form 10-Q, reflect the 1-for-8 reverse stock split effectuated by us on April 1, 2024. Â Overview Â We are a biotechnology company with an advanced cell-based technology platform. We have developed a unique three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, cell manufacturing facility. We are utilizing our technology in the fields of regenerative medicine, immunotherapy, food tech, CDMO, and agtech, and plan to utilize it in industries and verticals that have a need for our mass scale and cost-effective cell expansion platform via partnerships, joint ventures, licensing agreements and other types of collaborations. Â Our operations are focused on the research, development and manufacturing of cell-based products and the business development of cell therapeutics and cell-based technologies, providing potential solutions for various industries.Â Â Cell Therapy Â We use our advanced cell-based technology platform in the field of regenerative medicine to develop placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries and hematologic conditions. Recently, we have also launched a novel immunotherapy platform. Â PLX Cells: Our PLX cells are adherent stromal cells that are expanded using our 3D platform. Our PLX cells can be administered to patients off-the-shelf, without blood or tissue matching or additional manipulation prior to administration. PLX cells are believed to release a range of therapeutic proteins in response to the patientâ€™s condition. Â In the pharmaceutical area, we have focused on several indications utilizing our product candidates, including, but not limited to, muscle recovery following surgery for hip fracture, incomplete recovery following bone marrow transplantation, critical limb ischemia, or CLI, Chronic Graft versus Host Disease and a potential treatment for Hematopoietic Acute Radiation Syndrome, or H-ARS. Some of these studies have been completed while others are still ongoing. We believe that each of these indications is a severe unmet medical need. Â In July 2023, we announced that we signed a three-year $4.2 million contract with the U.S. National Institute of Allergy and Infectious Diseases, or NIAID, which is part of the NIH. Under such contract, we will collaborate with the U.S. Department of Defenseâ€™s Armed Forces Radiobiology Research Institute, or AFRRI, and the Uniformed Services University of Health Sciences, or USUHS, in Maryland, U.S.A., to further advance the development of our PLX-R18 cell therapy as a potential novel treatment for H-ARS, a deadly disease that can result from nuclear disasters and radiation exposure. Â Â Immunotherapy MAIT cells: In May 2024, we launched a novel allogenic immunotherapy platform utilizing MAIT cells specifically designed to address solid tumors - a critical area in medicine where effective treatments are currently insufficient. We believe that our MAIT cells, isolated from the human placenta, offer substantial potential benefits compared to conventional T-cells. Â MAIT cells are potent effector cells, potentially targeting tumors through multiple mechanisms while expressing high levels of various chemokine receptors, which facilitate their migration directly to tumor sites. Furthermore, unlike conventional autologous T-cells typically collected from peripheral blood, our MAIT cells are designed to be allogenic universal product. Benefiting with very restricted T-cell receptor, the MAIT cells minimize their likelihood of inducing Graft versus Host Disease, a significant advantage over other potential allogeneic products. We are aiming to design the MAIT cells to potentially show better persistence in the body for a longer duration, enhancing their therapeutic efficacy. Â In April 2024, we unveiled a novel method for expansion of immune cells using proprietary technology and announced we were granted a new U.S. patent titled, â€œSystem and Methods for Immune Cells Expansion and Activation in Large Scale.â€ This innovative approach ensures that the produced immune cells retain their integrity, functionality, and therapeutic efficacy, thus offering a promising solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases. Â 19 Â Â PluriCDMOâ„¢ Â In January 2024, we launched a new business division offering cell therapy manufacturing services as a CDMO: PluriCDMOâ„¢. PluriCDMOâ„¢ offers CDMO services to companies from early preclinical development, through late-stage clinical trials and commercialization, with a mission to deliver high-quality, essential therapies to patients. We have signed several agreements with clients and are currently generating revenues from PluriCDMOâ„¢. Â AgTech Â We are actively involved in several initiatives leveraged by Pluriâ€™s 3D cell expansion in the agtech field, such as: (a) cell-based coffee business activity through our PluriAgtech business vertical, which is incorporated into our wholly owned subsidiary, Coffeesai Ltd., (b) an innovative proof-of-concept, or POC, collaboration with ICL Group Ltd., a leading global specialty minerals company, to revolutionize bio stimulant delivery and enhance yield sustainably, and (c) a strategic POC agreement with a leading international agriculture corporation which is intended to boost the global vegetable product supply, streamline supply chains, and combat global climate change, while ensuring a natural and a more sustainable future for agriculture. Â In March 2024, we announced an important expansion to our intellectual property portfolio with a new patent approval from the Israel Patent Office, that is designed to reshape the agricultural technology landscape. The patent represents a major breakthrough in our proprietary 3D bioreactor technology, enabling efficient cultivation of plant cells across various applications, from sustainable agriculture to critical healthcare solutions. Â On January 23, 2025, we entered into a Term Sheet with Mr. Alejandro Weinstein, a non-U.S. investor, or the Investor, for the purchase of certain shares representing approximately 71% (on a fully diluted basis) of Kokomodo Ltd., or Kokomondo, an Israeli agtech company specializing in cultivated cacao production, for an aggregate purchase price of $4.5 million, payable in our common shares, or the Kokomodo Transaction. The Kokomodo Transaction will be subject to, among other conditions, the approval of our shareholders. The Kokomodo Transaction is subject to certain closing conditions, including the approval of our shareholders. As of the date of this report, there is no guarantee when or if the Kokomodo Transaction will be completed. Â Food Tech Â In 2022, we announced the establishment of a joint venture with Tnuva Food Industries â€“ Agricultural Co-Operative in Israel Ltd., or Tnuva, Ever After Foods (previously Plurinuva Ltd.), which is incorporated under the laws of the State of Israel, with the purpose of developing cultivated meat products of all kinds and types. Â Leveraging Pluriâ€™s innovative technology, Ever After Foods has rapidly advanced its scalable production platform, developing a business-to-business, or B2B, version of its proprietary technology system, Ever After Foods has demonstrated the natural production of muscle and fat tissues for various animal cells, ensuring taste, feel, and texture akin to conventional animal-derived meat. Â In June 2024, we entered into a share purchase agreement by and among Ever After Foods, Tnuva, and certain other international strategic investors, pursuant to which Ever After Foods issued and sold, ordinary shares in a private placement offering, for aggregate gross proceeds of $10 million. As part of such private placement offering, we invested $1.25 million. In addition, our wholly owned subsidiary, Pluri Biotech Ltd., and Ever After Foods executed an Amended and Restated Technology License Agreement, dated June 12, 2024, or the Amended License. The Amended License amended the partiesâ€™ existing license agreement dated as of February 23, 2022, to expand the scope of the license to include fish and seafood. Â The $10 million funding round is intended to support Ever After Foodsâ€™ B2B technology platform, positioning it as a sustainable technology enabler and will allow it to move to their own facility during March 2025. Following the closing of such private placement offering, the Subsidiary holds approximately 69% of Ever After Foods. Â 20 Â Â RESULTS OF OPERATIONS â€“ THREE AND SIX MONTHS ENDED DECEMBER 31, 2024 COMPARED TO THREE AND SIX MONTHS ENDED DECEMBER 31, 2023 Â Revenues Â Revenues for the six-month and three-month periods ended December 31, 2024 were $511,000 and $185,000, respectively, as compared to $159,000 and $105,000, respectively, during the six-month and three-month periods ended December 31, 2023. Revenues for the six-month and three-month periods ended December 31, 2024 and 2023 were mainly related to services provided to CDMO clients in the field of process and product development and in the agtech fields. The increase in revenues is mainly attributed to the launch of new business verticals, specifically in the CDMO field and an increase related to a POC collaboration with a leading international agriculture corporation in the agtech field. Â Cost of Revenues Â Cost of revenues for each of the six-month and three-month periods ended December 31, 2024 were $200,000 and $74,000. Cost of revenues includes (1) manufacturing costs related to our CDMO and agtech fields, which primary consist of materials, personnel-related and overhead costs, and (2) royalties which we are obligated to pay to the European Investment Bank, or EIB, according to the finance agreement, or the EIB Finance Agreement, executed with the EIB by us, Pluri Biotech Ltd. and Pluristem GmbH in April 2020. We had no cost of revenues for the six-month and three-month periods ended December 31, 2023. Â Research and Development Expenses, Net Â R&D expenses, net (costs less participation by the IIA, Horizon Europe and the NIAID) for the six-month period ended December 31, 2024 decreased by 2% from $5,957,000 for the six-month period ended December 31, 2023, to $5,814,000. The decrease is mainly attributed to (1) a decrease in salaries and a related to reduction in head count of 10 R&D employees in the Subsidiary (90 R&D employees on December 31, 2024, compared to 100 R&D employees on December 31, 2023) as a result of our cost reduction and efficiency plans, and (2) a decrease in materials costs related to a supplier credit, partially offset by (1) an increase in material purchases in accordance with our manufacturing needs and plans, and (2) an increase related to subcontractors activity in NIAID and immunotherapy projects. Â R&D expenses, net (costs less participation by the IIA, Horizon Europe and the NIAID) for the three-month period ended December 31, 2024 decreased by 1% from $2,964,000 for the three-month period ended December 31, 2023 to $2,925,000. The decrease is mainly attributed to a decrease in materials costs related to a supplier credit, partially offset by (1) an increase in material purchases and consultants activity in accordance with our manufacturing needs and plans, and (2) a decrease in participation grants from the NIAID contract. Â General and Administrative Expenses Â General and administrative expenses for the six-month period ended December 31, 2024 decreased by 3% from $4,792,000 for the six-month period ended December 31, 2023 to $4,652,000 mainly due to a decrease in share-based compensation expenses related to employee terminations and restricted stock unit, or RSU, expenses amortization over time, partially offset by (1) an increase in salaries and related expenses due to the reinstatement of the salary of Mr. Yaky Yanay, our Chief Executive Officer, or CEO (following his salary reduction from January 2023 through December 2023, whereby he waived 75% of his salary and converted it to RSUs, and options), (2) an increase in salaries and related expenses due to reinstatement of temporary reduction in employeesâ€™ regular working hours for a limited period in December 2023, (3) an increase in bonus expenses for certain employees, including our CEO and Mrs. Chen Franco-Yehuda, our former Chief Financial Officer, or CFO, for certain performance-based bonuses as defined in their employment agreement, and (4) an increase in share-based compensation expenses related to RSUs and options which were granted during the third quarter of fiscal year 2024 and the first quarter of fiscal year 2025 to employees, officers, directors and consultants. Â General and administrative expenses for the three-month period ended December 31, 2024 decreased by 9% from $2,354,000 for the three-month period ended December 31, 2023 to $2,143,000. The decrease is mainly attributed to a decrease in share-based compensation expenses related to employee terminations and RSUs, expenses amortization over time, partially offset by (1) an increase in salaries and related expenses due to the reinstatement of the salary of our CEO (following his salary reduction from January 2023 through December 2023, whereby he waived 75% of his salary and converted it to RSUs, and options), (2) an increase in salaries and related expenses due to reinstatement of temporary reduction in employeesâ€™ regular working hours for a limited period in December 2023, (3) an increase in bonus expenses for certain employees, including our CEO and our former CFO for certain performance-based bonuses as defined in their employment agreement, and (4) an increase in share-based compensation expenses related to RSUs and options which were granted during the third quarter of fiscal year 2024 and the first quarter of fiscal year 2025 to employees, officers, directors and consultants. Â 21 Â Â Other Financial Income, net Â Other financial income, net, increased from $928,000 in financial income for the six-month period ended December 31, 2023 to $1,437,000 in financial income for the six-month period ended December 31, 2024. This increase is mainly attributed to exchange rate differences expenses related to the EIB loan following fluctuation between the U.S. dollar against the Euro, partially offset by (1) a decrease in interest income from deposits, resulting from lower interest rates and reduced deposit levels due to withdrawals, (2) a decrease due to exchange rate expenses on a lease liability due to the strength of the New Israeli Shekel, or NIS, against the U.S Dollar and (3) less income from hedging transactions. Â Other financial income, net, changed from $435,000 in financial income for the three-month period ended December 31, 2023 to $2,058,000 in financial income for the three-month period ended December 31, 2024. The increase is mainly attributed to exchange rate differences expenses related to the EIB loan following fluctuation between the U.S. dollar against the Euro, partially offset by (1) a decrease in interest income from deposits, resulting from lower interest rates and reduced deposit levels due to withdrawals and (2) less income from hedging transactions. Â Â Interest Expenses Â Interest expenses related to our outstanding loan received from the EIB and all changes during the six-month and three-month periods ended December 31, 2024 compared to the six-month and three-month periods ended December 31, 2023 are attributable solely to exchange rate differences of the Euro compared to the U.S. dollar. Â Net Loss Â Net loss for the six-month and three-month periods ended December 31, 2024 were $9,146,000 and $3,110,000, respectively, as compared to net loss of $10,092,000 and $4,994,000 for the six-month and three-month periods ended December 31, 2023, respectively. The decreases were due to decreases in general and administrative expenses and R&D expenses, as part of the implementation of our business strategy, our efforts to reduce costs pursuant to an efficiency plan, and due to the launch of our new businesses, such as the CDMO and agtech fields. Net loss per share attributed to shareholders for the six-month and three-month periods ended December 31, 2024 were $1.61 and $0.53, respectively, as compared to $1.92 and $0.96 for the six-month and three-month periods ended December 31, 2023, respectively. We had net loss attributed to our non-controlling interest in Ever After Foods for the six-month and three-month periods ended December 31, 2024 of $308,000 and $154,000, respectively. Â For the six-month and three-month periods ended December 31, 2024 and 2023, we had weighted average common shares outstanding of 5,505,915, 5,552,931 and 5,178,555, 5,190,853, respectively, which were used in the computations of net loss per share for the six-month and three-month periods. Â The increase in weighted average common shares outstanding reflects the issuance of additional shares upon the vesting of RSUs and restricted shares issued to directors, officers, employees and consultants. Â Liquidity and Capital Resources Â As of December 31, 2024, our total current assets were $22,370,000 and total current liabilities were $4,440,000. On December 31, 2024, we had a working capital surplus of $17,930,000, total equity (deficit) of ($2,917,000), after deduction of $5,111,000 which is attributed to the non-controlling interest in Ever After Foods, and an accumulated deficit of $(429,310,000). Â Our cash and cash equivalents and restricted cash as of December 31, 2024 amounted to $7,490,000, compared to $5,841,000 as of December 31, 2023 and compared to $7,037,000 as of June 30, 2024. Cash balances changed in the six months ended December 31, 2024 compared to the six months ended December 31, 2023 for the reasons presented below. Â Net cash used for operating activities was $8,692,000 in the six months ended December 31, 2024, compared to $9,506,000 in the six-months ended December 31, 2023. Cash used in operating activities in the six months ended December 31, 2024 and 2023 consisted primarily of payments of fees to our suppliers, subcontractors, professional services providers and consultants, and payments of salaries to our employees, partially offset by income from CDMO clients and by grants from the IIA, the Horizon Europe program, and funds received from the NIAID contract. Â Investing activities provided cash of $9,230,000 in the six months ended December 31, 2024, compared to cash provided of $9,721,000 for the six months ended December 31, 2023. The investing activities in the six-month period ended December 31, 2024 and 2023 consisted primarily of the proceeds from withdrawal of short-term deposits, net of $9,550,000 and $9,945,000, respectively. Â We had no financing activities in the six months ended December 31, 2024 or 2023. Â Â On December 14, 2022, our CEO agreed to forgo, starting January 1, 2023, $375,000 of his annual cash salary for the next twelve months in return for equity grants, issuable under our existing equity compensation plans. In that regard, we granted Mr. Yanay (i) 41,853 RSUs, vesting ratably each month, and (ii) options to purchase 41,853 common shares, vesting ratably each month, with a term of 3 years from vesting date, at an exercise price of $8.96 per share. In addition, the Board of Directors also agreed to grant Mr. Yanay options to purchase 187,500 common shares, with a term of 3 years from vesting date, with the following terms: (i) options to purchase 62,500 common shares at an exercise price of $12.48 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, (ii) options to purchase 62,500 common shares at an exercise price of $16.64 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, and (iii) options to purchase 62,500 common shares at an exercise price of $20.8 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023. Â 22 Â Â In April 2020, we and our subsidiaries, Pluri Biotech Ltd. and Pluristem GmbH, executed the EIB Finance Agreement for non-dilutive funding of up to â‚¬50 million in the aggregate, payable in three tranches. The proceeds from the EIB Finance Agreement were intended to support our R&D in the European Union to further advance our regenerative cell therapy platform, and to bring the products in our pipeline to market. The term of the project was three years commencing on January 1, 2020.Â Â During June 2021, we received the first tranche in the amount of â‚¬20 million pursuant to the EIB Finance Agreement. The amount received is due to be repaid on June 1, 2026, and bears annual interest of 4% to be paid together with the principal of the loan. We are currently in discussions with the EIB regarding a potential restructuring of the terms of the loan, however, there is no certainty that such restructuring will be achieved. As of December 31, 2024, the interest accrued was in the amount of approximately â‚¬2.86 million. In addition to the interest payable, the EIB is also entitled to royalty payments, pro-rated to the amount disbursed from the EIB loan, on our consolidated revenues beginning in the fiscal year 2024 up to and including its fiscal year 2030, in an amount equal to up to 2.3% of our consolidated revenues below $350 million, 1.2% of our consolidated revenues between $350 million and $500 million and 0.2% of our consolidated revenues exceeding $500 million. As of December 31, 2024, we had an accrued royalty in the amount of $5,000. As the project term ended on December 31, 2022, we do not expect to receive additional funds pursuant to the EIB Finance Agreement.Â Â On July 11, 2023, we signed a three-year $4.2 million contract with the NIAID, which is part of the NIH. We will collaborate with the U.S. Department of Defenseâ€™s, or DoDâ€™s, AFRRI and USUHS to further advance the development of our PLX-R18 cell therapy as a potential novel treatment for H-ARS. H-ARS is a deadly disease that can result from nuclear disasters and radiation exposure. The period of performance of this contract will be from July 1, 2023 through June 30, 2024, with an optional extension for an additional two-year period. Â On June 6, 2024, the NIAID exercised its option for year two of the three-year $4.2 million contract. During the 12 months period from July 1, 2024 through June 30, 2025, the NIAID will provide us with $1.4 million to manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the H-ARS. As of December 31, 2024, we have received from the NIAID approximately $1.9 million and as of December 31, 2024 we expect to receive an additional amount of approximately $0.1 million for activities conducted by that date. Â On February 13, 2024, we entered into a sales agreement, or the Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P., as agent, pursuant to which we may issue and sell our common shares having an aggregate offering price of up to $10 million, from time to time through A.G.P. As of February 11, 2025, we have sold an aggregate of 42,729 common shares pursuant to the Sales Agreement at an average price of $5.93 per share. Â On January 23, 2025, we entered into the Securities Purchase Agreement with the Investor, relating to the Offering of: (i) 1,383,948 of our common shares, par value $0.00001 per share, (ii) pre-funded warrants, or the Pre-Funded Warrants, to purchase up to 26,030 common shares, and (iii) warrants, or the Common Warrants, to purchase up to 84,599 common shares. The Offering price per share and accompanying warrant is $4.61. The Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable at any time following the receipt certain approvals from our shareholders, required by the applicable rules of the Nasdaq Capital Market, and until exercised in full. The Common Warrants have an exercise price of $5.568 per share, will not be exercisable until we receive the approval from our shareholders, and will be exercisable for three years following the date of receipt of such approval. The Pre-Funded Warrants and Common Warrants contain customary anti-dilution provisions and are subject to a 19.99% beneficial ownership limitation until approval from our shareholders is obtained. The Securities Purchase Agreement contains customary representations and warranties and agreements of the Company and the Investor and customary indemnification rights and obligations of the parties. Â Under the terms of the Securities Purchase Agreement, we appointed Mr. Weinstein to our Board, effective upon the closing of the Offering, and agreed to recommend his election to our shareholders provided that the Investor continues to hold at least 10% of our issued and outstanding common shares. Â The gross proceeds from the Offering were $6.5 million and we intend to use the proceeds from the Offering for working capital and general corporate purposes. The Offering closed on February 5, 2025, following the satisfaction of customary closing conditions. Â Concurrently with the Offering, on January 23, 2025, we and the Investor entered into a Term Sheet, for the purchase of certain shares representing approximately 71% (on a fully diluted basis) of Kokomodo, for an aggregate purchase price of $4.5 million, payable in our common shares. The Kokomodo Transaction will be subject to, among other conditions, to the approval of our shareholders. The Kokomodo Transaction is expected to close during the second quarter of 2025 (calendar year), following the approval of the Companyâ€™s shareholders. As of the date of this report, there is no guarantee when or if the Kokomodo Transaction will be completed. Â 23 Â Â Pursuant to the Term Sheet, in case that the Kokomodo Transaction does not close, for any reason other than due to Investorâ€™s failure to perform his material undertakings under the Term Sheet and/or covenants as agreed under the definitive agreement, or due to any diligence finding which the we are not currently aware of and that are likely to result in liabilities exceeding $0.5 million to us, then we shall: (a) purchase a certain portion of Investorâ€™s shares in Kokomodo for a purchase amount of $1 million (based on a $6 million pre-money valuation of Kokomodo, calculated prior to the investment described in (b)), and (b) invest an additional $0.5 million in Kokomodo under a under a Simple Agreement for Future Equity, or SAFE, providing a 20% discount of the price per share set in connection with a trigger event for conversion of the SAFE into equity of Kokomodo and a pre-money valuation cap of $5.5 million in connection with such round. Â On February 3, 2025, we entered into an additional securities purchase agreement, or the Additional Securities Purchase Agreement, with Merchant Adventure Fund L.P., an existing investor of the Company, relating to a private placement offering, or the Second Offering, of: (i) 759,219 of our common shares, par value $0.00001 per share, and (ii) warrants, to purchase up to 45,553 common shares. The Second Offering price per share and accompanying warrant is $4.61. The Second Offering warrants have an exercise price of $5.568 per share and a term of three years commencing on the date of issuance. The gross proceeds to the Company from the Second Offering are expected to be approximately $3.5 million and we intend to use the proceeds from the Second Offering for working capital and general corporate purposes. Â Non-dilutive grants Â Israel Innovation Authority (IIA) Â According to the IIA grant terms, we are required to pay royalties at a rate of 3% on sales of products and services derived from technology developed using this and other IIA grants until 100% of the dollar-linked grants amount plus interest are repaid. In the absence of such sales, no payment is required. Through December 31, 2024, total grants obtained from the IIA, which are bearing royalties, aggregated to approximately $27.7 million and total royalties paid and accrued amounted to $179 thousand. Â In June 2020, we announced that we were selected as a member of the CRISPR-IL consortium, a group funded by the IIA. CRISPR-IL brings together the leading experts in life science and computer science from academia, medicine, and industry, to develop AI based end-to-end genome-editing solutions. These next-generation, multi-species genome editing products for human, plant, and animal DNA, have applications in the pharmaceutical, agriculture, and aquaculture industries. CRISPR-IL is funded by the IIA with a total budget of approximately $10 million of which, an amount of approximately $480 thousand was a direct grant allocated to us, for the initial period of 18 months. During October 2021, we received an approval for an additional grant of approximately $583 thousand from the IIA pursuant to the CRISPR-IL consortium program, for an additional period of eighteen months. During January 2023, we received approval for an extension of an additional 2 months to finish the program until June 30, 2023. The CRISPR-IL consortium program does not include any obligation to pay royalties. Â Through December 31, 2024, we received total grants of approximately $1 million in cash from the IIA pursuant to the CRISPR-IL consortium program, and we do not expect to receive any additional funds.Â Â On October 28, 2024, we announced that the IIA will fund our collaboration with Bar-Ilan University Research and Development Company Ltd., or BIRAD, the commercial arm of the Bar-Ilan University in Israel, to support the continued development of MAIT cells. This collaboration is aimed at advancing innovative allogeneic cell therapies targeting solid tumors and multiple indications. The IIA will fund our collaboration with BIRAD for the first year with a budget approved of approximately $148,000 allocated to us, with an option to fund an additional year. The goal of this collaboration is to effectively integrate both technologies and advance to preclinical studies. The program does not include any obligation to pay royalties. As of December 31, 2024, we have received approximately $28,000 from the IIA for the project. Â EU grants - Horizon 2020 and Horizon Europe Â On September 6, 2022, we announced that a â‚¬7.5 million non-dilutive grant from the European Unionâ€™s Horizon program was awarded to Advanced Personalized Therapies for Osteoarthritis, or PROTO, an international collaboration led by CharitÃ© Berlin Institute of Health Center for Regenerative Therapies. The goal of the PROTO project is to utilize our PLX-PAD cells in a Phase I/II study for the treatment of mild to moderate knee osteoarthritis. Â An amount of approximately Euro 500,000 (approximately $540,000) will be a direct grant that will be allocated to us. Through December 31, 2024, we received a payment of approximately $185,000 in cash, which relates to the PROTO program. On January 13, 2025, we received an additional amount of approximately $143,000 in cash, which relates to the PROTO program. Â The clinical study, once approved by the regulatory agencies, will be carried out by CharitÃ©, together with us and other members of the international consortium under the leadership of Professor Tobias Winkler, Principal Investigator, at the Berlin Institute of Health Center of Regenerative Therapies, Julius Wolff Institute and Center for Musculoskeletal Surgery.Â Â 24 Â Â We have an effective Form S-3 registration statement (File No. 333-273347), filed under the Securities Act with the U.S. Securities and Exchange Commission, or the SEC, using a â€œshelfâ€ registration process. Under this shelf registration process, we may, from time to time, sell our common shares, preferred stock and warrants to purchase common shares, and of two or more of such securities, in one or more offerings for an aggregate initial offering price of $200 million (including amounts sold under the Sales Agreement). Â The currency of our financial portfolio is mainly in U.S. dollars and we use options contracts and other financial instruments in order to hedge our exposures to currencies other than the U.S. dollar. For more information, please see Item 7A. - â€œQuantitative and Qualitative Disclosures about Market Riskâ€ in the 2024 Annual Report. Â Outlook Â We have accumulated a deficit of $429,310,000 since our inception in May 2001. We do not expect to generate any significant revenues from sales of products in the next twelve months. We expect to generate revenues from the sale of services in our CDMO activity, from collaboration based on our cell-based products, and from licenses to use our technology and products. Although we were able to reduce the burn rate significantly in the last few years, it is unlikely that in the short-term revenues will exceed our costs of operations. Â Â Â We may be required to obtain additional liquidity resources in order to support the commercialization of our products and technology and maintain our R&D activities. Â We are continually looking for sources of funding, including collaboration with other companies via licensing agreements, joint ventures and partnerships, and other non-dilutive sources such as our contract with NIAID and DoD, research grants such as the IIA grants and the European Union grants, and sales of our common shares. Â We believe that we have sufficient cash to fund our operations for at least the next twelve months. Â Item 4. Controls and Procedures. Â Evaluation of Disclosure Controls and Procedures - We maintain a system of disclosure controls and procedures that are designed for the purposes of ensuring that information required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our CEO and our CFO, as appropriate to allow timely decisions regarding required disclosures. Â As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our CEO and our CFO, of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures are effective. Â Changes in Internal Control Over Financial Reporting - There has been no change in our internal control over financial reporting during the second quarter of fiscal year 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Â 25 Â Â PART II â€“ OTHER INFORMATION Â Item 1A. Risk Factors. Â In addition to the other information set forth in this report, you should carefully consider the factors discussed below and in Part I, â€œItem 1A. Risk Factorsâ€ of our 2024 Annual Report, which could materially affect our business, financial condition or future results. Â Failure to meet Nasdaqâ€™s continued listing requirements could result in the delisting of our common shares, negatively impact the price of our common shares and negatively impact our ability to raise additional capital. Â On November 25, 2024, we received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, notifying us that we are not in compliance with the Stockholdersâ€™ Equity Requirement, which requires us to maintain a minimum of $2.5 million in stockholdersâ€™ equity, nor we are in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.Â Â On January 6, 2025, we submitted a plan to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq has determined to grant us with an extension of time to regain compliance with the Stockholdersâ€™ Equity Requirement until May 24, 2025. If we fail to evidence compliance by the required deadline, we may be subject to delisting. At that time, we may appeal Staffâ€™s determination to a Hearings Panel. Â We intend to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance that we will ultimately regain compliance with all applicable requirements for continued listing. Â Neither the Nasdaq Letter nor our noncompliance have an immediate effect on the listing or trading of our common shares, which will continue to trade on The Nasdaq Capital Market under the symbol â€œPLURâ€. Â If, for any reason, Nasdaq should delist our common shares from trading on its exchange and we are unable to obtain listing on another national securities exchange or take action to restore our compliance with the Nasdaq continued listing requirements, a reduction in some or all of the following may occur, each of which could have a material adverse effect on our shareholders: Â â—The liquidity of our common shares; Â â—the market price of our common shares; Â â—our ability to obtain financing for the continuation of our operations; Â â—the number of institutional and general investors that will consider investing in our common shares; Â â—the number of investors in general that will consider investing in our common shares; Â â—the number of market makers in our common shares; Â â—the availability of information concerning the trading prices and volume of our common shares; and Â â—the number of broker-dealers willing to execute trades in shares of our common shares Â Our principal research, development and manufacturing facilities are located in Haifa, Israel and military conditions in Israel, including armed conflicts between Israel and Hamas, Hezbollah and other terrorist organizations from the Gaza Strip and Lebanon, may cause interruption or suspension of our business operations without warning. Â Our principal R&D and manufacturing facilities are located in Haifa, Israel, thus, political, economic, and military conditions in Israel, and in particular, conflicts between Israel and Hamas, Hezbollah in Lebanon, Iran and other Arab terroristsâ€™ groups, may directly affect our business. Â As of today, there has been no material impact on our operations.Â According to the recent guidelines of the Israeli government, the Companyâ€™s offices in Haifa are open and functioning, however, if a war will escalate and expand, this situation may change and the Israeli government may impose certain restrictions on movement and travel, which will affect our management and employeesâ€™ ability to effectively perform their daily tasks, and may result in disruptions and delays in some of our projects. Â Any hostilities involving Israel, terrorist activities, political instability or violence in the region, or the interruption or curtailment of trade or transport between Israel and its trading partners could make it more difficult for us to raise capital, if needed in the future, and adversely affect our operations and results of operations and the market price of our common shares. In addition, to the extent the IIA no longer makes grants similar to those we have received in the past, it could adversely affect our financial results. Â 26 Â Â Furthermore, certain of our employees may be obligated to perform annual reserve duty in the Israel Defense Forces and are subject to being called up for active military duty at any time. Many Israeli citizens who have served in the army are required to perform reserve duty until they reach the age of 40 or older, depending upon the nature of their military service. Currently, one of our employees have been called up for active military duty. Â Warâ€™s implications, including but not only warâ€™s economic implications, on the Companyâ€™s business and operations and on Israelâ€™s economy in general is difficult to predict. Such events may be intertwined with wider macroeconomic indications of a deterioration of Israelâ€™s economic standing, for instance, a downgrade in Israelâ€™s credit rating by rating agencies, which may have a material adverse effect on the Company and its ability to effectively conduct its operations. Â In addition, Israeli-based companies and companies doing business with Israel, have been the subject of an economic boycott by members of the Arab League and certain other predominantly Muslim countries since Israelâ€™s establishment. Although Israel has entered into various agreements with certain Arab countries and the Palestinian Authority, and various declarations have been signed in connection with efforts to resolve some of the economic and political problems in the Middle East, we cannot predict whether or in what manner these problems will be resolved. Wars and acts of terrorism have resulted in significant damage to the Israeli economy, including reducing the level of foreign and local investment. Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Â During the second quarter of fiscal year 2025, we issued an aggregate of 5,071 restricted common shares to certain of our service providers as compensation in lieu of cash compensation owed to them for services rendered. Â We claimed exemption from registration under the Securities Act, for the foregoing transactions under SectionÂ 4(a)(2)Â of the Securities Act. Â 27 Â Â Item 6. Â Exhibits. Â Â Â 3.1 Â Composite Copy of the Companyâ€™s Articles of Incorporation as amended on March 27, 2024 (incorporated by reference to Exhibit 3.3 of our quarterly report on Form 10-Q filed on May 9, 2024). Â Â Â 3.2 Â Amended and Restated By-Laws amended on September 10, 2020 (incorporated by reference to Exhibit 3.3 of our annual report on Form 10-K filed on September 10, 2020). Certificate of Correction to the Certificate of Change, as filed by Pluri Inc. with theÂ Secretary of State of the State of Nevada on March 28, 2024 (incorporated by reference to Exhibit 3.2 of our current report on Form 8-K filed on April 1, 2024). Â Â Â 3.3 Â Articles of Merger between Pluristem Therapeutics Inc. and Pluri Inc. (incorporated by reference to Exhibit 3.1 of our current report on Form 8-K filed on July 25, 2022). Â Â Â 3.4 Â Certificate of Change Pursuant to Nevada Revised Statutes Section 78.209, as filed by Pluri Inc. with the Secretary of State of the State of Nevada on March 27, 2024 (incorporated by reference to Exhibit 3.1 of our current report on Form 8-K filed on April 1, 2024) Â Â Â 3.5 Â Certificate of Correction to the Certificate of Change, as filed by Pluri Inc. with the Secretary of State of the State of Nevada on March 28, 2024 (incorporated by reference to Exhibit 3.2 of our current report on Form 8-K filed on April 1, 2024). Â Â Â 4.1 Â Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of our current report on Form 8-K filed on January 29, 2025). Â Â Â 4.2 Â Form of Warrant (incorporated by reference to Exhibit 4.2 of our current report on Form 8-K filed on January 29, 2025). Â Â Â 4.3 Â Form of Warrant (incorporated by reference to Exhibit 4.1 of our current report on Form 8-K filed on February 6, 2025). Â Â Â 10.1 Â Securities Purchase Agreement, dated January 23, 2025, between the Company and the purchaser identified thereto (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on January 29, 2025). Â Â Â 10.2 Â Securities Purchase Agreement, dated February 3, 2025, between the Company and the purchaser identified thereto (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on February 6, 2025). Â Â Â 10.3 Â Binding Term Sheet, dated January 23, 2025, between the Company, Chutzpah Holdings Ltd. and Plantae Ltd. (incorporated by reference to Exhibit 10.2 of our current report on Form 8-K filed on January 29, 2025). Â Â Â 10.4* Â Form of RSU and options waiver letter agreement. Â Â Â 31.1* Â Rule 13a-14(a) Certification of Chief Executive Officer. Â Â Â 31.2* Â Rule 13a-14(a) Certification of Chief Financial Officer. Â Â Â 32.1** Â Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350. Â Â Â 32.2** Â Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350. Â Â Â 101* Â The following materials from our Quarterly Report on FormÂ 10-Q for the quarter ended December 31, 2024 formatted in inline XBRL (eXtensible Business Reporting Language): (i)Â the Interim Condensed Consolidated Balance Sheets, (ii)Â the Interim Condensed Consolidated Statements of Operations, (iii) the Interim Condensed Statements of Changes in Shareholdersâ€™ Equity, (iv) the Interim Condensed Consolidated Statements of Cash Flows, and (vi) theÂ Notes to Interim Condensed Consolidated Financial Statements, tagged as blocks of text and in detail. Â Â Â 104* Â Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101). Â * Filed herewith. Â ** Furnished herewith. Â 28 Â Â SIGNATURES Â In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â PLURIÂ INC. Â Â Â By: /s/ Yaky Yanay Â Â Yaky Yanay, Chief Executive Officer and President Â (Principal Executive Officer) Â Â Â Date:Â February 11, 2025 Â Â Â Â By: /s/ Liat Zalts Â Â Liat Zalts, Chief Financial Officer Â Â (Principal Financial Officer and Principal Accounting Officer) Â Â Â Date:Â February 11, 2025 Â Â Â 29 Â Â 011 972-74-7108600 0001158780 false 2025 Q2 --06-30

0001158780 2024-07-01 2024-12-31 0001158780 2025-02-10 0001158780 2024-12-31 0001158780 2024-06-30 0001158780 2023-07-01 2023-12-31 0001158780 2024-10-01 2024-12-31 0001158780 2023-10-01 2023-12-31 0001158780 us-gaap:CommonStockMember 2023-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001158780 us-gaap:RetainedEarningsMember 2023-06-30 0001158780 us-gaap:ParentMember 2023-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2023-06-30 0001158780 2023-06-30 0001158780 us-gaap:CommonStockMember 2023-07-01 2023-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-12-31 0001158780 us-gaap:RetainedEarningsMember 2023-07-01 2023-12-31 0001158780 us-gaap:ParentMember 2023-07-01 2023-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-12-31 0001158780 us-gaap:CommonStockMember 2023-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001158780 us-gaap:RetainedEarningsMember 2023-12-31 0001158780 us-gaap:ParentMember 2023-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2023-12-31 0001158780 2023-12-31 0001158780 us-gaap:CommonStockMember 2023-09-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001158780 us-gaap:RetainedEarningsMember 2023-09-30 0001158780 us-gaap:ParentMember 2023-09-30 0001158780 us-gaap:NoncontrollingInterestMember 2023-09-30 0001158780 2023-09-30 0001158780 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001158780 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001158780 us-gaap:ParentMember 2023-10-01 2023-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2023-10-01 2023-12-31 0001158780 us-gaap:CommonStockMember 2024-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001158780 us-gaap:RetainedEarningsMember 2024-06-30 0001158780 us-gaap:ParentMember 2024-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2024-06-30 0001158780 us-gaap:CommonStockMember 2024-07-01 2024-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-12-31 0001158780 us-gaap:RetainedEarningsMember 2024-07-01 2024-12-31 0001158780 us-gaap:ParentMember 2024-07-01 2024-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-12-31 0001158780 us-gaap:CommonStockMember 2024-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001158780 us-gaap:RetainedEarningsMember 2024-12-31 0001158780 us-gaap:ParentMember 2024-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2024-12-31 0001158780 us-gaap:CommonStockMember 2024-09-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001158780 us-gaap:RetainedEarningsMember 2024-09-30 0001158780 us-gaap:ParentMember 2024-09-30 0001158780 us-gaap:NoncontrollingInterestMember 2024-09-30 0001158780 2024-09-30 0001158780 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001158780 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001158780 us-gaap:ParentMember 2024-10-01 2024-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2024-10-01 2024-12-31 0001158780 plur:FinanceContractWithEIBMember 2020-04-30 0001158780 plur:FinanceContractWithEIBMember 2020-04-30 2020-04-30 0001158780 plur:FinanceContractWithEIBMember 2024-10-01 2024-12-31 0001158780 2017-04-30 2017-04-30 0001158780 2022-08-04 0001158780 2017-09-30 2017-09-30 0001158780 2017-09-30 0001158780 2024-10-31 0001158780 2024-10-31 2024-10-31 0001158780 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-04-30 0001158780 2020-04-30 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-07-01 2024-12-31 0001158780 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-07-01 2024-12-31 0001158780 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-07-01 2024-12-31 0001158780 srt:MinimumMember plur:RoyaltiesMember 2024-12-31 0001158780 srt:MaximumMember plur:RoyaltiesMember 2024-12-31 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-06-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-06-30 2021-06-30 0001158780 plur:AnnualInterestMember 2021-06-30 0001158780 plur:LoanFromEIBMember 2024-07-01 2024-12-31 0001158780 2024-03-01 2024-03-31 0001158780 2023-02-13 2023-02-13 0001158780 plur:SalesAgreementMember 2024-07-01 2024-12-31 0001158780 srt:ScenarioForecastMember 2027-03-31 2027-03-31 0001158780 us-gaap:StockOptionMember 2024-12-31 0001158780 srt:ScenarioForecastMember us-gaap:RestrictedStockUnitsRSUMember 2027-09-30 0001158780 plur:NonEmployeeMember 2024-07-01 2024-12-31 0001158780 2024-11-25 2024-11-25 0001158780 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-06-30 0001158780 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-07-01 2024-12-31 0001158780 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-12-31 0001158780 plur:CEOAndDirectorsMember 2024-06-30 0001158780 plur:CEOAndDirectorsMember 2024-07-01 2024-12-31 0001158780 plur:CEOAndDirectorsMember 2024-12-31 0001158780 plur:UnvestedRSUsGrantedToEmployeesAndDirectorsMember 2024-06-30 0001158780 plur:UnvestedRSUsGrantedToEmployeesAndDirectorsMember 2024-07-01 2024-12-31 0001158780 plur:UnvestedRSUsGrantedToEmployeesAndDirectorsMember 2024-12-31 0001158780 plur:UnvestedRSUsAndRSGrantedToNonEmployeeMember 2024-06-30 0001158780 plur:UnvestedRSUsAndRSGrantedToNonEmployeeMember 2024-07-01 2024-12-31 0001158780 plur:UnvestedRSUsAndRSGrantedToNonEmployeeMember 2024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-10-01 2024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-10-01 2023-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-10-01 2024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-10-01 2023-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember 2024-07-01 2024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember 2023-07-01 2023-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember 2024-10-01 2024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember 2023-10-01 2023-12-31 0001158780 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2025-01-23 2025-01-23 0001158780 plur:PrefundedWarrantMember us-gaap:SubsequentEventMember 2025-01-23 2025-01-23 0001158780 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2025-01-23 2025-01-23 0001158780 us-gaap:SubsequentEventMember 2025-01-23 0001158780 plur:PrefundedWarrantMember us-gaap:SubsequentEventMember 2025-01-23 0001158780 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2025-01-23 0001158780 plur:OwnershipMember us-gaap:SubsequentEventMember 2025-01-23 0001158780 us-gaap:SubsequentEventMember 2025-02-05 2025-02-05 0001158780 plur:KokomodoLtdMember us-gaap:SubsequentEventMember 2025-01-23 2025-01-23 0001158780 plur:KokomodoLtdMember 2024-12-31 0001158780 plur:KokomodoLtdMember 2024-07-01 2024-12-31 0001158780 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2025-02-03 2025-02-03 0001158780 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2025-02-03 2025-02-03 0001158780 us-gaap:SubsequentEventMember 2025-02-03 0001158780 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2025-02-03 0001158780 us-gaap:SubsequentEventMember 2025-02-03 2025-02-03 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:EUR xbrli:pure iso4217:ILS EX-10.4 2 ea022981601ex10-4_pluri.htm FORM OF RSU AND OPTIONS WAIVER LETTER AGREEMENT Exhibit 10.4 Â Â Form of RSU and Options Waiver Letter Agreement Â January [__], 2025 Â [Mr./ Mrs. ___] [Address] Â Re:RSU Vesting Acceleration Waiver Â On [_] [and on [_]], Pluri Inc. (the â€œCompanyâ€) issued you a restricted stock unit representing [_] of the Companyâ€™s common shares (the â€œRSUsâ€). [On [_] [and on [_]], Pluri Inc. (the â€œCompanyâ€) granted you an option representing [_] of the Companyâ€™s common shares (the â€œOptions)]. As of the date of this letter, [_] RSUs remain unvested and shall vest

according to the following schedule: [_] of RSUS shall vest on [_], and [_] of RSUs shall vest on [_] (the â€œUnvested RSUsâ€). Â This letter agreement shall confirm that both you and the Company agree to waive, on a one-time basis, the 100% vesting acceleration of the Unvested RSUs as a result of a private placement offering of the Company which closed on February 5, 2025. Â This letter agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a â€œ.pdfâ€ format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or â€œ.pdfâ€ signature page were an original thereof. Â Â Sincerely, Â Â Â Â PLURI INC. Â Â Â Â By: Â Name:Â Liat Zalts Â Title: Chief Financial Officer Â Agreed and accepted on this __ day of January, 2025 Â By: Â Â Name:Â [_] Â Â EX-31.1 3 ea022981601ex31-1_pluri.htm CERTIFICATION Exhibit 31.1 Â CERTIFICATION Â I, Yaky Yanay, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of Pluri Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: February 11, 2025 Â /a/ Yaky Yanay Â Yaky Yanay Â Chief Executive Officer and President Â (Principal Executive Officer) Â Â EX-31.2 4 ea022981601ex31-2_pluri.htm CERTIFICATION Exhibit 31.2 Â CERTIFICATION Â I, Liat Zalts, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of Pluri Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: February 11, 2025 Â /s/ Liat Zalts Â Liat Zalts Â Chief Financial Officer Â (Principal Financial and Accounting Officer) Â Â Â EX-32.1 5 ea022981601ex32-1_pluri.htm CERTIFICATION Exhibit 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Â In connection with the Quarterly Report on Form 10-Q of Pluri Inc., or the Company, for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Yaky Yanay, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. ss. 1350, that, to my knowledge: Â (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Dated: February 11, 2025 Â /s/ Yaky Yanay Â Yaky Yanay Â Chief Executive Officer and President Â (Principal Executive Officer) Â Â EX-32.2 6 ea022981601ex32-2_pluri.htm CERTIFICATION Exhibit 32.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Â In connection with the Quarterly Report on Form 10-Q of Pluri Inc., or the Company, for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Liat Zalts, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, that, to my knowledge: Â (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Dated: February 11, 2025 Â /s/ Liat Zalts Â Liat Zalts Â Chief Financial Officer Â (Principal Financial and Accounting Officer) Â Â GRAPHIC 7 ex10-4_001.jpg GRAPHIC begin 644 ex10-4_001.jpg
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
...

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plur-20241231.xsd XBRL SCHEMA FILE 995301 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Interim Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Interim Condensed Statements of Changes in Shareholdersâ€™ Equity (Deficit) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995306 - Disclosure - General link:presentationLink link:definitionLink link:calculationLink 995307 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Loan from the EIB link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Total Financial Income, Net link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Total Financial Income, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - General (Details) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Loan from the EIB (Details) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Shareholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Shareholders' Equity - Schedule of Share Options Granted to Non-employee (Details) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Shareholders' Equity - Schedule of Activity Related to Unvested RSUs Granted (Details) link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Shareholders' Equity - Schedule of Expenses Related to RSUs Granted (Details) link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Total Financial Income, Net - Schedule of Total Financial Income, Net (Details) link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 plur-20241231_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 plur-20241231_def.xml XBRL DEFINITION FILE EX-101.LAB 11 plur-20241231_lab.xml XBRL LABEL FILE Total current assets Total long-term assets Total assets Total current liabilities Total long-term liabilities Total shareholdersâ€™ equity (deficit) Total shareholdersâ€™ equity deficit Total equity (deficit) Balance Balance Total liabilities and equity Gross profit Research and development expenses, net Operating loss Total financial income, net Total Net loss Net loss Incurred losses Net loss attributed to shareholders Balance (in Shares) Balance (in Shares) Common shares, outstanding Equity Components [Axis] Net cash used for operating activities Cash flow from operating activities Net cash provided by investing activities Increase in cash, cash equivalents, restricted cash and restricted bank deposits Cash, cash equivalents, restricted cash and restricted bank deposits at the beginning of the period Cash, cash equivalents, restricted cash and restricted bank deposits at the end of the period General [Abstract] Significant Accounting Policies [Abstract] Commitments and Contingencies [Abstract] Loan from the EIB [Abstract] Shareholders' Equity [Abstract] Share options outstanding at beginning of period number Share options outstanding at end of the period number Share options outstanding at beginning of period weighted average exercise price Share options outstanding at end of the period weighted average exercise price Share options outstanding at beginning of period Aggregate intrinsic value price Share options outstanding at end of the period Aggregate intrinsic value price Share options exercisable at the end of the period number Share options exercisable at the end of the period weighted average exercise price Share options vested and expected to vest at the end of the period Number Expected to vest after the end of the period, Number Share options vested and expected to vest at the end of the period Aggregate intrinsic value price Title and Position [Axis] Unvested at the beginning of the period, Number Unvested at the end of the period, Number Statement of Income Location, Balance [Axis] Total Financial Income, Net [Abstract] Schedule of Total Financial Income, Net [Abstract] Other Financial income, net Subsequent Events [Abstract] ASSETS CURRENT ASSETS: Cash and cash equivalents Short-term bank deposits Restricted cash Customer receivables Prepaid expenses and other current assets LONG-TERM ASSETS: Restricted bank deposits Severance pay fund Property and equipment, net Operating lease right-of-use asset Other long-term assets LIABILITIES AND SHAREHOLDERSâ€™ EQUITY (DEFICIT) CURRENT LIABILITIES Trade payables Accrued expenses Operating lease liability Accrued vacation and recuperation Other accounts payable LONG-TERM LIABILITIES Accrued severance pay Operating lease liability Loan from the European Investment Bank, or EIB COMMITMENTS AND CONTINGENCIES SHAREHOLDERSâ€™ EQUITY (DEFICIT) Share capital: Common shares, $0.00001 par value per share: Authorized: 37,500,000 as of December 31, 2024, and June 30, 2024; Issued and outstanding: 5,565,449 and 5,408,212 shares as of December 31, 2024, and June 30, 2024, respectively Common shares, par value per share (in Dollars per share) Common shares, authorized Common shares, issued Additional paid-in capital Accumulated deficit Non-controlling interests Revenues Operating expenses: Less: participation by the National Institute of Allergy and Infectious Diseases, or NIAID, the Israeli Innovation Authority, or IIA, Horizon Europe and other parties Other financial income, net Net loss attributed to non-controlling interest Loss per share: Basic net loss per share (in Dollars per share) Diluted loss per share (in Dollars per share) Weighted average number of shares used in computing basic net loss per share (in Shares) Weighted average number of shares used in computing diluted loss per share (in Shares) Share-based compensation to employees, directors, and non-employee consultants Share-based compensation to employees, directors, and non-employee consultants (in Shares) CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile loss to net cash used in operating activities: Depreciation Share-based compensation to employees, directors and non-employee consultants Increase (decrease) in trade payables Decrease in other accounts payable, accrued vacation and recuperation and accrued expenses Effect of exchange rate changes on cash, cash equivalents, deposits and restricted cash Increase (decrease) in long-term interest payable and exchange rate differences related to the EIB loan, net Accrued severance pay, net CASH FLOWS FROM INVESTING ACTIVITIES: EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS and restricted cash Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets: Cash and cash equivalents Long-term restricted bank deposits (a) Supplemental disclosure of non-cash activities: Purchase of property and equipment on credit Lease liabilities arising from obtaining right-of-use assets Cost of revenues Research and development expenses General and administrative expenses Interest expenses EIB loan interest expenses Decrease (increase) in customer receivable Decrease (increase) in prepaid expenses and other current assets and other long-term assets Decrease (increase) in operating lease right-of-use asset and liability, net Increase in interest receivable on short-term deposits Purchase of property and equipment Proceeds from withdrawal of short-term deposits, net Common Shares Additional Paid-in Capital Accumulated Deficit Total Shareholdersâ€™ Equity Non- controlling Interests GENERAL SIGNIFICANT ACCOUNTING POLICIES COMMITMENTS AND CONTINGENCIES LOAN FROM THE EIB SHAREHOLDERSâ€™ EQUITY Schedule of Share Options Granted to Non-employee Share options outstanding at beginning of period weighted average remaining contractual terms (in years) Share options outstanding at end of the period weighted average remaining contractual terms (in years) Share options exercisable at the end of the period weighted average remaining contractual terms (in years) Share options exercisable at the end of the period Aggregate intrinsic value price Share options unvested Number Share options unvested Weighted average exercise price Share options unvested Weighted average remaining contractual terms (in years) Share options unvested Aggregate intrinsic value price Share options vested and expected to vest at the end of the period Weighted average exercise price Share options vested and expected to vest at the end of the period Weighted average remaining contractual terms (in years) Schedule of Activity Related to Unvested RSUs Granted Granted, Number Schedule of Expenses Related to RSUs Granted Compensation expenses TOTAL FINANCIAL INCOME, NET Schedule of Total Financial Income, Net Foreign currency translation differences, net Interest income on deposits and restricted bank deposits Income from hedging derivatives SUBSEQUENT EVENTS Forfeited, Number Vested, Number Non-Employee [Member] CEO and Directors [Member] Unvested RSUs Granted to Employees and Directors [Member] Unvested RSUs and RS Granted to Non-Employee [Member] RSUs Granted to Employees and Directors [Member] Research and development expenses [Member] General and administrative expenses [Member] Credit Facility [Axis] Vesting [Axis] Statistical Measurement [Axis] Debt Instrument [Axis] Sale of Stock [Axis] Scenario [Axis] Derivative Instrument [Axis] Subsequent Event Type [Axis] Class of Warrant or Right [Axis] Investment, Name [Axis] Related and Nonrelated Parties [Axis] Cash and cash equivalents Loan amount (in Euro) Subsidiary obtain loan amount (in Euro) Percentage of annual interest rate Balance of principal and interest accrued Cash and restricted cash Percentage of qualified expenditures eligible for grant Royalty rate Royalty payable based on grants received Contingent liability in respect to royalties Marketing and business development activities Royalties revenues percentage Spread period Aggregate royalty amount Lease term Terminate lease term Extend lease term Lease payment term Lease payment Lease payments, percentage Finance contract period Annual interest rate Percentage of deferred interest rate Percentage of fixed interest rate Consolidated revenues percentage Accrued royalty (in Dollars) Finance contract (in Euro) Due date Annual interest percentage Principal balance (in Dollars) Interest accrued (in Dollars) Reverse share split issued and outstanding shares (in Shares) Aggregate offering price Sale of stock issued (in Shares) Sale of stock price per share (in Dollars per share) Unamortized compensation expenses Aggregate intrinsic value of these options Weighted average grant date fair value (in Dollars per share) Unamortized compensation expense Shareholdersâ€™ equity Net Income Purchase of common shares (in Shares) Warrant to purchase common shares Warrant exercise price (in Dollars per share) Ownership percentage Common shares issued percentage Common shares outstanding percentage Gross proceeds second offering Shares percentage Aggregate purchase price Liabilities Purchase amount Pre-money valuation Additional share price Discount price of share Warrant term Unaudited Interim Financial Information Significant Accounting Policies Use of estimates Fair value of financial instruments Recently issued accounting pronouncements, not yet adopted Finance Contract with EIB [Member] First Tranche [Member] Two Tranche [Member] Three Tranche [Member] Minimum [Member] Royalties [Member] Maximum [Member] Annual Interest [Member] Loan From EIB [Member] Sales Agreement [Member] Forecast [Member] Stock Option [Member] Restricted Stock Units (RSUs) [Member] Non-Employee [Member] Subsequent Event [Member] Private Placement [Member] Pre-Funded Warrants [Member] Warrant [Member] Beneficial ownership [Member] Kokomodo Ltd [Member] Equity Component [Domain] Statement [Table] Statement [Line Items] Title and Position [Domain] Shareholders' Equity - Schedule of Share Options Granted to Non-employee (Details) [Table] Schedule of Share Options Granted to Non-employee [Line Items] Shareholders' Equity - Schedule of Activity Related to Unvested RSUs Granted (Details) [Table] Schedule of Activity Related to Unvested RSUs Granted [Line Items] Statement of Income Location, Balance [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of Expenses Related to RSUs Granted [Line Items] Credit Facility [Domain] General (Details) [Table] General [Line Items] Vesting [Domain] Statistical Measurement [Domain] Debt Instrument, Name [Domain] Loan from the EIB (Details) [Table] Loan from the EIB [Line Items] Sale of Stock [Domain] Scenario [Domain] Award Type [Domain] Derivative Contract [Domain] Shareholders' Equity (Details) [Table] Shareholders'' Equity [Line Items] Subsequent Event Type [Domain] Investment, Name [Domain] Related and Nonrelated Parties [Domain] Class of Warrant or Right [Domain] Subsequent Events (Details) [Table] Subsequent Events [Line Items] Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Additional Share price Aggregate purchase price . Common shares issued (percentage) Common shares Outstanding (percentage) The amount of contingent liability in respect to royalties. Contractual interest rate for funds borrowed, under the loan agreement. Percentage of deferred interest rate. It represents Discount price per share. Due date. Extend lease term. Finance contract period. Percentage of fixed interest rate. It represents Gross Proceeds. Lease payment. Lease payments perventage. Net income. It represents Number of shares (percentage). Percentage Of Qualified Expenditures. Pre-money valuation. Represents the amount of research and development expenses. The amount of participation by the National Institute of Allergy and Infectious Diseases, or NIAID, the Israeli Innovation Authority, or IIA, Horizon Europe and other parties. Royalty payable based on grants received. Royalty rate payable calculated as a percentage of the sale of products and other related revenues generated from such projects. Weighted Average Remaining Contractual Terms, Share options outstanding. Share options unvested Weighted average remaining contractual terms. Share options unvested Aggregate intrinsic value price. Terminate lease term. Unamortized compensation expenses. Tabular disclosure of unaudited interim financial information. Use of Estimates, Policy [Policy Text Block] Assets [Abstract] Commitments and Contingencies Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Restricted Cash, Current Common Stock, Value, Issued Proceeds from Issuance of Warrants Earnings Per Share, Diluted Liabilities, Noncurrent [Abstract] Retained Earnings [Member] Net Income Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Noncontrolling Interest [Member] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Operating Lease, Payments Weighted Average Number of Shares Outstanding, Basic Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Non Employee Member Research And Development Expenses Increase (Decrease) in Prepaid Expense and Other Assets Prefunded Warrant Member Restricted Cash, Noncurrent Terminate Lease Term Other Nonoperating Income (Expense) Accrued Vacations Current Common Shares Outstandingpercentage Statement of Stockholders' Equity [Abstract] Basis of Accounting, Policy [Policy Text Block] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Marketing And Business Development Activities Stock Issued During Period, Shares, Stock Splits Research and Development Expense [Member] Discount Price Per Share Interest Income, Deposits with Financial Institutions Income Statement [Abstract] Royalties Revenues Percentage Gain (Loss) on Foreign Currency Fair Value Hedge Derivatives Number Of Sharespercentage New Accounting Pronouncements, Policy [Policy Text Block] Gross Proceeds Assets, Noncurrent Cash, Cash Equivalents, and Short-Term Investments Unvested RSUs And RSGranted To Non Employee Member Other Assets, Noncurrent Contingent Liability In Respect To Royalties Additional Paid in Capital Operating Expenses [Abstract] Earnings Per Share, Basic Liabilities, Noncurrent Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Cash Provided by (Used in) Operating Activities [Abstract] Premoney Valuation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Sharebased Compensation Arrangement By Sharebased Payment Award Option Unvested Weighted Average Remaining Contractual Term1 Assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Research and Development Expense Accounts Payable, Trade, Current Equity, Attributable to Parent [Abstract] Schedule of Other Nonoperating Income (Expense) [Table Text Block] Noncash or Part Noncash Acquisition, Fixed Assets Acquired Subsequent Events [Text Block] Schedule Of Share Options Granted To Non Employee Abstract Forecast [Member] Accrued Royalties Minimum [Member] Common Stock, Shares, Outstanding Increase (Decrease) in Accrued Interest Receivable, Net RSUs Granted To Employees And Directors Member Unamortized Compensation Expenses Unaudited Interim Financial Information Table Text Block Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Retained Earnings (Accumulated Deficit) Depreciation Net Cash Provided by (Used in) Investing Activities Percentage Of Qualified Expenditures Assets for Plan Benefits, Defined Benefit Plan Gain (Loss), Foreign Currency Transaction, before Tax Other Liabilities Other Operating Income (Expense), Net Payments to Acquire Property, Plant, and Equipment Additional Share Price Warrants and Rights Outstanding, Term Share-Based Compensation Arrangement by Share-Based Payment

Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Prepaid Expense and Other Assets, Current Property, Plant and Equipment, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Maximum [Member] Contractual Interest Rate For Funds Borrowed Royalty Rate Sales Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2 Common Stock, Shares Authorized Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Finance Contract Period Operating Lease, Liability, Noncurrent Interest Expense, Nonoperating Subsequent Event [Member] Warrant [Member] Unvested RSUs Granted To Employees And Directors Member Share-Based Payment Arrangement, Expense Aggregate Purchase Price Additional Paid-in Capital [Member] Extend Lease Term Sale of Stock, Consideration Received on Transaction Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Operating Income (Loss) Net Cash Provided by (Used in) Investing Activities [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Common Shares Issuedpercentage Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Increase (Decrease) in Obligation, Pension and Other Postretirement Benefits Significant Accounting Policies [Text Block] Royalty Rate Payable On Grants Received Investment Owned, Balance, Principal Amount Debt Instrument, Interest Rate, Stated Percentage Sale of Stock, Price Per Share Common Stock [Member] Restricted Cash Equivalents Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] Share-Based Payment Arrangement, Tranche Three [Member] Statement of Cash Flows [Abstract] Operating Lease, Liability, Current Deferred Interest Rate Percentage Ownership Member Equity Method Investment, Ownership Percentage Lease Payment Selling, General and Administrative Expenses [Member] Receivable from Customer in Brokerage Liabilities, Current [Abstract] Net Cash Provided by (Used in) Operating Activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Royalties Member Share-Based Payment Arrangement, Nonemployee [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Fixed Interest Rate Equity Option [Member] Lease Payments Perventage Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock Issued During Period, Shares, Other Fair Value of Financial Instruments, Policy [Policy Text Block] Supplemental Cash Flow Elements [Abstract] Equity, Attributable to Parent Loan From EIBMember Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Revenues Restricted Stock Units (RSUs) [Member] General and Administrative Expense Schedule Of Activity Related To Unvested Rsus Granted Abstract Earnings Per Share [Abstract] Common Stock, Par or Stated Value Per Share Parent [Member] Schedule Of Expenses Related To Rsus Granted Abstract Increase (Decrease) in Other Accounts Payable and Accrued Liabilities CEOAnd Directors Member Line of Credit Facility, Maximum Borrowing Capacity Common Stock, Shares, Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Finance Contract With EIBMember Debt Instrument, Increase, Accrued Interest Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Weighted Average Number of Shares Outstanding, Diluted Annual Interest Member Gross Profit Other Income and Other Expense Disclosure [Text Block] Increase (Decrease) in Interest Payable, Net Spread Period Net Income (Loss) Attributable to Noncontrolling Interest Share-Based Payment Arrangement, Tranche One [Member] Private Placement [Member] Accounts Payable, Other, Current Due Date Equity, Including Portion Attributable to Noncontrolling Interest Share-Based Payment Arrangement, Option, Activity [Table Text Block] Payments for (Proceeds from) Short-Term Investments Long-Term Debt [Text Block] Equity [Text Block] Debt Instrument, Face Amount Sale of Stock, Number of Shares Issued in Transaction Increase (Decrease) in Accounts and Other Receivables Assets, Current [Abstract] Postemployment Benefits Liability, Noncurrent Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Liabilities, Current Increase (Decrease) in Accounts Payable Payable, Investment, Purchase Restricted Cash and Cash Equivalents Statement of Financial Position [Abstract] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Line of Credit Facility, Interest Rate During Period Cash and Cash Equivalents, at Carrying Value Accrued Liabilities, Current Liabilities and Equity [Abstract] Share-Based Payment Arrangement, Tranche Two [Member] Commitments and Contingencies Disclosure [Text Block] Lessor, Operating Lease, Term of Contract Sales Agreement Member Cash Equivalents, at Carrying Value Cost of Revenue Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Line of Credit Facility, Increase, Accrued Interest Debt Instrument, Interest Rate, Effective Percentage Class of Warrant or Right, Exercise Price of Warrants or Rights Equity, Attributable to Noncontrolling Interest Other Long-Term Debt, Noncurrent Liabilities and Equity Nonoperating Income (Expense) Share-Based Payment Arrangement, Noncash Expense Kokomodo Ltd Member Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Royalty Guarantees, Commitments, Amount Stockholders' Equity, Other Deposits Assets, Current Assets, Noncurrent [Abstract] Research And Development Expenses And Other Parties Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Intrinsic Value1 Operating Lease, Right-of-Use Asset Assets, Current Increase (Decrease) in Other Operating Assets and Liabilities, Net EX-101.PRE 12 plur-20241231_pre.xml XBRL PRESENTATION FILE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1 Cover - shares 6 Months Ended Dec. 31, 2024 Feb. 10, 2025 Document Information [Line Items] Â Document Type 10-Q Â Document Quarterly Report true Â Document Transition Report false Â Entity Interactive Data Current Yes Â Amendment Flag false Â Document Period End Date Dec. 31, 2024 Â Document Fiscal Year Focus 2025 Â Document Fiscal Period Focus Q2 Â Entity Information [Line Items] Â Â Entity Registrant Name PLURI INC. Â Entity Central Index Key 0001158780 Â Entity File Number 001-31392 Â Entity Tax Identification Number 98-0351734 Â Entity Incorporation, State or Country Code NV Â Current Fiscal Year End Date --06-30 Â Entity Current Reporting Status Yes Â Entity Shell Company false Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Contact Personnel [Line Items] Â Â Entity Address, Address Line One MATAM Advanced Technology Park Â Entity Address, Address Line Two Building No. 5 Â Entity Address, City or Town Haifa Â Entity Address, Country IL Â Entity Address, Postal Zip Code 3508409 Â Entity Phone Fax Numbers [Line Items] Â Â City Area Code 011 Â Local Phone Number 972-74-7108600 Â Entity Listings [Line Items] Â Â Title of 12(b) Security Common Shares, par value $0.00001 Â Trading Symbol PLUR Â Security Exchange Name NASDAQ Â Entity Common Stock, Shares Outstanding Â 6,997,140 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionISO 3166-1 alpha-2 country code. + ReferencesNo definition available. + Details Name: dei_EntityAddressCountry Namespace Prefix: dei_ Data Type: dei:countryCodeItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityContactPersonnelLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityListingsLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityPhoneFaxNumbersLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type:

duration XML 15 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1 Interim Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands Dec. 31, 2024 Jun. 30, 2024 CURRENT ASSETS: Â Â Cash and cash equivalents $ 7,229 $ 6,783 Short-term bank deposits 14,084 23,202 Restricted cash 261 254 Customer receivables 140 34 Prepaid expenses and other current assets 656 834 Total current assets 22,370 31,107 LONG-TERM ASSETS: Â Â Restricted bank deposits 800 634 Severance pay fund 527 470 Property and equipment, net 911 688 Operating lease right-of-use asset 6,236 6,558 Other long-term assets 17 70 Total long-term assets 8,491 8,420 Total assets 30,861 39,527 CURRENT LIABILITIES Â Â Trade payables 1,165 964 Accrued expenses 841 1,223 Operating lease liability 595 559 Accrued vacation and recuperation 730 702 Other accounts payable 1,109 1,006 Total current liabilities 4,440 4,454 LONG-TERM LIABILITIES Â Â Accrued severance pay 637 605 Operating lease liability 4,903 5,026 Loan from the European Investment Bank, or EIB 23,798 24,027 Total long-term liabilities 29,338 29,658 COMMITMENTS AND CONTINGENCIES Â Share capital: Â Â Common shares, $0.00001 par value per share: Authorized: 37,500,000 as of December 31, 2024, and June 30, 2024; Issued and outstanding: 5,565,449 and 5,408,212 shares as of December 31, 2024, and June 30, 2024, respectively [1] Additional paid-in capital 421,282 420,568 Accumulated deficit (429,310) (420,472) Total shareholdersâ€™ equity (deficit) (8,028) 96 Non-controlling interests 5,111 5,319 Total equity (deficit) (2,917) 5,415 Total liabilities and equity $ 30,861 $ 39,527 [1] Less than $1 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. + ReferencesNo definition available. + Details Name: plur_AccruedVacationsCurrent Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableOtherCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccountsPayableTradeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards
Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher
FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards
Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher
FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards
Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards
Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsNoncurrent Namespace
Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract
Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or
financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily
convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents
within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -
Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -
Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-
1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType
Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements
that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a
company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events
that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification
-Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-
gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section
S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -
Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance
Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item
includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within
stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -
Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -
Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3:
http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:
credit Period Type: instant X - DefinitionAmount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans. +
ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-
03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting
Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -
Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section
S99 -Paragraph 1 -Subparagraph (SX 210.6-04(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -
Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2Reference 6:
http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480535/715-20-45-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -
Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security
purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter. + ReferencesReference 1:
http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher
FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositsAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance
Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1:
http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section
S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3:
http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -
Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5:
http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -
Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -
SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-
1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal
obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1:
http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -
Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -
Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4:
http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -
Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic
323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference
7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -
Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic
470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -
Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher
FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards
Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -
Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher
FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards
Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher
FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards
Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20:
http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -
Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_
Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-
gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. +
ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic
210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards
Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-
gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -
Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -
SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-
1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -
Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10
-Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9:
http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -
Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -
SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher
FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards
Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher
FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards
Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -

Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of long-term debt classified as other, payable after one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_OtherLongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFor a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 712 -SubTopic 10 -Name Accounting Standards Codification -Section 25 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481179/712-10-25-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 712 -SubTopic 10 -Name Accounting Standards Codification -Section 25 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481179/712-10-25-5 + Details Name: us-gaap_PostemploymentBenefitsLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount due from customers for fees and charges arising from transactions related to the entity's brokerage activities and operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 310 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-310/tableOfContent + Details Name: us-gaap_ReceivablesFromCustomers Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -

SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 16 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1 Interim Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares Dec. 31, 2024 Jun. 30, 2024 Statement of Financial Position [Abstract] Â Â Common shares, par value per share (in Dollars per share) [1] $ 0.00001 $ 0.00001 Common shares, authorized [1] 37,500,000 37,500,000 Common shares, issued [1] 5,565,449 5,408,212 Common shares, outstanding [1] 5,565,449 5,408,212 [1] Less than $1 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1 Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Income Statement [Abstract] Â Â Â Â Revenues $ 185 $ 105 $ 511 $ 159 Cost of revenues (74) Â (200) Gross profit 111 105 311 159 Operating expenses: Â Â Â Â Research and development expenses (3,170) (3,338) (6,562) (6,704) Less: participation by the National Institute of Allergy and Infectious Diseases, or NIAID, the Israeli Innovation Authority, or IIA, Horizon Europe and other parties 245 374 748 747 Research and development expenses, net (2,925) (2,964) (5,814) (5,957) General and administrative expenses (2,143) (2,354) (4,652) (4,792) Operating loss (4,957) (5,213) (10,155) (10,590) Other financial income, net 2,058 435 1,437 928 Interest expenses (211) (216) (428) (430) Total financial income, net 1,847 219 1,009 498 Net loss (3,110) (4,994) (9,146) (10,092) Net loss attributed to non-controlling interest (154) (89) (308) (226) Net loss attributed to shareholders $ (2,956) $ (4,905) $ (8,838) $ (9,866) Loss per share: Â Â Â Â Basic net loss per share (in Dollars per share) $ (0.53) $ (0.96) $ (1.61) $ (1.92) Diluted loss per share (in Dollars per share) $ (0.53) $ (0.96) $ (1.61) $ (1.92) Weighted average number of shares used in computing basic net loss per share (in Shares) [1] 5,552,931 5,190,853 5,505,915 5,178,555 Weighted average number of shares used in computing diluted loss per share (in Shares) [1] 5,552,931 5,190,853 5,505,915 5,178,555 [1] See note 5(1) regarding reverse share split X - DefinitionRepresents the amount of research and development expenses. + ReferencesNo definition available. + Details Name: plur_ResearchAndDevelopmentExpenses Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of participation by the National Institute of Allergy and Infectious Diseases, or NIAID, the Israeli Innovation Authority, or IIA, Horizon Europe and other parties. + ReferencesNo definition available. + Details Name: plur_ResearchAndDevelopmentExpensesAndOtherParties Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -

Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 18 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1 Interim Condensed Statements of Changes in Shareholdersâ€™ Equity (Deficit) (Unaudited) - USD ($) $ in Thousands Common Shares Additional Paid-in Capital Accumulated Deficit Total Shareholdersâ€™ Equity Non-controlling Interests Total Balance at Jun. 30, 2023 [1] $ 412,939 $ (399,584) $ 13,355 $ 1,945 $ 15,300 Balance (in Shares) at Jun. 30, 2023 [2] 5,155,687 Â Â Â Â Â Share-based compensation to employees, directors, and non-employee consultants [1] 910 910 499 1,409 Share-based compensation to employees, directors, and non-employee consultants (in Shares) [2] 54,316 Â Â Â Â Â Net loss (9,866) (9,866) (226) (10,092) Balance at Dec. 31, 2023 [1] 413,849 (409,450) 4,399 2,218 6,617 Balance (in Shares) at Dec. 31, 2023 [2] 5,210,003 Â Â Â Â Â Balance at Sep. 30, 2023 [1] 413,446 (404,545) 8,901 2,137 11,038 Balance (in Shares) at Sep. 30, 2023 [2] 5,181,066 Â Â Â Â Â Share-based compensation to employees, directors, and non-employee consultants [1] 403 403 170 573 Share-based compensation to employees, directors, and non-employee consultants (in Shares) [2] 28,937 Â Â Â Â Â Net loss (4,905) (4,905) (89) (4,994) Balance at Dec. 31, 2023 [1] 413,849 (409,450) 4,399 2,218 6,617 Balance (in Shares) at Dec. 31, 2023 [2] 5,210,003 Â Â Â Â Â Balance at Jun. 30, 2024 [1] 420,568 (420,472) 96 5,319 $ 5,415 Balance (in Shares) at Jun. 30, 2024 5,408,212 Â Â Â Â 5,408,212 [3] Share-based compensation to employees, directors, and non-employee consultants [1] 714 714 100 $ 814 Share-based compensation to employees, directors, and non-employee consultants (in Shares) 157,237 Â Â Â Â Net loss (8,838) (8,838) (308) (9,146) Balance at Dec. 31, 2024 [1] 421,282 (429,310) (8,028) 5,111 $ (2,917) Balance (in Shares) at Dec. 31, 2024 5,565,449 Â Â Â Â 5,565,449 [3] Balance at Sep. 30, 2024 421,071 (426,354) (5,283) 5,220 $ (63) Balance (in Shares) at Sep. 30, 2024 5,507,304 Â Â Â Â Share-based compensation to employees, directors, and non-employee consultants 211 211 45 256 Share-based compensation to employees, directors, and non-employee consultants (in Shares) 58,145 Â Â Â Â Net loss (2,956) (2,956) (154) (3,110) Balance at Dec. 31, 2024 [1] $ 421,282 $ (429,310) $ (8,028) $ 5,111 $ (2,917) Balance (in Shares) at Dec. 31, 2024 5,565,449 Â Â Â Â 5,565,449 [3] [1] Less than $1 [2] See note 5(1) regarding reverse share split [3] Less than $1 X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 19 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1 Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Net loss $ (9,146) $ (10,092) Adjustments to reconcile loss to net cash used in operating activities: Â Â Depreciation 133 131 Share-based compensation to employees, directors and non-employee consultants 814 1,409 Decrease (increase) in customer receivable (106) 94 Decrease (increase) in prepaid expenses and other current assets and other long-term assets 231 (393) Increase (decrease) in trade payables 164 (713) Decrease in other accounts payable, accrued vacation and recuperation and accrued expenses (251) (410) Decrease (increase) in operating lease right-of-use asset and liability, net 235 (25) Increase in interest receivable on short-term deposits (71) 3 Effect of exchange rate changes on cash, cash equivalents, deposits and restricted cash (441) (373) Increase (decrease) in long-term interest payable and exchange rate differences related to the EIB loan, net (229) 869 Accrued severance pay, net (25) (6) Net cash used for operating activities (8,692) (9,506) CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Purchase of property and equipment (320) (224) Proceeds from withdrawal of short-term deposits, net 9,550 9,945 Net cash provided by investing activities 9,230 9,721 EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS and restricted cash 81 15 Increase in cash, cash equivalents, restricted cash and restricted bank deposits 619 230 Cash, cash equivalents, restricted cash and restricted bank deposits at the beginning of the period 7,671 6,256 Cash, cash equivalents, restricted cash and restricted bank deposits at the end of the period 8,290 6,486 Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets: Â Â Cash and cash equivalents 7,229 5,468 Restricted cash 261 373 Long-term restricted bank deposits 800 645 (a) Supplemental disclosure of non-cash activities: Â Â Purchase of property and equipment on credit 41 80 Lease liabilities arising from obtaining right-of-use assets $ 32 $ 78 X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-

24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from borrowers for interest payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInterestPayableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for pension and other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9 + Details Name: us-gaap_PaymentsForProceedsFromShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1 General 6 Months Ended Dec. 31, 2024 General [Abstract] Â GENERAL NOTE 1: - GENERAL Â Â a. Pluri Inc. (formally known as Pluristem Therapeutics Inc.), a Nevada corporation, was incorporated on May 11, 2001. Pluri Inc.â€™s common shares trade on the Nasdaq Capital Market and Tel-Aviv Stock Exchange under the symbol â€œPLURâ€. Pluri Inc. has a wholly owned subsidiary, Pluri-Biotech Ltd. (formerly known as Pluristem Ltd.), or the Subsidiary, which is incorporated under the laws of the State of Israel. In January 2020, the Subsidiary established a wholly owned German Subsidiary, Pluristem GmbH, or the German Subsidiary which is incorporated under the laws of Germany. In January 2022, the Subsidiary established a new subsidiary, Ever After Foods Ltd., or Ever After Foods (formerly known as Plurinuva Ltd.). Ever After Foods is incorporated under the laws of Israel, which followed the execution of the collaboration agreement with Tnuva Food Industries â€“ Agricultural Co-Operative in Israel Ltd., through its fully owned subsidiary, Tnuva Food-Tech Incubator (2019), Limited Partnership, or Tnuva. In March 2024, the Subsidiary established a new wholly owned subsidiary, Coffeesai Ltd., or Coffeesai which is incorporated under the laws of Israel, to develop cultivated coffee. Pluri Inc., the Subsidiary, the German Subsidiary, Ever After Foods and Coffeesai are referred to as the â€œCompanyâ€ or â€œPluri.â€ The Subsidiary, the German Subsidiary, Coffeesai and Ever After Foods are referred to as the â€œSubsidiaries.â€ Â Â b. The Company is a bio-technology company with an advanced cell-based technology platform, which operates in one operating segment. The Company has developed a unique three-dimensional technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice cell manufacturing facility. Pluri currently uses its technology in the field of regenerative medicine, food technology and agricultural technology and launched a Contract Development and Manufacturing Organization, or CDMO, business and plans to utilize its technology in industries and verticals that have a need for a mass scale and cost-effective cell expansion platform. Pluri is focused on the research, development and manufacturing of cell-based products and the business development of cell therapeutics and cell-based technologies providing potential solutions for various industries. Â Â c. The Company has incurred an accumulated deficit of approximately $429,310 and incurred recurring operating losses and negative cash flows from operating activities since inception. As of December 31, 2024, the Companyâ€™s total shareholdersâ€™ deficit amounted to $8,028. During the six-month period ended December 31, 2024, the Company incurred losses of $9,146 and its negative cash flow from operating activities was $8,692. Â As of December 31, 2024, the Companyâ€™s cash balances (cash and cash equivalents, short-term bank deposits, restricted cash and restricted bank deposits) totaled $22,374. Â The Company plans to continue to finance its operations from its current resources, by entering into licensing or other commercial, partnerships and collaboration agreements, by providing CDMO services to clients, from grants and contracts to support its research and development activities and from sales of its equity securities (see note 7). Â The Companyâ€™s management believes that its current resources together with its existing operating plan are sufficient for the Company to meet its obligations as they come due at least for a period of twelve months from the date of the issuance of these interim unaudited condensed consolidated financial statements. During 2024, the Company also implemented a cost reduction and efficiency plan. There is no assurance, however, that the Company will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of its products. In the case the Company is unable to obtain the required level of financing, operations may need to be scaled down or discontinued. Â On April 30, 2020, the German Subsidiary entered into a finance contract, or the Finance Contract, with the EIB, pursuant to which the German Subsidiary obtained a loan in an amount of â‚¬20Â million, or the Loan. The amount received is due on June 1, 2026 and bears an annual interest ofÂ 4% to be paid with the principal of the Loan. The Company is currently in discussions with the EIB regarding a potential restructuring of the terms of the loan, however there is no certainty that such restructuring will be achieved. As of December 31, 2024, the linked principal and interest accrued balance was of $23,798 and is presented among long-term liabilities (see note 4). X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1 Significant Accounting Policies 6 Months Ended Dec. 31, 2024 Significant Accounting Policies [Abstract] Â SIGNIFICANT ACCOUNTING POLICIES NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES Â Â a. Unaudited Interim Financial Information Â The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to FormÂ 10-Q and ArticleÂ 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair statement have been included (consisting only of normal recurring adjustments). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Companyâ€™s Annual Report on FormÂ 10-K for the year ended June 30, 2024. The year-endÂ balance sheet data was derived from the audited consolidated financial statements as of June 30, 2024, but not all disclosures required by GAAP are included. Â Operating results for the six-month period ended December 31, 2024, are not necessarily indicative of the results that may be expected for the year ending JuneÂ 30, 2025. Â b. Significant Accounting Policies Â The significant accounting policies followed in the preparation of these interim unaudited condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements. Â Â c. Use of estimates Â The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments and assumptions that are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Â Â d. Fair value of financial instruments Â The carrying amounts of the Companyâ€™s financial instruments, including cash and cash equivalents, restricted cash, short-term bank deposits and restricted bank deposits and other current assets, trade payable and other accounts payable and accrued expenses, approximate their fair value because of their generally short-term maturities. Â The Company measures its derivative instruments at fair value under Accounting Standards Codification, or ASC 820; â€œFair Value Measurements and Disclosuresâ€, or ASC 820. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Â As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Â Â Levelâ€¯ 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities; Â Â Levelâ€¯ 2 - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and Â Â Level â€¯3 - Unobservable inputs for the asset or liability. Â The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy. Â The Company measures its liability pursuant to the Finance Contract based on the aggregate outstanding amount of the combined principal and accrued interest thereunder. As of December 31, 2024, the Company does not reflect its liability for future royalty payments pursuant to the Finance Contract with the EIB since the royalty payments are to be paid as a percentage of the Companyâ€™s future consolidated revenues, pro-rated to the amount disbursed, beginning in fiscal year 2024 and until fiscal year 2030 (see note 4). Â e. Recently issued accounting pronouncements, not yet adopted Â ASU No. 2023-07 - â€œSegment Reporting (Topic 280): Improvements to reportable segment disclosuresâ€, or ASU 2023-07: Â In November 2023, the Financial Accounting Standards Board, or FASB, issued ASU 2023-07. This guidance expands public entitiesâ€™ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reported measure of segment profit or loss, an amount and description of its composition of other segment items, and interim disclosures of a reportable segmentâ€™s profit or loss and assets. The guidance is effective for the fiscal year beginning after December 15, 2023, and interim periods within the fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â ASU No. 2023-09 - â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€, or ASU 2023-09: Â In December 2023, the FASB issued ASU 2023-09. This guidance is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investorsâ€™ requests for enhanced income tax information primarily through changes to the tax rate reconciliation and regarding income tax paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, on a prospective basis. Early adoption and retroactive application are permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â ASU 2024-03 - â€œIncome Statement: Reporting Comprehensive Income - Expense Disaggregation Disclosuresâ€, or ASU 2024-03: Â In November 2024, the FASB issued ASU 2024-03 - which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion), which are included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1 Commitments and Contingencies 6 Months Ended Dec. 31, 2024 Commitments and Contingencies [Abstract] Â COMMITMENTS AND CONTINGENCIES NOTE 3: - COMMITMENTS AND CONTINGENCIES Â Â a. As of December 31, 2024, an amount of $1,061 of cash and deposits was pledged by the Subsidiary and Ever After Foods to secure its credit line, lease agreement, derivative and hedging and bank guarantees. Â Â b. Under the Law for the Encouragement of Industrial Research and Development, 1984, or the Research Law, research and development programs that meet specified criteria and are approved by the IIA are eligible for grants of up toÂ 50% of the projectâ€™s expenditures, as determined by the research committee, in exchange for the payment of royalties from the sale of products developed under the program. Regulations under the Research Law generally provide for the payment of royalties to the IIA ofÂ 3% on sales of products and services derived from a technology developed using these grants untilÂ 100% of the U.S. dollar-linked grant is repaid. The Companyâ€™s obligation to pay these royalties is contingent on its actual sale of such products and services. In the absence of such sales, no payment is required. The outstanding balance of the grants will be subject to interest at a rate equal to the 12-month Secured Overnight Financing Rate, or SOFRÂ (before January 1, 2024, to the 12-month London Interbank Offered Rate, or LIBOR) applicable to U.S. dollar deposits that is published on the first business day of each calendar year. Following the full repayment of the grant, there is no further liability for royalties. Â As of December 31, 2024, the Companyâ€™s contingent liability in respect to royalties to the IIA amounted to $27,565, not including LIBOR (from January 1, 2024, SOFR) interest as described above. Â Â c. In April 2017, the Company was awarded a Smart Money grant of approximately $229Â from Israelâ€™s Ministry of Economy and Industry to facilitate certain marketing and business development activities with respect to its advanced cell therapy products in the Chinese market, including Hong Kong. The Israeli government granted the Company budget resources that are intended to be used to advance the Companyâ€™s product candidate towards marketing in the China-Hong Kong markets. The Company will also receive support from Israelâ€™s trade representatives stationed in China, including Hong Kong, along with experts appointed by the Smart Money program. As part of the program, the Company will repay royalties ofÂ 5% from the Companyâ€™s revenues in the region for a five-year period, beginning the year in which the Company will not be entitled to reimbursement of expenses under the program and will be spread for a period of up toÂ 5Â years or until the amount of the grant is fully paid. As of August 4, 2022, the grant from this Smart Money program received was approximately $180Â and the program has ended. To date, no royalties were paid or accrued. Â Â d. In September 2017, the Company signed an agreement with the Tel-Aviv Sourasky Medical Center, or Ichilov Hospital, to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease, or GVHD. As part of the agreement with Ichilov Hospital, the Company will pay royalties ofÂ 1% from its net sales of the PLX-PAD product relating to GVHD, with a maximum aggregate royalty amount of approximately $500. Â Â e. In October 2024, Ever After Foods signed a facility operating lease agreement with a lessor. The lease period, which has not yet begun, is expected for a term of five years. In addition, Ever After Foods has the option to terminate the lease after a period of 36 months and to extend the term of the lease for an additional period of five years, or the Extension Option. The average monthly lease payment for the first five years is approximately NIS 50,192 or $14, which is linked to the consumer price index. The monthly lease payments will increase by 5% in the event that Ever After Foods exercises its Extension Option. Â Â f. As to potential royalties to the EIB, see note 4. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R10.htm IDEA: XBRL DOCUMENT v3.25.0.1 Loan from the EIB 6 Months Ended Dec. 31, 2024 Loan from the EIB [Abstract] Â LOAN FROM THE EIB NOTE 4: - LOAN FROM THE EIB Â On April 30, 2020, the German Subsidiary entered into the Finance Contract with the EIB, pursuant to which the German Subsidiary can obtain a loan in the amount of up to â‚¬50 million, subject to certain milestones being reached, receivable in three tranches, with the first tranche consisting of â‚¬20 million, second tranche consisting of â‚¬18 million and third tranche consisting of â‚¬12 million for a period of 36 months from the signing of the Finance Contract. Â The tranches were treated independently, each with its own interest rate and maturity period. The annual interest rate is 4% (consisting of a 4% deferred interest rate payable upon maturity); for the first tranche, 4% (consisting of a 1% fixed interest rate and a 3% deferred interest rate payable upon maturity) for the second tranche and 3% (consisting of a 1% fixed interest rate and a 2% deferred interest rate payable upon maturity) for the third tranche. Â In addition to any interest payable on the loan, the EIB is entitled to receive royalties from future revenues for a period of seven years starting at the beginning of fiscal year 2024 and continuing up to and including its fiscal year 2030 in an amount equal to between 0.2% to 2.3% of the Companyâ€™s consolidated revenues, pro-rated to the amount disbursed from the Loan. As of December 31, 2024, Pluri had an accrued royalty in the amount of $5. Â During June 2021, Pluri received the first tranche in an amount of â‚¬20 million of the Finance Contract. The amount received is due on June 1, 2026, and bears annual interest of 4% to be paid with the principal of the Loan. As of December 31, 2024, the linked principal balance in the amount of $20,819 and the interest accrued in the amount of $2,979 are presented among long-term liabilities. Since the project period ended on December 31, 2022, the Company does not expect to receive additional funds pursuant to the Finance Contract. Â The Finance Contract also contains certain limitations such as the use of proceeds received from the EIB, limitations related to disposal of assets, substantive changes in the nature of the Companyâ€™s business, changes in holding structure, distributions of future potential dividends and engaging with other banks and financing entities for other loans. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1 Shareholders' Equity 6 Months Ended Dec. 31, 2024 Shareholders' Equity [Abstract] Â SHAREHOLDERSâ€™ EQUITY NOTE 5: - SHAREHOLDERSâ€™ EQUITY Â (1) Reverse share split Â In March 2024, the Companyâ€™s Board of Directors, or the Board, approved a 1-for-8 reverse share split of the Companyâ€™s (a) authorized common shares; and (b) issued and outstanding common shares. The reverse share split became effective on April 1, 2024. All common shares, options, warrants and securities convertible or exercisable into common shares, as well as loss per share, have been adjusted to give retroactive effect to this reverse share split for all periods presented. As a result of rounding-up fractional shares into whole shares as a result of the reverse share split, an additional 67,836 common shares were included in the Companyâ€™s issued and outstanding shares. Â (2) Pursuant to a registration statement on Form S-3 (File No. 333-273347), declared effective by the U.S Securities and Exchange Commission on September 21, 2023, on February 13, 2024 the Company entered into an Open Market Sales Agreement, or Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P., which provides that upon the terms and subject to the conditions and limitations in the Sales Agreement, the Company may elect, from time to time, to offer and sell common shares having an aggregate offering price of up to $10,000Â through A.G.P. acting as sales agent. As of December 31, 2024, the Company soldÂ 42,729Â common shares under the Sales Agreement at an average price of $5.93Â per share. Â (3) Share options and restricted share units, or RSUs to employees, directors and consultants: Â a. Options to non-employee consultants: Â A summary of the share options granted to non-employee consultants under its equity incentive plans, or the Plans, by Pluri Inc. and its Subsidiary is as follows: Â Â Â Six months ended December 31, 2024Â Â Â NumberÂ Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Â Aggregate intrinsic valueÂ priceÂ Share options outstanding at the beginning of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.87Â Â $42Â Share options outstanding at end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.37Â Â $19Â Share options exercisable at the end of the periodÂ Â 8,100Â Â $7.41Â Â Â 4.74Â Â $19Â Share options unvestedÂ Â 9,375Â Â $4.40Â Â Â 4.05Â Â $-Â Share options vested and expected to vest at the end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.37Â Â $19Â Â Unamortized compensation expenses related to options granted to non-employee consultants by Pluri Inc. and its Subsidiary are approximately $11 to be recognized by the end of March 2027. b. Options to the Chief Executive Officer, or CEO, and Director: Â A summary of the share options granted to the CEO and director under the Plans by Pluri Inc. and its Subsidiary is as follows: Â Â Â Six months ended December 31, 2024Â Â Â NumberÂ Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Share options outstanding at the beginning of the periodÂ Â 240,291Â Â $14.82Â Â Â 2.42Â Share options outstanding at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 1.91Â Share options vested and exercisable at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 1.91Â Â Â As of December 31, 2024, the aggregate intrinsic value of these options was $0. Â c. RSUs to employees and directors: Â Â The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and its Subsidiary, for the six-month period ended December 31, 2024: Â Â Â Six months ended DecemberÂ 31, 2024Â Â Â NumberÂ Unvested at the beginning of the periodÂ Â 353,134Â GrantedÂ Â 48,653Â ForfeitedÂ Â (13,938) VestedÂ Â (143,243) Unvested at the end of the periodÂ Â 244,606Â Expected to vest after the end of the periodÂ Â 223,496Â Â The fair value of all RSUs was determined based on the closing trading price of the Companyâ€™s shares known at the grant date. The weighted average grant date fair value of RSUs granted during the six-month period ended December 31, 2024 granted to employees and directors was $5.20Â per share. Â Unamortized compensation expenses related to RSUs granted to employees and directors by Pluri Inc. and its Subsidiary are approximately $439 to be recognized by the end of September 2027. d. RSUs and restricted shares, or RS to consultants: Â The following table summarizes the activity related to unvested RSUs and RS granted to non-employee consultants by Pluri Inc. and its Subsidiary for the six-month period ended December 31, 2024: Â Â Â Six months ended DecemberÂ 31,Â Â Â 2024Â Â Â NumberÂ Unvested at the beginning of the periodÂ Â 4,802Â GrantedÂ Â 12,138Â VestedÂ Â (13,994) Unvested at the end of the periodÂ Â 2,946Â Â The fair value of all RSUs was determined based on the closing trading price of the Companyâ€™s shares known at the grant date. The weighted average grant date fair value of RSUs granted during the six-month period ended December 31, 2024 granted to non-employee consultants was $5.47Â per share. Â Unamortized compensation expenses related to RSUs and RS granted consultants by Pluri Inc. and its Subsidiary are approximately $6 to be recognized by the end of June 2025. Â Compensation expenses related to RSUs granted by Pluri Inc. and its Subsidiary were recorded as follows: Â Â Â Six months ended December 31,Â Â Three months ended December 31,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Research and development expensesÂ $136Â Â $62Â Â $48Â Â $31Â General and administrative expensesÂ Â 570Â Â Â 634Â Â Â 159Â Â Â 278Â Â Â $706Â Â $696Â Â $207Â Â $309Â (4) Nasdaq Deficiency Letter: Â On November 25, 2024, the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500Â in shareholdersâ€™ equity for continued listing on The Nasdaq Capital Market, or the Shareholdersâ€™ Equity Requirement, nor was it in compliance with either of the alternative listing standards, market value of listed securities of at least $35,000Â or net income of $500Â from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. Â On January 6, 2025, the Company submitted a plan to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq has determined to grant the Company an extension of time to regain compliance with the Shareholdersâ€™ Equity Requirement until May 24, 2025. If the Company fails to evidence compliance by the required deadline, the Company may be subject to delisting. At that time, the Company may appeal Staffâ€™s determination to a Hearings Panel. Â The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance the Company will ultimately regain compliance with all applicable requirements for continued listing. Â Neither the Nasdaq Letter nor the Companyâ€™s noncompliance have an immediate effect on the listing or trading of the Companyâ€™s common shares, which will continue to trade on The Nasdaq Capital Market under the symbol â€œPLURâ€. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1 Total Financial Income, Net 6 Months Ended Dec. 31, 2024 Total Financial Income, Net [Abstract] Â TOTAL FINANCIAL INCOME, NET NOTE 6: - TOTAL FINANCIAL INCOME, NET Â Â Â Six months ended December 31,Â Â Three months ended December 31,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Foreign currency translation differences, netÂ $762Â Â $(68)Â $1,754Â Â $(128) Interest income on deposits and restricted bank depositsÂ Â 572Â Â Â 792Â Â Â 251Â Â Â 356Â Income from hedging derivativesÂ Â 103Â Â Â 204Â Â Â 53Â Â Â 207Â Other Financial income, netÂ Â 1,437Â Â Â 928Â Â Â 2,058Â Â Â 435Â EIB loan interest expensesÂ Â (428)Â Â (430)Â Â (211)Â Â (216) Â Â $1,009Â Â $498Â Â $1,847Â Â $219Â X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/720/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 610 -Publisher FASB -URI https://asc.fasb.org/610/tableOfContent + Details Name: us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1 Subsequent Events 6 Months Ended Dec. 31, 2024 Subsequent Events [Abstract] Â SUBSEQUENT EVENTS NOTE 7: - SUBSEQUENT EVENTS Â On January 23, 2025, the Company entered into a Securities Purchase Agreement, or the Securities Purchase Agreement, with Mr. Alejandro Weinstein, or the Investor, relating to a private placement offering, or the Offering, of: (i) 1,383,948 common shares of the Company, (ii) pre-funded warrants, or the Pre-Funded Warrants, to purchase up to 26,030 common shares, and (iii) warrants, or the Common Warrants, to purchase up to 84,599 common shares. The Offering price per share and accompanying warrant is $4.61. The Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable at any time following the receipt of certain approvals from the Companyâ€™s shareholders, or the Shareholder Approval, and until exercised in full. The Common Warrants have an exercise price of $5.568 per share, which will not be exercisable until the Company receives Shareholder Approval and will be exercisable for three years following the date of receipt of the Shareholder Approval. The Pre-Funded Warrants and Common Warrants contain customary anti-dilution provisions and are subject to a 19.99% beneficial ownership limitation until the Shareholder Approval is obtained. The Securities Purchase Agreement contains customary representations and warranties and agreements of the Company and the Investor and customary indemnification rights and obligations of the parties. Â Under the terms of the Securities Purchase Agreement, the Company appointed Mr. Weinstein, to the Board of Directors of the Company, or the Board, effective upon the closing of the Offering, and agreed to continue to recommend his election to its shareholders provided the Investor continues to hold at least 10% of the Companyâ€™s issued and outstanding Common Shares. Â The Offering closed on February 5, 2025, and the gross proceeds to the Company were $6.5 million. Â Concurrently with the Offering, on January 23, 2025, the Company and the Investor entered into a binding term sheet, or the Term Sheet, for the purchase of certain shares representing approximately 71% (on a fully diluted basis) of Kokomodo Ltd., or Kokomodo, for an aggregate purchase price of $4.5 million, payable in common shares, or the Kokomodo Transaction. The Kokomodo Transaction will be subject to, among other conditions, the approval by the Companyâ€™s shareholders. The Kokomodo Transaction is expected to close during the second quarter of 2025, (calendar year) following the approval of the Companyâ€™s shareholders. As of the date of this report, there is no guarantee when or if the Kokomodo Transaction will be completed. Â Pursuant to the Term Sheet, in case that the Kokomodo Transaction does not close, for any reason other than due to Investorâ€™s failure to perform its material undertakings and/or covenants as agreed under the definitive agreement, or due to any due diligence finding which the we are not currently aware of and that is likely to result in liabilities to us exceeding $0.5 million, then we shall: (a) purchase a certain portion of Investorâ€™s shares in Kokomodo for a purchase amount of $1 million (based on a $6 million pre-money valuation of Kokomodo, calculated prior to the investment described in (b)), and (b) invest an additional $0.5 million in Kokomodo under a under a Simple Agreement for Future Equity, or SAFE, providing a 20% discount of the price per share set in connection with a trigger event for conversion of the SAFE into equity of Kokomodo and a pre-money valuation cap of $5.5 million in connection with such round. Â On February 3, 2025, the Company entered into an additional securities purchase agreement, or the Additional Securities Purchase Agreement, with Merchant Adventure Fund L.P., an existing investor, of the Company, relating to a private placement offering, or the Second Offering, of: (i) 759,219 of the Companyâ€™s common shares, and (ii) warrants to purchase up to 45,553 common shares. The Second Offering price per share and accompanying warrant is $4.61. The Second Offering warrants have an exercise price of $5.568 per share and a term of three years, commencing on the date of issuance. The gross proceeds to the Company from the Second Offering are expected to be approximately $3.5 million. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (2,956) $ (4,905) $ (8,838) $ (9,866) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 28 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1 Insider Trading Arrangements 3 Months Ended Dec. 31, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1 Accounting Policies, by Policy (Policies) 6 Months Ended Dec. 31, 2024 Significant Accounting Policies [Abstract] Â Unaudited Interim Financial Information Â a. Unaudited Interim Financial Information The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to FormÂ 10-Q and ArticleÂ 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair statement have been included (consisting only of normal recurring adjustments). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Companyâ€™s Annual Report on FormÂ 10-K for the year ended June 30, 2024. The year-endÂ balance sheet data was derived from the audited consolidated financial statements as of June 30, 2024, but not all disclosures required by GAAP are included.Operating results for the six-month period ended December 31, 2024, are not necessarily indicative of the results that may be expected for the year ending JuneÂ 30, 2025. Significant Accounting Policies Â b. Significant Accounting Policies The significant accounting policies followed in the preparation of these interim unaudited condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements. Use of estimates Â c. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments and assumptions that are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Fair value of financial instruments Â d. Fair value of financial instruments The carrying amounts of the Companyâ€™s financial instruments, including cash and cash equivalents, restricted cash, short-term bank deposits and restricted bank deposits and other current assets, trade payable and other accounts payable and accrued expenses, approximate their fair value because of their generally short-term maturities.The Company measures its derivative instruments at fair value under Accounting Standards Codification, or ASC 820; â€œFair Value Measurements and Disclosuresâ€, or ASC 820. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Â Levelâ€¯ 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities; Â Levelâ€¯ 2 - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and Â Level â€¯3 - Unobservable inputs for the asset or liability. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy.The Company measures its liability pursuant to the Finance Contract based on the aggregate outstanding amount of the combined principal and accrued interest thereunder. As of December 31, 2024, the Company does not reflect its liability for future royalty payments pursuant to the Finance Contract with the EIB since the royalty payments are to be paid as a percentage of the Companyâ€™s future consolidated revenues, pro-rated to the amount disbursed, beginning in fiscal year 2024 and until fiscal year 2030 (see note 4). Recently issued accounting pronouncements, not yet adopted Â e. Recently issued accounting pronouncements, not yet adopted ASU No. 2023-07 - â€œSegment Reporting (Topic 280): Improvements to reportable segment disclosuresâ€, or ASU 2023-07:In November 2023, the Financial Accounting Standards Board, or FASB, issued ASU 2023-07. This guidance expands public entitiesâ€™ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reported measure of segment profit or loss, an amount and description of its composition of other segment items, and interim disclosures of a reportable segmentâ€™s profit or loss and assets. The guidance is effective for the fiscal year beginning after December 15, 2023, and interim periods within the fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.ASU No. 2023-09 - â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€, or ASU 2023-09:In December 2023, the FASB issued ASU 2023-09. This guidance is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investorsâ€™ requests for enhanced income tax information primarily through changes to the tax rate reconciliation and regarding income tax paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, on a prospective basis. Early adoption and retroactive application are permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.ASU 2024-03 - â€œIncome Statement: Reporting Comprehensive Income - Expense Disaggregation Disclosuresâ€, or ASU 2024-03:In November 2024, the FASB issued ASU 2024-03 - which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion), which are included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. X - DefinitionTabular disclosure of unaudited interim financial information. + ReferencesNo definition available. + Details Name: plur_UnauditedInterimFinancialInformationTableTextBlock Namespace Prefix: plur_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1 Shareholders' Equity (Tables) 6 Months Ended Dec. 31, 2024 Shareholders' Equity [Abstract] Â Schedule of Share Options Granted to Non-employee A summary of the share options granted to non-employee consultants under its equity incentive plans, or the Plans, by Pluri Inc. and its Subsidiary is as follows: Â Â Â Six months ended December 31, 2024Â Â Â NumberÂ Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Â Aggregate intrinsic valueÂ priceÂ Share options outstanding at the beginning of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.87Â Â $42Â Share options outstanding at end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.37Â Â $19Â Share options exercisable at the end of the periodÂ Â 8,100Â Â $7.41Â Â Â 4.74Â Â $19Â Share options unvestedÂ Â 9,375Â Â $4.40Â Â Â 4.05Â Â $-Â Share options vested and expected to vest at the end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.37Â Â $19Â A summary of the share options granted to the CEO and director under the Plans by Pluri Inc. and its Subsidiary is as follows: Â Â Â Six months ended December 31, 2024Â Â Â NumberÂ Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Share options outstanding at the beginning of the periodÂ Â 240,291Â Â $14.82Â Â Â 2.42Â Share options outstanding at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 1.91Â Share options vested and exercisable at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 1.91Â Schedule of Activity Related to Unvested RSUs Granted The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and its Subsidiary, for the six-month period ended December 31, 2024: Â Â Â Six months ended DecemberÂ 31, 2024Â Â Â NumberÂ Unvested at the beginning of the periodÂ Â 353,134Â GrantedÂ Â 48,653Â ForfeitedÂ Â (13,938) VestedÂ Â (143,243) Unvested at the end of the periodÂ Â 244,606Â Expected to vest after the end of the periodÂ Â 223,496Â The following table summarizes the activity related to unvested RSUs and RS granted to non-employee consultants by Pluri Inc. and its Subsidiary for the six-month period ended December 31, 2024: Â Â Â Six months ended DecemberÂ 31,Â Â Â 2024Â Â Â NumberÂ Unvested at the beginning of the periodÂ Â 4,802Â GrantedÂ Â 12,138Â VestedÂ Â (13,994) Unvested at the end of the periodÂ Â 2,946Â Schedule of Expenses Related to RSUs Granted Compensation expenses related to RSUs granted by Pluri Inc. and its Subsidiary were recorded as follows: Â Â Â Six months ended December 31,Â Â Three months ended December 31,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Research and development expensesÂ $136Â Â $62Â Â $48Â Â $31Â General and administrative expensesÂ Â 570Â Â Â 634Â Â Â 159Â Â Â 278Â Â Â $706Â Â $696Â Â $207Â Â $309Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the change in restricted stock units (RSUs). + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1 Total Financial Income, Net (Tables) 6 Months Ended Dec. 31, 2024 Total Financial Income, Net [Abstract] Â Schedule of Total Financial Income, Net Â Â Six months ended December 31,Â Â Three months ended December 31,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Foreign currency translation differences, netÂ $762Â Â $(68)Â $1,754Â Â $(128) Interest income on deposits and restricted bank depositsÂ Â 572Â Â Â 792Â Â Â 251Â Â Â 356Â Income from hedging derivativesÂ Â 103Â Â Â 204Â Â Â 53Â Â Â 207Â Other Financial income, netÂ Â 1,437Â Â Â 928Â Â Â 2,058Â Â Â 435Â EIB loan interest expensesÂ Â (428)Â Â (430)Â Â (211)Â Â (216) Â Â $1,009Â Â $498Â Â $1,847Â Â $219Â X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1 General (Details) $ in Thousands, â‚¬ in Millions 3 Months Ended 6 Months Ended Apr. 30, 2020 EUR (â‚¬) Dec. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Dec. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Jun. 30, 2024 USD ($) General [Line Items] Â Â Â Â Â Â Accumulated deficit Â $ (429,310) Â $ (429,310) Â $ (420,472) Total shareholdersâ€™ equity deficit Â (8,028) Â (8,028) Â $ 96 Incurred losses Â (3,110) $ (4,994) (9,146) $ (10,092) Â Cash flow from operating activities Â Â Â (8,692) $ (9,506) Â Cash and cash equivalents Â 22,374 Â $ 22,374 Â Â Loan amount (in Euro) | â‚¬ Â â‚¬ 50 Â Â Â Â Finance Contract with EIB [Member] Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Loan amount (in Euro) | â‚¬ â‚¬ 20 Â Â Â Â Â Percentage of annual interest rate 4.00% Â Â Â Â Â Balance of principal and interest accrued Â $ 23,798 Â Â Â Â X - DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashCashEquivalentsAndShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIncrease for accrued, but unpaid interest on the credit facility for the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityIncreaseAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_CreditFacilityAxis=plur_FinanceContractWithEIBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1 Commitments and Contingencies (Details) â,ª in Thousands, $ in Thousands 6 Months Ended Oct. 31, 2024 USD ($) Oct. 31, 2024 ILS (â,ª) Sep. 30, 2017 USD ($) Apr. 30, 2017 USD ($) Dec. 31, 2024 USD ($) Aug. 04, 2022 USD ($) Commitments and Contingencies [Abstract] Â Â Â Â Â Â Cash and restricted cash Â Â Â Â $ 1,061 Â Percentage of qualified expenditures eligible for grant Â Â Â Â 50.00% Â Royalty rate Â Â Â Â 3.00% Â Royalty payable based on grants received Â Â 1.00% Â 100.00% Â Contingent liability in respect to royalties Â Â Â Â $ 27,565 Â Marketing and business development activities Â Â Â $ 229 Â Â Royalties revenues percentage Â Â Â 5.00% Â Â Spread period Â Â Â 5 years Â Â Aggregate royalty amount Â Â $ 500 Â Â $ 180 Lease term 5 years 5 years Â Â Â Â Terminate lease term 36 months 36 months Â Â Â Â Extend lease term 5 years 5 years Â Â Â Â Lease payment term 5 years 5 years Â Â Â Â Lease payment $ 14 â,ª 50,192 Â Â Â Â Lease payments, percentage 5.00% 5.00% Â Â Â Â X - DefinitionThe amount of contingent liability in respect to royalties. + ReferencesNo definition available. + Details Name: plur_ContingentLiabilityInRespectToRoyalties Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionExtend lease term. + ReferencesNo definition available. + Details Name: plur_ExtendLeaseTerm Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLease payment. + ReferencesNo definition available. + Details Name: plur_LeasePayment Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLease payments perventage. + ReferencesNo definition available. + Details Name: plur_LeasePaymentsPerventage Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: plur_MarketingAndBusinessDevelopmentActivities Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage Of Qualified Expenditures. + ReferencesNo definition available. + Details Name: plur_PercentageOfQualifiedExpenditures Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: plur_RoyaltiesRevenuesPercentage Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty payable based on grants received. + ReferencesNo definition available. + Details Name: plur_RoyaltyRatePayableOnGrantsReceived Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty rate payable calculated as a percentage of the sale of products and other related revenues generated from such projects. + ReferencesNo definition available. + Details Name: plur_RoyaltyRateSales Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: plur_SpreadPeriod Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTerminate lease term. + ReferencesNo definition available. + Details Name: plur_TerminateLeaseTerm Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3 + Details Name: us-gaap_LessorOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount the entity has committed to make for future royalty guarantees. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477866/928-440-50-1 + Details Name: us-gaap_RoyaltyGuaranteesCommitmentsAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 34 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1 Loan from the EIB (Details) $ in Thousands, â,¬ in Millions 6 Months Ended Jun. 30, 2021 EUR (â,¬) Apr. 30, 2020 EUR (â,¬) Dec. 31, 2024 USD ($) Loan from the EIB [Line Items] Â Â Â Subsidiary obtain loan amount (in Euro) Â â,¬ 50 Â Finance contract period Â 36 months Â Accrued royalty (in Dollars) | $ Â Â $ 5 Principal balance (in Dollars) | $ Â Â 20,819 Annual Interest [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Annual interest percentage 4.00% Â Â Loan From EIB [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Interest accrued (in Dollars) | $ Â Â $ 2,979 Minimum [Member] | Royalties [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Consolidated revenues percentage Â 0.20% Maximum [Member] | Royalties [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Consolidated revenues percentage Â Â 2.30% First Tranche [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Subsidiary obtain loan amount (in Euro) Â â,¬ 20 Â Annual interest rate Â Â 4.00% Percentage of deferred interest rate Â Â 4.00% Finance contract (in Euro) â,¬ 20 Â Â Due date Jun. 01, 2026 Â Â Two Tranche [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Subsidiary obtain loan amount (in Euro) Â 18 Â Annual interest rate Â 4.00% Percentage of deferred interest rate Â Â 3.00% Percentage of fixed interest rate Â Â 1.00% Three Tranche [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Subsidiary obtain loan amount (in Euro) Â â,¬ 12 Â Annual interest rate Â Â 3.00% Percentage of deferred interest rate Â Â 2.00% Percentage of fixed interest rate Â Â 1.00% X - DefinitionContractual interest rate for funds borrowed, under the loan agreement. + ReferencesNo definition available. + Details Name: plur_ContractualInterestRateForFundsBorrowed Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of deferred interest rate. + ReferencesNo definition available. + Details Name: plur_DeferredInterestRatePercentage Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionDue date. + ReferencesNo definition available. + Details Name: plur_DueDate Namespace Prefix: plur_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionFinance contract period. + ReferencesNo definition available. + Details Name: plur_FinanceContractPeriod Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of fixed interest rate. + ReferencesNo definition available. + Details Name: plur_FixedInterestRate Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedRoyaltiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncrease for accrued, but unpaid interest on the debt instrument for the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtInstrumentIncreaseAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of principal of investment owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedBalancePrincipalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=plur_AnnualInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=plur_LoanFromEIBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=plur_RoyaltiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1 Shareholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 6 Months Ended Mar. 31, 2027 Nov. 25, 2024 Feb. 13, 2023 Mar. 31, 2024 Dec. 31, 2024 Sep. 30, 2027 Shareholders'' Equity [Line Items] Â Â Â Â Â Â Reverse share split issued and outstanding shares (in Shares) Â Â Â 67,836 Â Â Aggregate offering price Â Â $ 10,000 Â Â Â Sale of stock price per share (in Dollars per share) Â Â Â Â $ 5.93 Â Aggregate intrinsic value of these options Â $ 2,500 Â Â Â Â Weighted average grant date fair value (in Dollars per share) Â Â Â Â $ 5.2 Â Unamortized compensation expense Â Â Â Â $ 6 Â Shareholdersâ€™ equity Â 35,000 Â Â Â Net Income Â $ 500 Â Â Â Â Stock Option [Member] Â Â Â Â Â Â Shareholders'' Equity [Line Items] Â Â Â Â Â Â Aggregate intrinsic value of these options Â Â Â Â $ 0 Â Non-Employee [Member] Â Â Â Â Â Â Shareholders'' Equity [Line Items] Â Â

Â Â Â Â Weighted average grant date fair value (in Dollars per share) Â Â Â Â $ 5.47 Â Forecast [Member] Â Â Â Â Â Â Shareholders'' Equity [Line Items] Â Â Â Â Â Â Unamortized compensation expenses $ 11 Â Â Â Â Â Forecast [Member] | Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Â Shareholders'' Equity [Line Items] Â Â Â Â Â Â Unamortized compensation expense Â Â Â Â Â $ 439 Sales Agreement [Member] Â Â Â Â Â Â Shareholders'' Equity [Line Items] Â Â Â Â Â Â Sale of stock issued (in Shares) Â Â Â Â 42,729 Â X - DefinitionNet income. + ReferencesNo definition available. + Details Name: plur_NetIncome Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUnamortized compensation expenses. + ReferencesNo definition available. + Details Name: plur_UnamortizedCompensationExpenses Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of shares issued during the period as a result of a stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThis element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy. + ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=plur_NonEmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=plur_SalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1 Shareholders' Equity - Schedule of Share Options Granted to Non-employee (Details) $ / shares in Units, $ in Thousands 6 Months Ended Dec. 31, 2024 USD ($) $ / shares shares Non-Employee [Member] Â Schedule of Share Options Granted to Non-employee [Line Items] Â Share options outstanding at beginning of period number | shares 17,475 Share options outstanding at beginning of period weighted average exercise price | $ / shares $ 5.8 Share options outstanding at beginning of period weighted average remaining contractual terms (in years) 4 years 10 months 13 days Share options outstanding at beginning of period Aggregate intrinsic value price | $ $ 42 Share options outstanding at end of the period number | shares 17,475 Share options outstanding at end of the period weighted average exercise price | $ / shares $ 5.8 Share options outstanding at end of the period weighted average remaining contractual terms (in years) 4 years 4 months 13 days Share options outstanding at end of the period Aggregate intrinsic value price | $ $ 19 Share options exercisable at the end of the period number | shares 8,100 Share options exercisable at the end of the period weighted average exercise price | $ / shares $ 7.41 Share options exercisable at the end of the period weighted average remaining contractual terms (in years) 4 years 8 months 26 days Share options exercisable at the end of the period Aggregate intrinsic value price | $ $ 19 Share options unvested Number | shares 9,375 Share options unvested Weighted average exercise price | $ / shares $ 4.4 Share options unvested Weighted average remaining contractual terms (in years) 4 years 18 days Share options unvested Aggregate intrinsic value price | $ Share options vested and expected to vest at the end of the period Number | shares 17,475 Share options vested and expected to vest at the end of the period Weighted average exercise price | $ / shares $ 5.8 Share options vested and expected to vest at the end of the period Weighted average remaining contractual terms (in years) 4 years 4 months 13 days Share options vested and expected to vest at the end of the period Aggregate intrinsic value price | $ $ 19 CEO and Directors [Member] Â Schedule of Share Options Granted to Non-employee [Line Items] Â Share options outstanding at beginning of period number | shares 240,291 Share options outstanding at beginning of period weighted average exercise price | $ / shares $ 14.82 Share options outstanding at beginning of period weighted average remaining contractual terms (in years) 2 years 5 months 1 day Share options outstanding at end of the period number | shares 240,291 Share options outstanding at end of the period weighted average exercise price | $ / shares $ 14.82 Share options outstanding at end of the period weighted average remaining contractual terms (in years) 1 year 10 months 28 days Share options exercisable at the end of the period number | shares 240,291 Share options exercisable at the end of the period weighted average exercise price | $ / shares $ 14.82 Share options exercisable at the end of the period weighted average remaining contractual terms (in years) 1 year 10 months 28 days X - DefinitionWeighted Average Remaining Contractual Terms, Share options outstanding. + ReferencesNo definition available. + Details Name: plur_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionShare options unvested Weighted average remaining contractual terms. + ReferencesNo definition available. + Details Name: plur_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionUnvestedWeightedAverageRemainingContractualTerm1 Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionShare options unvested Aggregate intrinsic value price. + ReferencesNo definition available. + Details Name: plur_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1 Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average grant-date fair value of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=plur_CEOAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1 Shareholders' Equity - Schedule of Activity Related to Unvested RSUs Granted (Details) 6 Months Ended Dec. 31, 2024 shares Unvested RSUs Granted to Employees and Directors [Member] Â Schedule of Activity Related to Unvested RSUs Granted [Line Items] Â Unvested at the beginning of the period, Number 353,134 Granted, Number 48,653 Forfeited, Number (13,938) Vested, Number (143,243) Unvested at the end of the period, Number 244,606 Expected to vest after the end of the period, Number 223,496 Unvested RSUs and RS Granted to Non-Employee [Member] Â Schedule of Activity Related to Unvested RSUs Granted [Line Items] Â Unvested at the beginning of the period, Number 4,802 Granted, Number 12,138 Vested, Number (13,994) Unvested at the end of the period, Number 2,946 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: srt_TitleOfIndividualAxis=plur_UnvestedRSUsGrantedToEmployeesAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=plur_UnvestedRSUsAndRSGrantedToNonEmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1 Shareholders' Equity - Schedule of Expenses Related to RSUs Granted (Details) - RSUs Granted to Employees and Directors [Member] - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Schedule of Expenses Related to RSUs Granted [Line Items] Â Â Â Â Compensation expenses $ 207 $ 309 $ 706 $ 696 Research and development expenses [Member] Â Â Â Â Schedule of Expenses Related to RSUs Granted [Line Items] Â Â Â Â Compensation expenses 48 31 136 62 General and administrative expenses [Member] Â Â Â Â Schedule of Expenses Related to RSUs Granted [Line Items] Â Â Â Â Compensation expenses $ 159 $ 278 $ 570 $ 634 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=plur_RSUsGrantedToEmployeesAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1 Total Financial Income, Net - Schedule of Total Financial Income, Net (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Schedule of Total Financial Income, Net [Abstract] Â Â Â Â Foreign currency translation differences, net $ 1,754 $ (128) $ 762 $ (68) Interest income on deposits and restricted bank deposits 251 356 572 792 Income from hedging derivatives 53 207 103 204 Other Financial income, net 2,058 435 1,437 928 EIB loan interest expenses (211) (216) (428) (430) Total $ 1,847 $ 219 $ 1,009 $ 498 X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from increase (decrease) in fair value of foreign currency derivative and nonderivative instruments designated as fair value hedge recognized in earnings and from related hedged item to extent that fair value hedge was determined to be effective. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_GainLossOnForeignCurrencyFairValueHedgeDerivatives Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInterest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph a -Publisher SECReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph b -Subparagraph (1) -Publisher SECReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestIncomeDepositsWithFinancialInstitutions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 40 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1 Subsequent Events (Details) - USD ($) 6 Months Ended Feb. 05, 2025 Feb. 03, 2025 Jan. 23, 2025 Dec. 31, 2024 Subsequent Events [Line Items] Â Â Â Common shares issued percentage Â Â 10.00% Common shares outstanding percentage Â Â Â 10.00% Liabilities Â Â Â $ 500,000 Warrant term Â Â Â 3 years Kokomodo Ltd [Member] Â Â Â Â Subsequent Events [Line Items] Â Â Â Â Purchase amount Â Â Â $ 1,000,000 Pre-money valuation Â Â Â 5,500,000 Additional share price Â Â Â $ 500,000 Discount price of share Â Â Â 20.00% Subsequent Event [Member] Â Â Â Â Subsequent Events [Line Items] Â Â Â Â Warrant exercise price (in Dollars per share) Â $ 4.61 $ 4.61 Â Gross proceeds second offering $ 6,500,000 $ 3,500,000 Â Â Subsequent Event [Member] | Kokomodo Ltd [Member] Â Â Â Â Subsequent Events [Line Items] Â Â Â Â Shares percentage Â Â 71.00% Â Aggregate purchase price Â Â $ 4,500,000 Â Subsequent Event [Member] | Pre-Funded Warrants [Member] Â Â Â Â Subsequent Events [Line Items] Â Â Â Â Warrant to purchase common shares Â Â $ 26,030 Â Warrant exercise price (in Dollars per share) Â Â $ 0.0001 Â Subsequent Event [Member] | Warrant [Member] Â Â Â Â Subsequent Events [Line Items] Â Â Â Â Warrant to purchase common shares Â $ 45,553 $ 84,599 Â Warrant exercise price (in Dollars per share) Â $ 5.568 $ 5.568 Â Subsequent Event [Member] | Beneficial ownership [Member] Â Â Â Â Subsequent Events [Line Items] Â Â Â Â Ownership percentage Â Â 19.99% Â Private Placement [Member] | Subsequent Event [Member] Â Â Â Â Subsequent Events [Line Items] Â Â Â Â Purchase of common shares (in Shares) Â 759,219 1,383,948 Â X - DefinitionAdditional Share price + ReferencesNo definition available. + Details Name: plur_AdditionalSharePrice Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate purchase price . + ReferencesNo definition available. + Details Name: plur_AggregatePurchasePrice Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommon shares issued (percentage) + ReferencesNo definition available. + Details Name: plur_CommonSharesIssuedpercentage Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionCommon shares Outstanding (percentage) + ReferencesNo definition available. + Details Name: plur_CommonSharesOutstandingpercentage Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionIt represents Discount price per share. + ReferencesNo definition available. + Details Name: plur_DiscountPricePerShare Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionIt represents Gross Proceeds. + ReferencesNo definition available. + Details Name: plur_GrossProceeds Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIt represents Number of shares (percentage). + ReferencesNo definition available. + Details Name: plur_NumberOfSharespercentage Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionPre-money valuation. + ReferencesNo definition available. + Details Name: plur_PremoneyValuation Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of payable for purchase of investment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(10)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 405 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478790/946-405-45-1 + Details Name: us-gaap_PayableInvestmentPurchase Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plur_KokomodoLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=plur_PrefundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=plur_OwnershipMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT

begin 644 Financial_Report.xlsx M4$L#!!0 (!: 2UH'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V/0L",1!$_\IQO=!=!P=!2L+(/>QLOD8&1#^L1!)^OCG!'CVX> ;QA&WPIG M*N*I#BV&5(_C(I(/!47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E(+ P4 M " 6@$M:,,&*.NX K @ $0 &1O8U!R;W!S+V-O&ULS9+0L2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/
[...]

'=>#YG_-/D]O_Y@CV(;/T=TM,B4UO;W.+^;_ M^[;X/OTROWU >6U5I2X7]41/:BB[@L'6:/11G M+OD!@S;6G<:N2H3[+;3-_&1&8XR.3S%7)#'TPQR3N@]I<"N5>>M$?"]MIYZL M"
UN)S2S0U+47>=$;I.3H$7@M9;0!_(1+7?;;6+.[(%/ MQ$Q&"9<[8=B1/O3*&T;[B670RE[>?-S\3MI.?5+1E*"=IOR:'IK-IJ QY+VCKTTI%4_F(YQ$YA@I_S)3/BT_]$W-YZW:\RO_?)9_
MKJO4Y%\/OQ(!$UJBA*Y!I?=I")X5^0>Y_$;QK?FFM>)*\=1<;BB)J= "\'[- MN3KS?N_-16P>A"W3CAJSR7[N%2&;LYZT_[S8VO.EL%NC$^/RUEIKZI
M\&=YX_!KW%I)=:X*KVTAG%J>]2^F;R[GM)X7_%NKC>]<"XID8>T=_?R0TD@0W/A>V^RW1]+&[G5C_1W'CE@6TJLK:_ZCT[ZZQ_U M1:J6LC+AJ]W\KNIX?B-
[B36>_XI-7#L][HND\L'F]69XD.LB_I?W-0Z=#4>3 M'VR8U1MF['<\B+U*X,\/W5V(QRMAC6ZX%!Y-YS3!27E6W!XJK$GO+]7A7+2 MG(X#C-
&M<5)OO(P;9S_8>"@^V2*LO+@N4I7N[A_#B=:36>/)Y>Q9@V]5,A(' MTX&836;S9^P=M)$=L+V#YR,3_[U8^."0_?_M"S+:F.^W017QQI]Z9OQ%#4)GIR M)&Y,Y;3X4
#%EURLQCR(N\)NBI[T\:D/*A>W*\!2JBKHQ//R5P,AQ6>UEJD4 MB76E=9(*9B VV*>+YI9*!:KHDWP04T[29-H]\]=?CF;3UR<>%O(^G)[L!+Z"QU)L5I9B1^3PV5<+KU,-P1GT M>.7P4MN@DI7X&-
(:*N4:J,0.5+0"Z-CHPK>M)1RA84$_PF?KKI$;+^PR[@MX M2#\^>">5&?4^%.(/650P1%R?#!Y9%\H'N3 :19T^CN:]0F*+'5>V[K[/%[^W MWCY9N=_GWE.?X\Z'D=CU<_83/PLH<
=L<;V&W8MEP-]WUJ:>T63W'C_I_2@) M1;66,0FCI^9^#G[$NTG6$C#:#1;2$G6ODHK;0DQ2#SIJY**FOI"94PJM)T"- MPTKF)N,B<3M $*E*;*SO\4BHRLU;PK_:ACCVLG*TR MY"!XL:SV5PL9 -
O+V61Z##I^U+FF@&^D"Y XO]EP\H[.6NH M+.PD'?T'.?MAM5S9Y5(I+_4V<]M;_[0 FAP$BUZYQ@Q0"L)*KWE]PO:Z)?S8 MX4%O+YGWT(MT9.L?
U(=F!N4<9=P2IED8&JK*D&RR15E#_(LZI_ZR(37F7$_%T/2%CK_#%QJD)_ MKQ0 09T,VRD-_-]S)"K/L5>H.ACC<:[Q6M?EA)T^D89*9KBRE0?.5&V?(#]+ MM&[2@DS<4!?
7B8K&\NZS'JZTT>&AX5)2 >XB@-@PYKGB.JXA:$K!4BN3$DN= MRGA:X*K-5:H3=-P!'+<[(%)Z9;?:._F@9T9611(KZPK#$;DKWD;46$QHS6Y(M7UPF"_U7W7"IPMY^^C(0B\K#
1])#1P+3\2!8!G]EJH3C&Y5B?T X&3-$0T M&9 \1$7%#L\H%Q+8P78$G-8GUH>A HEY1'Z%(HQ%) MSJ#A"$7+GNPDB9#NL+-T-JV2$(,D,VW4'2O-'EJP'5O8Z3T\)UF&V34*"IPH MT>>+P-
RRAM7><_QK%!LXUD%M))*G?(>R55RS5%U)4N658='"S]^L&>RQ&GW M&B\"DQ[,9\=#PZF$W:OW>T477#X;8T9ZXF5M*Y06:1=(CV:%%H4G'0V[ZSF M-Q<=*#@
E%"1)*JD>$;B@E46L[/*%U"<9GZ.,MJ1.9[-@J6YBT/ MVIAD;JLB1)UZ<328S(Y&XFU,'D]A^GZ8T]@OX)Q&<2@:_G]R_!:*.FPX_.)X M,)T?1J# @*<@/(,!C:7P[?!X]G^&S\87TI!.>O&2?S*3Z$)]K]"4#
CC!X#(MN@"UA7@M9'$'>$KK-3T!U<&8A)M7L[]S;V?UJP@X;K_]'3P>K[+L;:N$R"* M64?1]5(7DE,,5.KHF;:$!MVK=8W.M)5#'! +='7DC).D"]@PT$B4+C'."4N% MPU.Y<@EJ82#*
[=Q05]+^V2>:;LN)I4G0.Y F^,AOH^,R]BYSL@B-P2A^O,I7 M)<:#P-XW0L&KNE7>22\]8H,>T'%Z:2>E)SS@> 0U[WT2HD"]2Y>O]H!MLTW MQ$=F<8Q;*/BZ5K4@[@42OF:*P>+FQ(?
>8[#>K5Q*&G=T7RVI9,C$LAZYF\0B MZ)R^IW .,6QE=1)CXW^@9"B1(M]PQ2CI0ZW*=4W11+I1ACI1?,-F-.B M'Z1 MH&OM?
<5,B;\]J0*1($=OEE6JXWB%\BQ\O((&ZI0%+'*,=9%>33C7;9D_+5_T M$2MT7AI>R=V-&@:0(_EFRB!EJH8CB<3FC#AR$SE"Y![]$MX.Q HS./K3(&:B M>\Y&0^870&5AN!3L(DA=Q-D&Z:?8#5&&
(MZ&T,D?&8S#%LCBZF;'PZ@MLEC- MZ:-NO*V+N@DW?&N:$_39 /5KG95S1/2N[[&9EB?_MC9(AMT2SK'FS2W9&Q' MU-R-413T_@.W4^T;6&9^^X[$0]#3J@&S5I"G(0:]&
MY%W]H!E3!I'T].CZPR4THG)$KT#.Q8%Q_WDQ;N:$L3S/<;ZXBU#HJ,6#P_G) M;")R9)>&G,:#C[8F2;,:?5*A!:0$+!4'9*I"Z.78%(#@% V9J^O@/2NO;8JDA4I6/J3 MGF=T<<>S51-
UG$5JF##&N(K;%#=!;J5VV7LQ.QB\/CZ*:XG[D)-8Z5"@K%,^ M1LL%C=F[^CM_-=KW-6S<^2J)(LOXVRM]($*VXP?*]F[[>?_M\8?P9;\C7-A0[Y7ZX49,/1 CS')!^:'W1 ^]'[M_&]02P,$% @
%H!+6L4NU=8H# 09?F1EYT8D+W.UNUNDHWL;8&B M'Z@92F(S0\Z2'-O:7]]S+SD/V;+3=H'V2RS-D/=]SKVD\N[.NJ]^I500]U5I M_/N=50CUR?
Z^SU>JDGYL:V7P9F%=)0.^NN6^KYV2!6^]ROW#R>35?B6UV3E[MQ\\^N[-WM@FE-
NJS$[ZI*NG6YZJT=^]W#G;:!U_T2(/'G5EVHLB1!,..W)'.G4TD;AY];Z1_8=_@REUY=V/*ON@BK]SMO=D2A M%K(IPQ=[]R>5_'E)\G);>OY7W,6UQT<[(F]\L%7:# LJ;>)?>9_B,-CP9O+$
MAL.TX9#MCHK8RA]DD&?OG+T3CE9#&GU@5WDWC-.&DC(+#F\U]H6SF5X:O="Y M-$%,\]PV)FBS%)]MJ7.M_+O] "6T=#]/ L^CP,,G!+X2/UL35EY4>=QT+ML0M")KV6NWN\
(EZY6[5S]OUW!Z\FI\]8?MQ9?OR<]+/9U8\?KSY< M74P_7HOIQ<6GFX_75Q]_%)__71U<74YVV;N\P(_?KJ^S Y/Q)[XAF@AQ^+& MR*;0017BR@3EE="4^:"--KF6))Y$>"&?
7*Y5)Q+6JI5E39'5:WG0"GQHI/G QX ^L&+E;Q58JZ4$8AH+1W6:0)S;EV!U0IX"2MQ,YZ-Q5(9 MY619KNFUJB&2#4D)KIV&\+I4?B2L$S].IY]' F9W]O7]]< =:8JH(JP47]J T
M&N83+X(51 SB8++W"R^;NJ#S4N&!L(N,39JIO'$Z4%W1BLO[?"7-4HD+6U7: M,[-]4W\;) 63(UI8.@755L78'Y7 W]A_VG+6DDG%-&?^'-CE#B:1/(:,S;H
M[1[>HIF47,"Q^<)0*>ZD1TMQZ%,PS=F*Q0U0\PVL8#="N:%S).9-X/*A%!;: MYZ7U#;@I&Q0)@T$ 6YWW8_&I!I8H15CHT>)\YY[7]WL5<;S $FV+Y"IX6E5S MY*?
EZA%+)-5MB6CD6IL"W$NMF&PE>:W\L)(!*5P#[4+=UVC;Y&=4FK4QI=(8 M.OAR+.: V3+N!VN&M-"N6=@2$TJ?^$@W$5[14J_^()> XJENJ*=K#?#\1M-0R:83W!2H=UI+O'
M9"JVDFE+-G[%^1:);^JWI)1]L^F6/:XDQY38)UXE/).I8*ATELCYZ!0&K0* MT=36;-+-S7\ -[$UMF?7 Z%+%1,)IV(#XZ .LZ5Y1GCZC07UA M1Z3=<4'."6ZYXDX#M.*85)
(43A$IJJ7F%\B5\52Z4I1:SG5)!$$#&,C$P77$ ME9?(>,B:JW"'7I_A@/<5@D \X#J-V!)#37WFFQP%M=@T7L35>Q'T51^*:##R MEBPN%&4/0VR1",*:QTRR177RN6$")^[*J:\-
W1UX1W;B.Q1HGP:G..M0,,G^ MHWTA "*RR5X.]HQ7&:JQM8 MVOB>=FAGY+U*@30*6]HE=2IM4I#(HCZ6)]E/ZE:55"Y';T_% <;Z7QI+P.2R M\&
(778NG*E6\R'1[(DX!B[[VW2F"E6+31@;J3S=5'$+%5;0[(A@),(*79 <] MK]LYG808T>T,T06^"_M(*,TR"C23/-!4Z'A8B-]."151NTCJCZ#]QO3"LQ3" MIW7$ 6Q0?5U6,!UYV[K[U;
M$42VI"3C4 =:HDB^9WH3Z)F((Z(:>! ->0-I-0:U0\K7(2BI)AQH^B\C7'8 M2GH]R.O&^4;&9D[^Q-,>66?X>-Q#D(.]7#JUA,'"PD/BP+Y+M4T*O7+.X$W3 M
U69X3,:,SS/5C3F\"C.Q,I8Q.XML^6@Z^& !.MIT,1I@*Y['GBRX,,#&!^< M9]>R).?D.L:L]3)[RLON['=Y=8[1E][QT/I0$!4Z9,Q5I$Y)+(#Y.,=+3$5/
M]NEHUG!TQ+Q]JTQ#G0Y];L_Q.)FL2_'$&#^'W:K =*^6VIAXS$;7]P1=GI4I M2ER4U)?*!Z^.)F+7*Q[.E3C&^0J5]T61K32A@]X>3GO6X'.NTAA!H5X#6[*P M/!A.9S?91SLFG4=[D]?
9>IP,\6#5SHMD:C=:YPP91M^+9+SWBEI"UTG!8JEA(MT1VBAI"">KDE_QU0-HUISQ JI &N2Q(2IGB@I\[6=H)8_/$,V0-&+F!&3RT' M+T>I>H8VQB.N;X/62V,H^6^*
U,Q@RA.'0.&4E/3'!,"';2O&=RQT*CCKZ^A3R2V)SO(\0'3VI8'O^3/+9GO1/DN3.82J-&SPP#BL>FCKQJYX M[83=3+%\5N?K.3JEI4NAYP_ @XR/'[#&VYXUK@PJ28EK>4]#2R2,U\?;"*-?
M^?3 W.+Y+1-%EY\!40#_C^'_]B'\M>>B, EYRJQDVPQX J:[29.O$S@B!&D(M6#2E49XK7$=S@[S/-B+QH 20P8$=*)K"D0!M;M$=K>L8AP@%3^+$D^PI!DHV
MCLX]%6$LL,UR)>)5I&\['VV@9G HO,H7]V5XO4VOE.QJQ!6VGF-/\>.J25H".&/?;X2>@D(^,AI[\;0A5DB(I4)9?H MX$IGCH%14-[0 _G^(0Z]L2=T?7 7@QH*UJL$)(Q(@
*=&JJZM&O%TR6M3R#;Z)%T(:;0BJA/IJ#E,ITR>ZI-L^]" MYMV E_#197)$D^ =GZXWDAK]SNC<30EK_=S,]:-F]A^UGE>C=,7MGNIF0W'9 MM\2]?H0FF/=T'TL7N6T32X>
[W8,70YC&;K8- %FJ*K+>=77=VA\MI'CW\2GX M\+&(H*0H8N?NX8L_VCZSI]OG_YH4-IK&MM\3]P>_ U?*+?G7;KZ"-"^)-P] M[7Y0G\;?D?OE\=?XGZ5#.> 4I1;8.AF_?
KDC7/R%.WX)MN9?E=$ @JWXXTI) MG-EH =[3+ROM%U+0_3>#LW\!4$L#!!0 (!: 2UK@AIYTZP@ $T4 8 M >&PO=V]R:W-H965T&ULG5C;;N,X$GWW5Q">[L$,/B6
M2U\F">>#MW8Q<(55,N/%- M63H8#X=E@TSJO'MZS_N,P[-FQ*7G'J#T M=JX/2XD LU4_Y[<6=Q-VBL)#I3N=#F%u,F%U;-3[J3T>>S UK/"WYHM7:M:T&>1,8\
MTLTT.>D."9!*5>S)@L2_E3I7:4J&ZEQ7(.-G9;;'$D;V]U2OV';Y$TJESD_ZE M$[\\Z7[LBD3-99GZ>[/^JBI_W&LE>%;+^?\4ZK@W B'7/IO,FJS;C/=![^RZ>* MA]:&C_V3"N-
HP9=SB(45Y(+T^/K5D+2ZMAC2[85=X-<#]GH,R\Q:\:^_SI MNZ#MZR?GM]>7T\? MKB]O'F9B7LUU@WS9W<_MPV=G_+/;$FX:%[(N)$V8N M$ >51B!/B$S4^:>?
G\WZ@V/1G052[=D:A-5&*?!\UHZ4:0J6:A$1!OA METK,RLCI1$,&>.GE"I8G1S!_%HI16YEXIUQ=17WQ'9EH&\BVW\N6X\N62-KR_S MV)06,D0VR8UIGJ#ZK):IN$C#W\XH9X@YR 3U#J$T
$:#H2P M;(]HD,=<*R"N)W2.G?%2HE(:R@JYJY'G_5%8M)4VCTD[2/V\5JA'=@MI$[ZX@'K($:%S#=-<RJ#(+!!]N50=M MO8*!N%8L3RY1>4"O2J1IS;@KXV5GIX=]9#4#E)ÆK
S$]D9LFJ(ST9ZE1 M>0$K&KKS,$;N1S*5U7:R5O&PUFDJ(D2^C"CEX$)'H^R03EX@TZ6PTB-Q?Q+6 M*CJC\5Y&_4+,N-@3<0LAR*F1BBN=XPPZ[1[;N,AFMU?WXK=
((>Y*"GSDN2C MD:(?7Y/#%Y9TH06 =NYW-%9S3VODW/;N]_IQ)+=2RIF&"C%;NM@G&I@I*B M1(30;!.BGDZ;:POO(LH*Y9!!"!E(49*J!YSF":QLD,/]SA5,FG65/&)>@BM*
MA;J$MD3VZ)*$SU$\YJ6E6VB?C'2J_8:SODF(-^39[TBP5NYL#6J:KDB"*&2[M*RCH/-S&LW?C#[W#HT/*%G"2QVG).<%DBM^X=E[%AB+WN]AF]6:@]9%,"DC MZ%M?
Q)R/PI%/+46:G2AH)KG6OH.L?I$GR8++2@2N\WY.)#/O_ GU&-P2XN%H9)A $P%!:E%7%2B[7K"@O9&(L>I3!V$HD%#&N%#U98N M7%8P=Z9/!1:I#1U(B!YO*"BN14_+#
[G78*X6N&>Z%Q1@Y9A_RE!N[*HC"(M[:[(83!+J#OQ=)5[[OA..,^""? XF4_=21IZ74K7'!EJ@I9"@L,T4U:/):W$ M:GH3*JR@Q]N.2L]?Y*>NZ[E50-
AP['[;$5^R:R9$[>:F:T%NU(.6G^I80EI7: M(^40@*I-TD.,,-;DM8#P3]BX7FIHS2LH5)L(*FC2/@V!M4IG46E=,^'P*."4 M>]V/.<<;.>>7O0I6 -.:-!B((S4-;9"[2S,5-
J)&:D::!UJY^P75FI0+U)PX M8)D8]UK*S]*P:T=(ZFQ)@BP\K_O1QR"#;[NSQ#=.=:2?$0GK?]Z6NC4)+B$C M1V03<+U/!HRC!8]'1OLM(K,:/)TCUNQ#7& M6+0%
<:Y(";D'3>.E3LT*B>H**$[*?0RRQ'4FQ=V2AMWI8#H5818%:W??_KUW M-[EXKB/U+.01+%]'>(93C$[V[M6<7FH,U.U\:4VN8_'%RKG?^Z&L*QW*U/F]
M"^UHLF947WY\O7B5^"]U0.5'XQ^4?H M+)K""3@5?B@J1BL3.N0A==.(V26>#-%/3&&29YUN8$B>4>]/1!9>TKE.
M#)!0)PCI4Z'8[F=T6QQ(P:TEPMIAK,U+T"79XB\VMPPKL"*!'>]6X5S$HV*I MFG[JW W#U)8 8NEY'&^F,[S<]$:?QG3>N]%!3;%VG6K0KJ86E) K,WB.@2*F
M9I>HIX!E)X9J>D7CL/P8_0#270DSZ;0/C?-5NJ@G96--*DHYW7C7;SOS+F, M:)HWGM08_#45T:FP7D[/>IC1%26)$@?]79\+!JU//'!KP1^R:*!#OH>O/&PO=V]R:W-H965T+HV]
M/1Z'I8 M"*G[L].P=F-FIGZ;R2FJ\L]"JHA%"*+XJ>F!_ ^V&!%K.**\A+^0"F M+^&7=80]\E#P&K&DVJ:;-
A1*L0KUJ4I*56OGUQ/@"'2U:3,7/0&' #Y^25(/ M6\CLN(#)VG+O1RQWAI4F=$F_]=XO"/LWH\8?]O0 _A @Y)E,AQAU/A"K](F M6B13CQ"/4]1Q')6#RBR](@=(L9X'!&M60GF)34/-*
[)/JWB/NN+%)_WG> -6 M**SK.2]LB%[X8"7!A=1M*\ZE2ZDE6#+P=D@#98P4*A:IIYH7I4Y5E?$:=]UC MOO=B/&),8!SQQ;H-,(B0=N=2!'<**I9 M+Q=9\#1-;<6&0F7)VWSVT\$
WI("#<3OE&&#<8;56R[7Y_G(==;+27 %K% MS@"U0U:%5F$G>G4LAU&H2,+EW1IJ@J>1"[FG3I/9FC3I!-&I+$V>$[^0K- M*?
4=N;%6381BMWO;^:)3Z6C\IB%/7#O49GJ'1O3F-2E8=HV.9,U%IFUJ,44_ MKTB_(=$(I7DUA_ K>2,U;$8/E1Z3L;.<.6*&<"1-$!YWK3CPE"^D%XSLZ$(F_A0N@E4-.
M!863(I+1KO";%Y_HD;I%U8X*S4!IG%"!LIU#[\)Q2Q.O^=8,:2[T@B)N4J]% M8(UGYB^I'%U)'$%LJ.5&A9FG>U>5LG;$1KV5255[PQQ2DU%I/#,7>9/)>TF' M5>9"&,Z!>B
5CA$8T9)IOY/JNWIV'_/%VH#W9D%DMQM3H!KON9\-NW.!=A&^ M$)A#]+?J:W2WVGV$G-=W[[5X_07S2=@%%ETKAG%1'@]<'?;#U5T']XDT9;N*) M\72O#X\Y?4BA90:GQN*O'EA
]VGV>P_4$L#!!0 (!: 2UK/?B_W@H M $(? 9 >&PO=V]R:W-H965T<1PW2<>-7:M9V=G'R 1DK#A105 R]Y?O]\!0(FR)3MI M[8SB<4<+<.[?.0>';Y:5!AAV?2E:KLW-
V9QX5;,CO5"'9W93D1_%G4[_J."RW%#M]8Y]=J],W56UR68IKQ71%=%P]O!-Y MM7R[U]UK'MS(V=S0/Z/3-PL^$A;A?7?92"TR9]:8O:]ZZ)^2]9]M6F\ F\7
[%4K>N&N6DRKHO=/,I>[O7(ESD)=>=$"&"&+\Z6GNK5C2Q9IEA^W\ZX(6TSD^7Q7]M(9 MNZKFSV]KJ:NUFHMG:JDM~~
[M] TRANSCRIPTION-ABBREVIATED

EDOM/LO" MF'G5E&X:8%<&5Z!#M1 >*8OAKBYV_V"XVS*T:WJ3)CA>#'J3YL+;S4P49CY% M&[#K)"$#D2^H,Q6_=^XZ[="$:\<52M?3WVX;\\/3X#0 <5V5HVHH/!F?M0?]
ML]>:C/W#6S.[[1G[1N/V>#S<-Z+M"%%.4S\\J>V26?_X%%.&&'<4K#E<%/&@ MT1:AF8NY"_C27?C MP]9*V05_OB-7(5G#-ZYZM?Y". D?QIKCX?/B)VD7-#BD:HZKO<[)N!7:^>K%
MFYP_D\V,1_?/CTLE@2YT /MS8WSU0@SJ[Z97_P=02P,$% @ %H!+6O5R M4%V" @ OP< !D !X;"]W;W)K&ULK55M3]LP M$/XK5H8FD
;.6[O2I9%H4S2D,54PML\FN386B9W93@O_?K:3AA:%"C&^)+[S M/<_C.UMWT8:+!YD#*/18%DQ.G%RI:HRQ3',HB3SC%3"]L^2B)$J;8H5E)8!D M%E06V'?=
(2X)94X<6=]"Q!&O54$9+ 22=5D2\32%@F\FCN=L'3=TE2OCP'%4 MD17<@KJK%D);N&/): E,4LZ0@.7$N?#&\]#$VX#?%#9R9XU,)O>R)AQHL-%/YQ!DY M*(,EJ0MUPS??HH8"
[POR73_L.<_L[?"@+YW_4Y^_6WVO&$'W"@++%[SG%?1==D,7]M.9 MWC:6%4EAXNCF)4&LP8D_?_*&[K>^2G\D6?*19/,/(MN[D["[D_ 0>_Q3#XDK MEO(2T/$/+N5)WSTT%$-
+84;".C[USP?#"*]W"]P3%9Z[@_VHI"=J- I&^U'S MGJCST?!9L&PO=V]R:W-H M965TNJY, M2ZBPG/ :F'Z2B<&4M &>RL_.5Z M8>)MP"\"K3P9(U/)GO-G,]EDL>,9(:"0*D/ ^G:
.Z#4@+3&GY[I#%N:Q-/Q MD?[-UJYKV6,)=YS^)IDJ8^>3@S+(<4/5CK*?H:]G9G@II])>4=O%AI\=E#92 M\:I/U@858=T=O_3G<)*@.><3@CXAL-[=1M;R'BN<1(*W2)AH33,#6ZK-
UG*$ MF9?RJ(1^2G2>2C;Z>#,0Z$@G@C+ "K83 K ![]$I&KM([F#@W[6GKCA9W+S06Y^ MU:D]@=!?$;[@-LY\SVTQN"VN/KAQOW'N13_WI#]4(K;!25*><-4URJ&U:'1
MKKK^\C>\Z](/6!2$240AUZG>9*%?I^@Z7S=1O+;=9L^5[EUV6.J?!0@3H)_G MG*OCQ&PP_'Z2-U!+ P04 " 6@$M:609E*F@, D(P &0 'AL+W=O M_[GG-)Z_6#
M=5_\4JD@'JO2^#>C90CUJ\-#GR]5)?W$ULK@S=RZ2@9\=8M#?5LE"]Y4E8?: MT^F+PTIJ,[IZS<\^NJO7M@FE-NJC$[ZI*NE6-ZJT#V]&1Z/VP2>]6 9Z<'CU MNI8+=:O"7?
W1X=MA)Z70E3)>6R._"S($]FUGZA M+Q^*-Z,I&:1*E0>2(/"?O7JKRI($P8Q?D\Q1IY(V#C^WTM^S[_!E)KUZ:\N_ MZR(LWXPN1J)0<]F4X9-]^*-*_IR1O-
R6GO\5#W'MV'J.L]M8X(V"_'1ECK7RH_%;!6_K,1>^W#_]6& .MITF"?1-U'T\1;1+\2/ MUH2E%^],H8KU_83WSP:%N_K7)^2C[=+-LZJ57OI:Y>C-"LWCE[M7HZOOO MCEY,+W=8?
MI9?KI+^M6=D4VA@RK$!Q.4TY5XKXTTN98EGL161/8!>2'L\[>3[@ 1H_>+&4 M]TK,E#("YM3289VF5LZM*[!:H5O"4MQ-;B=BH8QRLBQ7]%K5$,F&I*363D-X M75)Y6R?^<'W]
<2Q@=F=?KUX/W)&FB"K"4N$%RJ%4-/$B6$&P((ZF!S_QLFL7 M=%XJ/!!VGK%)MRIOG Y42[3BW6.^Z*&AQ%M;5=HSKGU2BZ:,NFX/_C'A.G0% M+"Y78U*Z$H45Q@8HS\NF4
(>)F/6K9Q;&[.JISZM=$4J=DJ(S_93N4Q2] HY@5RILN%.DP*E?> \Y9BQ1SJ5TO MF?.7LV(-T@5EAEPI83GBY>C%0-O^A (MYHV#A6[H]YA8 590 M'6@/BQ$>I(4&"K%@_0@ M%
>6@FG.5BQNT#7?Z!7L1BC7= +*F\#E0RDLM,]+ZQLT=C8H$FX&@=[JO)^(MO]7H)4H1%GH0G._<_KQH")<%UBB;9%G93C#]!@UL M M&= K> Z QX\
W"H0+Q@S5#_&K7S&V)0:JOT(B+$0=B2+WZG:"+Q&5H;RC. M\8([RD*HK.M2[U(L &3*P^S8)!N19D>"7G3Y>K&;_#P7#S3IBA1N2M!."5L2 MA.'BJ6C.R!-'-X8,,4%
<"9ET6$7&>,Y'8B,?M7CM!Y!+0:_D%]5;,LY^:8I% M#UW28XRN$Q51ZU"W82KWUL@96(@FU4(TM37K3'$O=366V4^B6,@.Z M_@9M7'FY=
(XCT\8U]=E35MHH89S@G/;GTB\YWOR!Z@W:XR(8%IQFM*678Q 2 M4G<_ *A01.9+5B"77J=\#5;32['VTC)!$X53":-,%"G ! U>KN4JEEVW+C6# M7WN%AZZ!<&(H!6V W61,
(_$*@9OWT9NI7#:^Y1(\[IMNX ;VIC&,:[L- MGZC0+D2&@AQ@XHW,-$P#VF2@KP&(NFP W; @M&+;C8 +>NKY]*RZ. MIY>"TH3_.>D_LY@?H^*^#7[HF9E7'UT.1:P5C*8=B(\.
":=*\H@5U0Y[&U0GGQOF00+:G.:8H;L#[\A.?(<"[=.@'&=;"B;9 M/U0Y;C-"X(.:U1C>:'=8.J4.4&"MGTM\E"Y?8H9_6&H(@1662O K1J\XO=<- M+&U\CY&T,X)TI8!PA2WM@@A?
FQ0DLJB/Y:OL+^I>E50N)R\OQ9X#\UEAJ3 MR*+/9 _3]&JV,]T>_^1 A9][4D^-BO%IHT,5%^NJSB&B@_1[MC!2(1O"0[MZDG(S@CIN*/;F;$+?!?VL5":911@OCS0*<#QHGQ
&ESK0+L$&>6&C"EH%+22LU+4KSV#L2PG@X6./W1Y=X33^9\6 3B M _/L2I;DG%S%F+5>9MN\[,[Z[S[TIQ;:F'BM M;WU+I\ M-J(H<5$2+Y5/7IU,Q9Y7?!A3XG1_U[QTT/&XC^6]?
[Z]F;<>CT03)T.&ELT.EZ.88K"9BI[<%4>04Y'LU"/ MK<79P&)JUBH>U6>KA)!D1;^$:GMX1FW=;B>VX6F$KK9H9J"8Z:(O[!S8!%1M M[QC
]+FFV[",SCPN#H*#ZPCN2A0\HV)WM$A QO8D&Z!GKB,)6$^SHVE[B$06 MRN=.U^TY3O/9HN+Y-3UB6LM::3@W5RRDZ,[3PTAAO=R0_Z[9UXUI#VTJI"&T
M2Q(2IO@$1>S]G,.,'AZ/SL:I>H8VQFL9WP:ME\9PX+\I#FC+ M**@X==PPE)J:9K$0Z'+H,V.3,D5L@WYB:V\(G K.^CKZ5#*MTOT3#T&=?6EH MW7U(7*=([;-
TNH!0E08F'GJ'50]MW>@8KTJQFVF"[Y?X2IF.Q>DB<_==R"#C MDR>H\;)'C0\&E:3$9_E(@U<$C//338#1K]P^]+?]_)*!HLO/ "C0__;_^73 M]M>>B*DSE-F*5M"XRF>[M--ODK-
$5N0!IEY4QKEN<)U-#?(QVPM$D]* !D< MV(&B*1P)T.8>#&]=AS@$*'@2I[9D3S%0LG97T4,11AO;+)8B7I_[EKUI Q$F
MG6TL,H<9H+L.I_&$[]&'TIFK9^CRMN3N#%^.W0:^[(E=1+8I)SX!?.:+W2\ M[Y^L.3CLV8POON.55UO;OZ''R$["B+9-XA%D(MZMM5WR!>V4QG=NL3SY"?3K MVS);
[Q3Q_^X4]O-@>O*L2V[;/:\&+$N&.[6DO_9":5R9'8AWD56H5]J9DSS? MW3JDE5I'#F(GV=&OK)"/C0:V_C$,59(B.U"67Z. .;8:A5U#>P(%\;1(']\@)
M'0_N8=A$P7J5&@EC'EJ!3CY57=J5X@F9UJ8K@X*.\;E.W\!;",S7^"V+'4I_ MP,'7_?90N<:1= .I0$7$DREHN4PGY1YJT_P^QS35#JFI/[I,CFF:?> ;@K6D M1K\SNCN@A+5^KN?
Z&9G]1]3S8IS^+..VL=E07/8M<>?/N@GF;>>Q],>'EL32 M 77O:'_8II'--C5 EJJ*K'==7;?V1PLIWGU\"CY S6-34A2Q<^]X__?29[:= M/O_7H+!&&IN.'8>#7RY4RBWX]QE\YVM"_!%#]
[3["#@ &0 'AL+W=OQWRZ \4;(;VH-H,DV2[FZZ*RU MSL][/;580T955^3 <68I9$8U=N6JIW()-+%"6=H+/"_N993QSF1LQV[E9"P* MG3(.MY*H(LNH?
+B"5&PN.GZG'IBRU5J;@=YDG-,5S$#?Y;<2>]T&)6$9<,4$ M)Q*6%YU+__PJ-NOM@B\,-FJG38PG^A:8U]06W?57 0\ TLNB3T M71)X070 +VS\#2U>^"/^_G4Y5UHB0?YN\[@$C-
H!3=*0$"W(1\%?0Y:G MX@&@S8&#*MH=N'2J+#6*]1J(LLI%I7SUJ)SO*"<+G,1TP$E%"F2) Q;4.XR MXPO@)@=)GE*N7"*DA;XM>_,';!62D?<<0TYY8F2=63%7+&'&$J8(560I4BPD
MZIS,V)9D)=G D(T@52";H\Z:+N1C8?M?;6KBBJ9QN5I)6%$-U:;6?F'54FA] MPOB*4&VMF\.*<6X&JIW(03*1$'_@1H,^^97TNT./1-WA -M1SNZ:*M56M@VK:J];G-
3AEP,UN:KL!)>G8?Z"KUX/W)[0V23Z: M5#PQ:8>(=5U33ZBHCG/1>N$G>^.3D-9'E"L.QD[S'GO.7HO,Z*&F MBCE0ZY1[.NLH'ZWZ&\"B'DJI G19$$^"0-"UGBI92N5B7 M-
0#N\1V3XZM$D\98+*%AC-\X,.?I$#^A[[P##I*F5HHF>'-GYHIIKS^-8'_@ MD3B,B-\?D6 P=/#L]BS0R'P#SYR7+ZP.5R$]%4EBBJ-<=8.F5Y6NF[&B1VQ?$7&A\C]CF&A^ (,T"
MG%*H>N.4= *2?_ E!+ P04 " 6@$M:E5,S;.H" !4!@ &0 'AL M+W=O=7$-XPM$!0?\=)EP1H MVA7+H5O1=-MAV$&QZ5BH+662TJ3_?I3MN"F0YK"+J0_RZ3U*I,=;J9YT@6A@
M5Y5"3YS"F/6EZ^JTP(KI"[E&03NY5!4S-%4K5Z\5LJP.JDHW\+R!6$NG.FX MX7KM7T['@-U7%U,L,2[F=.+ZS7WC@]\+8!7KZ"]O&-_(<2#?:R*H-)@85%XUENS8/!P'#]P*"-
B"H>3<'U2QOF&'3 ML9);4-;T.R@EEI'$SDN[*4LC*)=3G%F^B@-*^&6"R923J.Y2&6%??A&[^'L MD2U+U.=CU]!)UM]-6]19@QJ\@SJ .RE,H>&+R#![&^\2PXYFL*8\
8W.HYK2^A2KUF*$X=J1*-Z M1F?ZZ8,_\#Z?8!UUK*-3Z-,%E62V*1%D#B<4'*-]$O@X[07?0=5<(]IKA,=" M(;Y9ZMGKL'<20C?J4;50+0AZO4JA2%^ DBETR>HJS'B>HUU&W0=!V?
X(R2"@ M[]E@".=D_7X21W;N![30FPM#[MH K_6!A<"UU-QH8"(#NZ=X:HC>DHFGU\TX M"2 9!1#$/H3QH-?D!W(E*Z LKKA8D;/BS\RV!0V^9S5$$%N3]+Z; M5!>GF; M7DO9[T=A
B/B%_2]> A1&/>^S&=02B;(L26,.VJ%M3V45D'VL^E-/N)/:#[MD4S_ 5!+ P04 " 6@$M:[TS_Q.@$ #B'0 &0 'AL+W=O]1,K-I66)."$9%A=L0W+U9,5XAJ6ZY6M+;#C!R]
(H2RW7MGTKPS3O32=E MV3V?3E@A4YJ3>XY$D668_YJ1E+EVO>T[OM>"!KA.I"ZSI9(/7Y)I\T]5W=6 M0UG2C:2"LAQQLKKNW3B7D>-I@[+&WY1LQXU,;
[EZ_TL.R\ZHSSUB0.4O_H4N97/=&/;0D*URD M\H%M_R1UAP::%[-4E+]H6]7U5.6X$))EM;%J04;SZA__K%_$CH'KOF/@U@;N ML0;]VJ!_K(%7&WC'&@QJ@\&Q!GYMX!]K,*P-
AJ58U=LMI5E@B:<3SK:(Z]J* MIB]*?4MKI0C-=2@^2JZ>4F4GIQ')"<E2^]HFJKX$1-+*M<:8,6UFWGEQGW'31_=L5PF @7YDBP[[.SO6^P MMU27FWZ[K_V>N4;@S89?H+
[]&;FV:Z/Z0&=U1T]["J=&;8@L8(Y)W_)G"_?5$/T*TD MF?BWHW6SBN)U4_1$?RDV.";7/363"\)?2&_ZZ8/CVU==0)6T#" DA8" F+ M@&"M(/&:(/%,].E-
'!=9D6))EOK[1&,JNV+$"#DU1BJ87\+T0N!E^H?GCON. M/;%>=N6'=!HY#"%=1H,#%<="MX!^(Z!O M%/ VCPO.U9!+F1"D:[4P,P).U/Z> !TL
MQ[;';KM:!-3+E@C*1H2A480Y%@E:J4P#K3C+D,I=.)8T7U>+?RIIMS!&Z*G* M0,(6D+!@V#'._'W]PN&AS..!O1<,$5##6BJ/&5!E)OU=9K=-1K"_T_/B"4Y++ M3FV-J%.U'1V\0=?
M&TP+293 ZD*/#90CI,@"'M;0=-]J.C=I^85BEZADK M@5L:N*<=:$=-#?:FP;G1YZEC$A(60,)"2%@%!$&M%@6._ M>9>BV,0Y"FN,\)FBN,F"N9F^TI3)!P>T,?;LCV3/AG7F/&7KJ:
>E+4!I 2@M M!*5%4+1VZ.QL[C@@27*-@0H62-H"E!: TD)06@1%:P>+^Q8L+O3WIB;N?G#< M_0^.V>O)TO!)"T!I(2@M@J*UH^%M>\TQ;LQ,[PF/U4(2KPEB*[7$S LUC]!< M$N5,
(I5+D,Z J*!ZVFLBPKZPO?V8 -U(Z4%H+00E!9!T=HQ\;:;YIBWTV8X M+5:[6Q*S[77'Z;Q<>*"KM=07K/$HPRLR)_)W
M=L_5F551(IJ05%"(6DZ6UYT;YRIPAMH@;_$W)5MQ<(ST4!:,/>J3']UQ]8] M(C$)I49@]?-$)B2.-4GUXT\)[50^M>'A\0M]E@]>#6:!!9FP^!\:R?5U9]A! M$5GB32P?V/8[*0?
4U]R0Q2+_B[9%VX'R&&Z9EIK,X3FA:_^+E\$ <&KON& M@5L:N*<=$N#[JD&O=*@=ZI!OS3HGVK&E0;>J0:#TF"0!ZMXNGEH?"SQ>,39 M%G'=6M'T01[?
W%I%A*9:BG/)U5VJ[.1XPI*$2J4M*1!.(S1AJ:3IBJ0A)0*= M^41B&HNOZ,NG8==SOR&:HE]KMA&JK3A'GVOG(TNJ'FFN%9;>9X5W]PWO'KI3 M_M8"3=.
(1'5[2XVD&H^[[,IQ;UPC*Y07J.N<(]=V>^CWW$=GG[\V]&O2!O/C MYQR=E0^@^;;87.2*9BM8<[T*>I&7.3\9,P,S/&)^%)3RAXIS>;U06R>SG& M;<;4 MBM]-C-N=T/Z?'?FX607$U?
_S7T^*+8@]YK)>DZ_$AD.R75'3=]J"\"?2 M&7_YY'CVMR:R0.)\2-@4$C:#A 5 L)IP>I5P>B;Z>(+%.E>,0DM.0TDB%*K M34(QDMH*!1+F0*FD+!9 ?-RF%[?/(T=VW-&UM.A (
\U@30KP30-PK@GO!0 M31MJ_838$OW9X)@NJ1(!>5;+MHC*C7*)2$Q7=!$3I!9Q:,5Q*IOT87345A^0 M,!\2-H6$S0J88Q\(Q+[H'^D#R&--'UZE#\^HCP>VP['<(8XE:0JZT;IMT"%A
M/B1L"@F;>4U!M[M'40=R68OZH(KZX*2H9WB']7NOTY8(J1PH?_F%^EJ$1.5" M49,BC.2VBH"$^8&YWXT&T\A75G$>FC__+^M$B6**S2F M*NA49\LB4UDOD@SQ7
IJ&=D4:R.;:PA83XD; H)FPU?+0G<0=\[GO.!?-94 M<5FIXM*HBCO,'XG61;XR7&R$NB\$BL@3B5FFLXRB%D+?DH41WU86D# ?$C:] M?!U)][(>QQFDP
(5A.%8^]K'O8)'P6=4*EA'2C#K)]=@D S.OK0Y :3XH M;5K2CC\M1R_U#-1I $6KR^&@!.88Y3#/B[A: I0U+@3,]JW##TGS06G3=YY4 M'^T(YLV%/LA^!%"TNB+SK@8ZY(%A\!3*\R_/
-R5@AI@D\%%+WVS96@*@)3]06@!%JTM@ M7QQTS-7!F@0:HS]XO?[HU==/D[*-X]166TRQK>H.\Q5-A?KD+Q72OABHSP\O M=BH5)Y)E^4:9!9.2)?GAFN"(<-U W5\R)E].M(-
JO]CX>U!+ P04 " 6 M@$M:0KV<+R& 5, &0 'AL+W=O[O4]:(I2S6)8*:PQ,[9VE:DDPY M_JVAO2;/,N'Z^2O]LJ]\J3@NX%_%N(01<$GA ,< MHHMOM^B@+NC'EM*=^V&G"]7
@ITPXH<1%AM86,$&Z-L=00?O/WIJ'#7O+*JX MT=[O[/M?\PBZTBS+_VDIY]F*-VCGE4/+YWQ!8W;2,V-'SM03ZTT_O M'P9-INFZ-A,'K8.1?>98/[.SGJ VH::MQR'X M^&C++!M:
Q#Z'< U%SPKLJ;/&FENJ["-L]S?D4$- "B-0-%<3:U;"(?0'1G4 M-H#2"!3-%=-ZB=!O)LZER&7*$ZI+1\&>F"A,R]PQ!8.Z"5 :J6DA=L.# &_I MR=95A'Y;<4V?W]B30:T%*(U T5Q-K0D)Q]
]&=2,@-((%%T5T_J1TT!NFOZTG M@WH24!JI!9L]&4?M/1E;OX']?N.2*Q.XW"LJ8M/J?%W7#^H]#RB-0-%<$:TE MP2%%PU\6@U@241J!]HKIC6FF!OM/XKWXG]Z,ZJXI^%%.%/-
+\50.;I:6>>!_BH+P M$RK7)4>M300TYH>BN5)99X#]SN!^*?*>)D"- "B-0-%<":T1P-!K&(%,: 5 : M@:*Y8EHC@U/U&X%%B"5 _4-/6EZ["\68T\3O6'B+&K!:)N:P_;9D@_IO,&!U G
M$.U:$7&UL2%^Y%]U>:X<=VU@HTT*]IFUIM\921C P?3O:C7CSWL)!1J[M@])(3=L4*MPBU-K(G_X^C]!G=6!W53T.W8513.;CP;0^[- (WQ0 M&H&BN6)@(Q#YC<
O3)=^-EV"AOR@-%+3=DV7 M_;5]U!E3C]5^]!S%Y5"SVE+=W&WVO)]6.[W]JO'5AOEKJAZYR%'*9B9I<'AD M1@:UVH.^NM!R4>W*?!!:RZPZG3.:,%4^8'Z?2:2:E?
+\H,FO&F/X/4&L#!!%O M(!: 2UH__8]0< 8 &TY 9 >&PO=V]R:W-H M965TYY7$XY?DB3A]8/R+V% JR;!5+M\W14I\$R#XJCKMWKC;IQ$":=V30_]I'/IFPK
MHS"A'SD1VS@.^/3QP&ZXW,CO0G4W38$WG5-ZE'[G:ZU:491C3 M1(0L(9RN+CJ7UEO?'F4!^1E_AO1![&V3[%;N&?N2[;Q?7G1ZV171B"YDA@C4
MGQV]IE&4D=1U?"VAG2IG%KB__4CW\IM7-W,?"'K-HD_A4FXN.N<=LJ2K8!O) M6_;P*RUO:)CQ%BP2^6_R4)P['G?(8BLDB\M@=05QF!1_@V_E@]@+L 8_"+#+ M /O8@'X9T#\V8%
&# X#AC\(&)8!PV,#1F7 Z-A+&!;-XT3R& V MY>R!\.QL11/4XL.!;'^<64;@3_:XX7JNS>$?V.Z,V,,\?- 0[IC#/7I_1JQ^'MYO>IK'7WQ3=L\<[M"% M,=PWA\]IJL):XI^I1]Y+&XJ^&:
[PJF(-F9E;7 MWXHT6-"+CBK<@O(=["O;!&O?C8V$.4B8BX1Y2)@//@FF2&522&9CHLUNZ M4V*A19TB(HU"24(AMG1)5'TBJB<64FV$R?JQE)VH^I4+39PVJ69 M%(>FB3
HRDM@I PIP"-MIK-*NG?O1&5,6#H:H/2J>IP.K5EDK/ M/+K8F[F^>G%N6^-WA.;3UR8%F&%M)5#2]L?R_>&38:$#3>I":1Z4YJ-HNA;V M[#7+J(4/5)+WB:H&C=!]^>?
#&>CA:@*5THS/2?!1-;WF[;GG;7 7R MN<7O^4B1?+ZA\3WEC9:5F=-:!$B: Z6Y4)H'I?DHFJZ6VNRTGL/MM*!V)Y3F M0&DNE.9!:3Z*IDNG-CTML^OY_^:K9GAK"4%-3BC-
A=*\DK;?V1YTM3XJH:Z+ MVN6TS#;G!Y:\<>,T8M\I-7= 4),32G.0-!=*\Z T'T73U5([HM;H.3H@J ,* MI3E0F@NE>5:CZ+ITJG]4LMLF,+=,7.^UJI"TAPHS872O)*F>^N#\6&W]Q.
MJE5;J9;92_48IXM 2'.7!#5(H30'2G.A-]*\U$T72FUG6I-GJ-+@EJJ4)H# MI;E0F@>E^2B:_A97;<':9@OV9U9\XU2H9&K_4K?TXGEMSMM6#U":Z5Y4)]/
MHNEZJ&U8VVS#/NETR#_DE@HU75YD Y?"]\M?:B0GM_,[<6KLG_@;5U_+M^)^\!F]&MA8.U.6%TEPHS2MI^R_C#.RQ/3DPY%!)"T5T]Q:#Q92O M\W5^0HTSMHDLUH551ZNUA)?
Y"KIN?7]Q$/$FX.LP$2B>P$*Q7:.QNK.^%VKYB M1[(T7UIVSZ1D<;ZYH8&J2MD)ZO,58_N)Q)TM0K;"<_0M02P,$% @ %H!+ M6B-J1O@E!0 S!T !D !X;"]W;W)K&ULS5E=
M;]LV%/TKA%%%L*=*!#L_OZ4.4&ZW\L.IF/R^#-JI:3-KF/2&\2]@+0*AUH M,C7(XHT%UY1_Y3O8)"S/&4#Q\M_!5\K+@Q8Z:-LWH/>%#_PFR9V4,*&F+8PBX!>%?9]VL+H&O
M_UE2&DZ^*"=7ODIAX^>@LAQT7;-GDI3HRG<+J7(\HY^Z1V:U@@!QP5&HQO_%%@+'9\A'@&HI0G&AC(/Q=&;P;L'/-M6FRJ\:_OK:\<](T7Q4/OG%N>))
-R(25+Q^+Q<$&]K&G,+$$\&9=A'5O*0BY+&ZM:AZ)&YF0DM;1_WK/=@MP^FK1&Q^-+$B4B!)3ZQKT@+*2[BR$&6K+"^Y=_+ZBQUJJ80![D.Q1?GWTL^,#)9^FPQ%!&TZM5B*/ZX\LT/@:ZCSRBQ3B.A
M7\DK;?VI=SUUBV!_8OV@20$-MWC+T@QQ6)+^>R$#&/@,R*4^S42+AZ23Q"_DEDGIN0(:9X^CZ8\XO_A%^=AFXV@/(JV@X=/QBG+-V)N_QH4;2VTJV>0]H2B0!ZG6@9*#YJ#GT3PM&#.
O+;>IX6WCR&#P%)F02D_0&E6<9LI^C/8)%DK@1U9OW@$5)UMM&[N6?I@C/*^%>9=)XEVCD;+O"U[3AV2KT^7\0.36ZX#Z!
OPPNCPT&KKQ0KHW@#MJE#A+@>V9$9>&+1%Q&NJF+!X>2@$SB<\20-XK6
=R=6ZH+MKM>/;AHYZJWXM8#X2P#+3O9QFG65NDERW6(>%(GGUO6JUAC)5?(=)@FXMJY9YUXCVXWZBG$9>9TAY/TX;9C+;7Z2H39RX=!#TVZH
M9.8U]GV!L6:Z%6Q$IP(S^RR(A!3J:N!BE34O:OXH4+9*OQOVF&+Z3^B"'V)EDZ0@^2P>=@&IHPR9A/8!EK)XCMO&\P[HMT/A6(JJ=Y7(3ZPWK)34G+3QF[@&A'GY[>N[=FI.WZ(CNT"Z@^T)ZO-%]
M2T(XGZ*P84MCO%(GI+WZ(=+5VTD3;W\S)77/3(I.V\;6P[U&H%TW+&9#Q%;D_[GQ8KM?X3IR+3Z?^\J1I;7/R@^Q(G6"[6WG@@@J37N_=[C/1?U$0;.GJ&KO,3)D[`"2KL"`:?
1L=Z5DH?3Q$!ND,04=:72>L9F/?_"7_96(B/DF\2=2O6'3WF&#NCW[4G,VK@+MZ41HUO3D%Z$>6C'[!'.X;'2:5ZL=8%I&70G'2+`^(H_S`Z)R)\&?5&#*5>!D%2)?HBW1FKZ-@?%%HRC8B]H9)5Y'8G0R@(8,.'5
@KSCA0OGSRM,3MN#"F!)&&-C2;%E@P'ASD$DU+4ML>RV6(G]7MW;G$CDP[Q2F\QJ>XAKG30BM*S%#Q/T)<0_/CF\L9T\30JY>=3.#VXAG&ZU84TP6+:(N`@FAL;]0_3&A2N/X/`\U7C8+;S%?LT^7!I/=.N.0
/'@P,H0`1"7)2=!+P>.+GT`QA:,W!TR%7I-OGNS*_@H9,%ZR9V&I@H.>0<&'BA=TB6+K69V?&A;N/+2)C0C:$%9;+X2]3E[\/`=V4Q/;^N:N/-+NYHT;=I41.BF[0O<_AFWQE(R44'QOW#/N@F43=/2U/
3DA)S*K:53UUK/EU9+L)T!>:L:6A;[)5%D+O*J,EBB_,IA/?9-*:.*4BS8Q@=R)H1_M:#N8S%%WS$PG;&0>:U/(=B)[<6L8>@Z&E`(7Z_!GX;:+76V7=SK\SNW\KA5W5YZ]N4U$HNG:@E\GL`)]-3%VL@
/"3@$P&\Z9'`'5\(DAP%R&3+_(-;0>S1,L1V>DNBV>6,-;8JP2>>D$VK0(EF'R*`U,]X5KH)O(Q8?G#W%;VO0?\2,G#+`C-;L29^KU/+`@2%'DXA:'R$(V3@(\JX)7K?(\W!`"CC?H#GJ^>I['+]!.QIR_<
2L>TT9J>V"*("%[N*R3+&@Q=2!4^F#WK>E!A-'TL9)LK"NNV!JBEHYT3W3M%4YPOZ.(!JNS33+\-MZ@GI%5A-BG]F7(7DL1;6XEU-.C-7M5R-QSQ-OTJ`?@WPZ-7)`KRJ'1$8V&JTW3R`CR!X)(*1!JY]!3!1.`!
YC.JV$9?W,?07KGCOUPJ"NC\SGZCP<2NHZ(N:1+V\N)NNAU5NL#MTQ/2%!9E1>@K<4F5+WN`$OD6-0:.#=#6:!B!$!/1IV)=\0VY7NJ`?%O>NM"%N\&S&R+Q.`%@KUTPM4U.Y)M!-0)P30%3`O!+!-VAEG/B@)8
@X<^`$EM<\N`$"@Z)@A`4/G`5M7\;T7+'9LZ@1\=9E&!!RPM6H<%#_W(A:RR%7:16WS6#_3^P(G!I>8R+-Z<2>AP0KM>>88CTJ@XP5;&)KIG;K>T!E!HR54-&;62<#4DCUBYUJ@U8K6A(9U^EN!6,8Q</R%
[!T,BO\%QDBGO=/X^"B3=?:B8'Q4%!6C9A(3=`6E+T_@1TJCUNB-#/:XSA8=!,NR*ESIW9DX4!S\X>U?+Y6O'.QI8/C>LX`@%N&*!-.+WYYN(H^%:YCLF:ZPM)#%`CZ:NSO_ZU5&=Q/OO3-&!M6%;7-^$W:QA&ZRBJQ1#
MIXBU>5QZ\@Q>P?K!B%=8%6JFQ!^XF:;Q/*9PFO@:5D#@%)6D0X75E>0\9/0&@M@`MCZ=Y"*SJFY=:H.#W!;\WKTX4/E&S4?Q)XG$+`8!I81>.+[R75Y%0R@/+&Q1#5T@]MK9YC'JTU#*M;
M=EHV@)MD\R.ZTTV4\MTC9=UZC0W;`?P5.#;A_"0X$O4`E+L?!P\79MBCAH4/F;M!]HBD%HJ&W/_=-(/\A!I%)=2UHW;+>I0:/#`P%Y6,@3<[.`.BG86QW&1)OHI!E#!OV3T;6;G*H!$;_C&[
MZ(')1$<\@TZ-"C`W2J\N=+W8WK'H,%Q$G&W5N);A6X-Y&#4%QCYLV^7;ZR53,"F=>R4&W6C.22#FX7%5\P8!Q=4PUG=B!J^<:=I!E=@`P_IXQ55@A^3*`_@T=3,ZJS0+E`'-0$-)!1\7QNCF
!VB3\06+R5;U=C1!`7^`+6Z/W'[DK@>N(2Z=W%@:0!"S%IO'$GF!(8Q/6+1&DJ9*[#;!@OJ-UC,KXU#Z2R_#>Y`K=?$\-*0>(TGG#0FZ*O(_6/\5_S`=U;6`.:`WC(A4BK4EJ;@W#HBTSJ%<
M&C%H<8$?VM%\PU2V_C>&1$<&D2O1$V@/9Z!5&N`O97`QV?\+AZK%U=O+SN[IOMN%2@!&QZ5OL&<`\>,(Y?<-G_+MOA/>Q_#`Y]/U;HL>#$K/R)A4.'@9J?>Y)R8(J:7M7JRU6:D=UXR>@
1L7+SY]2H8+!G,A<=6L9ZJ%NF:K5-`<T]]!@/[`3"LN4,8R#GI=<U4U!=_G*_`H1>,9O%+=:=[V+T46^9C*-`4DD5`5ZJ9YNB(LJ$RAO`E2QTW<DA8-QE)[Q.%A+G@5YY;;B>
M\+ZK-S6UA1IIVM`TOVW>K,-7UT3`YI((-<K-C.I&I:P)ZQN8Y9F55+EPU>8O1SGX+EE=\`;:S7YLO]=+9$;U>W!>OPK`H@H4MV*G^FO?&=E'A`GM^4@)\8.QL]TIMT8V3XC4-1"1X
[?J,3G@;WJYG<6[UD2;#-)FD_,U>UC(:\BRFNW*JHHEY6`I-(TYPEA;U.1R\;RSF:9'&LXFVGH.RPV1B7Q[!=L\9'-'JI+2"J:@4[AM/*%Q0AX+9&ZT,1/4$+&Y/_N7<$EVN%J)Z0H
4P"E6D&O&2!:B@FJ%_,]J6#K@_J6A^X#'17)W%0U;7-X,8L\O]*,O7W<X(-T<+SF+`/?G<8J.F@Z.KN3VQ\<V0U&:-S+M9-[T!3V0QG7+V%3>2_Z<Y_XF?%N)A1V\NT>8-;#N
JKHW<A4=A>P3/!ZB7^D:"J?EF`$]IT\KTJJ67K?[,6Y*27L!RUJ0<K7+<6^3?A,C[9:?4VS0B2D[0Q'MN<*F0V'#+X8%6(2BLJ>F%^D=-.@-Q(\KAUA=G4-T'X;P3FSJ[LO_S!MK-.S1.FU
MGY7IM<XN5(QMM<V)Z:QJL/KKW'2U4#A`E.;20;?2.)UMI^LIYFX*E3U1_5XE1:(6;(9B:U>?:)30G*>T-G;)2:PYU?5F2KQ[#!Z\Q@.C_/9=_ATOIT0;K28=O%Q.*5J#/FG(]\+!;30S_S?KNP
M`S^QKS5.7SKP$LO.P6GB+DI!\N^,0-(NB[BWAH4XJ7OL*ZZ?,6'`R&LH8Q)P]4D0U3E5F<=$L=P`AE[Z/0EI`\6Y];<+"DC0PB#T6DD@QCR1$R-@M=\1+P`S.`;MWT$RB8W`LW2<</QZ2,
M4B-8>X_AO/`Y`Y5[R`UQ5>TLH*Y>C7%V^C;K:+_9MT,KX;*[3<4Y"/-@J[BZKU6'+1G((_L)6%_,$^,XAJV=JR@UP$=P*W>[N:L,"GV#C^/-VS]0>\(*X9>K;2R/^J:Z0+O;\E[X7MFV8A)
HE:KVT-"<S/14UU(?;J@S?YJ)2_CG*&(S@;*_SX0[Z*5'!R3(.N'!ZZ`LXF?8\Y1@!E>-:2\:9'#W3]@YIB/8>>NSV=%-3_5XR:<VLFP.8$Y17I\&3FO>.E?:I/1\9*:(:?Z!F\L!X'=SIOP
MD`9Y[O9#+6M"!$,S'(@WY2&:M!X2/_W?O2?!!R&_+DD+7\@S*!?YTPRU+YYN`JR[`7Z,B/?1-+)V`7UV#G/5BG-"M,X>=UMAP@=C"!>Z7H^I<KK8'K4T]`%&6GK>`/RYM3!?U+6#!C^N(
7K-,'1$MUX+5XIX/]P@8)_S[#M!3:U:]O%I.\G9[71^8)A*!A\-U(%0Y'1T_A]QTW6P\9]TKW,[2L/3[3&LZ>6DPQ,0WIM#T)%$J>!G=B<6:'($%X@/C24;)+S*%#:`!@;/G.V9Z/
MS*?Y%>JG#&/W6[`.'#?6W]8?9J@T/H1Z,0UW3+>R*-B#Q_R=YU;)&]:!>DQ5VRVR>MTT(S^Q6NLJ8$/?:>W]Z*T**V6#X*EH@=\FW^9QYV1$0\=Z;^N@2Q&!3IYRBTR)PZO8EB:!@P-

[(('K>#!6<%_ZC7(@]$ MFM9THM8'E@SB3AG/^Z HC#MR^Q@_"CN>I'W0*#A1Z\-6[_"LWO1V1@I!.0IM MBAZ>

<*14]K,=]A*X#/QN.5M!W7JV@*+N[S^U@4+/+GC4"AZ=%5R]>VS:1OVV M-8PZ)S#O@P)_U)%F(?*\#BCM@Z)1]RC=@RFM!+FJQF-%,K'ENG[QMJOM!'Y3 M#9Z=]9E_/?
Y_I!)_ZXH4L,2MO*L!'H*L1^CZ1HM--2,^ M"(T39W6YQG\=(T GR^%T,\W9H/V?\ST!U!+ P04 " 6@$M:H [_]8T& M !H-@ &0 'AL+W=OC0RX4:FP@S55F;NDY72
MJ;!N4Z]'9JNEB(J@-!FQ\7@Z2D6<#99GQ7LW>GFF=C:),WFCB=FEJ=#?+F6B M'LX'=/#XQOMXO;'Y&Z/EV5:LY:VT'[8WVFV-:DH4IS(SL'QB[/+V]V= MD5]V,K.$W[O?
AKP(I!5Q8EZ25^3#;4!>_/CR;&3=KO* 45AA>8EE1[!3\DYE M=F,(SR(9M>-';HKU/-GC/"\9"+R6=T,R]G\F;,S\COER4G[]-8-(6^L3,W?'?.[+'F3;EY>C%Z; MK0CE^_=$F-
"0LP81P)UDK*I$[*!*(OKU2:NLIG-L*Q M26S,3D9D*W7H$N1*;E=60&#?K&#" DP8+V%T7-#RSG6_' _IV>B^0VV_5MOO MH;;K@,:*+(JS]7$!9@P[O>0?%I+/@4E?QN+NSB);2Q-
E[)@<%]E M,6$!)HR7L.F>L/XX_^G6=E9K.P.U_2BT%JZ<6ZG3+G'!Z+[B8L("3!B'1?+(M-RFT 6KUO)9[#I+^4)]5JB)%WMJ(?'HGTSNI._LFB.FK.R8LP(1Q)%@K%XLZ
M%PODQ,+QN"_R,U.AQOGP(A(U2ZS77F "7T3@4H+ M4&F\HNU7?3H&RC[=LU\4EEG+5VXA([^1>Y'L1&Z>.Z4&*;VEQJ0%J#1>T?S]
M!@MU6,H:J1DH]444Q;F^(BF7C62KX[!SD0B#>JN-20M0:;RBG;J=YV$'!%0W,ZJTV MJNM$I7$L6CLKC4&E/O*ZAJ*:4U1:@$KC6+1V:AHC2V$G^^BVY%>IP]A4G8"\
MB#,2J"1Q'B,_BU!6K*Z3GYF2MI\KRI,AM/&K5<9.&44QYI96]G&QE+8
MHOVJE7'B:15*&1EB9*BRR%7_E=1QMNZ4Q4C]9V\@\YV<7"^^C]=47UL:@TCD5K9ZNQLA3;RU)4,XM*"U!I M'(O6OGS4^%D&^]G;\DPQ?'889O3-!BHMJ&@'B\?980/
VFE;YL;/,MC/7JS7 M6JZ%=3WU\03"49L%HWJKC6IJ*]I^MYET=1N.M=NVWHVI9;"IA?I#?F[A>I=? M@"75BL> ;0+>5>]\H-I>5!K'HK63UIACAGW]EJ%Z9%1:@$KC6+1V:AHOS6 O
M75^(44T!"_>O-79F!]53H]*"BK9?R-AT[#TI8\]AEEECEAE\.?=_.S*8WSL% MJ-ZYHM%)JW.[5O*D=S^'+6:-+6:P+89ZR6."P/Z!ZHI1:0$JC6/1VHEJ7#:; M8?T=I+5]_W#DZ3=
R;3_S%XK F M/8>C9HVC9J M1&@,J :[HM'6Y:FA/YT?BGO:.(XUN_9MA(TI]KYCBH&*?RDS MN8K#6"1$/612FTV\!-QFBFF=4&L>BM;/6>&R/(I=_#]5IH]("5!K' MHK53T]AQ#
[;C?];_*?"))AC3.R&H5KNB4=9:KM+%D]: M=NVUGLW0<.7F&]T M?)^?:+I)W#[2@^K5ZYHHO*/>V<"]/QKW!NGG<-=>XZZ]"7;E0K76J+0 E<:Q M:.W4-
[<@QUX?;^76K47K,5:JSQ[WKG @KF],^0_N?UGYB\8/:@]0<1PA84UO5+6T=Z3-JG4Z^(1)T.*6UW*AV[J=^O'J"Z*AX=&S?#R&:QW0J_C
MS)!$KESH>#AS$]7E8TWEAE7;XKF=.V6M2HN7&RDBJ?,![O.54O9Q(]]!_7#9 M\E]02P,$% @ %H!+6I4MD1EU P 3Q< T !X;"]S='EL97,N>&UL MW5C1;MHP%/V5*%VG5IH:
(&L@*R!M2)4F;5.E]F%OE2$.6'*AX.T=-M.?3HO-22H(,YMP]:@#WYQX@[AY;._LK!Z,,#Z?>R&_*@VF## M?IJ+>I^%OC7HZ"2CWAWA W]$.!M+!EXIR1A?6G,'#).H-K.6VPE/<6
M;ML>[/V*)V,BER:VC6"_Q]7P'6#5 X&,\[7 CF\-PWY!E*)27.J.&6R,CR"O M:M\L"ZUP*LFRW3GW:P=STT'&N4RHK)\W_LHT['.:@AS)IC.XJ[P(%0JSW0C
M862:"V(TK#RJAJ:=4,ZOX<'X/=WB7J0;ZVI*6:R;6E#5M#2V _R;;)9[DS9Z M%J]7L+M?->UBSQO@LBH"2(;49.])HB,&R"R^V)/ MS:>(;#=!9*<)(L-
7*3*H#I4;)]>M<^O:ZL'O@X'_#7Z-\#JH-YXSKIBH>C.6 M)%0\.KYJ>D7&G&[SZ_$)3:L'D6KT==02*J477["TQ/GX57 M/TYT+"82NJ#)J.K*Z=@T/=W04:L+'':12W.Y$H@C^ MW&R8-
O# XD"DI^4:7VV\0O;7 ;:F^RH$FRE>B=A,\5P#XLX;>,2Q>[6Q.."! MK0)6.Q#?'0=JRNT3AK"JF#9L!^-('&,(U**[1J,(R4X$'_?Z8+LD#./8C0#F M5A"&& *[$4-8?
20$3;8T.P6BP^0"X99K>]9!:G4BBL1:8)4F5JV(U\E-3HB%+\5VRLJOGYVLFH'J:"\>3XDO M<3Z?Q.=S5++KC; MC+/N7$!&)%=<\F>HQMD@([;13U^UX<]:.286I=%"C+.B;
[@#XWCYIGH1(&_9 MTG8UCBU_, \RSD8#/V#-C75=CVY\YAG7X#OWI=;I*RX\A*DN6PG*]7$T(*@L@U?V8PH)F&<3?0:3)B/ MO\&LZN?F/%04*7/*?
8.951U>.I29\@'ADDRTJD!9J,*9U8)7GJ0! GGPGI '$>00@1S^;\A%(E76:+K"/(0@3Q\ST@.(\@1 CE*"WD- M"@P3$9P6N8[/DMJ@#[,8;$ M9%(DM@FRH -
KC(GII$CLDS\&)GM3<(R+E_'#)%(DM@@J.K(7[ZDQI]#$3GDC MNYV1I)A::&*U[%XNNRC1KY/4=ME%^8DL_-!5*^(T3C'7T,2N03%??$51S#8T
ML6UPS/@[BF+"H8F%@R5)3QMC8L*AJ87S>N>S>_E@NJ&=;O+M;Y$*:JZ@NO'# M6U]?,E'.#0F'?ILW/ S)MVZ%F/BZ[\JGF6K[EV7[A^C\-U!+ P04 " 6 M@$M:?SW?:4RO>G&D\
(.;>;'Y5#J M/LMO66DTQW&BA]<9ZG1\G1E='KWYST1;%'5N/FW^W9K._S%8_]CAYBICO(HN MV5 :GRI];^9MIZ<'K<;)*CI?4S6 $ +$1 3 6T-O M;G1E;G1?5'EP97-
=+GAM;,V8RT[#,!!%?R7*MFI<&R@/M=T 6^B"'S#)I+'J MEVRWM'_/)'U(H!)1%8G9Q$H\<^^U1SJ+3-ZV'F*V,=K&:=ZDY!\8BV4#1L;" M>;"X4[M@9,+7L&!>EDNY
"9&HS$KG4U@TS"U&OEL\@2U7.F4/6_PUU# M"*J";"Y#>I$&J]A&LYBV&F+1+W$BHZMK54+ERI7!EB+Z +**#4 RNMB)#OJ= M$]XP[)[\8O].IL\0*^?!^8@3"W"^W6$D;??
0HQ"$I/J/>'1$Z8O/!^VT*ZA^ MZ8W7^^'"LIM'9-UR^1U_G?%1_\P<@DB.*R(YKHGDN"&28TPDQRV1''=$&UL4$L! M A0#% @ %H!+6D1Z5(M>!@ QR, !@ ("!#0@ 'AL
M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %H!+6HH/ MR[.G!@ ,AX !@ ("!8QD 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ %H!+6J$X-6QL"0 !< !@ M ("!8C
'AL+W=O=.L(!-% M& @(%B1@ >&PO=V]R:W-H965T&UL4$L! M A0#% @ %H!+6K[[7=&?!0 I@T !D ("!@T\ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %H!+
M6B,>N74R" 0Q4 !D ("!HF, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %H!+6ED&92IH#)", M !D ("!/G$ 'AL+W=O#@ &0 @('=?0 M>&PO=V]R:W-H965T&UL4$L! A0#% @
%H!+6N],_\3H! XAT !D M ("!]H4 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ %H!+6C_]CU!P!@ ;3D !D ("!)I< 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @
%H!+6A5$ MP'"9 P LA !D ("!PZ8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %H!+6I4MD1EU P 3Q< T M (!/;4 'AL+W-T>6QE&PO M=V]R:V)O;VLN>&UL4$L! A0#% @
%H!+6G\]WVE' 0 V! !H M (![+P 'AL+U]R96QS+W=O XML 42 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 133 208 1 true 32 0 false 6 false false R1.htm 995100 - Document - Cover Sheet http://xbrl.sec.gov/dei/role/document/Cover Cover Cover 1 false false R2.htm 995301 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet Interim Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 995302 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_Parentheticals Interim Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 995303 - Statement - Interim Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement Interim Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 995304 - Statement - Interim Condensed Statements of Changes in Shareholders??? Equity (Deficit) (Unaudited) Sheet http://www.pluri-biotech.com/role/ShareholdersEquityType2or3 Interim Condensed Statements of Changes in Shareholders??? Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 995305 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.pluri-biotech.com/role/ConsolidatedCashFlow Interim Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995306 - Disclosure - General Sheet http://www.pluri-biotech.com/role/General General Notes 7 false false R8.htm 995307 - Disclosure - Significant Accounting Policies Sheet http://www.pluri-biotech.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 995308 - Disclosure - Commitments and Contingencies Sheet http://www.pluri-biotech.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 9 false false R10.htm 995309 - Disclosure - Loan from the EIB Sheet http://www.pluri-biotech.com/role/LoanfromtheEIB Loan from the EIB Notes 10 false false R11.htm 995310 - Disclosure - Shareholders' Equity Sheet http://www.pluri-biotech.com/role/ShareholdersEquity Shareholders' Equity Notes 11 false false R12.htm 995311 - Disclosure - Total Financial Income, Net Sheet http://www.pluri-biotech.com/role/TotalFinancialIncomeNet Total Financial Income, Net Notes 12 false false R13.htm 995312 - Disclosure - Subsequent Events Sheet http://www.pluri-biotech.com/role/SubsequentEvents Subsequent Events Notes 13 false false R14.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 14 false false R15.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 15 false false R16.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.pluri-biotech.com/role/SignificantAccountingPolicies 16 false false R17.htm 996001 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.pluri-biotech.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.pluri-biotech.com/role/ShareholdersEquity 17 false false R18.htm 996002 - Disclosure - Total Financial Income, Net (Tables) Sheet http://www.pluri-biotech.com/role/TotalFinancialIncomeNetTables Total Financial Income, Net (Tables) Tables http://www.pluri-biotech.com/role/TotalFinancialIncomeNet 18 false false R19.htm 996003 - Disclosure - General (Details) Sheet http://www.pluri-biotech.com/role/GeneralDetails General (Details) Details http://www.pluri-biotech.com/role/General 19 false false R20.htm 996004 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.pluri-biotech.com/role/CommitmentsandContingencies 20 false false R21.htm 996005 - Disclosure - Loan from the EIB (Details) Sheet http://www.pluri-biotech.com/role/LoanfromtheEIBDetails Loan from the EIB (Details) Details http://www.pluri-biotech.com/role/LoanfromtheEIB 21 false false R22.htm 996006 - Disclosure - Shareholders' Equity (Details) Sheet http://www.pluri-biotech.com/role/ShareholdersEquityDetails Shareholders' Equity (Details) Details http://www.pluri-biotech.com/role/ShareholdersEquityTables 22 false false R23.htm 996007 - Disclosure - Shareholders' Equity - Schedule of Share Options Granted to Non-employee (Details) Sheet http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable Shareholders' Equity - Schedule of Share Options Granted to Non-employee (Details) Details 23 false false R24.htm 996008 - Disclosure - Shareholders' Equity - Schedule of Activity Related to Unvested RSUs Granted (Details) Sheet http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable Shareholders' Equity - Schedule of Activity Related to Unvested RSUs Granted (Details) Details 24 false false R25.htm 996009 - Disclosure - Shareholders' Equity - Schedule of Expenses Related to RSUs Granted (Details) Sheet http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable Shareholders' Equity - Schedule of Expenses Related to RSUs Granted (Details) Details 25 false false R26.htm 996010 - Disclosure - Total Financial Income, Net - Schedule of Total Financial Income, Net (Details) Sheet http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable Total Financial Income, Net - Schedule of Total Financial Income, Net (Details) Details 26 false false R27.htm 996011 - Disclosure - Subsequent Events (Details) Sheet http://www.pluri-biotech.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.pluri-biotech.com/role/SubsequentEvents 27 false false All Reports Book All Reports ea0229816-10q_pluri.htm plur-20241231.xsd plur-20241231_cal.xml plur-20241231_def.xml plur-20241231_lab.xml plur-20241231_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 48 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0229816-10q_pluri.htm": { "nsprefix": "plur", "nsuri": "http://www.pluri-biotech.com/20241231", "dts": { "inline": { "local": ["ea0229816-10q_pluri.htm"] }, "schema": { "local": ["plur-20241231.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd", "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["plur-20241231_cal.xml"] }, "definitionLink": { "local": ["plur-20241231_def.xml"] }, "labelLink": { "local": ["plur-20241231_lab.xml"] }, "presentationLink": { "local": ["plur-20241231_pre.xml"] } }, "keyStandard": 175, "keyCustom": 33, "axisStandard": 15, "axisCustom": 0, "memberStandard": 19, "memberCustom": 13, "hidden": { "total": 36, "http://fasb.org/us-gaap/2024": 28, "http://xbrl.sec.gov/dei/2024": 7, "http://www.pluri-biotech.com/20241231": 1 }, "contextCount": 133, "entityCount": 1, "segmentCount": 32, "elementCount": 541, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 426, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US",

"decimals": null, "ancestors": ["b", "span", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "span", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Interim Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "shortName": "Interim Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Interim Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Interim Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c5", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3", "longName": "995304 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders\u2019 Equity (Deficit) (Unaudited)", "shortName": "Interim Condensed Consolidated Statements of Changes in Shareholders\u2019 Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c8", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.pluri-biotech.com/role/ConsolidatedCashFlow", "longName": "995305 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Interim Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "unique": true } }, "R7": { "role": "http://www.pluri-biotech.com/role/General", "longName": "995306 - Disclosure - General", "shortName": "General", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.pluri-biotech.com/role/SignificantAccountingPolicies", "longName": "995307 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.pluri-biotech.com/role/CommitmentsandContingencies", "longName": "995308 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.pluri-biotech.com/role/LoanfromtheEIB", "longName": "995309 - Disclosure - Loan from the EIB", "shortName": "Loan from the EIB", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.pluri-biotech.com/role/ShareholdersEquity", "longName": "995310 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.pluri-biotech.com/role/TotalFinancialIncomeNet", "longName": "995311 - Disclosure - Total Financial Income, Net", "shortName": "Total Financial Income, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.pluri-biotech.com/role/SubsequentEvents", "longName": "995312 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R14": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true }, "uniqueAnchor": null }, "R15": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrTrmntdFlag", "b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrTrmntdFlag", "b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "plur:UnauditedInterimFinancialInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "plur:UnauditedInterimFinancialInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.pluri-biotech.com/role/ShareholdersEquityTables", "longName": "996001 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.pluri-biotech.com/role/TotalFinancialIncomeNetTables", "longName": "996002 - Disclosure - Total Financial Income, Net (Tables)", "shortName": "Total Financial Income, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.pluri-biotech.com/role/GeneralDetails", "longName": "996003 - Disclosure - General (Details)", "shortName": "General (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c61", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "eur", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "td", "tr", "table", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "unique": true } }, "R20": { "role": "http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails", "longName": "996004 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails", "longName": "996005 - Disclosure - Loan from the EIB (Details)", "shortName": "Loan from the EIB (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "c70", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "eur", "xsiNil": "false", "lang":

null, "decimals": "-6", "ancestors": ["span", "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c74", "name": "plur:FinanceContractPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "unique": true } }, "R22": { "role": "http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "longName": "996006 - Disclosure - Shareholders' Equity (Details)", "shortName": "Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "c84", "name": "us-gaap:StockIssuedDuringPeriodSharesStockSplits", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c84", "name": "us-gaap:StockIssuedDuringPeriodSharesStockSplits", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable", "longName": "996007 - Disclosure - Shareholders' Equity - Schedule of Share Options Granted to Non-employee (Details)", "shortName": "Shareholders' Equity - Schedule of Share Options Granted to Non-employee (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "c93", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c93", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable", "longName": "996008 - Disclosure - Shareholders' Equity - Schedule of Activity Related to Unvested RSUs Granted (Details)", "shortName": "Shareholders' Equity - Schedule of Activity Related to Unvested RSUs Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "c99", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c99", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable", "longName": "996009 - Disclosure - Shareholders' Equity - Schedule of Expenses Related to RSUs Granted (Details)", "shortName": "Shareholders' Equity - Schedule of Expenses Related to RSUs Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c115", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c115", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable", "longName": "996010 - Disclosure - Total Financial Income, Net - Schedule of Total Financial Income, Net (Details)", "shortName": "Total Financial Income, Net - Schedule of Total Financial Income, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c5", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.pluri-biotech.com/role/SubsequentEventsDetails", "longName": "996011 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "plur:CommonSharesIssuedpercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "plur:CommonSharesIssuedpercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0229816-10q_pluri.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Other accounts payable", "label": "Accounts Payable, Other, Current", "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r32"] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r10", "r32"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r35"] }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalty (in Dollars)", "label": "Accrued Royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties." } } }, "auth_ref": ["r75"] }, "plur_AccruedVacationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "AccruedVacationsCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accrued vacation and recuperation", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees.", "label": "Accrued Vacations Current" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r541"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r45", "r471", "r718"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r364", "r626", "r627", "r628", "r630", "r682", "r719"] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": ["r597"] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462bFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": ["r597"] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecuritiesEffective413b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": ["r595"] }, "plur_AdditionalSharePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "AdditionalSharePrice", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional share price", "documentation": "Additional Share price", "label": "Additional Share Price" } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r554"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r554"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r554"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r554"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "plur_AggregatePurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "AggregatePurchasePrice", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate purchase price", "documentation": "Aggregate purchase price .", "label": "Aggregate Purchase Price" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r588"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r504", "r515", "r531", "r566"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r507", "r518", "r534", "r569"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r589"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r554"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r561"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r508", "r519", "r535", "r561", "r570", "r574", "r582"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r580"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable"], "lang": { "en-us": { "role": { "terseLabel": "Compensation expenses", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r254", "r256"] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r511"] }, "plur_AnnualInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "AnnualInterestMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual Interest [Member]", "label": "Annual Interest Member" } } }, "auth_ref": [] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r73", "r86", "r101", "r118", "r143", "r146", "r151", "r152", "r160", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r270", "r274", "r290", "r328", "r393", "r451", "r452", "r471", "r483", "r646", "r647", "r701"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r97", "r105", "r118", "r160", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r270", "r274", "r290", "r471", "r646", "r647", "r701"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total long-term assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r118", "r160", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r270", "r274", "r290", "r646", "r647", "r701"] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM ASSETS:", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r511"] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": ["r496", "r499", "r511"] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": ["r496", "r499", "r511"] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": ["r496", "r499", "r511"] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": ["r593"] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r577"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r578"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r573"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r573"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r573"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r573"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r573"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r573"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r576"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r575"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r574"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r574"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": ["r499", "r511"] }, "plur_CEOAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "CEOAndDirectorsMember", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "CEO and Directors [Member]", "label": "CEOAnd Directors Member" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r11", "r99", "r447"] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r616"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, restricted cash and restricted bank deposits at the beginning of the period", "periodEndLabel": "Cash, cash equivalents, restricted cash and restricted bank deposits at the end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r11", "r57", "r115"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Increase in cash, cash equivalents, restricted cash and restricted bank deposits", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r57"] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r612", "r714"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "(a) Supplemental disclosure of non-cash activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r552"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r549"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r547"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Shareholders' Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r102", "r103", "r104", "r145", "r202", "r203", "r204", "r206", "r209", "r214", "r216", "r357", "r358", "r359", "r360", "r459", "r605", "r623"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r19"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercise price (in Dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r217"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r553"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r553"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r41", "r78", "r331", "r379"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r62", "r167", "r168", "r443", "r638", "r643"] }, "plur_CommonSharesIssuedpercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "CommonSharesIssuedpercentage", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares issued percentage", "documentation": "Common shares issued (percentage)", "label": "Common Shares Issuedpercentage" } } }, "auth_ref": [] }, "plur_CommonSharesOutstandingpercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "CommonSharesOutstandingpercentage", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares outstanding percentage", "documentation": "Common shares Outstanding (percentage)", "label": "Common Shares Outstandingpercentage" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r473", "r474", "r475", "r477", "r478", "r479", "r480", "r626", "r627", "r630", "r682", "r716", "r719"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, par value per share (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r44"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r44", "r380"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r44"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "terseLabel": "Common shares, outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r6", "r44", "r380", "r399", "r719", "r720"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, $0.00001 par value per share: Authorized: 37,500,000 as of December 31, 2024, and June 30, 2024; Issued and outstanding: 5,565,449 and 5,408,212 shares as of December 31, 2024, and June 30, 2024, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r44", "r333", "r471"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r558"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r557"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r559"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r556"] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelFaxNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": ["r499"] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)." } } }, "auth_ref": [] }, "plur_ContingentLiabilityInRespectToRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "ContingentLiabilityInRespectToRoyalties", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent liability in respect to royalties", "documentation": "The amount of contingent liability in respect to royalties.", "label": "Contingent Liability In Respect To Royalties" } } }, "auth_ref": [] }, "plur_ContractualInterestRateForFundsBorrowed": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "ContractualInterestRateForFundsBorrowed", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual interest rate", "documentation": "Contractual interest rate for funds borrowed, under the loan agreement.", "label": "Contractual Interest Rate For Funds Borrowed" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedLabel": "Cost of revenues", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r51", "r118", "r160", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r290", "r451", "r646"] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r173", "r644"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r173", "r644", "r645"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Loan from the EIB [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r9", "r34", "r35", "r74", "r77", "r119", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r454", "r455", "r456", "r457", "r458", "r469", "r624", "r639", "r640", "r641", "r696", "r697"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance contract (in Euro)", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r183", "r303", "r304", "r455", "r456", "r469"] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest accrued (in Dollars)", "label": "Debt Instrument, Increase, Accrued Interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": ["r624"] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual interest percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r37", "r200", "r303", "r304", "r469"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidated revenues percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r37", "r184"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "label": "Loan from the EIB [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r119", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r454", "r455", "r456", "r457", "r458", "r469", "r624", "r696", "r697"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r9", "r119", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r454", "r455", "r456", "r457", "r458", "r469", "r624", "r639", "r640", "r641", "r696", "r697"] }, "plur_DeferredInterestRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "DeferredInterestRatePercentage", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of deferred interest rate", "documentation": "Percentage of deferred interest rate.", "label": "Deferred Interest Rate Percentage" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Severance pay fund", "label": "Assets for Plan Benefits, Defined Benefit Plan", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans." } } }, "auth_ref": ["r72", "r219", "r220", "r221", "r392", "r460", "r712"] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DelayedOrContinuousOffering", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": ["r523", "r524", "r538"] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Short-term bank deposits", "label": "Deposits Assets, Current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": ["r615"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r3", "r18"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r367", "r370", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r407", "r408", "r409", "r410", "r413", "r414", "r415", "r416", "r432", "r433", "r434", "r435", "r473", "r475", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r27", "r28", "r30", "r70", "r367", "r370", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r407", "r408", "r409", "r410", "r413", "r414", "r415", "r416", "r432", "r433", "r434", "r435", "r448", "r473", "r475", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693"] }, "plur_DiscountPricePerShare": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "DiscountPricePerShare", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discount price of share", "documentation": "It represents Discount price per share.", "label": "Discount Price Per Share" } } }, "auth_ref": [] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": ["r523", "r524", "r538"] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r499"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r496", "r499", "r511"] }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCopyrightInformation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": [] }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCreationDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": [] }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentEffectiveDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": ["r496", "r499", "r511", "r562"] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": ["r496", "r499", "r511", "r562"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r497"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r485"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r499"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r499"] }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSubtitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'." } } }, "auth_ref": [] }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSynopsis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'" } } }, "auth_ref": [] }, "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r539"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentVersion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r488"] }, "plur_DueDate": { "xbrltype": "dateItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "DueDate", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Due date", "documentation": "Due date.", "label": "Due Date" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r551"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Loss per share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Basic net loss per share (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r112", "r125", "r126", "r127", "r128", "r129", "r130", "r135", "r137", "r139", "r140", "r141", "r142", "r265", "r268", "r284", "r285", "r325", "r343", "r449"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per share (in Dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r112", "r125", "r126", "r127", "r128", "r129", "r130", "r137", "r139", "r140", "r141", "r142", "r265", "r268", "r284", "r285", "r325", "r343", "r449"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r295"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, deposits and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal

Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r695"] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveAfter60Days486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": ["r601"] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": ["r601"] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": ["r602"] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": ["r601"] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": ["r602"] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling462e", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": ["r600"] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": ["r602"] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveWhenDeclaredSection8c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": ["r604"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unamortized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r255"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": [] }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": ["r487"] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r491"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r487"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityContactPersonnelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityContactPersonnelLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r487"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r603"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r487"] }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityHomeCountryISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule

405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r592"] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInvCompanyType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": ["r591"] }, "dei_EntityLegalForm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityLegalForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDepositoryReceiptRatio", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth_ref": [] }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": [] }, "dei_EntityListingForeign": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingForeign", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": [] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingPrimary", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth_ref": [] }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingSecurityTradingCurrency", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'" } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r511"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r487"] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityReportingCurrencyISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r487"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r487"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r487"] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r594"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r545"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r587"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r587"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r587"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Shareholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r6", "r94", "r108", "r109", "r110", "r120", "r121", "r122", "r124", "r129", "r131", "r133", "r144", "r161", "r162", "r163", "r218", "r259", "r260", "r262", "r263", "r264", "r266", "r267", "r268", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r296", "r297", "r298", "r299", "r300", "r301", "r305", "r307", "r314", "r342", "r348", "r349", "r350", "r364", "r420"] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": ["r157", "r158", "r159", "r261", "r607", "r608", "r609", "r678", "r679", "r680", "r681"] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": ["r157"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r555"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r504", "r515", "r531", "r566"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r501", "r512", "r528", "r563"] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r561"] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462d", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": ["r599"] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462dFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": ["r599"] }, "plur_ExtendLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "ExtendLeaseTerm", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Extend lease term", "documentation": "Extend lease term.", "label": "Extend Lease Term" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r5"] }, "plur_FinanceContractPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "FinanceContractPeriod", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": {

"terseLabel": "Finance contract period", "documentation": "Finance contract period.", "label": "Finance Contract Period" } } }, "auth_ref": [] }, "plur_FinanceContractWithEIBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "FinanceContractWithEIBMember", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance Contract with EIB [Member]", "label": "Finance Contract With EIBMember" } } }, "auth_ref": [] }, "plur_FixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "FixedInterestRate", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fixed interest rate", "documentation": "Percentage of fixed interest rate.", "label": "Fixed Interest Rate" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation differences, net", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r291", "r292", "r293", "r294", "r417"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r508", "r519", "r535", "r570"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r508", "r519", "r535", "r570"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r508", "r519", "r535", "r570"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r508", "r519", "r535", "r570"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r508", "r519", "r535", "r570"] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": ["r498", "r522"] }, "dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r550"] }, "us-gaap_GainLossOnForeignCurrencyFairValueHedgeDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnForeignCurrencyFairValueHedgeDerivatives", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Income from hedging derivatives", "label": "Gain (Loss) on Foreign Currency Fair Value Hedge Derivatives", "documentation": "Amount of gain (loss) from increase (decrease) in fair value of foreign currency derivative and nonderivative instruments designated as fair value hedge recognized in earnings and from related hedged item to extent that fair value hedge was determined to be effective." } } }, "auth_ref": ["r27", "r29"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r53", "r403"] }, "plur_GeneralDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "GeneralDetailsTable", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "label": "General (Details) [Table]" } } }, "auth_ref": [] }, "plur_GrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "GrossProceeds", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds second offering", "documentation": "It represents Gross Proceeds.", "label": "Gross Proceeds" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r50", "r51", "r85", "r118", "r160", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r290", "r450", "r451", "r631", "r632", "r633", "r634", "r635", "r646"] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": ["r496", "r499", "r511"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r164", "r165", "r166", "r287", "r288", "r289", "r345", "r347", "r404", "r446", "r464", "r715"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r165", "r166", "r287", "r288", "r289", "r345", "r347", "r404", "r446", "r464", "r715"] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in customer receivable", "label": "Increase (Decrease) in Accounts and Other Receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in trade payables", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Increase in interest receivable on short-term deposits", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in long-term interest payable and exchange rate differences related to the EIB loan, net", "label": "Increase (Decrease) in Interest Payable, Net", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Decrease in other accounts payable, accrued vacation and recuperation and accrued expenses", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in operating lease right-of-use asset and liability, net", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPensionAndPostretirementObligations", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Accrued severance pay, net", "label": "Increase (Decrease) in Obligation, Pension and Other Postretirement Benefits", "documentation": "Amount of increase (decrease) in obligation for pension and other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in prepaid expenses and other current assets and other long-term assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r2"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r508", "r519", "r535", "r561", "r570", "r574", "r582"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r580"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r500", "r586"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype":

"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r500", "r586"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r500", "r586"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 }, "http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement", "http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable"], "lang": { "en-us": { "role": { "negatedLabel": "Interest expenses", "negatedTerseLabel": "EIB loan interest expenses", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r149", "r618"] }, "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeDepositsWithFinancialInstitutions", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Interest income on deposits and restricted bank deposits", "label": "Interest Income, Deposits with Financial Institutions", "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts." } } }, "auth_ref": ["r82", "r92", "r93"] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": ["r524", "r525", "r526", "r527"] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActRegistration", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": ["r540"] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": ["r540"] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": ["r540"] }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalancePrincipalAmount", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Principal balance (in Dollars)", "label": "Investment Owned, Balance, Principal Amount", "documentation": "Amount of principal of investment owned." } } }, "auth_ref": ["r366", "r368", "r427", "r431", "r437", "r475"] }, "plur_KokomodoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "KokomodoLtdMember", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Kokomodo Ltd [Member]", "label": "Kokomodo Ltd Member" } } }, "auth_ref": [] }, "plur_LeasePayment": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "LeasePayment", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease payment term", "documentation": "Lease payment.", "label": "Lease Payment" } } }, "auth_ref": [] }, "plur_LeasePaymentsPerventage": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "LeasePaymentsPerventage", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease payments, percentage", "documentation": "Lease payments perventage.", "label": "Lease Payments Perventage" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityIdentifier", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": ["r484"] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeaseTermOfContract", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lessor, Operating Lease, Term of Contract", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r698"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r49", "r80", "r336", "r471", "r625", "r637", "r694"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY (DEFICIT)", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r36", "r98", "r118", "r160", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r271", "r274", "r275", "r290", "r471", "r646", "r701", "r702"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "CURRENT LIABILITIES", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r9", "r39", "r40", "r41", "r42", "r118", "r160", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r271", "r274", "r275", "r290", "r646", "r701", "r702"] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM LIABILITIES", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityIncreaseAccruedInterest", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance of principal and interest accrued", "label": "Line of Credit Facility, Increase, Accrued Interest", "documentation": "Increase for accrued, but unpaid interest on the credit facility for the period." } } }, "auth_ref": ["r624"] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of annual interest rate", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period." } } }, "auth_ref": ["r33", "r38"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loan amount (in Euro)", "verboseLabel": "Subsidiary obtain loan amount (in Euro)", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r33", "r38"] }, "plur_LoanFromEIBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "LoanFromEIBMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loan From EIB [Member]", "label": "Loan From EIBMember" } } }, "auth_ref": [] }, "plur_LoanfromtheEIBDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "LoanfromtheEIBDetailsTable", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "label": "Loan from the EIB (Details) [Table]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIB"], "lang": { "en-us": { "role": { "terseLabel": "LOAN FROM THE EIB", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r63"] }, "plur_MarketingAndBusinessDevelopmentActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "MarketingAndBusinessDevelopmentActivities", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketing and business development activities", "label": "Marketing And Business Development Activities" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": ["r169", "r170", "r171", "r172", "r224", "r257", "r286", "r322", "r344", "r346", "r353", "r369", "r370", "r426", "r428", "r429", "r430", "r436", "r444", "r445", "r453", "r459", "r461", "r465", "r466", "r467", "r468", "r472", "r648", "r703", "r704", "r705", "r706", "r707", "r708"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r553"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r553"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": ["r169", "r170", "r171", "r172", "r224", "r257", "r286", "r322", "r344", "r346", "r353", "r369", "r370", "r426", "r428", "r429", "r430", "r436", "r444", "r445", "r453", "r459", "r461", "r465", "r466", "r467", "r472", "r648", "r703", "r704", "r705", "r706", "r707", "r708"] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r48", "r79", "r118", "r160", "r174", "r176", "r177", "r178", "r181", "r182", "r290", "r335", "r382"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r573"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r581"] }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventDateAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth_ref": [] }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": {

"label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth_ref": [] }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r554"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r114"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow", "http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used for operating activities", "terseLabel": "Cash flow from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r57", "r58", "r59"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "plur_NetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "NetIncome", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net Income", "documentation": "Net income.", "label": "Net Income" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributed to shareholders", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r52", "r59", "r81", "r96", "r106", "r107", "r110", "r118", "r123", "r125", "r126", "r127", "r128", "r129", "r132", "r133", "r138", "r160", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r265", "r268", "r285", "r290", "r341", "r401", "r418", "r419", "r481", "r646"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributed to non-controlling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r26", "r69", "r106", "r107", "r129", "r132", "r133", "r340", "r617"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Recently issued accounting pronouncements, not yet adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NewEffectiveDateForPreviousFiling", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": ["r524", "r525", "r526", "r527"] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": ["r598"] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": ["r598"] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "plur_NonEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "NonEmployeeMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-Employee [Member]", "label": "Non Employee Member" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r553"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r508", "r519", "r535", "r561", "r570"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r544"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r543"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r561"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r581"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r581"] }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Purchase of property and equipment on credit", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r12", "r13", "r14"] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": ["r23", "r218", "r626", "r627", "r628", "r630", "r719"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement", "http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable"], "lang": { "en-us": { "role": { "totalLabel": "Total financial income, net", "terseLabel": "Total", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r54"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Total Financial Income, Net [Abstract]" } } }, "auth_ref": [] }, "plur_NumberOfSharespercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "NumberOfSharespercentage", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares percentage", "documentation": "It represents Number of shares (percentage).", "label": "Number Of Sharespercentage" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r85", "r450", "r631", "r632", "r633", "r634", "r635"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r309"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r309"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease payment", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r310", "r311"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r308"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "General [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.pluri-biotech.com/role/General"], "lang": { "en-us": { "role": { "terseLabel": "GENERAL", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r31", "r68", "r354", "r355"] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r100"] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Total Financial Income, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": ["http://www.pluri-biotech.com/role/TotalFinancialIncomeNet"], "lang": { "en-us": { "role": { "terseLabel": "TOTAL FINANCIAL INCOME, NET", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": ["r611", "r677"] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": ["r76", "r329", "r374", "r375", "r483", "r713", "r717"] }, "us-gaap_OtherLongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Loan from the European Investment Bank, or EIB", "label": "Other Long-Term Debt, Noncurrent", "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer." } } }, "auth_ref": ["r9", "r378"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofTotalFinancialIncomeNetTable"], "lang": { "en-us": { "role": { "totalLabel": "Other Financial income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r55"] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Other financial income, net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r553"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r499"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r506", "r517", "r533", "r568"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r509", "r520", "r536", "r571"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r509", "r520", "r536", "r571"] }, "plur_OwnershipMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "OwnershipMember", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Beneficial ownership [Member]", "label": "Ownership Member" } } }, "auth_ref": [] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ParentEntityLegalName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholders\u2019 Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r542"] }, "us-gaap_PayableInvestmentPurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayableInvestmentPurchase", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase amount", "label": "Payable, Investment, Purchase", "documentation": "Amount of payable for purchase of investment." } } }, "auth_ref": ["r372", "r438", "r483"] }, "us-gaap_PaymentsForProceedsFromShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromShortTermInvestments", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Proceeds from withdrawal of short-term deposits, net", "label": "Payments for (Proceeds from) Short-Term Investments", "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": ["r619", "r620", "r621"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r56"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r552"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r552"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r544"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r561"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r554"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r543"] }, "plur_PercentageOfQualifiedExpenditures": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "PercentageOfQualifiedExpenditures", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of qualified expenditures eligible for grant", "documentation": "Percentage Of Qualified Expenditures.", "label": "Percentage Of Qualified Expenditures" } } }, "auth_ref": [] }, "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PhoneFaxNumberDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r545"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r590"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r544"] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": ["r485"] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": ["r485"] }, "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PostemploymentBenefitsLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accrued severance pay", "label": "Postemployment Benefits Liability, Noncurrent", "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer)." } } }, "auth_ref": ["r649", "r650"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r492"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r494"] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri":

"http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": ["r485"] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": ["r485"] }, "plur_PrefundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "PrefundedWarrantMember", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pre-Funded Warrants [Member]", "label": "Prefunded Warrant Member" } } }, "auth_ref": [] }, "plur_PremoneyValuation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "PremoneyValuation", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pre-money valuation", "documentation": "Pre-money valuation.", "label": "Premoney Valuation" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r616"] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Private Placement [Member]", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant to purchase common shares", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r1"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow", "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement", "http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Incurred losses", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r96", "r106", "r107", "r113", "r118", "r123", "r129", "r132", "r133", "r160", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r265", "r268", "r269", "r272", "r273", "r285", "r290", "r326", "r339", "r363", "r401", "r418", "r419", "r462", "r463", "r482", "r617", "r646"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r4", "r313", "r327", "r338", "r471"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r542"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r542"] }, "plur_RSUsGrantedToEmployeesAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "RSUsGrantedToEmployeesAndDirectorsMember", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable"], "lang": { "en-us": { "role": { "terseLabel": "RSUs Granted to Employees and Directors [Member]", "label": "RSUs Granted To Employees And Directors Member" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r169", "r170", "r171", "r172", "r222", "r224", "r250", "r251", "r252", "r257", "r286", "r320", "r321", "r322", "r344", "r346", "r353", "r369", "r370", "r426", "r428", "r429", "r430", "r436", "r444", "r445", "r453", "r459", "r461", "r465", "r466", "r467", "r468", "r472", "r475", "r642", "r648", "r684", "r704", "r705", "r706", "r707", "r708"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r169", "r170", "r171", "r172", "r222", "r224", "r250", "r251", "r252", "r257", "r286", "r320", "r321", "r322", "r344", "r346", "r353", "r369", "r370", "r426", "r428", "r429", "r430", "r436", "r444", "r445", "r453", "r459", "r461", "r465", "r466", "r467", "r468", "r472", "r475", "r642", "r648", "r684", "r704", "r705", "r706", "r707", "r708"] }, "us-gaap_ReceivablesFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesFromCustomers", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Customer receivables", "label": "Receivable from Customer in Brokerage", "documentation": "Amount due from customers for fees and charges arising from transactions related to the entity's brokerage activities and operations." } } }, "auth_ref": ["r614", "r710"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r501", "r512", "r528", "r563"] }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "RegistrationStatementAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": ["r485"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r156", "r223", "r315", "r316", "r330", "r337", "r373", "r374", "r375", "r376", "r377", "r398", "r400", "r425"] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r156", "r223", "r315", "r316", "r330", "r337", "r373", "r374", "r375", "r376", "r377", "r398", "r400", "r425", "r700"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Research and development expenses, net", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r258", "r446", "r451", "r709"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "plur_ResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "ResearchAndDevelopmentExpenses", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedLabel": "Research and development expenses", "documentation": "Represents the amount of research and development expenses.", "label": "Research And Development Expenses" } } }, "auth_ref": [] }, "plur_ResearchAndDevelopmentExpensesAndOtherParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "ResearchAndDevelopmentExpensesAndOtherParties", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Less: participation by the National Institute of Allergy and Infectious Diseases, or NIAID, the Israeli Innovation Authority, or IIA, Horizon Europe and other parties", "documentation": "The amount of participation by the National Institute of Allergy and Infectious Diseases, or NIAID, the Israeli Innovation Authority, or IIA, Horizon Europe and other parties.", "label": "Research And Development Expenses And Other Parties" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r502", "r513", "r529", "r564"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r503", "r514", "r530", "r565"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r510", "r521", "r537", "r572"] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and restricted cash", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r11", "r71", "r99", "r115", "r332"] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 }, "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r612", "r622"] }, "us-gaap_RestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Long-term restricted bank deposits", "label": "Restricted Cash Equivalents", "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r441", "r442", "r622", "r711", "r714"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Restricted bank deposits", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r87", "r613", "r622"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs) [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r46", "r65", "r334", "r351", "r352", "r361", "r381", "r471"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r94", "r120", "r121", "r122", "r124", "r129", "r131", "r133", "r161", "r162", "r163", "r259", "r260", "r262", "r263", "r264", "r266", "r267", "r268", "r276", "r278", "r279", "r281", "r283", "r305", "r307", "r348", "r350", "r364", "r719"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r83", "r84", "r111", "r118", "r143", "r147", "r148", "r150", "r152", "r153", "r154", "r155", "r160", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r290", "r326", "r451", "r646"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities arising from obtaining right-of-use assets", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r312", "r470"] }, "plur_RoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "RoyaltiesMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalties [Member]", "label": "Royalties Member" } } }, "auth_ref": [] }, "plur_RoyaltiesRevenuesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "RoyaltiesRevenuesPercentage", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalties revenues percentage", "label": "Royalties Revenues Percentage" } } }, "auth_ref": [] }, "us-gaap_RoyaltyGuaranteesCommitmentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyGuaranteesCommitmentsAmount", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate royalty amount", "label": "Royalty Guarantees, Commitments, Amount", "documentation": "The amount the entity has committed to make for future royalty guarantees." } } }, "auth_ref": ["r324"] }, "plur_RoyaltyRatePayableOnGrantsReceived": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "RoyaltyRatePayableOnGrantsReceived", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalty payable based on grants received", "documentation": "Royalty payable based on grants received.", "label": "Royalty Rate Payable On Grants Received" } } }, "auth_ref": [] }, "plur_RoyaltyRateSales": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "RoyaltyRateSales", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalty rate", "documentation": "Royalty rate payable calculated as a percentage of the sale of products and other related revenues generated from such projects.", "label": "Royalty Rate Sales" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r581"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r581"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate offering price", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock issued (in Shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock price per share (in Dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "plur_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "SalesAgreementMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales Agreement [Member]", "label": "Sales Agreement Member" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast [Member]" } } }, "auth_ref": ["r225", "r629"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r134", "r225", "r606", "r629"] }, "plur_ScheduleOfActivityRelatedToUnvestedRsusGrantedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "ScheduleOfActivityRelatedToUnvestedRsusGrantedAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Activity Related To Unvested Rsus Granted Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r22"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expenses Related to RSUs Granted", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r22"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": ["r157", "r158", "r159", "r261", "r607", "r608", "r609", "r678", "r679", "r680", "r681"] }, "plur_ScheduleOfExpensesRelatedToRsusGrantedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "ScheduleOfExpensesRelatedToRsusGrantedAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Expenses Related To Rsus Granted Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": ["http://www.pluri-biotech.com/role/TotalFinancialIncomeNetTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Financial Income, Net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share Options Granted to Non-employee", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r7", "r8", "r66"] }, "plur_ScheduleOfShareOptionsGrantedToNonEmployeeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "ScheduleOfShareOptionsGrantedToNonEmployeeAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Share Options Granted To Non Employee Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity Related to Unvested RSUs Granted", "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r486"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r490"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r489"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r495"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses [Member]", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation to employees, directors and non-employee consultants", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable"], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r244"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable"], "lang": { "en-us": { "role": { "terseLabel": "Granted, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r242"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested at the beginning of the period, Number", "periodEndLabel": "Unvested at the end of the period, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r239", "r240"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable"], "lang": { "en-us": { "role": { "negatedLabel": "Vested, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r243"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable", "http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable", "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "label": "Schedule of Share Options Granted to Non-employee [Line Items]", "terseLabel": "Schedule of Activity Related to Unvested RSUs Granted [Line Items]", "verboseLabel": "Schedule of Expenses Related to RSUs Granted [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Share options exercisable at the end of the period number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r233"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Share options exercisable at the end of the period weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r233"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r245"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Share options outstanding at beginning of period Aggregate intrinsic value price", "periodEndLabel": "Share options outstanding at end of the period Aggregate intrinsic value price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r20"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Share options outstanding at beginning of period number", "periodEndLabel": "Share options outstanding at end of the period number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r231", "r232"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Share options outstanding at beginning of period weighted average exercise price", "periodEndLabel": "Share options outstanding at end of the period weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r231", "r232"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of these options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r248"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "Share options vested and expected to vest at the end of the period Weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r248"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Share options vested and expected to vest at the end of the period Aggregate intrinsic value price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r247"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable", "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Share options vested and expected to vest at the end of the period Number", "terseLabel": "Expected to vest after the end of the period, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r247"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "First Tranche [Member]", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": {

"terseLabel": "Three Tranche [Member]", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Two Tranche [Member]", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "Non-Employee [Member]", "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": ["r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253"] }, "plur_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "Share options outstanding at beginning of period weighted average remaining contractual terms (in years)", "documentation": "Weighted Average Remaining Contractual Terms, Share options outstanding.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2" } } }, "auth_ref": [] }, "plur_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionUnvestedWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionUnvestedWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "Share options unvested Weighted average remaining contractual terms (in years)", "documentation": "Share options unvested Weighted average remaining contractual terms.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Option Unvested Weighted Average Remaining Contractual Term1" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "Share options exercisable at the end of the period Aggregate intrinsic value price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r20"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "Share options exercisable at the end of the period weighted average remaining contractual terms (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r20"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "Share options unvested Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "Share options unvested Weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "Share options outstanding at end of the period weighted average remaining contractual terms (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r67"] }, "plur_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "Share options unvested Aggregate intrinsic value price", "documentation": "Share options unvested Aggregate intrinsic value price.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Intrinsic Value1" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "terseLabel": "Share options vested and expected to vest at the end of the period Weighted average remaining contractual terms (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r248"] }, "plur_ShareholdersEquityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "ShareholdersEquityDetailsTable", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Shareholders' Equity (Details) [Table]" } } }, "auth_ref": [] }, "plur_ShareholdersEquityScheduleofActivityRelatedtoUnvestedRSUsGrantedDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "ShareholdersEquityScheduleofActivityRelatedtoUnvestedRSUsGrantedDetailsTable", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable"], "lang": { "en-us": { "role": { "label": "Shareholders' Equity - Schedule of Activity Related to Unvested RSUs Granted (Details) [Table]" } } }, "auth_ref": [] }, "plur_ShareholdersEquityScheduleofShareOptionsGrantedtoNonemployeeDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "ShareholdersEquityScheduleofShareOptionsGrantedtoNonemployeeDetailsTable", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable"], "lang": { "en-us": { "role": { "label": "Shareholders' Equity - Schedule of Share Options Granted to Non-employee (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.pluri-biotech.com/role/SignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r60", "r116"] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r493"] }, "plur_SpreadPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "SpreadPeriod", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Spread period", "label": "Spread Period" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r6", "r44", "r47", "r48", "r94", "r108", "r109", "r110", "r120", "r121", "r122", "r124", "r129", "r131", "r133", "r144", "r161", "r162", "r163", "r218", "r259", "r260", "r262", "r263", "r264", "r266", "r267", "r268", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r296", "r297", "r298", "r299", "r300", "r301", "r305", "r307", "r314", "r342", "r348", "r349", "r350", "r364", "r420"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r120", "r121", "r122", "r144", "r307", "r323", "r356", "r365", "r371", "r373", "r374", "r375", "r376", "r377", "r380", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r398", "r400", "r402", "r403", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r420", "r476"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r134", "r225", "r606", "r610", "r629"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r120", "r121", "r122", "r144", "r156", "r307", "r323", "r356", "r365", "r371", "r373", "r374", "r375", "r376", "r377", "r380", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r398", "r400", "r402", "r403", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r420", "r476"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r505", "r516", "r532", "r567"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase of common shares (in Shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation to employees, directors, and non-employee consultants (in Shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r6", "r43", "r44", "r65"] }, "us-gaap_StockIssuedDuringPeriodSharesStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockSplits", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reverse share split issued and outstanding shares (in Shares)", "label": "Stock Issued During Period, Shares, Stock Splits", "documentation": "Number of shares issued during the period as a result of a stock split." } } }, "auth_ref": ["r6", "r43", "r44", "r65"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation to employees, directors, and non-employee consultants", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r21", "r43", "r44", "r65"] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock Option [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": ["r475"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity (deficit)", "terseLabel": "Total shareholders\u2019 equity deficit", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r44", "r47", "r48", "r61", "r382", "r399", "r421", "r422", "r471", "r483", "r625", "r637", "r694", "r719"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS\u2019 EQUITY (DEFICIT)", "verboseLabel": "Share capital:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "totalLabel": "Total equity (deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r23", "r24", "r25", "r94", "r95", "r109", "r120", "r121", "r122", "r124", "r129", "r131", "r161", "r162", "r163", "r218", "r259", "r260", "r262", "r263", "r264", "r266", "r267", "r268", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r296", "r297", "r301", "r306", "r314", "r349", "r350", "r362", "r382", "r399", "r421", "r422", "r439", "r482", "r625", "r637", "r694", "r719"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS\u2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r64", "r117", "r201", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r215", "r218", "r282", "r423", "r424", "r440"] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r302", "r318"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r302", "r318"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r302", "r318"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r302", "r318"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "plur_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "SubsequentEventsDetailsTable", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r317", "r319"] }, "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "label": "General [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r560"] }, "plur_TerminateLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "TerminateLeaseTerm", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Terminate lease term", "documentation": "Terminate lease term.", "label": "Terminate Lease Term" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable", "http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable", "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedtoNonemployeeTable", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r636", "r699"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r552"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r559"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r580"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r582"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r583"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r584"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r584"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r582"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r582"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r585"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r583"] }, "plur_UnamortizedCompensationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "UnamortizedCompensationExpenses", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unamortized compensation expenses", "documentation": "Unamortized compensation expenses.", "label": "Unamortized Compensation Expenses" } } }, "auth_ref": [] }, "plur_UnauditedInterimFinancialInformationTableTextBlock": {

"xbrltype": "textBlockItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "UnauditedInterimFinancialInformationTableTextBlock", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Unaudited Interim Financial Information", "documentation": "Tabular disclosure of unaudited interim financial information.", "label": "Unaudited Interim Financial Information Table Text Block" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r579"] }, "plur_UnvestedRSUsAndRSGrantedToNonEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "UnvestedRSUsAndRSGrantedToNonEmployeeMember", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable"], "lang": { "en-us": { "role": { "terseLabel": "Unvested RSUs and RS Granted to Non-Employee [Member]", "label": "Unvested RSUs And RSGranted To Non Employee Member" } } }, "auth_ref": [] }, "plur_UnvestedRSUsGrantedToEmployeesAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20241231", "localname": "UnvestedRSUsGrantedToEmployeesAndDirectorsMember", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable"], "lang": { "en-us": { "role": { "terseLabel": "Unvested RSUs Granted to Employees and Directors [Member]", "label": "Unvested RSUs Granted To Employees And Directors Member" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r15", "r16", "r17", "r88", "r89", "r90", "r91"] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r548"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r473", "r474", "r477", "r478", "r479", "r480"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://www.pluri-biotech.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r683", "r684", "r685"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used in computing diluted loss per share (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r136", "r141"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used in computing basic net loss per share (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r135", "r141"] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r596"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r546"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-

50-9" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477866/928-440-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r359": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(10)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r453": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r454": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r455": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r456": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r457": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r458": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r459": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r460": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r461": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r462": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r482": {

"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "Global LEI Foundation" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" }, "r605": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r607": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI": "https://asc.fasb.org/610/tableOfContent" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "712", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-4" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "712", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-5" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "310", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-310/tableOfContent" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 49 0001213900-25-012189-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-25-012189-xbrl.zip M4$L#!!0 (!: 2UH+4CDV?-0 /B]" 7 96$P,C(Y.#$V+3$P<5]P M;'5R:2YH=&WL?6EWXDJ2Z'=^10[3/6// 0J)W57-.Y2-Z]+/A=T&J]WE2[ZU[^(3&V ($$2%CWG.NR04MD1&1L&9$-U[(A?5R28ID:EFSJR]?WM[>2F.XQAPK!C7UN3&F)GY BD7[<=<& MQ8==D>&?M:F7K7O8\,M632<>E9?_T"7WR!IU?="RW#O1 !9Q?KQO,7^.*+]3&C>+58 M+%>*%<&YAX[EX(?#%PL/5TR]*@J-X!>(Y7+EBWV%>\/[NFL%N%93%8W^X_OC
MG7>Y%7R]=^D7RZ&29 &=$;QRL2P6!='WD"(L8.%!SH(V/4>H%+ MSY(T6[W0_F+Y8J2Q&7@U^V;A]: M#P]NX#QN9"K)[1S!_[Y9BJ72-OGVA?^2RWU[H99$QKIF40UH;-%WZPN[D6:1 MH?)"3=%G;^C?
11?Y&T O^@0 ;44"9Y=A<"\ 7_3;;]0%?R8MD/"O:%<%+R_"\ M+S/GF8=YJOU,%*.W"E5!B#[.55I\D)XI2DP_%MX4V9KB^\I_SJ^@IV@J_Z;P MYX\<
/,M;!3XP -U10?U*D*>+DJH\ MPT=CX&)JQ G^MU'[J=\;=F]R@V%VGVU\&QFP00;=ZZ?'WK#7'9!.X9T_W'] M6Z^HTNNW_^[T&O?L^O^Y)7,6M_2X44WI>L2Z-]:M?
7MRZB=9H0X)$WW M*FY!Y>:^*>]7FJ[UYR]PX9@+RG?KD4[^DA^7\T237N!-8-IACN$:SF(@D M"M@IROMKL5:OP:P&81RL6_?NR*1VVK%S!C2^^"D9OW+W&KU,[1*"VL">W&I\$5
MF:5Y-=U=22IJFZ-]/<@[OW;7#(1/7CD/1*A=R)?D_I8,?V*L2GY1T M)63G>HA?"ZU*-;542/E* \&7LZ:4_.$P YG!E;H,3JI,97MQH1GO2@:/L_@"
M%TR1WXJR]%'\H))1I%H0!SZP5W4U^09N_BOVF!29V&1# LR'>L&\XRNY@"> M@6Y3OGU#Q_1E1 U2$0KHTWJ\A/)J61*GE$[G(87C%F$L.*(@0P3(,-&68=4U
M,FSXV.D/>BBO0@LQO^1*+'1.1&)9+NT=D34Q]!?RN_L?L73?7ZE=;)K)=:V_ MO"@F1C]S$T6E1)NCK ZE6+S]WM4LQ?JXA?O[['9OG]=;.^F*B+B,>=2G5O+A,(,5V8]M'^JR8
M**VL/GSCL6ZC%;.!\ '%C;I];]+"T;,G=;,OXP3D^* WM\W7=I;#%J$'U' M#)<*1#*).:-C9:)0F2@:42R3C*?,_O6\0P]+7]C&L3=3)@H2)@KXWHTH#:JM
M0PF#99/6M,#5F1GZ*_+EHE?$I45/ [TULU77 *^^UN>:97Q+3$F(*5' MG[Y#*LK1-<$3"LOCG([-]5(/QQ;+5!]*[ST9;@69-&:7[9S6LV8Z=UJ%LN5 MFM# T$NF+"
[83B.Z073P+0SRK[FAF+(R9NX%: \6P0==X=N;[&+C6=*4?[._M+Z.S73HVQX$IT2L]E@8ETGV9J?H'D(*C?G%WD+Y>RE1UIJIWE,EQRL\=!7Q'
ME@UJFO8_=^","@O!JDJ^_;,S[/PD'?D53_QE,J3CJ]::K^O,'>9",7\NBN<#W M160PQ 4PJOGV][FB(I_A'B.UE=?N^<9K^/7>&.IOVL+[:OGV;Y(RD79^S;)= M->9&TCJKRH&"7[4 0CW?
[IF&1-6-IW:9[7,PV\>FS8,.MK'Z_Y39HJ$KB)68 M=VZE5FY6RZW,[%E:^,>39R9 >:-,I-40M_I>&XIK^@W@\:E9F;:Q(-M8&Z"
MW/U)3)>D@^\%YO[K/YNBT/AJYBRJTME4UY;BU.$#S O7H68J*N_%J2*#^7I% M^+\ []@J+N=5;;I6R+?+@E!L-<1BHUIL".5FO5QVT;[XSP%/!U/$.G&".@!I M:"B60LT<#R)2
\RSV=PPYQA-M'2XDSN*@G@QND19BN=3G;%UE8KU90[(3BNH MB EP0(:8THN<1J7QE(Q5R30_KZF:#(H8$O.:!A\O(UW-B'%28O3M0Q^V.^C[M>"IIS_"!1MZF"GSBB?$
0RPF@Q^0 (M^-L#CE%'0Z<85^<_KZV[W]C967R"L MKV5KL0]!*'AX?.PZHV8#2P\P=D#Z:2@5?.)(.\2NJ):<4>F \<,AF(@[QKA0D*T&N)R-W;7%W&*20:U> M:: \-
&7ICV4BDFMIIEC@\&-N-+66XUV98YHX[^+Y.-Y%=N21QR*Z^&)_.5Z0 M=Z)TI5C3!'2-E@(E14(0=N 0GNMX,9]K-9"'6,@DYA;P_S4W+67R$2?\/4W& MLV&:&WV0\93"OH#W_P)
[G[+S?!29O@RP"^&23"638$:J3"15A2\Q?]R$?_^8 M*RB!0?".J'T'!/-,5PA4\]^=)X;8H]B0X<71P#L0S?HV5+42&;\$QQ$MGDFF! M'">L0L(D%_
H4/+$G(-38DYUS$!SDIFMJ60M@_TF+0+($FK9S3;XEP4B:3*Y M$-GR#[T;\ >+R>70HW(3CVUZ(^>/X)]]W7=Q-<7\^KGV&^XUX,,7Q<+N M%E0%?C1T#:6^^D$H:(
/TD.))HW9L=.-9DL[V7MZ/W#+^!A,7/N6JYACON MD3[/51:5)X/BD%P@GAM?Q8I8LB^PI@K+]IQAMN?"WC3HF+(0SIX;%%^:6]ZB
M'&*V4\W+G;>4#RF($WN'+6RI5N"6(B%W$\DV4JHV$O"N1%0 D!)I#!:RW2\& MV7@8: =$Q3-Y-O0W:^I\ M78+%4"+3B:*Q^AMV?(Q':&+YZSK8V-?"5^>RK1?
8L.5687,N1$5G7[P&3N=* M16,B O;UJ"@Z6MM1U>A)E7QW*KCK\7$N%7G3RCP@FL5_X<)^KO M@OD^MK"Z4(X5W&6Q'_F8HAHK>)V4X3'F,Q3.FSL&%!YG!P)"%ZN19-SZ"$N'0
MJC*N[0L\0T*LQ%I/T]2. >K$$@3>$S-L!-$U"1EBLH<=U^C\>=MZ%A:\FRCN5 MBY8QIZL\R^#\/C<5C9H^?U*LQIP&8?>[B)=+XP2Q&VSGG(!0$TDU RCE /B# MP7?-P?-3K'9(0)99
BL6VDPX(T='.>3+O;]7[F^36^UD%\RXH'O#SWIL"KX;5$ _!U5 NOBLF4 MMR9I8T52T;S%!'J$%/L2RI(AFP2+&15YW9E5Y4*Z#':YLLC#[J7EO]\B#.07G MT6%/<@%,QZ(
O(QZLX]]63H2I@SE>6JEELZQ0_]/:N86O)0-P<"XS(!LLF* M]J_5T6!;TU8LK>@]C1#@U:JXQ7B:.FXXDV5;$7UN,=F,0MK.@,O9VU$QS3FF MM/-
<=WZ"25GP;LP3MNQ'2*:S@55XC6F!B.<8])B%C[#UY#*;?L"[AS@56$ M/(B%L0)6N_F7?*]_N\@Y '%1UEG^/%X2<([$@!E8^O@7SR"]Y:4)R9X490% MKN::PE_(P5Y@-"'?
KA=:K49!]J)8=5G. ;2\MEZ%%9O%$*/_(8%G*W=&3),>,# M2,>:B]5*R4XG.7SFR[&;Y+I-<+-G*]SXQYQJ8X3)0Q;+ MR> W^"C'\XI)HA(0_L3ATQU'UV7^AM[J2OYO1:VFA/AOIW!4PX
AV>R(K< MI:Q;VLB@TJ_BB(+X DS,&&;\CZ\'/!Y1X%*,#_<>:=>^W,^NGYY3CY#.]-!Y M'.9Z[!Q}$+Z2VUZ_T[_N=>X(J*W[QY\=; 28FIJJX_2(C!GBGD5? M?]A]/[W,7=_W;[K]0?
>&P&^#^[O>36<(?W@B@/5X_]GM#\]@T2?J'1O[.CHF M.C,!'7_3OK!S(=!3:5#*W=S?W74>!Z!$R?"W^Z@WT0(']XQB%_\EH;IZ(
M]*6XJAR<4O2D%%Y0CJL'A/N"VDRH4I=*(]S8,0UZ^,CR_C#\P>)JHG)<,NF83*B.OSL/ MP"H;*]B30*]O$ID: #PG]+OY;*)YJ 9^6%7.N@)#4\NX;?V&9F66C?)15; MZY'!E%++) LFD=3.N'%?
2,6#,V(R^"V36I]5:KE68RO>5--%"29NE6"^T*@ M(?:FOP<_K,DUA3MP$4K$=/\V ^)E5O8!R]<MYI_?*?TQFS<>*,T1@5^3ZOB]<]?I7W?)X+=N%^A_\=3O/-WTX)M+DMP.CP?(
M5R,WR$X&"SE94WUN2IH,)@U]'U,D#@:A6'70C!H,:OX)6$/2Y5H\'4)C'S&C M;>,NWK =%SA^YUR,C;LX;#Y#D%7CK!8IM,ARQ3>*TA4?I\I?B;U:3\OA_ERX M?
EUV\P'&>+KPF"$>WO90@#P0EXXF%6"&1%]OA+7G1)_S8%&Y_1^*L%WR1!:>G!G,.AB M7CP';-/^V+X=-_RY">$%M()GKL[5L. E>%N#>ZNGQX?N_TAX?QWE2$Q8\ C
MX"XHF&<\CR[$FW M:P0[IJ"71RJ-IJK20/UHV\7% MTZVAOSCX,T,Q0!-UT&I3JC3@+-J.B8"S5KY=.=Z>B4/_K TG/AAT)BDRH>\S
M3*XP>=\QUG%QS,4(D9B.#A7UV^@5K(D3AMZV(>[?Q%V'B*6'??=N3SJTO+!I MWN4D!Q_H'NF]LRE6*X/4ZMOW0<9W6*267'13*,PKOL8E]8-;ZSC81@]TCQ
MU;ZNC7?=0XU7P'LJ?,6 4 6,DXC,:,> AT!F(]^NAG %CZFF M'@Q]K!=_L/ J9M?,L%"M0#1J9;MM8\B+XPVYP>IHX6_)I!S+17U2Q.JS+$R8;8-3..B[PZQ]XAO MNY\\F93)Y#!<4\<3
:#8]C.!)*(NRGZ+CCHV(JA6.]Z6BQ!_9^<.1-7A&Y95 MED7@QCPU%>%:FN[2Y"1*=:3PAW)5&-D$D\NH;(SA"0"B7@_ET$UG: \5,%82,K,]'*@U5_+/3,XZC4$+)IWJ^72D7FB%R
MS3.RQ*- 0I&E 61I%<*$TO3N3#,N>"&U28 6[TQORF]T@;NQK$,?1,'&[Q)ENE[A2:G#CD*/ MIF65K#_92G\R,>M/=@;")S7]R1+1@BS&5EFI;3ZV>*.QP'Y:)T;E:3N.;>TV
M=IA>8^RG()2$%2,MD>/_LI9D.T6C3MB2[#]QX)LF<-83<=NH+O:$&UQAY T M+")H0//.3!';'OGTK=ON>IWOO;O>$*PH9EH-?NL\=G^[O[OI/@[<(2M_>^H-
M_TDN;KJWO>O>\'+7B.0G[A65]=F*!7=.HS[$\4C):!&"Z\V M9KX3=KS@BK38Z88AR2PI?*#3T%=,:[;NL#M]GJ3'1LDB'&.,QT-HR-SCB&15V M*+.L8T./@E"O9"W?
#HKF5K[=JF\OZ3A)R]>P.QQP8,RIU_PC'K&02<1V&N IBK;>\LFUQ5]RJ-)895C&<; M=#QWAE9GFRZ(=6;JW'!D^-]MU.TDP:OY=J/R>:J%(^.KAFG9Z>IMNB;>&5H-
MLF(2R3;"7\S0IP^?&+HYCV<)0 ?QJ-E!-]E3]291UO>KG8RBAW&.=Z98@VD M6+E\H-Z 1ZAQ"QTC6^A$IWI>3B:_DK4;HLBO/9W79KY=+51#]-;-"!63V-J3 M4"U&J!!=L)-
:#;=53,5YZG)BDSWUP)S"^_5ZW<5^@)E^"B0*F$P\G)P$B0+F ME,$QT]*["S8X7"-B733HB\S5?_ 6A*G494;4]VMVK6)?5,JGZ_]5[Q(Q XJ
MY:A1_>RH*&'\=8"CHAWY2D3WH%6.>@B9ONT9#_KPR*A0%]J/VA$I0T.=.ES0R M,?07+$$DW3GV6H-/>MHK-2V49.2[I/TJ$-T@W=[WHT:"PF;X?L[80N262'>Z M]CRDQLL-
'5D[;H,JFUO7:&UO\)61+,[F2!%(AJ,&JR"Z4C6PX*"!;J^94A;J M3NR6B2G4O>-FP^9K(+ZN.Y?)E)2!$PR1_UWM)Z6?3_^VH&ECW\]2,:],<"V=C)K]?9 #<:-KB=87O0$X7L.
M[2ZN:4A@&P<$MEPJPW])71+'V"0/**3_$X74K81U]SS0Q%8&-H9]]@6_L(9'!R!9-1Q&.$3[DVL_X&KA@+OW M<+01PEJA5J\5JM6@)/H5<@'N#\" XG'0O1]PE;C172V#02$$5?
(LHYO?PS<) MUV%A=DJ!P$TS"L]XI>J9Y 'XVSQMBB14[!9%^W:!^I^%KG7I67?U).M.IC/> M@4]P_["K@%H,-SC6]WGLA8,58[EX>P"T];1KCK0P#@ M>KY=%86"V(Q:H'@:
MM$6JB(J -IQ'*99! :=@N-<.*:/SE[F*=CP@=:*,%6MY+=DY\,&/%B\.."+: MDG T:UWG_5- I>L6$/8#$4G@\+,99#79XY_:*-JXZ7!BTN MPZJ-[:)_5_JE, ^&F>Q3706*F\Y) $[UM3[(A2T-
8V#.3!PF1APR%] F>)<1 M>I?MTRAC]Z="68PQWR+]PN]@LF\SL=;22,".;@E-B(E/@/5UK8B8-G15Q8(" M'*MB4/-(@Q$S>744)^^GHND&\'W/)FXH_L>N6
4AQ+#TC$PQ":J]R,J"2K" M@;JAI- 8RPROD^^08QI>/6VLSA$]#[J![^I8EJ&,HFYP>QU#'1%A/NP5MK.W&
M&I9J%%IQCK'.C+4C$@M76OL7$;87B*:0!M/W%TN^DHTV/$1EY/;UAK+G-+= MI./GG(@94YE&1Y/W]'>R$:8G*=78GV!I'FZ:L@%>GVTL'Y^C&"<1+O[GTG_: MO!]T?
C[YU]RTE,D'WZ037;=P.JPO^\K^)$_>7]0K54)Z4JWX-(AS47?4-(DU MA:?]27!7YP/GJ'/PCC%A-IG31;-!P?$/"JYF@X)7!@57LD'!V:#@XPT*9C\D
MIM*DW\L8C_WV16HGR5Q9]@Q\C&BS+1G*J9#DSX-?,$QX,X1]>7I_2^X?NH^= M80\NV#NI9.!'H/>U\80;UMAG#*UY*3)+BT(])%BOK4XP4WCWR&>>SE_9##'-;
MZ_'/;1TH[^0%'C8U"05+5>;S6WU)X2'CE:&('"<7%<.I0>EF9!3BP<;^0VW# M\^?YC]-.[C#D*,8?IV2U^[TJSGJ&U6T*/,BS:"MNK,OMYY;>Q*/=)7JLVS6;[
M'4N4(V4)7;0HAI>NG':.U(&!7*@-'F9QA] M7#\61G$$:XBNVD^9Q:-]EI@#+@+%&R61I8B=.$XNBR]"X]Q.;L4/QM8B8& M5%:Y)Q3%P#AP#UP! 5:AM5\^U*"",I2X>1P?
U3]1F;*.7LFB1OFI7XYE%"0#-U;EPY>.MH M\HV'M:Z-M%!&2#/?KA=J]7U:6^W<]3LN?.UC\L>%KQ;BJU'>G-($+VL?UC MPI=8!L^R(#2VAQP3A*]]G("X"4OL+KU35_FZ,V'KUSLF-
IR14K65#&RDQBM:A] ML F#?IT!^P]:_\!4?:[\.(4-0Y8=FB2 MM,KK RE,^)0-SWO5 ^U7T4,0&?3OPX>LCL0^=CYP8$F'9XK^0YD3NQ#OBK. MJCQ09X-S)=^!K)M]R%?
#COHQ'M\EWH\M$(V>Q]'5X9(-K)9*+:J8\>3IG!$ M'RTFM$5+P8N*M@:BK57;K@V3AK9H=791T=9D?9/$?0YR3HNV:,ET4='68FBK M1]BDJ7)T?U"-8G4^:@9)?
E$TQ;3P:."5K@0Y,R\S(:E,D3(P.+UA?W06J+W# M%JF4\"UJH5Z+O_?TV5(L4C)(#!03D&*-5D:QH^CN."B&";$%H5K)*'8,LR$. MBE608I5:_%F?62K-9SKGSH!):RJ-JIN)3@A(0
S%159/&^LO] XPME,SX$H5 MD(J9X0(AW.\$&<+4E6V[GLTU!E&94FZ/!" MM;*/,CH]B)9/]%QU\JW6R'&?241,]LI.AI,9 HZ@HA[H.D^N:[G'_*&X7<29I-E+Q* &!]+2JH&3*
MVFT<)0H1E5:82QCG&,!SIU44I1^55C6D58Q32].84<+'76UT#S-[(1DIMU', M!?_>6+".0VT4;,50*)VOD@O5;.MUL%H;J[/[F61EM]_[22)XIEO"]Y6"_F0GF/K.K/1Y\HMO"^
M]!%9BP]A]S#GYR-/%--W7_)46')5:_=\Z6WD.46%K:.PB619AC*:XV!32R>P MK"(BVM!5%5-$%3N^F&1C^31]HUQ'BEI>WEG'1B9.8AOJX&/Y<.F$:G=CNBI.
M68_0Q.:XR(P4\SDL,C':+6ZW3A*3U)R!$.B$R.B(8!'$H3,2/&2PR*SD6W M]^F'?*=+SED@ZAHWGG.HJF 2)+C]D(%N[9C9F:R9I369RG6&KNA"O/L"LWZ
MY]0).Z&JSA+K6K54H2HVB;\JECU<'*[5E-YC=4$US,F.!?),W&7++!H@#(.W1/2KXME.I! MB:Y9^'X7;^^4K%;=)8'M*=M*R&Y?EP'.[C-5V\99/R6KU7;+O3LE=JC7R[7*H%
MU<)GK+9+M.&4K-;<)7'P*=*S60E9K!0643G; >C@O,HNW9$ D'Y@$.8__2W$9 MX#-* (+T3 E(IA%XC?J$.XXFF9OPK8*R[K64V9QVM1B$<3G+Q/_\3@PKZ%%[G M#IGL6S1G1G>
(>NO$4?<07R>_-WG":K)X8\]*C32Z4 M@4.&R@O8V'WZ1A[U%TDK\ *9$ -9?*5O&C&LP]PDO+0 !S)FG%'IQ0GTHNB M?EQM>PZ[UE3^Z?EK/:#Q@#V;
E4!CZ8UJIJHX%"78%_TV1K2E>6OXS>/U\ MEX#'KTHS$R!Q?G._F#&\"Y<[OO7?-OO((5_Y[(K9>DS]BAY;_#+);&F:'%B MGSM'-NZ!;_8#$\^*_YJ;EC+YX'MTHNN6IEO4W6:_.Y_DR?
N+>J5*2%"J%9\& M<:YJ0,%/Q-?6+H1+8M!GR4#6@=^)B:U'4-SIBJ6NW@?M&UO"RUMH)CV3[#? M>+0]E:3M_VW4'DYI3AJC5R]I'T@FI(%)D$3P$BQ)>,8),#A3%*,!UI0"">: M-)
<5=/E!]LM8R!U^0!);5&LB9AVB1@:5?5A5'%.P)BK-W$>-^8.L!P")" M_:CQ\8I'W[4O]\.+Z_(F41VA.WLK.B &XS_9(HPV)R-<;'J?*:GFW!41%8-"+O+WFAF=_PQ"#C8;N9,O"5(]F[EG3_
MF"O6QS:_VYGJD)E#-5X[P-+5$?\HO^J\4A&\.XR8>I.J\1U_LK+BZX1'A2'(*FXEB M6K:8@O@@I^U S=CD$I2OXV,+VVPKA6YJ[CGONKG>XR5]&O//1.5LN:8G+0! M@O+,%]_7M2)?NZ_
]\S7S D>RQJ/H06BH6H_^9[X_S9D3D$]_*> NXL#2Q__VBWIH8M S10OUYO:VR5'P$Q7Y*X476_#NMX**)AT7E??B5)@!IZX(_[>(6"S6;0(<_Z1[M(9H8>CTKN<GPM,F_FQ&Z'O!&-
%V\[AHZFEC=8[<^* ;^*Y=VQ^MZY/1:.7; M50%SLK:W/DH1!V\N$FHEBC1>YDTR_EVI=4JU)K;6WV=P<81HK1L.M[.:6(K MUTJA$F*L=
(HVSF;*".F@C(BC#%K53T8,1V*P7+6]J%2WMY=P*Q->GJ5P2 M> K#HL'L?KP*!S,6BR.)9SJ]X0/0&B9*"T@EF:GZ!T7[1U8,.K9T W[%DU7L M\.I\RQ*DYBK8FM;.G?
AV+$;;S$*5_>SI1J]S7BJ9YIS*M_,#>0DL !U.Z'#Y&4:C6LOF56[>MF([#[%8= M!]E40H18/VFW4S6=!R%%M\QRJ[ML^
ZNY#H\]C6^VL6<5DG41O5\LU(&Y5:C6LOF56[>MF([#[%8= M!]E40H18/VFW4S6=!R%%MQHYRDD4M@\(R\C*R%I]UF;^7:]4!>VIX-F#:2R
M>NNLWCIPQ5F]=59OG0C:7_[ZS6]V"(M0C[!X%9W0(@'KT\"0D>DSJV8CDKM !L+0T<^Z:A!!>-_^JJ,'1J6[;!AC\J=,BG7]>*%N_(;R<=9'VK\]!ALZ_73$>-%]KG3_\7)1_!KW9+C
ZNY\H\]C6^VL6<5DG41O5\LU(&Y5:C6LOF56[>MF_1BU9(&%DPW64#\$(K]PD1;M?_E_Q:9/ES.%>WT!GE'!^IN_+*8^3.2Y>KDJ/5I/IO0ZH$Q;C[E53J$Q*,D/-MN%T3/%)^
HE/2_HX6)F^4R/XNM5L^*A[>G5 V$B85B3_JFP:\ZJKH]<@E8I[V51B\&S[N*NNA9T[(;8SZ>J[0MM,5<^2=EU)7* M4]P5CYAKB6U1OBK)ZAK)0L;U*E*SK_8H0FU@3
M7RVTRMNC9/)I:73\!@9-H<)V4FM[M%]BLZ/K\BZY%(2NZ3GK1]<'Z/7[ZZLUT%%TWT>?*BJYW2Q-(5]%U4ZAG1==G M5G3=%!I9T?5.9$U*VLZ/KLBJZ8;W:ZB/OKBJZ)-KG^D[+
=X^QI'JD0;;ETN8 M7!(G]B^PX,@SUO>#SL^)_YJ;EC+YX'MTHNN6IEO4]Y*=S[L>^SD_-^K]I\$@7=4=-DUA3>-J?!'=U/G]I\$@7=4=-DUA3>-J?!'=U/G]I\$@7=4=-
M/DL&2@'X#8A@4L(" <2N%A$@\#^Q#$3ZOC986ID@\JG_/"4 M \#A;.-;N[/JKV3X,8,5=PQII(R_DCX89!PS?1V14//],6YBZ&'U<-CU<\^JY]N1]>7(='RB2R*VQE9T4'
MW&#\9VDU.38H/!EU/0]W3X^]7*]_72*=_@WI#0=D\/1]T+OI=1Y[W<'&A2;" MX%P\UHAHF 2=?>R_"&>+C $29PT[/6'W3P;\]7W_IML?=&_PM\']7>^F
M,X0_!D?XYV>W#7_Z]OR77OW7Z[H#TNN3P6^=Q^YOO]W!W"#LWCW;J^T^Q] MX3_Q4WWMG?=^&UZZ0!"GT!=Q^GOW*&R-
/* Further uuencoded lines below are of similar form */
M9GUN2IILD@OZ/J9(T"E7XS*948-!S3\!'2U=KL53TNVK<)(NA6V^SJF7%VQ. MWCH@W%G\P;MZ!64R1NUTDDR@=N\"DS7\2G!_H*SAUWFO-&OXE37\.E[#K]0U
M:TF)C,\Z:F4=M;*.6AO:+=F=\0[E%"1W^5F#K:.HN 0UV/KK7/VPNVM5EY&0 MU.Y:E=IN><#QY/WZ\BC$,F8!5\M *6'[8*\T=?$(G;#;S'IKK>?/9/5O6I<- M)&*]D5@NU.JQ]CLY-6FV5
PEJWG3UJ194>1$JC8B"YI4;)UTM' 2*_EVZZPZ MTFVF2CIJ",0JJN6*L#T9^6P(DPZZU)BY)$3N#IBUU8J[PTAUQ[9:!VVCY6>9
M>KXMU!K@#9U!5ZW6)^FJ54U>5RVQD6\WA.UUP*?BH9#M-=#A3%%7K6KRNFJ) MS60SPD9T]J^KEMC"N>;I[*H5N6PR=FQ68'LW(S-GUE4KZZJ5X!91&&[*6D3M
MAC(Q0UFHJ%[U!%VU*@+V5V^&:!:=M0**PR[#(S78JI[Z8+W"(L6U>JU0S?H M[1%]% _6P/_3-^2IIN-0OX)-ED2A(#:WGQ=_FOVSQ>=Q)64I !7LNB:U"1:E3=GY7-6 MWIR5-W^.!6?
ES5EY\YDO^9.7-]^/+1U/U-6X5R+5)81PT%L56 'L>5&H5+> MGI>:IG*JT$>IU:S">3U_IF,Z257DAZ'EQO;8>XIX>'/TO):V\#D.ZQ/KA4HM MLJ!)R-;90I]D%6UNIP^KJA6;V\?
=I8,ZFXD3N=3F.(*-Y4F)XO8$@/,1:[5$ M46;[MJGGV_6X]DQ6[!Q'X5>MGLQBYVH#=G.5(%2W%)@GO=99K'V26N=:Y*2Q MV*L(JSBT+4262=)KG>NIJG6N14Y"BI\16LEFA(W3PI-
7G5LK@X.27-&\D3F3 MATP!>+.VO8(D*F4W.FZZ7E3HGKVZWD=7M[HJR9H:R<'YPE'SV/0O_:B++< TA MMK/RS#C,PGW)5,G(M".9(F;^Y*IBKW-M@>[,R+%8,7N2Z-
:OETI"M46&6E MSMN8(2MU9AQ6STJ=(T4:#]95,:NK2T>I:DS.#M9J?/9ECJ#CY25 M.I]5J7.]G)4Z[[1E4Y:K51>R4N<(II&<0*P/ZQYQJ8WA MXRMA)[[P*%
(LVC>R_<9O]1WOURS/1U1$+=?],7YRZ&'L2MBYAU MB!H95/I5'%'0]?#<&<.X'AZ +"(4#]J?+SBT7?MR_WPXCH\4B:176$K.RLZ MX ;C/TNK:8]!D:BHZWFX>WKLY7K]ZQ+I]&]
(;S@@@Z?O@]Y-K_/8ZPXV+I3] MD)@5)OU>+E?A@5^D=F9OA%N\J]LW]&7(F3@+W^L/N8^\G _[ZOG_3[0^Z-_ MX/ZN=/3'E/2_H3'F#Z]\(F]R&,OQP_:7\OA0>;]XR]G]R@$!KB0TUPZ9]I4>!AE/3`/ZN)7+L\MS$6\]X$KL9IN"<6?`<6\LX:RSY,WD[C2]#M9AHR*2KL[O1ZQGG1'`=7?[7O)@Z]VD*M6TU;8B.;5$UN[L.WJ-3EGIY]4D%BJ__**;;7WC*L5$^,J9TJPHG-%SF"KJAXEB]H/!&C[X8+7/`WA8S\O$!6$,UOVOC-"V`<
WTX)I+LL)P>%< M)\)OS AI*@U*Y 89RS!!-X,VUN>FI,DFN:#O8XIDFG+-+9,9-1C4]B>L+-N\ M7(NJE%M56;>DPW>M&2COY 4>-C4)!:M/)KSSA?\(<+.1!7^QM(8*RT#8W(DIN
M]7&84\3SJ;6&U59.S34!#_9IFMO^Y_D_J'[V!GV^C](YWK8^WMO" ;(U<8L M51_2-B2U1KS[*-7EC7I F4W41$Y'\(8JEA)V*I5J[5,J=8*-)7-*YAA* 6M0!Y-
/LC"&@7TM]52R%FIME5/1,^NT7'C&M?Q]@CI 5 MOY74B45.HH")KYYS'1UNZ RVF<+J,DY9@1)%%_G7$.KT$1,K*]MK;IM;I-8J1-% ML>R,IQKB*6I]V+%K<,+Q_:[5RHDM5HY4!
[=W>5:]'LO;" MG*7VM,YXS.*'4V^MZ;4>'07:8:B=Q/-\7T*&X[F_L4.-SNV[3 ;4S;W-M(M>PLT]4Q29$+?43; M#>$HN^,DV@MC<4P])23:2G-
U3P$^,.;A9K]*8NUBHL#.V9$C)2ALG4H1S\D/RQ9-M(T2J,B.:UN&PN%V4=4"-RR%,<;N9$+'+-^> MOH^GDO8,FDJR*.&_FF[B+\.2WP,]_Z1]S0(^*)\4%=TO9AJ5I&K#E:G=

M9AP?]Y.NC8U'0,:]=@U+PO^[WOH?W07C%V#[+'[@N](M^[I13,"8I/X "3F# M.^!OA%O1@ /O':M\-XNIB8($#8"#L\" 13AW1[W^%9F Y[>+/XF$K;T32VS[2KFFEB
MJR]QG\.L,U+:FW&X%G65?+M93]8Y8*3&E;M0DP*(+!&0;#3%O;+QBS7]#:< MBOF0@VHF%F-K\H,.ZH%:BL$*".]' -(^\KX:RMO*VH<=YE@E;FK6\NWX&_:E MKD&NE_T)U E,_SP-
EX;K 7$Z<0.X0U/SP=!?%9G*WS^>3/0VW4!.Q\7?;ER) M>4"%>HBP4<))V'HWWP;7RK&PYB M;P&O T3D$/#8TUZI77.VD^'4*C/#]19CY^=P+>S23]N] M'F(GJ>X_KG_K]']TR6-
GV"7W?=Y:"MN,L5^Z?WOJ_;USQ_I.'3^1(DUY%*$D M1!4+)).:,)BFE(A0V,9*Y:CIF0E/;U#6)T M;=7E[3N2M%_'RCL\V#Z.Q$-\
M).7J(9V=;./G5L[!H9@.)W<+4<_QT[?'$T@)S"L.84BGQD^[CF&C$\EB"4PC M!H4P(XN3ZA(F4WQ1+&_O> Z0G@CR>S=*ICHCMI'8?G^,U?:M)TNM
M8W/G%I5M"Z^>IPL>W\[<:(=XV86Z#BK0$P%C9&_61CU&O9&/4$CE'OWP^[P;Z\)[8,]77S5._[?4[_>M> MY\X_6=TW2ST;I7[^H]3#R3AN?/;G+_"4\8H31,&*G:'/:6 VP*)U?&\\2YKR
M;Y9F=.V:,W;_+P,_'\UB?]Y/;AW39N!:-C=N<&X([_NNZN-?GFE<$3 E(R[Q MZTE?UQ=F'QY@>^8$>#CYT>UW'SMW2V@'C*=K08', ZO(],'*(KB./Z]'>!O M[PGDHB&"LX>5R4>*
^,)@/ZMQ02$\;E\@%"PFHZ@?YI>EO&@-9,@F[MP@1Y1<#K,T ,SH%S3;+9%(*Y729: 4XV9SGL3%\B;A%&K^0C\/%TC/Z4/ M(@@%(I;+0HEX[_VO_VR*0N.KB;,X7UC#?%
[ICV'2>=@8 YF7S)EZ0]BCQV MQQF_[/D50ZH6.Z]@]0\LD)_$B4J PPD[AMUK?KR,=)7@]\3R5S01V:_"5S\@ M9 I02^1MJB,. /8UW0^,A59D8R/ @.$75W\KH"[.YZ2.TNVT48-!VV+*,,K
M $LZ!V/@/0U>H\ 3E"4\>2"KTIOI9+\S?8%_]$Q@#HFJ)@=+3R%\E;0X/ Y2* MY<+2&T!GH812S"D\=FE5/R@06EL QP/YQ\OH-Q?BE2N#X68 K<+.[_XH+<$J M;H%5
^[U(9YT05J1S@1<37*KZV"S(%89B,O?,#C6$42;OTJ<(*751VXG!,>] M0[@)H%-_PU[16*CP3L=S)\T8/F!@,-$]TITY1\\&92J?=?4A0P8,OAIP(_Q MD!-
XGFT%X2OI/(,1,E>M.091KO6B'5Q[996@' X;!];4T.?/0 _+))/Y>K[U MWE<<(N<"O\]'D@4HO!#+0@M8]$YY8;$9/$?0J&%.E1E#,;N341!V'-P)]*N& MH-_&772M3R:4FI+B4=+[*.S&
<.AAZ42FKU359P1QIKQ*/,2$S_-O[V6@"ZYD M"=@.*_R!-BMHC!U3F"!X$I.9\/PX/C>S/ ML0K<1G#FJ_OQA:QG^/=,J\%Y)?L7B%)GQN3WDW+N%S%3)0O7HJ#'>19FR
MF("N45]799,^H[HJ$3\4:"'9PI9)^KFF_#&GMN0"!5>4846L^34HKH#7LL[- M"!G.^I/8A2[DBJT,?*/9T;P01&C%" 044W^!/MA(HTM5.3/Y(&=$HWY=@;A MX_N.00-_L?,G1P'8@W-!
(\UQHBZJ2Q]X=I7/!..VJ%H,^DPU1^6^4%F!'4P+ M +R^@$PVN]"OJI=HPV:K27-MS-7B-= 7P28W'(/,&L!K%I?FCR=PU7CS\[Y M1G,3@#"Y)@\!B9*>K Z5."8@ 4IKEGAPN+
($-0.D@7$A-6AMK8[:DN 1W@^ M1SXKC=%-JTA9*3XB8HEN#DT=% .'3O0QZ\^MX/DE#/ WD?[BK<^KR1.HR1F69,!VTJBC3$-48EZ)"'$- \ZB*=\I#&7-F M6Z."'8_G+W,^)TBF$U
-3!!),Q N[\H+? Y*YD\'+*7@R1==R_% M%P!Y:C=!P+8(L++-N/+H9M,(L+L9$9$:[1KZ1+'NX$V[(:".K12%ZFI^-F<] MT/^K;+6!JS#J>+A%'F8*0TMHK!NC4?+I8Y)\H;EB0Z0 YIW$#F-
!N_C?)!?C M=17D!7^K[H6RGMV*@"ZYH(./#R?" FHP.IJ\K:WR6EYN8K/V0J6QVJ\]8^:C M6BVN@^A,CL3?>6H==Q9U=Y D%ZCXF>TD(T/J 9*CC=
M&DN+QAE,Z'FQ\37:5WTWT:0C\BCW0!%9F>Q_OI$QWP^L! M ?RZ"Y-2EM-(&I='X5POKRQ=C.8*1[A/>N8'"',*M'NE=I0AD+& =L^4,0^+ M_C BO"N\$[FGVI&)66S;G$_0KL-
'3.R#*8?1@0E>*.6OT;WY:G8(_ .9DQ(9 M^!] 4:ED6G:HP[:E\+SFC:H8YD$3R]X,^ +9/G+#WQ73G+.=X^:RLL&BRLO6 MG%82F,[JF'>K9AO(<)TH+W;U%@L;810&,(?Q$+:%L ;
(1L>8;W06HS,03.!9 M+$F8LU&,!3+5WW N8X%3PO^>-T55@5"$^?B 0U[>P .(L!UP[2IN(5RQMP0? M_?"!_-B!5Y6XA/&&K\I+82Y/3MC1+6?_.=$>=LK$VNU@*8:U&/T$3"_"RB-,
M]MN7@=6>"WX1]R)]\#@7W ZK9IH,A 2>#@+8LF_ [KGL]GN-=&:&HI)*N> [M'UX]SV7BG74ZPH,C5TX@E39O#-G2G&NL3FY,V(FO!
M/A0CX\J=4P]"@LLQWMC5Q551]"$+V(+ZL25BA=X*LOYL;\R9I,@>7P'_PE:> M\?$W+O9R2\&]"6#F1]2+_#+3.^Y+P:-EZ/P*OR_,LRH:9S-?6-[+1OVRD- 9;W;J4?/9-^6NAJ@J
M:655)2M5)IVH51JDH2<9"6K+R3K' D*QSY%(4CKE_9 9OK]P&0 M5P'7'>=@CL>('K2>@=7!F3?= I#BN/P[WO>[L+GP)-S3_.4D.+([^>$EIXA$ MQ"*20>]'OW?;N^[TAZ1S?
7W_U&=C@1]@IUZ#X'4'JRX1 \M+XLX"^*:X/*8L MK6,'QIJI<^/W)R<4U>.Q*;?:J*=QH@L[2'NN-,AH^]VOVQ?H[#:6G)4(!9 M]G)
0FQVH8I1T=QL.+'@#697EB\SQQF9[XN)ZO*$"YK?5"TR:<1LOR:5G6 MPO)L022YP8?8I)+(!4ETX7: $LJ#'JXLMM:(=-3 DSQ'E&H87)E)/-*+P200
MDCR.A%$R9N7QG%>LVH"OP;*C,@.$VQ5.6$I%V'6#_.AT'@HLZ._ Y[U>\6C" M[$(W$*=H/#S&PG.63F[A,LY>0KGX-W9M!^6M2IU/,<3%@!MXAW.L!,*I\;K6 M7UX4%O
CC_09$Z'PUT'Q'^"HL44"[.I'@1\&R3K&C3 W1IW+8*'RW-$5>">Z M;O&&)N[YPN@CAROF^%TK[K&;Y MQ+##@]F/;-0"QKT7N.'_N@=*'U0R[)PG%AFW#S2J+(R>PV^+\"V_<6$T
Q[A M22Q."OAE,7;W<,^WD[;L'Q9E77PQYF);C)&0F%Y[13/G8Q>V0=@)F8,'_\D2 M4PQ^R7D8P_6(^1$!RB .X7V0^O?#H<5-!@-6,.>J9;I<'#Z+#WD&F>KBG^?PE$8_',G\I\Y=&L?
A+\3L#OI@3\=B:.%&G M9+A$IU=[N\N15*DY-+Q,'R?XW02;$[P">=O\X^Z'F_<30QH5:LJ<@MXO2AQN MKNK8DW4V4Y5-+R98+H%'ZMP"7=-
Q\'QTXQJN#:T4GTQZ/^D"6%C=8H95?HMW M^954J?3EE1% MH-)16)03_5;,&6>AK=7 &0D,G#GAI(5L:4Q@EGY1C]L*N7_-Y6*;"E;:< MIG,]Y'+RBFR^*-
T5C].3J.J/K=2CR!G[S&YGZ90Z4V%L#XAU%:'M6BZ?<@1R M6<$^%,#[-Y21+A6+KM25YIQ*T8UEI.Q+NU+/KL/B4TL*=H_%F?3![03W.MMZ M,1>^#ML1,?
2W'3BU?"Q9R7YE@'WVL=Z)_>X MDV%11]E\E;TV7\]J.6/S5'R]@!>/!&ZLB8X=\DMTET5TL6K\^KF1M!'.^R.7 M MZ6#-F$A\HLGN7V7>H,KDE3+']U^N@Q]
<'P2G[R%WO6K=?'V;0[[/D?42(^ MU:.P4A[ZKEC@;RA8I@5;#VY(@1 ML'/0>M6]-EXE71NO8^:PQJG@WTZL*QUG'KO?UHNW,^RZJ*G#P#)%D<]J__BU MNK;JW
9PHKT%YBQ>C.XTFO\Y/_?[F)W56$GX L6TLS5X@@7K:8Q@W.\ENKF'FFF4%0A7V"%D!/P:+]5GFL//75W2B$B:BTF0. M-?820_5,#'U",90*^6/+R@J(H2?-DS"V
<3DTGIAL[%=\P$ER7FX5LV]9$DC M7<$,#.'[XABN?\\;<+GG]!BH TQ:O,\8-@G"9NO(=79HVZ^;+9DK7* MN;9Z[=L48V\!P8#%KOMCR:+/N@$/E F5L&L_[YOE6\"+/R#I]/)WLNQ8.
(.W MR&+G%.YJ/UN,;P^^;L;%UY5:J;HRL-KUAN+F[< (N1<1]C?K"FKNY07HF(1] M?L;V2=@/#[@6 ^;>P9=S[C767T8LM+?0OBCG'!JY;8Q8=1"+PH=K^DQDG9JL
M'L*@$Q6S3Q97,F\U3-8<DYK55BP_",U< M7X,J-B9L1@UL5(/-6-8=_7&P_FL.0,V(5 M"_ ^X"&-UP"2B8(MEG@U%&*)"1H\Q%"7OJJ4ESLD;=CCP7V2XNO&X.ML$W>[
MFI5G;NB"))2S-D@K;9!:61ND@_8/63<+/NM_E/4_ROH?'0K'6?^C5+9Q.^5! M03]TMZ$+V"3#TN5!$7)%13H'^W=M#1TNU:"(9&[>FA_NXHBWF13\[;3I#W=$A<'I%3 M*U$Y-
<;,WR-AMZ:[PGEALR*F, <018(X? 2C4G3)G,W?.Q]P8]GSAO5I&'_;Y 4+A78)1 M0G_-O+-#G'1Z?VT?]K'"5-V9/6O,;<4T5>C$-R %&[=CZZL<5A :/$O?UW&(
MQ3?!9V%G!FZAGAT29O#8,,S8_#9VAJ:;F-CO#F3@LW3,L:',_!,[L)0/BPOL MCUB*0,YYFF+1%_80V:WO]V,*AR4&B HW;+H(C%,"2;&U%AZ*N$0"@GFS:9W#
M0!X*Y8UOO/"IQ&:ENX%FH5:PN<("DF#EO2@*U$U-9KKF?Z^%M;HHN[XL&=[. .VLPQ#K)H9-@=RW;W)O!1_'C
M5G:D5)A7HPKS&+/)3V)VM#RSHZ>QJ4U#Z1WS'[G%T:@&61S>E>LK,!PIW\HL MC7UYJQ:5.:NI8TZP-%P![[,TP(!8M1]:R_:#8C*MHMFJFVI3R3E;9-4WV(<3 MAW=Q[
"L.TU3#"1H&B0%!#,66%]PDM+2S0K_1SK$TF M[^'C*,<02AKA1"/#T;.\5]1$N@MZVUX+Z&,[V9KIZ+&]3C"?/+V^?B#1F:O: M2]RM25 MK[W-
2)^#$PTR'!QJ5B#/<^2X@^DZU1>SN0'*RYZ CFI1 [6(Z>@O,U7_H"QQ M":^5>-FOC*6X8\7^"YQ@X'P^K+*0X]H:6S_#GY=.)>""PXW-@?A8. <$,PN M;_3\-CNM:B*-O0FC?-NY4KV
249OK,IW0<#S=>>P_A=WI+/.T@(:5SSCG?S8 M>L%NZ&RLUQC1;/BH+>U3K'=RM;QB.VJ@0OATJ^RN6LB)=1??'<>E_|V 9"+A$]$/#)<5)6CB./ MPT_-
$X0L7VPE7TPH9PEC*RP=1(/4)F%DN619+EF62Y;EDITJEVQS'M&F[!\V M!H8/.>EH\C4S89Y!.X$_X/FA0;D_U6HU?KTK*4_3(JI:$(Y2W)4+J9UE;)P-0*B4^76MM+9-WE@[?;Y[6+D88
MUO[H=O^[ELPIRD#XI^MU$PPUH5W,MX5"N2ZL#F@'V-U&A6YC01RM-%.I_,PG M'J&;.IB/3$56(@5&],%[$]ZS.N^U=%A9KW+QIA^P%Q7-EL>!]_3 E%QKCR1
MG@UJ1T!\#=WP65-X$0LS:':#P^>Y9$B /K]7NY+DEO[VG)GP^]S";Q19^5,@5@ MX!R<|Y^P))2D#OIS4WGZ6IC?6XXK=)!"/4T>8Z"C@V.,RE6,?/^BUC\G M?YL#D!J=BP#XA7#?
J[T+XH^\3^#KQ;D?R7?KI57A/^?G2 UK/E?.=QE:E'? M&UC VM_A[\,94\;Q/68&.@AK['T+=]KC&QU"VZ6V..Z15]^R$3*&/:[/!-@1 M" ! GH]9KT]&.>Q[[_*-3<&2;PZDZ?
O:SP>^7K1VBMTR(#EXFP>(?>R-5-8G M!Z3C(R|\?I0L.H EAR5;-=^N!%%-8X@S%S"'(QM"%AOL86YB!)L\?%4PS:% M'WX$FW974E#.-D>SJN/CH.&!-R"'UWZP5S_:/5!#
(J8&]DPY@*%S-D,SAUQF M#GD1C)!?L%RV1 S2XR@(15Z(W;N,KX]@G_-S*& -8!D;/Q['**9],/W,N)I' MZB4^[L#A9NQ&F0LDC#M$5!]9+,1]7\WIB:G^[H91O"&E'%9_B;XS#M-
>KDV^ M-T55\8S%G(_^Q<8YZ#FW/!]34'EJ!SS4&:I$B2#:PPO9&%9 TSVH=@UC@T]R M+;P-Z<7$[N#^]I&SQP4/]I*_2MH<;4*OPG_IN7>ZJNM:C@V(9,;=/0Z!@!>Y M#
[WK?;]_O'32,%#&PC-\!/3,4B;!%3M[UYSZ#MP4 Y8X0H[&)!E98@-3678L M-@N\H0&^#HCB#%9=;$_@;SO#A0\P"4:T3X?$C)A9Q7@OCT"#/_Y%>>=HL2A-D-TNS#L\R=,>E3 M?
+#3W-<_*>0W'7[\7_C!#3V^+(4]ZVB+,0 8(5$O^<@^FLO/%+LGF>)!C_UU M1OX4Y1'EOC"[#0K7DR&8::H MW7*-6?9@E,[8//@@RO%Q)>ZT!!8:-%FB"U" ^CW53* M"P.$](^:X.\|'.
(ZNW[U,?]=[E4-C@S[C-EC7K[3("J]X=I2_?Q5>S+Z" M&WG:W KNT!+!&>98:Z=R3C2H\L)Z83EFMYO6M^+ULTWI.C; ())L@V6/6P^, MP@2>-"()?"0HFG1\)<^--
]#&P'4+%!BP%SVP-RP@M@6(Y6]B27++E=;HS_#6 M7;[&7WZW OT)]#H^""=N5G;F3^#A")59I&)!=_E-L7@K@ &JB:',!6PBXRO M13F1X%[\#S=*[S^C94L.(]\K9?#AFZL^/, Y@?
GK@_RD,AN#<,U2\5CHJ#>>*JK^"K: .0.C3F7A)QPTCJ:, M1!XP/YSTOO1ZA)\L@*AJN/M'\:%SLVBJ.3%B"Z2^Y>BD ;Q%5^0B""433H8 MD-30]= K?
PPI(E5_#LU3)")\'*K>*.8>,K)H/KQ]]]N5FR+I24&0+ZL-_>Q M..HG#LQ6!!#]ZPP/-)4U/"YQ8M>X9(<>C@%]4(SPHV6A,T3:M=<2;](I?_'U M+'6Z>7IJ=B<5V#B]"A3Q6&%5!69Z*]-
;9ZNW:"KTUCT(?*^T:27;Q5%=3CSA MP]>[@Z6[Y);DO00?FZ9N<"^99\0XWA3WF]#"=3HI@7\UUPJLW.<= PW4\7G8 M:$T0=!O=G&88-\>19'<,K'L'^CN$;
AON9\XS907)%8EWT9WD 1Z/^QT"S]@%G25Q *6;./DIWFA;IFHF$X0/-<.@/?><,%(-[$A>W3AU;F M+1RZBL\I#4U*=:V85=>N5M<*675M DK0LDK:SZN+LTK:@^$XJZ1-2R7MG:X]
M8]C@AHZLH(+96]VV@W*DWPWVLY MGI!6*:.TA3(_POH!' 9O\)4+,ON*3XH+,:VML##"SDLI67WN&/[41YC"E9.(MJL-?MH_NG0>QQ!!L@%:I5S>?
G#462AJ*]9U"+G>*1N\GUZSF\=8."/_DQU7? M=<-@^>;7$BI(Z\.-0M1]00@Z-_PQB&HYL%R' *%4%EGU$OR]+#9%Q<:0&L4^ M4!B&-C#]'8?-\201>SJE/3(2FU7"MV;!PST+
[^7L+UAL1S%9/!OP& J#0I(P M*.3;XD8,8G]+F418KIBDY6)];W/MJH8D19<2=*"*[#@@-"JO>#<"4^Z"=M3(.7=%\79C MB4U?63%9S9#L>5)WP,5.#4U :?@#B$LE-
Y5XCCFO"7&SAE>"18=KX=7AKW;+ MNJYYF^B.)O=US>X9'29!IU8+RDTYG,#-9*L' \T0499FE#CDXHZ^E<9T*1=]0T2E5M\8,5L;K+#;O+,UNK@ ?2+/F:[9 M%'AI"HNK0T'
NX;@LHJR],&J#HM+J8.W*DO*X!S0[HS8-FQ,N.%+'R'D M)3,.>(]?=ZO=:B9W1'G98T..$&7W;QJ5OW.('AR0PA=8U%K(U(6FL%I&3IP* M0Z_OA:T@=EQHLQ)AI6^;L54VR
M[,&G07:FT]*AX+]MJJO,K\'']-|;["_A2RU!&E#M66*-2YG 9:-26?]2_NW$;9_E3)EE#A._#-VOU9$=*^F#QQK/D93TP4J6 M/KB:/BAFZ8/9<(XLI3
9Z6Y92F&64IB>E,)UNCA4+N'B_.V!I8]_H=%$#1.[MSUL?3?3+ D9PN#_-A3.M.CABF*@]\ZC]W?[N]NNH\#9SYO M]V]/O>$_XT]5/-'8RT1H@F15[R]20]63N#7WA; B@&> |XD(17
0BDUV$+.$_W6.]85T2:0YZ%,#X))9)WAL38XWFE^9/KT873KC8/%/ M?POKA:MY&#GHU2,Z!K7A&^NL.XTP[; EF+.JNOBT@MUA --;)8/WQN9=N,=X M"<5U8ZE^P.>RYT-
RPO%/4DZG^'F,+?]S"4RD'#%CV MY0#A\8K6R[[ )U_20NQ3R+?KC4+32[WT@I\+=.0I??Z9OD%,KS"9>Y"S'^AOD/"SB*4]:9?U")LV 7I>*.?<(C M\FJY*PVU5PT<:_]4>>;4FP
IE_F3B=F:KPO((=P@:RLD?#OZSOG(Z##6P] MLZR14$OP#L.^_F7L!C;%FO7/<.M5MIPW16G=B2N\GS 1>XVY=C+EK.9T>;O7 MA] N3?]>4.=.6'E0+I0#NIAQV6-
-05D]._1EG901#Z;=!4["3OA;CB3=?H'@ M+(9H@M>L1]!,'G[+090X]&0*ZM>H'HV:*=*OEV52PTUK:R7F04KP'N$C>R M"1Z:VZO'Y9D=CF%W.[SVX>(!7P9*FN$B<-W
%O!]P,JK^7:MU%K-"N)K=^VH M@W9'^@?L-X*;OK*BZ1/:=P3 99O\[5"8OC#<$8^^X"-N+:[V'@=/ MK%L(?9FI^@?Q\N.0^>D3]ICW[.U;98Y<%VT\+|V'*)4:R'78>.VSA88S0
MH#-T;CI<,8V%DSX7QKFF9S^&71QOX^4V")E5G1VY-(.#$1!_!OQT+MKI^,! MK#6>,X,!I==WR:0RVFT4K"5$&S,C; S:,B%">5S-3)(K+,
(T8:/5?/Q_N'..D^]5#0IB09&$7_#V4XYE7<$/ MG'GDQ5T!"IE%$5M\HYA)@->K\E=B+|;+\BC5_!AP(B2P'D3&7_)"-;_A:4%9 M,-OS;0:*NU,0S9,*5YR^Y84$0FT3T@_1PD)60ERGP:
8/P*Y7QH/DI*^UO]E MSZ#RMY'QI>VXOOP/I]FF]4>B@_KI<6+0%TG!(BO^YUAW:S;Y!RPTQG^]4.Q* MK%$$$ /T#ZS(QU4*KIQ18SGT858
MKA;$2K,@UF]7BR%V6\O4Q#^O!M'7(GO1Z_0?; 15Z+$4<'8HLXP*1\7].319 M5V_<1]Z@LX%@9K,?VMKYH4Z&W:;866LAL[_7O]TM?!9HG7;P.))//?_^X5UB
M=RONX,@UVW:]]TC$17[8>%'.1FX4]HW52K%>=\$DS[8!.%7\Z\4/L&$V-CQT< M#=#ALK]K:T(6I-TM.%O'X&S #*IS8Y2#BH] M]D5W%8@[B#]DDRV@[8XR"
M&6,]7SPZUH"O=P/V_Q,76 ;@I2:C97Z@[/C@%.*BEU/Z>*3%3W'T&%U&:%. M]+# <+46/6Z&"&L<+9H^\9@[_.1CHY&S&V/&X\].P(>U5-HPK= V3$1I='A*
MK\B=0Q,Y_79)HQS2+DD||>/?YOO:&@OTWM_6TK1FQ%#'C_8-,C?+69 Y)8[O&LH?PA]N"EGL.:F.^,YL$,H\:(I9 M2#H5(>GM\M_-\ML]9-VL'#IDO690=%ISY--4-/$$C*B#M?EO*N?
&/MYC-IUF MTH7>H[N44@261OB'%+(V8MADY1UVA$75CVW5W8T]-AASL'QK]&^OKKW'4'N@ MFL=IU2M--"P]-*.(6/]66.=7NS& K;EZ[:A:60=39<[FE:SC]:K'4TK64?3
M!$P2SK]7[K;X^DQ"K:/(-N.L8Q^B+ZAY)VQ:!TF>[% M;F]#:Q>32ZY!?*7QK)UPME?+VDQ;>\YGQ.@3]91@W:ZF"IV0[CL=SUE)_OUD MHHRIP8KRK[OW?)21T]#S>.TF3A)C6)8,?
%O'V6HB79YH^.8/C).ZJXQ9G&9! MOMYBK+/#]NA%UMCA3!LJ[E#]'8X>@>SG@]9SX?D]7PX<'^#>C6@ MO\$!&AF$*3C=HZ!XYZ.U>AHK]9]U?%NLE@MB:WL&^?
[XW)=(FVI^H]$G_45V M34R4KI::.Y7Z'HEN$397<(Y"(PVU^,T&#M#V:J]#U.(GM\;ZLV7&-5,IO9OA MI7>6_K),Y3/0 :VP.B#QU#]6MMMV39*02NL6IK>6O(T=:UK;J8IP%]*Q$UR/
M>U)ML&\];DL(KPV25*QX0]%\B SDEAA6*"'>M)/=XLC%BRF^K$DXVIK6Z3^L M2%&,/.WIG1TSMWYZC#=OQVWZR?M]VJK"]+3+FV1N2\]LD]B__V;<7(N0_MZKY
M]FK10RE>ILCF07RNL_OQ.9_=KXOE88OR'[BF>A9$?!,AG-K=1W?,#3NB?!(! M-X^PF6YU Z5]W&-PNB);92E@XPG-(QHHU#E^:-X#VHSA M5-
*"N^V$#335\NU*K5(0*M7X#A_#FUUXN?NP97X!4<;C,)50Y/\HMTTMQ%SZYD;^3;0]70 MJC3W(/OE_AMXR_G2W_=LM;;\^!,?2*64F3CV=^6D)D;_*P6QNEV"A#ZZVIG#
MJC%&0N=-+-LE,:1))(QAM_"KD$Q^W=.8:>&I6;50+]I*|VM M)I;M\V?LF8 @_WX9/O4RZ(:V*%8*U=:!N?-PW4U.'F?3(Q]+VH==F&KRFB.3 M_-+T-\U182R(2&3)HB4",) W^U
V9^>]^RX@B_MQ"#EN<' V"%R&")^F=M^ MKE<^70K!HIL59S=3V/VLF9FX>]YG5U 'ME-.1_S93OV0*V)P@;LXV]+U(IP M[MVUH004O()<"=XPKO'%]H8YU"U)]7]_K9M67[?
^20$BIP_1]G-MV +8W:VR MVM@+T3>BN;5-C09T9G%)$]C8:"'3XW.V-JIEK8U66QM5L]9&66NCK+51UMHH M:VUT:]V-CM@1)_%YHTEJ7W2$U*?#]BNJJ-
VO2,SZ%24NYU$^^YQ'E,>&FV3G MB663]2AZ'*!KY6N2>[PDR%/";:T*XJ:!YDNUS*6Y$1D-6"H.%HQY[*+E?R[6JA68ZQQ4MZLRPK MR:3L'EF60%@EG*W M?TY3-
9G,N*=>]X.I66A5CYC2E-+^O2ZL)\IDVE=E"-$*E/K7'.9&IC+5&UD MN4R)A7_W7*:E^+-V!1ZN)]4UA:N;JZ].)S#YIK+E%A.8_CK7*_J56LP;XE21 M]0V-
!_Y_>V_>W+:1!]@O_CT^!US&]K'@M(J;$"#7;PD8&0+0L7L]O$ M>IFGM $_,F Z?9S=_S;)1'Y%T&#?Y:!N!A&0?X8^DQVX\/!+_8C2WU!F-%7G; MYEJ]I[>9LES79U&Z4YB+.1"QHW#
U/(@KX8=C]$*UB]& --,\IPC4:T^9H"ZM M4^&6&Z]RUO-,/@4B/S?O#Z#-#?Q_!7=|>REVO X^PO8S#EMXP0U_S SS!6QX M':%(UF+#GX)*.L<-;[SYV)SC&)AGR0S]*@(1.3[I$|
<=>8$7)UCW>"6FJI37 MEAMZ2F_?*FG^>9CNS/9]CJ7E,ZK/;QZ;3D.KP7*;08TK\WAY0ZOOAR'A[G] MUP]F+[,;P[CR\I^03YGAXF OOW&_F+!AZYJF 23*".ZFF&Q-
4/G"DV[QVRTU%P.6NJ\^=AY!(Q1XVF"8&5/K;4/2$S)RK1.[SM_VOAAX?0\LTUO[6"1@ M$G\HL*B]J+?)S-&%/6)^&W82V%_#*PDYV38G6,JVE0I6V KO"BMLP1?6F^K3 MIA+V"OY:
[OJQ_'00A2/Z_-B#)0>7]K]2> >XV.&9E_MB[$0)E="$ ^IXD3<@ MJ6)_<:+O(K&/C_?H ?Q=Q0Y"'W5X2(7"'\|B>TEU* #OT]BVT ON>@D@6W+M M)4.].KF8LQ1D4+O=KKWMO7M;?
U>QKX=>?P@O"F(LDB@A^NZAC:-=$_A_V #, MU(]2$2]ZGGZ8IR19EGADYW:M@?.:*^W:-'A?V",O<3Q)15H$CLON2LK'ON,3P[W :DD(EKP2DE!>-@,J'JS'! _(M->#$NUH,
(9YC*T4%>?1'I4#=;X4]@V:'HIY&7>$ JV"&6 #,X<7(?13PEP5:)6:@[,>\Q]A/HP]?17)$#YEIV9B8G]IF MDB^2CHB P'J6HL7CEKQ1"">"HBM(_%NF H%G-_#PV3:.AR;*PI]?AXH>$EG@
M?.^U<76C2B95R6\.F(C1K;U-BJ2=4R1VG/9&?D+MT/;8AX>":$4AE&-2S>U] M&=_B^,>]_J"LH]R3:#8O.GS_-8KSZ6XF?$\V4HE]1!6FCHN(J#E]W$$ M]^\AJE7O+Q#N>"]72-
E5M7<3UH?X4I.7.>.Q (^3YS!0/>C]OUBVQYNY]B? M@<+A=K%]Z@3"WY!Z29NPWE>P#01Z]+!QB?-=4,-P!/H@#,C5&<&?*1H5SA4< M/7U42FO9M-
,28T6AWZ$EHI00G!7_LFI_#]_%%9I=[!. HN M@4 ",D8GDVW M-RGAVH,EIGZB&ABG$#Z^"!",#T8;KCK*"#TN5^,:BG2R5=I;4Q8R&2DE#6' MZHSSF'H7&%PR/9&
(^%ZV/PM!@-D>BD&M?T4Z=;S*4WG<--1&&C$1#9XB1#4 M,1(!PTW$G=:80:?Q[:@7^C8^HE'[6.]&?]ESQLO0I:W8%L.-<@UA($2Q[9 M-$HF'5M(8+O3OV22L"2]8C2"-
EKS&"&]B.#9-@:/+DXN=H^-F/#1U[V3+P>@ ML@\N"B[Y')HUGP/U?4Z=P73 7|- VJ[!)1^]//)I |-;C?;V?7&T35/HIBET MTQ2Z:0K=- ZNT-MNSG;%FD(/PPC6!7Y3&D44$@?K.8A]=J-
=#PQU_!B5:""2 M)6_F>DH_AJR'/;D-%[@+_(Q?P:T\#N/X$7Z7#@W,P7^6F\^=EY+R^+=:(U/ MJ>1]Y*[< T|ZX[N:[_YN/W$_L5W+[_Q=^[0YVIQYTWM8,S7*YWV_4U,KX#= MGU)-
NS!ZQQGRC?D0_#Q;1]]\/$)UBD.1568&M(H8AS&B(.6'88!R"[[K+]7* M7P+P^"EZ1+TON\'[\FW^]>+AH1KTONVXZ7 MV,]G*(=-%;&47U"]W-;?R*?)^ 5O9Q.G8]?
M;UI=Q*Y\BPA>QE75,;M_?A;0L M#8=W@@+POG#MS%"XEQC.!T_*NZ+ZA%<."/ 4S:$L@).@8"5HS-?/L)U <7HO M9Z*M!E@&M>:F0?FYM-:"CK&)
8<-2,"S:9SH_"%:WF_2>XC,;K4Y33':/:N\^9C M=X9(PS+NW%>TP1QV;@=+CFOMU=X@NA9OMU>$3'43C^]4(P@).!6LNT >:Y#4*@[^OK2094,0"0(4 6P)
34]@$!S2"V"CJ!Z=6>U3P"=>]N*P2?;X1S>ZU MG]4\H(H.\/:&X+*7Z_5' S5G-,?3XV+/"&$)]CH._YIPP6FL95]T6 M.D.U10'SO+]#>HIB?-
I!M4$M=A]NP]SG,3U%)S[MF"BXL%,R;&US4/-6B$\[MJ ZJPQ?$(S/_O;0X3M/:!QZ /];9X(I-XH]M;_#'5AFYY_GPQS;(8QODL0WR MV-HAC]VC=Y_@)A%,XSG)C3 M-.H/G5C8NY>1D$
U"M?F[E]1+_Z7"!28+_X"=HU"^P_A!7$"_U.QY#V.: 9P M&%%XFBI!).$*QI2=%XBWT1<2;FD@$-M!/_XD^V#PP7[KO;/OP43.S5FJ/1S& MYBB.4^'NTZAR'G%+\!IQ'M'&',X].9:
[M8.N8G.G6>F6#%O*=[L76N(K\([P MDN-(; VPF=VUNO[HKCK+3F%@?P[I._L/_1WLYU@=3SK&N]ZS3SN/WZ?3*.P+ MX<:'43C"[4(P@).!6LNT >:Y#4*@[^K2094,0"0(4 6P)
[.K$1>_S+TDVP M9MJ$[DMN0AND$ZKTNY.NJKY3:@2X('B!.0:<"CT;>>TM3O_W@#*1&V5Y\ M#UA2O9&+3C8>M %[OA/"HU/HC,TD"6(ESC%-6;;(;^ZP^;;M_&?%%U>SQ
MP1M2P@<:DD+(=?!F6??"1M4;.42TUK+M1./-QUJU5]M-[D5&"!6;_BXR$ M_B*0.(00XNG3"IV.4//&!&_7!SN1X.-P;/P5O'X&CU>$Z3"1TY +K0+ZD+TK M[\%LRX!#ZBA0[]B#U/?Y]

K..^7D[@?\]C=RB%\/BS,]P\DA4%BU7=*S9AZ< M 7@2A(G5RQ\C[Z.IR27H85RZ^;3W=*_"?08D-[$=GC#""B3AHB:&[P>"+$N$J\+=?
SJ9+>QGMZ,:&CD2B+Y%QF8<>MAG'FH&M$[JPQX]*MELCS MG^$H D*GA.,)U?UMWQMY"7?D9F=<>]0@RL,>[J)P>?/O-,O4EL?9GEN1)LB
MQM=)]%9+1>%)!"='75\T2NA;TY"C#[+S1%-T%&@ 38Z5\#W#'MBN\I&2HA!; M$QY9)1OY>4WD!8:AGM/:? /QF\8Y0G0T?5[W&.NY(QV/0ZQ3?0B=R\;[['D@$./-)2U6:8?
3+BL1^0]C*="P!H! 5R$!]RFQY36T$@]"

7W5N//1]N!Q?)6?X(SLQM-ZAZ$7DZ+>5GZ\D]&44QL0:Y)PH9M;8 M>@C =Y\]E4^$MV>GMU_QVR% 0-]("2L!@8U@B<9^FEY; CHQ\K)T4*P].<1TY*Z 3$L#.3C"_SHG#\:
MR,]T+,)P,&2\0QLB>#MR.FX4U,]A-E^I!S\FB+0T\F)32W-AFSU,H>>_$[?.O?P^_A*1#^SAQ]J[17ZA/>):]1\%<9]LU ML]/3?BR3;FQM92"0FS,3MV*M]AW<6@'+]I8<#8;K-
,X3!:6WA0#(('MV:)O MM!.3N0,53 "@14'M+[GKD>V)1.S%?PKO;AR+6GE%F?O:G-+^64)&D3 M/&&4"A5#Q$Y]4M8!UCQX-9=#T5]-%]Y9U[JG&C%RID7[DA/M]7 8[$.&)B
M2:UM"E9D*100#)\]7#=4/"4 :)9)6AN)>*OY!]X!?R2(565N-2^$@&[_[$RZS,@5IS* !(%'0,G MEUV02\#UX9\@0KU+]I482%U#41'22M>"P@+T9EK-.=?
X&4+W"+Y(D;W11L%GW"UG&X^0LKGFF,/LT;.(V.T:QOGN MK)LCAL!T@+W_]@OW7>92%O1ZM:%!(2/WSBA*4:AE]I$B(RR900YUAGT4+Y
M&]_MAP7065ED<1>ED&;:]#KX)%.WR7[;4W#LSKWOT"G$.Y F%8T$Z")QBS50 M%.&8:>$-,'FG+QSS/G13FNI =I4,8Z("0L#OIS[.[41; =4]RPI/;R.\3=R/ MO!X'7-
_VWKV3293>._DKLCU8&OH99'G-;&AL-^_F@ASML]!Q M^+._N<>ZC4C%H;$?9@F*-0XWD?"YWSW* B0PADB-YG?'8>:?PB.#*R$[W] MJ8AH*V:S/+=;V(Y<8GFZ\I[*1"AFA&
(AAXL$@5!:'R'3[23R+B_A9P)+ RP) MDWX%!H<:-H Q)-@9MOKE4!33F*7 31F5 F&.9Y$8CR:FQW%;FZ+O=U)2<9?B M%(?M8(M@]558%2]N()T$EHY7S%"7D)--QBR;3#U-
U"AD@N:>"*C%Y0H"OP#V MV761#U R8![#/]Z>5BN<@Y+(]9XN7"C&/A] M87L;7.!VMU)653TCI+],XV=9_ =7+#1-%F_W0'GMUUIEX!\E"7K"Z%B&T/%YJQ,7XY#,^,2 MGN0G/N"
[X\^ZLJ!(!URYD,5<>B(?&K3NHX+'>&J/"UIW$-3MQ]#U8OM 'J1^ MC?K_EUO$Y./O:BS9V3263#:6=#:-)2O$"%06?)2(D=VHVE^S%Z.QGH$Y[*KY-
OSFC@!;%A4_T0,$]%QW/^YW4;BU]SVA[M#L,(QX)N'8[;4[0HUL_A](R]S[Y3O7THR'Y1OU6900<09B"TR9'@840,Q0)NR6/6E\ M %Z%UU?MP^DO@A, O:#OIZXP/K8P617Q[+
TLB]#4/ 5,]\3PS@CS@!/A"7 M'N68:$U8%E>A"8YQ1=Z/#?#03>52$M$?!J$?7MZ"S7 E_'!,CZK8 PX3#30# M&@DF*U+L%^'-_N*0 ?U3A]2E 2/YTCX"CP !4S%L#_>^#5,:?
8=S%9$X[CI3 M3%_1T$->).VC$ZM99K!1%3G+S)(?85)'?:9^%@_#U'>+G_(:BY_RE,#BI[B) MQ<^P7*SOC6&IQ6_H3*Y$<6G@/Y,--W%S\/B]R96,PP3WQ_'5Y["_\BM5V:,O M0=
(+,)>)N04@8MHGJHM$ MQG'Z0SP=)G2+)LNZ(*6B6W4G:76K1_EM'E(2*+,=DR#DMD]&ON*Q_$,IE-R MU3J',YG^ XMF?M*<6U:6=-CUC!YF5YWV0U6GIB.L?=#S1R,;ME!
<3))_&%1NDFVM'8F6EK+U=06 M=[].UY4+[#Q]T 2WTH9&>5>I:^^?*Z%:?2>[NN88@.UN=[]_F-V*,Z'E+'!) M2'C:W39T8(5Z!< ?V)*SQ:D!4XED6<2@42;_]R"86&O
M#UQ,V>O\KYQ+-7.]0(Q0."3HMMO[V:O3ER!M4I2[7.MQ$EV"0?6#I 7=9V__MRPFR> S+BTERV]<"Y]#&V2;Y;,5($2YEK*]O5@0L93]'O$"#X>QN*;9'H PX M!L$EUF&
:;&6%M;B3>&X.3X=66_C+LS7";D3)#*+DN9EY">4+DK)I#:/B-22* MMCTNH_Z&6]H=T._RT6_G%0/8Z1@(EZ*IG%&$!-^6;[1]_J(2V3TSE3LO["Q MPM"&V/
B6WYB[9A0@)KNW0]#99-R!EH5-V+,G#R$RQ ./" MYV MNC94O*'BY:-BK(@"L@U(Z)+EKOX1)ZE[.QF/!#]+AF]I.%;Z&-]VAS^#*/1] M=LITL(=] KR)KMC"8,V&*39,L61,P?
%&)'%P[K%@-8QN,XB!#;UNZ'6YZ-4 MQ%!9H)2]$'3-RE$<.<*WCX(@O&)K?3=-AF&DPNQ'1[WA9.]G<_1KD>!]#'5<&T[OA]BML7K MVZ>2YWS[2]H/8_CO;AR'?8]RNT!
7]FCDA^%Y@&<6&\S:0]5^?Z=>Q,G%#6%O"OY"#M,$RSMU.A/8(4@88-]DPQ9-$N7 M?4P-]#EG'@LF\]62]AV\(N\380-[RC52:L9].6L\D!"F=D_>]?G>8/E>:M7 M3]{%FUX"
[F8@3MHFST%2/@'>?BS!?_C2V?K>[X'[Y+[2&9';A-,?YCOQ2S#C M-NIGHWZ6BU>]@!M]=?$4(?Q)Z,C@5B9(*/U,_) U#.GR$EU98F^H>T/=2T7= M' +U9>TL*
(D0LR:]Q@1[Z,'2ZAMM:K9L!21X("H\AP\DNKR0#K(PRU"H]8?4 M%MM>].A ":4!S:^7=_OBN2[0UX$3)Q*B?22H$&7@>\!]/9%<"Q&H!"G^XK,S M6 M64C1N!W+CU?-+(5]0G0:&
(AT['N4#B3]\-6]7>=O^U@B_)RE0!SM=KOVMO?N M;?V=&L4@>X8P0+A7B-LU],A&39X-MXH):2.GQK5MHDD%2/>CC0%9=A78FAE%MEO)3QB5S#
[+W'P&;E3]CB]XIKQ8B;PA7V/Q@>^D'"HKI[RF@4*HKN!@IB$ M@MC90$$L66]_LUUMT93FD^E!:-LPV03^1#@>R]+*SF 6/]">$;"5ZQ>R9N%; MW6>L]/(=+>020H!!(
WHX.]+8A\L ?S"488O5\$9$TF(*$NRPA;A-^*^1QWZ M_"DW6'"^SFB3!/%\]E_.:/S+?L7.U?V.P8!2_^;:7-L-*<"5P31K#-^LE*#GF)AEG6FVW< X?PQ>'D6\%_X<<1&WB*'#@41S^B
MEF9*1@-^0Y!>\!K4&]H>X]!;!*1[.>12@]P!1NU1);!]VV*7K5/N!YGTZL M="ZUE?O.=04M5@4WC W5QBP9GA3B$Y.,4_BX[]_N*58$"DN@P-C:SH.%)$Y% M?"?'Z#Y[ZH)W!=L0
YQ PGB9C/7@1?UTA'S;%\#1@T2A'*-=3?@" YM16=6U M^&W89XP(1C1+@PQ%P97WKMJ'LGC)]&BQ6E!76N0 ?IT7 ZUAEJY3!B<;88 MF\$P#X5#%K_LJS\#@6,?
\AU5'SR<*D#!'!4X6;\^]ZJF-H- @0=F.Q^_UW' M? <>)IP)/LP6-!3]-ZSL:-8HN'0^]M2&8'E+".8=@JGZ88RM6DAQU)5+YT^< M
EN]$9RTA%TTA@UHD_#*@%%]!BSB11&B9!T5&E?I"Q$Z U_1'>0'YL8$M* MO ;US:F?1IY"'$'\&YL^L8^"/@Y= -*]!FL;] ";KFD#0;6O1]5FHH4F.>(67" MC5H$T]-
DE1RXKN^!5)N:X?23A'APX 79\?@5R9R[%6]\%!2*DW8 MA8?[=KUBH;1[KM-Z"82S$]@0%*^+P>M:AM" !9E="HQ9+ KHRS# A M&9<40$Z6;N'\-58\TH;":5D(0/DWCDA 6,XM%Y9-
G6$X7!.HN[E?7@1&@8,< M3(1>C$*CP*8T]@T#[P[GK@O[5T31R&-?G!*L95]P^76AC S^HC +K1OW(4W@
MWS]4,8.Q+N6HH.M'UO4#H3X]$G.#!\9E*!X8T*=9#O1@@<6G7O:&]^)M6$_" MV["O/"?7U#W9\LUMX81LF@U5-&*@X-_3/,1\#?LKE13E+(2>GB-
'FC&E^2L'28.WT99QH1[:]/@70$=]OB*[DZ7IF*R%;?% M9I+'(<\PY622LB@S,]PNP3Z#E/Z'E_^_B,HO]N!>WA[E_(?HNE6-<2G!6(M4Y3'%,F>5!W6%/@D+6'M:0(61:6D?
MUI(]DEU_>B4!+[B!*-+FVL_3O=_6),1 MS_+ =T8CZN]LV*,4/"A4)W^E6O8.!7Z+O&.FI]!CZU,XH:)+:;?"<-^D-2 M>]QLDU,(F:)<=P(!WCD]_K>-S!,CPWRP3[BAR:
(N*39*7!DE!!D$S_:Y@8IU MH,39I@XK.XV5QF[N&[:(O*.\#'LZ$(W;Q<1'S.4A"-T/!,8QD<%@"XYI*QX* M?\ #%L(TL7L^]G"D'9K^B;B"_2$]+C*C1[UWAC;@WGXC1QHHQ[&NJ%JK
%&)\Y$F9;]2@T".'3GJ9R3IB6Z!2%,0VUC!AF+QR%"M4C04OD&QL "2:5K3V1' M+%+&X"-0%:D,N,@#,5W*M5-7H[,3H%1'6C"L'0,<%@W!2K!@5)@62$D M M4W <,-
S]UIBE%V,)]HE$PZ': \B,@3(LU-#[AA<@E%Z23:Z9!F6 53I MI>]LGIH74^G9%6)?R MP5U(B['71M'0GUK5ADX38P2'0&[TD-9O53CMR2YP/*%=WQ?1)8]?/PK(*T'[M4I)
<++O#=X_V9>;(PK@^1D\E O37H\]5FT>%$S:N>C@MG@9!9OZ'**QH7^"= ME*V\]+P989*N%Y2Y5@!R&$89?D)!#<(3),#F31KNEWX26N7MX=G:4]0]^"SQ4 M-G"/ BQ,7/&7?
868QL+R:F,YA:A>TCI?SM\1YADV<)IBDHIH.I#LM/F-,,# M9X$"32DL@+,9E6![I -X*%H:DY(8R3%:(5 V+($"B1IS8IC"SEO*9*]P 7$N MH H*+MU >9QA9\C1,2-<$GB2XLIOI M
^1[F%X.P4]Q$P\'#HX$SA3SXE',"AG-;"0KO&;HP2\S<&X5)T C].09*Z(M,:;B5 F C+ !,>#\4R\" 7$I(0)=#WZ=\Q36@PHG41D"43X1%"2P?LN\L?O MI.21X:,E)6 @2G($:@+N'R?
BP_3P>$AV'9GR%2M/K+1Q)A>ACZ#Y,F59CN3) MIE_5_L3424.?4-&0=89%AI%'3^45Z9W@_(_Q/*]I\GZH_: YK]Z0G(P!15QH M-M&$?::4)0IN7"Q) (PBH9+ (>
VVHFJ3%CSDM$EK^)).MCI$'2712XUWK*X M4O2.#-*)AV!P]D2"&: Q*CC0!ZB>I./>"]U;.8 56[\$SL6-I%4]@]'#,Y?X MI0W7!]D5WJ1_N_;.?
*32+5IAI$#SP(&NI10&6++D$&6LV@ND@VC#_"QL3<, MIPTW$PDF]8QP"UGWRMHCZPD5 "'QL&*"MR*S"7/ZV,3A)3YBF,@TY?DMIA0M M@IBFM7!$<6&/1/->F@2'?
(H&FL.UJH MW24<>;2)*BQ*I9-"\"H$AMFY.\8%:RC@(/S<(2+6GA\>-&H+:-'37SE17]G= MU%6SN-7S8I!2-
HH;KXBAZ5Q8HK2Y!YLEY.2_6K$)WSKF#%]U2TL+N!@N&NV/\%YYI$[96A&%6U^H[NT M%9,=5ZPPS,.AZ#$.B"(8DV(%KI6W^GK/=GNQ5\@""S*U'>\?@0X;I
M6)7ZP;9QW>RE'_8PXX]1),=/;M$AQ3V.5/]+VQ:]4GA=B,'Z48]9! MT\EV)MBU$]8MY6W!6T5CW.GYTN)^VW^*#]ML5NWC>C/)HF286AI5; ^7[7#"!;KHM8?
H(\-16_+]KL"FYHXYE;2)T_$8EQ5CD&N$\%/R([L_MQ"&%"I5ZU -W0]X%A!X.$L-?@M;41$1=$S85X#5II&L#@=A"%)GA-H#82D(
M5IK=HU]G]>4@14:Q'T%K\BP#@40_PCI&AR<12D:6_(-G3O&=E&,R8V \4*_P M\P$8Y:&B*+0&I >:1SHP\&]/^?L3] ,1B0R]3*XY)T7(I?GQ$/Q%*4+4*:$J MS3QJ#-^#1SB6 &?
P8\P=F<\ M 50X$A/2FU A6!M7HOSJ<$!E9(D*:/5I=+4*SI'[^RHQ5N%-."@T/VT]S$+% M0\I;]"D-IX]#UIYN3R:1)(AZ)=R$Q4-5##@*IL
T47DZL1>_PWOJ'GX/1Z$;9K7>_$G@AB@3);]X2HE"<-$T".8CMK8KP,ES=C%VHKZT+%63.W1)^24?)E MT6]/],HO,_.\]N9#E*-GI+*+*]$A\RXF1 ITQ]3
MF"NK3@I[,\@3,4:QFOWK]SUN-U;94#6PWNB&]_03WQT$!H=6M=#06-"O<'4 M_:+\]=4362+^5;-Y]46.#0TV&N4;FUPK:!!NC:Q]]O,*9!(]HWB8H?'F:H99 MXET$Z95#?
2(@QW0MLQJ)NFNJTKUP2XXRO2)NE]I9RR*Z566B_<1Z.\;&*-!P MOO0"Z)%XV;MI5GC61(9#G!4[T;1N_<_N9+5#X",&HVHX$C2;>PGD]:GQ]4)Y-E00F$]!^T]\G<24 M_)BR0
,%ERM#E&=@K V'!W(Y&$'185:#B@KS5==. *K;5\E;[6LD6'\BE0@ MB?+T[QMB..>[%TQDR/DF6T#OWI4DU+4G1"I["D3F=)@H89;#^K8$I@SC#.3? MD:DPV0^%O)=8"T_MU:N-
=G::7'OZG9&/LNY%?%G<",O<"'$C^F2Z@B&Y.V+77P[%3HCM+C)>/9;C M# T4.9=^0Q10;Q2:>=7MY&5LW!4^M!SY;RZZI;DD&AWE1B*;3(Q1E(IU>*RW MZ$6FI]"@6 O7,=-
MXSYXM$HQ]7M1LSN-Y<;FY"%E7V/A8&_1VO,TGI-!OGK8 M#7C9@6L5@D08[L$&R2*+]5,$75#6BX85-#%1,GDZ"2<*3"?:N(A\=2S>@T,B M?
P,K,*XMCSA\%%ZILFTCE0;0'6A8+$%U7BHLTJ["VE3)+[7,2O]A%KXDLR9K MZD4?(K9S;]&UW?T9;U7E 7/(9SP[,/]V M?"%NGQS:)2[L71R=?S[5_<_'Y[.# WOVZ;Y\?
_=OZ#,;M99!=E[)U].=_@]XN3_(7VG1B#5-9U1H==/[7]] M4]O52#W%]-]IXS\]"FN4\F^$8F)6WOY4;W>-:VIEUUA2?>66:#]LB4UL]IOV MNC/>R]*OB[_'F_)[(^X=0:AH?
$B=]>=V6/Z0DOD]T5UL2"2+68)AJ9Q2L9^7 MK[',=*,%&HL+.K@D]\)]HE<&8X,]G]I7!R'*+"V 1^<*VW0O>"5?"&X7"V] M 2\9*\],H@R@?;+R\0WFXDK3A0W-Q)>G55]K[35)A#Y.,
<"(O(I66P-I6[Q^9 M?(IM%)96T61[+^TH\-4"R:%'3:>'?57OB[=(;BNVW]7?Y8AX+@0]BD]3UW.T, M>4'RI8H2@B$]0BN90)7X26@C4_%-A2J=PR 0_I:Z*:$? !LB$!4!+;V6MIKUF%-
_"$AO)3YWCO+, <>A%RN*Y-KLF (M8=SH[2?HX4XZL.[3 :^3G:0M8Z#P[1N:XT!.?]C (Y]UDRD2)5"/OZB ODOL MM\18%@%,4:R%4.90Y4@$*1I2]R;1,A_IICQ]7Q70HQ,?%-
ED"M855)E4>-G M3I;_U*YTVQV41-8#;]BDZ YFM'8S^]%4+;-$9LX&VW['=PPXGM]>2LPCKLQTS7 M-=]QO"1#-.1\;IP8]Z=*(EG^&%LXL?
*V<74,5/1[F16[KU2%&3Z,J):MR'PW8!1B+GF32%]\I)@T6&:3%74E*Q]5[G8K)RMFOF63 MA 7L;'3DG7R>/TQS6+@^.=T(MOOIF UD(O\HQ"=0X96"'7
EM(ZR;>6!NB9/;$DO)@2QFSB@$+OHA"P4QV)]XB,\Q(^_G+ ^U,'US^8(,<89%;1*# M6'N#>$6&(& %W)_.]UOXG\"YY83@WM 3 Z!K=$^0PKD0DPO@]@Y.[+<9Y D6
M.LF;938#'9K1$M+4S10Z&B0!+K T"MX/5G3M4#]\TZ;DAW%;*=$PND+%?!?A> MI/-2.(5CVOEWE0G5/LL><26IL3^4X!-8Y)]_(]B9-]543BH2ERGGE RVE)/A(431C0H"\D2
MM#SNQ7'%(,-]QWP9KX]C;?GA8&];DZ6"/"F0R]R+7_M9MQ5 CPGS&B;4%)T]]&]0CLW.F_;)M@"79LBD%)5]>+NCMF06]M4A! M;\]NZ*V%"GI[5D%OE0MZ4YX?GN2N79#(MAY*
[(L2V=8#1;:]$=GS;N5O;"H_M)BL_ZIO*CY5A D:4IQ+0S! ^0E!'03&KQ?CP2\'[-8#_=9>]M:D;+?2)Q<95 MM]%#IA7(_N(5#_7]V=B]5UK-SGVWM&8-$U05-,T])INXX?90F]
'U:@AK"TH M4UPR V?Y(:B_S/(9^"E-7Z# I9Q#]3$,74 M-2U$\^1/\ANE-X>:TPC^UO(]-?C0,".Q83>X3!36)Q&MZDD]'XKOPI< DHA] M:&P1;)V]+W<.+0ZPD2A*;.
["4+C4F9!D#5$;=7TG$_,1*A9N-=OWLO"#0^"U M]KURP9K=LRO6WVRX>#8NUF'YE6&:A<;FC]16]DB\O2@UOCSEA_J=RX)FZ"2& M:8(GN1 $BL@["%YWCI1@]4F%*I!E%[BL-
B>0[5@2V>C+:4F'EMWR/ C4AA0 M/3]X!8*!*:=+!:F,D(,GEF*P^_,4U,^3]KZ" #H.XP5EFI9"P>$K^M@%-:^R MVFZEWMK.*M>:E7]]-D-
I;:#6P4U8E9K,/V$]P4^M2K?;FI*.>B"%YY>1CT3& M_I2_F>?@L:14]NMR4BK$4O$\.)$8M[)XW=[V%F.L1]']4'F)CW*SCB9%Q(# M>-
\DUN4M0M9YF*UR(&D*Y2(<53*LQ]Q^%F]JUM#B B4$4%8S.U$>6+4UE>#L M-6X.S$P&9'6S0?_)AZ1(J5[=KC,5 ;$V[ZW-KG8;EOQU=WO^E*)J_=16Y&TF MVMDPV*
(T/(@[S.X;9LIDI^S3-PDYI5G;,0K2.3Y?6/@26",ONH3#)Q9B9@7T MQ]W?]N1C]H&FMSMA+:+AP#'*VOZC2GZ6@4 :W*2DYA3<'38O;(/$F M00."AQRK?
H%&I=G)6@;ROU3!)$_9.&!2M5HU3L:>E%:X2E'GZ"Q<7QY"G$9C M/Z7)CS_5.R#,I'G'3\3IMG!J;S'_U?<20E5ZB[5\=8I&O@.]34K0%084Q$\@
M_F0WEH8KF6P#*]A7[=%;)>I5CI>D&KP4P?HH"<9KHB>^;36ZE2:;IN]6RC-Y M2/0*RXN=F"4__8"<^7XV-5E%801_["<^C!/G@;R+'[J5%I=>>@Y"ZQ=V6G) MGKK2VS05K&!V"1
%AZDMOB0W8+P*C]KZCD^C6:W5;Q-ZD!0;#8ILOL=8SMS MC.^^I*FK55%%H'*5:&*8W15^>+U.RA*M?]{*LCQHONI8PMM:LLZ5! H@^2=G^A%4&U!#E
M43@2NY5&8L_$RNQ7U<2@M/,U[31@="#B6!H'A3[+R>RX'(1K/$<76LAG M&=GVLE IAR8MBCCE.CCQOO!]L728"L+QCT)1.*P0?CKB]2"01%P2SGJ9NN.E
MY19N7"M0GVJIM8B/4/%T*PW6F(]E%+J3;M7E6W8:]6)XI/R>NB)+I0)*UEQD MO_O*Q>[CFX3G53#&#E%/%EHG;)UA&"5;6*F5Q?#)H>%W:[>-1LANI=LJZ;I>
M>^++&A%EFBAWI-;L0C",GK7Y\"5R&]#.=5;5&\IH"*TQ*D^#.NXB">![RY# MQ%-&F0Q;KTKT="CIIV:'LX.R!,\) H3M)5Z657Z*=P-8AYU<"Q^'_?)A4:-\
MDD8!=QFSBL;T(RVA,)CD3W,E9-1I0JA4A/.+4%B12_:^*A;C M$O7 3/>>V>#2;?3;LK*0"4N0,\BLC4/GJ155LB>?.O!%:H.#3M\%828O$L! MO/2.VZDN?)(+L&M-*CN3
D1=AXA2H*02BH+>X%B 6%@9C.H.!@)U1*2 Q(5[M_2F$=R=3-2M8P]G%VGGG39TJRRI7&H M?[NZW9KSTB0AEJ_/FGGK:'V-6G6^.[<,DG6%*B";FPK(R0K(QJ8"\I<('!"F7CE%"_M?
_VFEN MMWYI:PA!939JP,P<%CEE$JCPI3\4$MHG;^9/7PS%(,OP"-%Z43E4^72%#&)] M"^3T@^)48+PH,@?'Y48<9=B%'!>U>[KB0N,5JQD$WEC0- P$*'2B[R+AUU(J M'*NM9
\Z13UX"UBMTUPB-KS#H& UJJ3N'_K2??[7.ZBP&?K1/HZM)#UB4FR MTJA*(X7E((FT4;,4SJ69#)]*<7R.\C;Z>9XN]NKA*L:.YVJESB>WS533HR.6 M1KM.Z\)R6C];?
#5=FX27@B@SP\V&U\7&;5\CF89.H,>.FD.%<=IA/Z5849P' MJ&$+70YDU.-,*7*;*O"%<& EDE!C\U$5>QA>(^IT'A9?MK DM^P#4 E_H9J M0
8Y#CB=\:2YCEN"PSFI4()PAVXM%46C(-Q69%8KR@7!AO> =HH56KQMH1JV$)!5 M0)=K;)^> .(/Y+ ')MI""PU+5"Q>R=J*$$\[_T,T'!$G(%!+$CBK#*_DZQO5 MYL\93$CY2L!?
.\R$]H5,&8:I5=9QE5Q_$5M(S-#VI3[I6M0-R@Q,?W M,R^>3BZ62BQ1;H9H11[9)+W\)/$?=F,EKGF4!(IC5ATE%C9#];LAT#E7Z_'P M"(TL&B&1_:E4;FCY4 MY#>35A01-
D8.F(5/7X\^D]PCP9+A[8GL:BH5W!=XD>H8W!<#+*-2./DTYVL_MW-?_MG=2P MG@1/-M3GK=VS\ZI%_R$!!#=W7)HF0]-J6:+VJ0"48'Y(N 1IW\<-A!\A>+T,
M_4>.Z^F^OA!'_$HSB@.NF'/(>@SUG!-CWWE<"7>%T@&JXG'9%9I+IZF02B#= M8LS6WL"KTE I-94FJV5(KD,^=%[-VONM)](PV#;U'E&\I>(&/(N!=Y=VE/8/ M-E(QP7VL!/2?
U0/7&RK^)^FA>,ZMW#E;\IS;QLJ8VV2RP$ZE8?%3O=K2CR93 M5V'2,+>4LP8;SSBS!^$^P2VDT5U77A*%"O#SRKL*K3@!=<<9*\EV^H8SL-=0 M@'40CD-
/X&1J&L2C1G:I360.G&Z/7/,43VM:QBIOA6#=8$[E34N!7XLR;9)C MF2F6CO53K5K/<-F1T[)LB]Q0;K8GV8$*=L-M038BH-XTCK8P8"QV? S?34!
MGM/GQLP#HOS=ZJ_5T^K[73@)$JF_\FS#4U Y =5:P=7\&ZHO=2[ITHG)%+B. MD7/+A5MR" &PRL1T+J1#LMO-<5]Z$*\.,K*Q9V#WR^%T"$5 5@G]5[(Z+T]2 M?[9%#+_3UM1/
S**#[9;C4JGT2TLLF@ %;9.QD95J6,6&FU7NTTCNKZ02C!/ MTZ+WLOT?,\V[H]T3X-4Q:Y^JD/AN?LPG9=[U3#OJ(S%@34\4?80#CO_7*\V= M9J7;VLD,\5P2!0PF^PICI%CY#/9RK6X9
6N*TX\CL876+CEF$2>.%*>' M_-T?^CLSH"]]D>T*^"O%9V>A]HG[[M$OK;ONN=.JM+L%3@D,L$ML^(@-XV" M5,$XT; 0:G:=#((5Q]=A@>_?]1,7"DCQ
MEH.6\7S;,#L"&FG([\X;K]_;+G]OBUFXO9U+;Y"]@(Y3+__Z_, L5J,6;LP3 MG7A16P_^*-R,,YTZ=&;E]U/-]%/[JJ9\J*=-/6 N%2V\/%I6-',0F#L<,;Y5 MXLDH*$:/T#:*-3P,#?G,)A8Z=KU;
[79_AC<(J'@0 SG7J"J&WIBQ2-A^Y_VY M>T.01,,>K@;#*1?ELL+*9(5<>FRL70^W-/#/) -H4-1L6+FDHSTYI5(A,2G1 MP]5'^MXH\$8!H:C3B,@(*Z,EL B#-IM&F)SZL_IH@P_0
=_TT+QFM3V%4=!3)F<)G5\7D9ON[6 M*S)W8;B8Q+8"X,LO*_-/LW!5CC% MH)R0TN9HOMQ$Y0>/0[8GQB%;LXU#GO/0XGG-)0[S5LB#1Q.S.R^K*I$+9#IM'ZOG78=C.^^*+&
(NQM"]>M#G0P896\F3!AG;:S/(>/Y5 M)ZU-UR6D4(: M;A&HQ+I28UH"#AQ0,Q%])Y,;9+0J:'6+JE@3G.1[&1MCJK.EHH9\3^;JE0C8 M[XN5+9S]GO
7/;*F\%!!44=D,+S+HF&X;=DQ7)T#ZTT.:Z&7E6K<>>:1M@, MI)+&F$"$PTF_2X@,F?&!K30;[HP,:# M!T:84K:Z)G8TFWVKCXRQ,K/[9!G5+ []EN$ER0#X26?@*50$"E?<4DR)7<&<
M*0 *L"\;ZD#WHP6BTO1Z<(\KXG[D]3@P\;;W[IT,%/7>R5\5XN:Y?3'?@_3 MX?]:CGU.\ F%]J;#E#(7!U3K3&=\OGMX4)&N#M=--,"!P0(+M0^R-B,76L(> M&H]R,8%0:I0K>,$5OH2?
8\;>6MG.HL4N M8ZFY#2BN@0LT<)#KVBMR,S$P-1";)Z\X"[-,CK3.!A]G%]P9PY6IA"\"OP!J MVG61+) ",1YE'V/RP*)PFRS"5S.N"S9A/O)[]]AJE=1@FS0+ Z@0<:?=K33J MW?(
L349(,Y%.E79_O4=D=H6(AVB712\EF M6;'>M.(\E._*X%:-_+R*@L\N)9L*H&GGN[A8#A9GSD1/%).,S6E>OG6GEU]\ MT#W.OEWB[*]\@(ZR0%_-RE79Q;C0G-
#S"KZBL^)]9%1'4/8!N).D"';39!A& MU%Q_=+3[[A6]_4RP",7I?['3 @6!6,K:L"@SJ[(^8)Z#B&E !F?,GK_'Z0.V?_728ID7J-\!VNES^3!AKB*F3ECOPV6%@JN[7@!7NQD*5
9!+0^BL8'Y#ECA:% M#W@'4*05P.&-HDU":Y"/5UF)0F,P6\.X#*Q_Y5GRKK(NSH_/3LZVC8Z[7!+I[PU@"00X)C2B0XI!,O4AD9'3=UPQ\IP*+-#U M0/=*6P/>&?8@NJV8%4*[1S:[(Z
2MY)P2[!2"T=B"R=TX0KBD%-V;'?$PL)& MR2U5]8\QQQ&B?F[1+& X';[<5I=K#J[9Y!@; ME4>R,G4,9L8(K+.4Y@Y7S%G W/[H_)TZ:CBP?$],DAE[#/PY<0;:SR FZ:7N
MI2@IES;J0_!+8LZ*43L\6774VJEI-J*";$<"#,FN1G XP[[B8/1%53R9/&<< MH MH(5)36 6ZLD>_+M>)XNWR$&_%+?(TK$32F[MW/^D%3PQU M_P26UQ$(??M;X%$!ZSIJ;.
(E=N'77?D@G\Z.MO=Y^I:?&]^!\NULL3_^R>W1!Q;>QQ-W/OPD6GB]PYRL">PI6P M4*ZC7L0"VJR$EVIRX1R$TJ;8L)2.U) 64IYCRMBY2N^Q@)IM9W%OM *A)BZ+ MZIRE;I-
:C>4IXY84>:XEH2R+6BE?MJHOKR.$;(*)L(O1L^<[,^UJ3]79R74GBON(/OSVHEDP^\N,Y9KGX*< M1 [V?L_+I2DHBC[29R(T(F2(<9BN;#T].SDXH2L7G*3>;*;XQX]BQ\1
9T8;L:574Q0L@M>A M&])8KL#NX%OH[])3$(@DQ:G'SSZE<.K1^Z,C$A\9X$O6 $WAQVG_1F%KB"Y M]#T0P@IS._&]67NF8-!TIX= Z-LUAHQZ6_0Q&/+R7=;=FG>
(V,E6W^7UT)W1 ME)S+H&,Q)3IN1\\(0:M2A5AXE(".-VOB0L8A?$[=3FYF/'(.UPQ-*'+ZXH,> MONZ4=D%%F(;6QP0CQ3VD(6-)-YYG%B8A%AAC3IEB9+H,QXDB3U#!9%$N50I-
MXZFLN*5/.+*CBX2*(D^Y&E:6]L9PC:Q.AHM.&7X0Y,Q%V/- /_A!=]]; 8_MU7WI$K;NTJ%F!&E,WR\L$='8A%S0LK)B_9;Z'KS&'Z$_&!BWH.KL3-)^2>-^ MZH?Q=^$+],7.4S!-H]N-X_.

(072@.4IEHN<'>Q69!2++N=&H_1(/A3^@O^N_Y)=)&=X8 M; G52H#3>/"7I3^KR#[#DG; BNXXM(K=8)$8B @38'$2 M<:+2)YG+:23B[4 M,]BL#)HGC(PLD]X.@JL(
V'\A#/3;+#G*H15$'FRW_&GAH$R|38#R&#+)>;6 M1>.H|OV(BT#K7BV^(*.$BM+Z>GJTG@YG87QI $(Z-.:[P:D9@YAB%9+$P@,% MD:=:T$W[PQPYA^
PW%:$)!#1X80T_TQ(S$E&," BDZM#1|XH"=3|)>=!(2|S M&7D!H1QP&F=, Q"[ZL!;0HBKSFX5G'K)6_"N"MU75VQ20$?^.K?^UZ,=8FT M"O
&P=KBICG[S(N_2X94H%;4T[W+B#YG5'"]1G3%8UG3Q _#[|\X6FTIN$=K M%6,R@*-F U!7I#$:P ;)+A'&|(^QG%D.=(79HE]=($TFL&:D7K#R1M8F;3RD' TG-*I"_(3?I^"RY51&#
[,#@T4Z,.Z T2CY] MHNM!*<0+ZH4'D%MJ=1(-G$8]PIUIY16L7L(KC/H(0C&75U7M71_S>I=#G;ZF MQI!LIA6NNH?@MO1&QG;Y&A+(=^+$&@ E4#E7!8?5>UA M'/+#N
Q7QJIC3OM(Q/AG[%?*@QLO!SL@E$$O7SG#%2&6$5;P]4262$UAR6F" M?&9#94>|'XXYRQ79E,@&%155.ML8@!F0!GK5 >BX.$X0408_RBIL7H2S2RU
M_3B'@$$<*W9F194D9U3O%.:ST*B]\AS)PF1VZ8[ABOT7]JG:LJ UEN,(&!QC MZ(V5F8BWLW(Q8;4D-4Q.XH49^% 2>P5S;.$^H;=SUDU&[9 M%?8U :QI*3K99[8^"GT]'?
6$C_A]MJH?8FR05$X.3'@N@4JIT1Q3+1*YYD&U M "NIE(0|0$>HKNFILRQ;WPG-KEF9@+*|&|7-;K0##K MRD"WINP@6/J<NNQ9I(ZP;'C6|*JA9NX^B9VW[S).+N)
[LUQA82Q,UIEJ2X: M;P3R3_5[DOV@?9"<*NP)]40Y90:8!+Q^V:5)J [8?X^)K8KRW/'.!WA#(P? MLEF>?XX +" -I:U"'KV:/DAU:P./6AAL&5K0V30&!B'[*Z1]5|V!1(+37#N6 M!YBF+1?
HC5*,81O#*N&DG4O9T) I#[(4#V@&]$5_'YXP$A*&N|&!1PL-RSVQ MYY66CWW#L&Z&+U3K)B2MI*1_*%##+9HK#|+N]DT)DS6 XPBV|P> M8"A,,9^,V) MN>&..>0,B-6N-
YVM>ONM>#<)DY$%U##TAM6%W6:+R6Q$L)Y5ZY/R18C&S524^*%,DZ^DM'V"|_4.=3B(R; MZ$I6@]B^H&[UH8/PLB(@E&$^9"DS9?;*5V=B(\4;(:9(W3,W$YT:8"RC"[\
MM=OF8\?'JA92;-2DHT4IC(WRL6Q/I1$C6;?FQ.|KLZS3TNM<.-EPCJ2$0F;) M"6UO_IB.X2Y\8 M#RX\$X-_ONFWW]ALV_SSC7>3?!AX-|+=&CA^+-[8 9SO/]^(OOOA:QB@UJG7
M>NWZ;A1=1*,@<0]]Y_*-[;EXY=76=]W3P(*LISYJANGAR]F7WXNCD*XA_|]$?' [OQ3LI!MTMTC/* MW,/Z;I42#O8ACX%|3J=P*7N MEB\;XZ63R%E%WN<,08-!/-1/RY%/
|PTRT+NT1A#C1FN0]D51"#919:|"'_' MF""L8_FI3ED=RT.F5.Y -]WE1P%<9(BHYU38(%.[Q|=[V "+:|9[MI+$.=2K\%L+30!QQ]N17CK%%=Y%07))88(2 !-F%F5)'T4TP-",S U\@)O
ME(ZXL"$/XQ&7/$)(F)(6_F%Y5#V>V*!PB.!*5UGQY>%?U>(-L.;1AJFFB-@]D-2"Y0L M4)I81Q:-FHWI9+,D)=EYZF]I:A|-|+T1/H]:>!#%%&]M/*5W:W$IKHH]XF . MZCN^UDE.
]Q7:Y>]O2MKOJFT2OJ:&8|%%]8FH/&U%E/[H5MZ'"R,Y<;I4R<0 M_MH'D_XP 4P3YSM5TF<1&&&-X$|.PEW!86;% $6BR8*;DAZ5GCC3P7 @%X7-V,I]^.>J&O7(C3XV]GTF-8^V,]
M&A1A_Y3"L*37QH*UQ/QFBT^=74#3DQOL2^H^ M",/,4??",5$L>?I*3$<$P274HB84DR30"2[,,3KB:%#1DBH#BQ%A O?"UYUA M&1XLZ!
K[,/B*CS76H$V2%>'R5U[EMA]"DK1)/HBFNV'I22]A,X*Z\7&Z#,% ME_]\4WOSV&7=&?35,>@8W#9X$'YX|\L;.$0W&?[S#:+L@,^41.KAL)|$U*%> M#^[]Y]/UC\15/Z
+U0N^_UCV38,3)/#$P'RGK=C[(?C%?K'I@X$#1O7MA[M? M$W>QN]WIPC;B'<&92USSL>5>X,3#9WS6!0E-5;95)BOSZWB?1/@_>)[3R"QW M2I-
GM*&2U:,2\N58_4V/G&P(94,HA3"95,TR\BG!"0U<"T=!Q^:KRC:4M*$D MJB5,%6]9)UM$9?NR 6>ID%-C*^O,UHD _E(.X=T(K V9W4MFDIB07A2%:;]R M-
G2UH:M'T96TG4;@;T;QAF8V-#.59F2]DRTHDDA9U2Z6,8HHD'5OE@]2D$7. ML .G(K$!N0$.?TG3U/20*Q,]T.B3CQ@!#WXU\#ULINN)Y!I+;K-[69^=D0-O M^5G\Z&$[V-!HZDY$%
(41!6BC2R>0'7I&!^FOS@_'/D\B;TQ7'8N>$Q"\K@-+ M<[#=DTIDHW2LRESB-!YGL*AF98QEY(TQUHHU[-<.R;E-.46!IG3/XV.I"+-=
M")@X#O"A%",Y=/AR.M79]$P63[%'0.I[T05ZRXBLR>(#"[6U'(4.8%!=5B2 MFY&>SOT2*G7,M,507.455FN?=9&](Z&+<"!)KM3>"K):=E4');,'1G\SOX,]
M@://51CV9>IAVB80ND>%#]]S+['^/>!:&&,;ALZ(A]A+* @9G*B12!0>S*<_ M2 /*EE"3ZE!E9;V![: &U"/U\)92PQES4%5*^D3$TB"]KD>*5C<9^>"N$)EXC
M&&9BBLJQ5EB+X$6V"S8?_,2)O\NN+7R3K,S-]6(I2-G*@T-P;N,LMZ3[IK%] M8<,&N\$M4%&<*'$(SGKH7V$/GQ:!6KUEO>.&2*1HD[;!(_O*"WV]Y%538C# MP_
^&>2:H>GZ*5*5KXK29$]9$M!C&6C5HF[^:YBVN7EC4>!AG7V;0'3;8';6_:@U:<"0Y!/H-QA.*T MHDT %F26UM^]%E!B<\M907(8I<-- .C@15$"73YAS8RZ78?@Z98);=&/L4@>-
AF6'5?L+_JF,FCY(V!\"O:9A M*$$;<#:U:1H(/>#LY[TB^0V[Q7$L)UU"Y#H^W1(Q2W)96#4ME]+H$/5DPVDA) MZ?GS@4/]"VP1@C&C'0B)+E2U]]1PS KCPK'.R+::EDX-H?
=OQ]]+|#^<;*HG M3KI4I? XG54Y_SWPH+&J/41X7A\5TPLZOV.0(2T*A,S6AD12775$5,%5?7E&D9.?THS):=S1V@ M>G4NM?44D U,/LTMRM)74BD|.1@#]C?'?V/Q,]PBO
XNR4;S)MZICPM.$'2* MMO56_67]Y)7@.]P=ZV6E=]C;?--|0_0^4X1-1S-L&<'H%I:XL\9EE(,2@2R M#+E(C9OB?[DA33F]\+8/>AA/OX"U3/&*8^%< MIG+&%>L2"6>
(Q!YB%3CU+WQ)8]_#;@D0M3CO28+&%7D(_0[?BX?H/!BH:%*K MH#3@)9T)X6.*T]7XQTP|@7SW5] M81^0=4^X%@$*,BDX<*X]]Q0R|@U)F:!N@*NQZ6YG_)V"E5;+L6MVB W>?
X> MX5?B*4HG<*0<#'01^-U,.#[7&:&B5!,%I>J5PLZ,N%+1]|(D)#'B2U $8&7 MW>BU,2:G"A;H@%|E.V=-K@W$L&706B+9896@5Q CX Q:">.OT7/AM^U*K5/7|2OA%HJI$68U9^
JHTP. MOD9AYM#H6XS-.ZIDV?=$BBLAX*_M%A"='J9?Q T8N;1OF#BQZ9#F27XL+,)/DP&'$J;X,,#!/J^(|"UCLUK_DB(J0P<6[_P<
M=B"/SGD(0?]B/YRDRPZ_"$&V"M3>6!9]A__;KM?:[P?UVG><16B0.F*9SIO6 M=YE0Z>W0YSH3-!7%M3_=;AT[USE*SD8!UGD8<>WAU*PCY452_IU)F192^]P< M5=MSD2N-
G7]WP7*EL=/NL%QI+$ZN(,435(G@UQR 4(DBH?M-2G^+Z4.94=2LJ$RJ8^)&@4#M<>9[(6S"$@OS'5W'EN(Z62[0.-25W MYM-LZ#0O!_*+Q[FC3A,_V1U'GF_7ET,T38 =K8)L:MK+
(IS@9>NU[C:P#*CA M1]>!_%)?&+^8&O:+P$EON]#L5,E#.4-.I/#3F'F"L*$S%F5].L/(>K?4M#' M$LRHL2'|1Q!U:UEH>HH:6!Q9ETIX^]08#R^%|)FX\A!Q!X5WBM,V98S'[NQ4 M&
[7NO4K!?K@^>+B=^B"VR>N"#=<|F&O:2\XUSV(\S=-P>A2/;.RE)6:2UKPB M%_,+-3V=W=JU6F>[NT/LUMCI[A"[M9228EXC4J)\F=@Z3,EI^X-G.,Y(J*T' MVD 28:[!88BU/FT:Z_%1-
/];C MA"NV2R2]4Q3H:R] $6QM$^.D:+[1#;"D"8TMXG;LH"Z9Z-]/)"-")R!!V"C M&D\DV;($-U8YS)HH7IP8?12M:CFXK+0Z35"/7S6ASE58-]='6.?,R4|>]R!< MX 3?
|Z$0#Y/0%7MOF"8_QL[0_ASZ+N$R'R>N"B6#:>((_F!FRM\8|LJ. *W_ M?UFIGX7W#]R;:=5-()5.O#L_)OLK9#H!XZ'<\1X)$)6U+TACP='3NO5^LSD ML7 2;-;S^CN;?8B%FT8D4_:P[
T,0#I@@ LV !U0MWST3.2P6H==6.ICKKQ M*/.AB9NCO]NHVX 5R_163?R;#TK'Z.QK7-_]1W[6_6|NE?5V;YZLUW;G/^4 M|V\LU_DW9CC_">;>G/^CC;[9E?
HSV7P7!31_[OV40%GH#_Q+EW.>Y3P"7C+7 M=,I^#S7 E@OP]D6?"^*;,C^]^?SH[MM^+?-&$']]T_]49' M/7[7/G:"R]2Y%.|^@#\CFT2HEPW+-KT1S[EWL5G=Q;^H,ILK AV?QA^0?
P5; M\-9[P,643.6&1&"$$]W!2K?QWMGEM\A?97O\[^(W_|HFW#UUSSTSWL[N7K$3Y_(2>[5BN^>'_>^RV_F4>!9 MKD!|F.K&HG\0[R^=O[=O'0Y^I]87(1,(5[#N)
X0!O/@VQ[%'!L=RBS)-A^,O MLU!"_5TY8>0 %5>Y=>;[_3'RKHW6^&:>YUE*7]\]$2X<4&\)X*U:J/!\%|/\^ MR_"6U:*%%R6&-]\>/@B!/'(;LWNIEMSLEMS9].MN0R3Y,^/?OVZ>_'M[.#\
M,4>)/S,,2*C$&QG?F19;@3A1&>X=: &J^TR[DF]VVQ5-,8A]]J#ETIXOJXY M?YOQJQ08B!S2UA-#QO]@D@2OIRYU_H'$(DT1L,3%0GJ'(4=^/!]8P"OJ$89[MH2KXYYO&G-
MC<7[A$6_3T=>]]3W #_<9IBO^+K&(J09!>ZZMT9]N/]QE#\S< MZ=R<[]+>Q^_M/YWOM_ _@7,[0|?V=NWG1SA]]SB=|WN?[%T]4X.GE*.-1$QU M"O,FT
6_W]M3+@0)!6+OGN5=YLQT<]P;<)O%![64DIV8HWFM"D_I'%F[M\GB ME>_|$X?;O 7:L>?I<%V2VP:ZU+@X!'(I,T,>369Q4!;_(]>]/ZCE?T* MD>,152X7%;Q-D*>I0]I-K'V3*MXO,A[KAC#_QQ1".-M
M7"|>^PX<61 & E[4N_DP% Z\T$?;MNA?G@M&]/H7_.IK.H*]2FT#S1VABGC M/KB3GOO/-_SC+1S8L@4?!O.QVVEL=5I;G7IM9[M6N^N!AY&NG2<|8>]
<#3R".LYK&Y&J:9:L)@_,D['^G0.6#E_"H36F]P#):D\MH3RXC3DX&9XC M_)@UW+V SN0"MHL+H!V0"5U.Y!XI(-533%N'P6Z21%XO)?5S$7X- WQ&%-)\ M,DJWB3AYS.[=O?
9ZR2%V2A=_1("<#.1YBAC4+ATH9:H_(2+QGH&;N8!CKKK-,+4[HA6?@D'N66:*]ZA-ZX^676;::$WIE82S4K)<\]?D*K/"\' ME^N%I6.#$CU1+U<4R[;T5AG-36B.%V>-5@D'-
R:TR\LOLV0W&Q-::&$LU"KA MX,:$)EGN(99NZ=LE2Y_0&B_.&NT2|=XH]UE>=)EE MNSFAA1;&0NT2QZXQH4F>EX/+M<&RL4&WQ(IN:@V!+00?B(!Z10+:1: ,'B_Z MZ3;
[R:ESBQ_M7CN1>|*]@|]HJHAPCW#42Q![?2++^I.JW[YB-V]W*C|T2@:?8G$7 MOO2A[UR:3P _ M[N/ \6-1$L6;_?;[83^EN]/LC3^%$QW")W'N0?4W'SET7GS.8Q_#\F/R08TW
M'__5>,ICY,"U[&4. A<3$;FG--]\W-J];0,AEAS+>S.\R4_6K<_QQW\ KWS_M$/>'8N3 X^T;^C>WR" U;V&_0KW1K%=OB.CHZ^1V#,N+/.>2<^XIWI(M'*8T,N]FY =QKI/\IA?YU3"Z?-
^HU9KOU0@O#LQ&PN<&@Z$W5I>^H2X,6%]< MX#P[%Z*SO9O_6_N_^#?^5==_-?1?3?U72__5UG]MZ[\ZJ<-<:.PGYH7SC,$R" M,,%7SG;R[L7"=3OZIMUL:
<8JLV76LW76LX76LY76VY/+]A>6->/"C?Q[S+]]>S,ZIWLSVS3Z]FN-[)= M;]0G=[)9LI-(J-X'R9[9$I#W@$^)#&Q;_DJ0!/U('^D/-09'9!.3B5)$A;VC
MW_/"M7@QQSLQB5=XEO'\,/9F_,5>CGXSB)K=E'^_R&U[_SWHK42>Y$3,|W'B)GFXL1,>_6V$)BKMDR2>GOU MMK#YF"U<(!5V7F(+LZT1E^BM&"|OOW)A(3X|>
(W'TM2XGPO7MC$(XS5O2|LJXF'N+DX0;SS^L]O5P[D!7_6 M\=RC8,]9>XGCWW.6]W:0W==_D&>"^Y$/G"A 3+37QXUU]KY>]S&>.AC]>86' M5U^#PRL/11]_F*MWFHT7.^!
(;LYZC;*Q#7&AIPGN+.|9UB!"]<'AO<8?W,@&AM;.*GNDT7R:@M:R[L0Y1GF4P M]FK=!05H&^L0I5D]8V]Q1|D.(9>E,?86=XSK$$$YZ5SNP@YO':(?RV;L+>XT
M7R82LJ2[T5R'8,)RY'*7]U:SN0[AAY>V$9>; M8AAK%$N=PE,_UU*.)Y\5SN MDIWY.D1VEL"076XB6(?@T,N'|Q;8+I=4FH/4].'(3T%KAP]L$ MM)[%*G]>TVQO
EK/%&!>5(U=>Q.9>NY|W<*.A4 M+.XT7R9ZLZRJ[L0Z1D.7(7BX7^G1[']>(F+VTC+C<%K$/(98FRETMV^NL0LWGQ M|.5RG?
GV.D1VEL"076XB6.G@T%XD0*4?.GW/AR7SR=.P,OP'EG>WCT3C_Y MPTN&!T>?7B(!*?=6I"UOKW2T:!E/:L1I;M1W8D(4HCI<)\SR9I+]/(:GNHDCJ94(F
M)9OXC_[O:|O^WW]^9_M__,_]T?IS=_!NVN^Z-S=?GG;?!M/[W^M1-U.[\W M_OIV<1O[G:O^CYK_6_(^.1>_ >@TO[_4^|=)[3^'AXWSW]]?W7S:^[-VY9Y' M3G+SVZ[_]V__^4_#^?
7+;^T@C*_^L__GSF]WX8^CO^+3__G]RZ?Q^W3W??3K MCWCOSYN]_TG2=-SK]]OUQ[_MC?[O]?BM__L[^[^+8?+YXO/1^|'Y;K/?^_VL]2]/>V WG M/_^/O7=^MK55%[F+A(?W-
EXI<)V#PM<@VJ=3%E"MLK JLS:6HT'VY]U!9D M:G1>)B*PI.Y59Z5=X_|1<>(%E_EHR/G0B<0G)Q8NQDO@$AK^O'OM1.Y%!!:X M4)P$XK[@R*JYR9V5=I,?>8X7U^&K.|>5]GT?
>X[#2-S+D2MXEBOHU"Y=,*BS MTITGJZ"@EKKQJ+/2Q1]KH->6^_A7NF1C5=3A +,2R6F"_1F^L="!K M]MS=#8+4[6 P"D?WUVG8;#-K%PT5PW<:6#0^I=+_9HK&1-;T^7#
VV>.H/KD,(Q$WWE6"R%WV)V\ MR)OML#L+E),K&?W)#(O(NP)C_TIDYL69%W\ON ?(^"=C] E>GU>^LI&:N3/K M0PB'??UN0SWP(OB<_.O[U4R_(""[^Z*QG-0>*X\!+4YD>!
MZUUY+CA]ADK_&@8'H[$WF[B^]E)OTR\YXGRLK[5:"^$[E\F_/%4DLKMQ\PD M95XT5Y):R6C$'<)C,I!XZMQ2K"**,*& ?X)L$3/+ED79$0L+,'57$I!D18]T MN?
7%2A8$K2@E/(^3T%W).,YJQM]>PC+7:?V+;@2<2+Q@N!@4N;VAR+6FR.9C*+*Y2(KL;"ARK2ERV>#DZK6=#46N-44V'T.1Y61 MW0U%/@]%G@N"0?Y5!"*"!0?NKCOR B].
(JK$E*2YB25FM%E_=2'E#6V^%MNR M_NKBW!O:?"U69OW5Q>PWM/E:[,WZJTM"S(DVU]\&>>W7IAZ4]^^6SES;YBN?C M^V6S1S:9@>?C^V73]RL7@S?[X,7?*48-
K^!_)KL>"S^8NP5Z1R.^GJI&?;SB MU'?Z+#R-WP:[JVVH\$.(A<-%'|"6_E0NUZ4H_OQ/'X |'^RR2D^C,NQR:Z"^G MD1BD@2M<^8N%$-[<*7]=2&
[E8NDSD)SZR6S$MJ&U9Z*UQLK%QI?_Q(W2K<+1 MS;5TJ[%RH>.-9EH:VEFYT.Y%Q;P\T:QDS/4D-2\26KE0KG+?W1%@[.Q57L@=DGAHOD:G"L7 MP,U*P7S8!?<4=O
6<8UCIX^9O/C3K?F-(39^#[^H] -CQ/W_H#**R;_)?-X M5BZ*_(P$.&_=L]3SC%Z*A^E>Q)5/$D"J>!=_B:CD3D)&%!1,R\MAQM%&XX\;!]$80C+Y#? M3GG@G7M=^LC";4U:T.\]ZQZ*-
+KOE Z^G3WEE,9PP3V$AC\IW>S9GN#Y\7WO M<'1\/LL[O/=N/L QA&G4%S'_EH?8$LES_<['0[K]WKT8=NJU]OO3 MI@_@?[:[KD[/.VT]D]/'-W+A]N]]\%'&+L?
AZR%PT8'W9I>%8AH?@1+3F3F&B*FIP,>6TVGW.]?W M,S$1!D4WW[;W>FC(]9[(E?FOXXE.CK\ZI7U^\0[&H_Z)P*_W6[MO;UNM_>;G M9.I
=^B>.,YV"K[5_17O<&KK&%;]]WALN+)GTD5@0Q@-/X +/;A*C%"QAK^ M8.*,*QAR@S/KM>Y4<1[ALLV1V=*]RMUT.K^Q.$] 3>WMY\:<- Z.'S)UMY<
MJ.8>7"C=A%LTN$K)7=]77.LJ9:ZY]W9[PU/HGPZ'U]W]X/SRW8G3"PLD(Y2RM#_G&HC M@@6Q0]L=%,MR<:WFH8BL-U!9]/H 0Z7Q84\,$YGQ(6UVS4247V.|>'> I=
MS^,A5XS*+:|V*X-X5QV1#13>2]M?Q#ZG]:F/Y1BNT\]IKPQLPXO [JOU]YW)=1PN+%:V6?=D!HG7(?%C(%|@AQHX1G M\(4VTOL":8P4KGB" ZB1 DV:D.!(XH,H3:
(T>#**4+^>,9Q>4H]9TH7&9KUV M\[3%|*S!4|5B4U@<@[0,NYV-|=JJHIRK=SXUH:N+]3XS//LN-,*3Z+MAY9-+ MJ#5B(L8HW6'@T";R!T6'(=
+8)XGE4\6&6FE!3(,Y9Q>:&_&_33D1R2L7LNV MC/']XBPN#2LS=|C]?#2E%*T/A2FED/\,5/Z\>G"7N0)6[+19W.HU3\:!P$W: MS)@!),%9#B1_%2[9,LK:G*BD09%F^(_O&K00)DP+-
),6$&7:9%!2V2H)Y0 J M028SJHL#8-.H-B3O"6!(R+S-4!@'ZC^+*$(;Y3'@S\$*IN:V.;SY1=G,^ MS';F_[,.P8O8H2;<- H_.$Q>G)E-JSA"FC<:/#A%-0-<,\]D:YAP'T@2"B2(&
DS)HW2MI2)]OH\ MI*T)+9LL(&">%I$($C(:3I"*K; 433(=Y%:PF+! BQ8\B\O)GZ0US92BHH0 MR8,;C#X&9,-<&(6IQ-,-PET)*[:,(]]U(+[#=H M$X[.9X@]F'"4&*RK0>>R^=S?
60LSFNAQ]S$+.,;%1MQ*6 8!=6SP;ZDA85.> MY8!H'P|=(F8A:5%;/UEH=+7PW@3F'X"VCBM,F!\MER_[,\$#
M,,.I)/8$[B=702"_/"X-.CA^/@2KSV0'^R%4K:K4Q.:F*Q%M*>6VUOL#FP# MD=_F%!([8UE6L\VGO,HR5VV,ZJ9=:?M&.5)"O4DI?FUIFL \E*GX4 MA^V=OJ$;S
KE/1W$*B_"A'!OW$LH,"?3*3*[-I;ST4;9ET$6V]&1E>$:%N^,OI5L M< BT3EO:=)H\$"RM=E?2M[N?9-IOAW]?=79WVF_]W[J^,_IK#P?#[WZG?>3_MH_>HZ&Y?
O.]]9!^&'Z_ZKQNQ3K,SUC]>9&PH$V'9.S%C-SKA:=,W--D'863< MP$,O2['9>(N.^!*CM(S9N1HG)VSA)N1Q.-QH].^Z/3OQC*0&7O9.FRUCR[@
MR/6*BKJF*YHA>GS.JK;_S6TFXWFC\R(-[.1|2U9"D6;"N'E=]F^&@S>#R^YP M\/[=+SBQ1E?09!_Y[1P?*9|W,3=#AE@VYMG9=S2#2I=KRS2L'MQU6>7_:NK M#]?=R|&
[OUXWCAON^;ZY7/C[8]DU$VM'C/QHN MK#FU++E"88U=:!E?\);W"A\OCPY%2FC4[K$*'4]S%N[28.V)A/!3-B*L5,1%AL M:=FGG!O 2LW1/M$F8SIE;
[1)H.C@'Z9C=JUR(]D@#0_/G7%\W/C9';EU['R' MC?*?AYCC6M>+1IE&@M0?E,NQ@LI?=EM/OFE;+IC%9F+;DCF]3?5,B6@DFGYW MBSV--
";8ZHR%T,AERG@Z9WF:F5PPF_%,)%A8VNP$WXWDBL4\1(-A.D'ZS+27 M8GQ%(!6AL);.8DD_%; :D6C15L$5V!047HF"R002A/F"<12#(G, V^?T;HMM+[Z)K0.[VWM"V,_Y?K<%G@L
M6 RE)QW'$H]I=M_M^X!Q(QS"@!@9*$%(8 *P#I2T8QI!8@ER,^5G>HZD#96V M.<91UC9>:A-C Y%A&;+]H"L2 "J'CJ]NW#,TY%@7:3$FUO!HO62'[1.]X3W MHG4:^2?_*
(E/IA[BI)]1WJP@WR.1?*EM*+YG*(8AFN=J/$""F,C9UC!>C\4N M(5R%["JDO]*3 Z#3>;-H"'26Z:1HNX?SSV-|PV1H @OPKF#<+^R&[OOZE(BS MI1H(OKPY9:[,G+!H E>GOXS0)E&
(D.?(\+L[-<=0,0\$X%:8\O1 YP9&D36G MTKI<#"F1.CUT9EAF\6HE,$)QA]^"RPQV-S=|66">B52.IRQ6LF(9VYV@961 MY$;2%*2G.;XXI:0]MT0M7,A;QT-
I"H7(_Q\?/B(_B:^*B=7X'&19P\M9AVAB';43.]$:'8:Y(415*,2:0$FTS=!.-\309;%X MY;T>V]OD28S@0,I=$2]_6F-L%XP*_X2Z81.3HGEN1 MHL3,F9*W0A770ROR[B"\N[-
F.K47Z2D%T"|V##[].<=@=P,=E3'47*9&2M55 M&"^S).&P/I5ZR/47WG'0_4P;N^ NK@$]DT1FF1"?J42]!CVB_DC"/Z=D#UA' MVK=45_"?3AUEA(I/N83[+AKS-'371/O/I]TGD^IKGG;
["BP631(8IGL+N@$) MI0#B"MZQ.'3.!+\E(N%9AKMKGI&[*_3RJO!10"XNQ/VUT9ITRB,,M&*133=6 MG)+'8PR@"[K=]'S&8@]MGF"[$.QN.D4A6WNK^I0R[6^/WYJGT2X826R0Y)H
MDW"I&?!T[U$*X#9].9?I5*NIH])>]$[M+D3J4_G(IDH/1?HGHVU3^#\7EP MQI_A//4A?_A3\;4E*STL]1E[(P*3TWNR5]O)3HY/3G_P"_OMTY1SU$@3"7,0
M;J7XQ&#?>O9#"%OC(0 \7#6]8Z/(5:[]INPJN+P*%7#I'_*CR,X/UA*>0 M_Y/DRU6[5Z@?Z_?;_=CQ19-76RHG_3H0Y'739>_%7*]_QEE6T@N>'^;- MWK6_O$'
/W!IOXX7WR\?/(B.(_HQDO]U$OV(Z7]02P,$% @ %H!+6]#P M@FS9!@ 124 !L !E83 R,CDX,38P,65X,S$M,E]P;'5R:2YH=&WM6EM3 M&S<4?
F>&_Z#Q3#LP8RXFH0_88<9@TWC&32CQ2_]FW=7:*M]5(VEMW%_?]TB] MMC&&&!(:VL(#]NIR+W)WSODD;^O]X+^Z^Z96ZWVWW<$GH[_6H#?H=T]!^*$3
MO0=0=E=^OL8+L<3AV:" S8=D^,657.N-Y/334V2=A9%K# M1$R]K.8Y<>/VN)+#_(09.1RY)LNX&4H\'M9.6V>GW9N1C*1C^QK[1ZV#,QAR
MN2)B4]5+DC'TL,GNZ*Z=_IQ'=MQ)AVQR)TPWJOS[M6@=]$[;PJZ'S\HUM_M%M:)=/;,CLVU]JL+[EC?W#E,#,6AMJ9&W%W\@]]]&B?];QLO-OO?[ILG_<^ M_/]N=ECSSY?M3]=Z?
K0E4YFX$0T]_*GF0Z0UN*JD3,C=F*O*-?*M3*,6H/.ML]X]*_\20>%-?<1:9X-YZW> C?A$,",F4DQ%@[67EGTIN 'R MU SM8VT=R)!> M:#,S?#>2*Y;R& V&Z0SYT^DPBO&5
;F(A;7,1L0?\6\Z?"B%((F9])P]1/9#[$$KH1W+-C M$7L#2>X8IND$3F);L"31;'D17M'Y1'2^>1YT"I;*' @@,"UVO YH8CBZS5*_
MS%.D'.XDY,@\D54"F4#5TO:6@4A):6H,4!":">5*+0!;8L6N]9))(UVE$ M@=I#*-6 DE=GO3TQMR.6*CVU%82-&$KK#(4.DG=-9V78+YP]C_!YGR($Y M>%|]2S"9V9M!2QR] 0T:(6
404FB*#&PH& B0]*LDCJ:$5U9 MIY>"U@/:0S7$VZVA2QSOI51QKDW@+/!L?BARL2:G9]A:Z MQ)B"D<:@H!"" D$KQZ@WKX'Q0@(CWBPPNA.N"I];"3,B3<&CY02[;=?PX3FK
M6A2+[:W[JD5X7,^1?1Q@(A*]#4P\TH6[WX0-"AJ .1\NZ)R1?OW!Y&3#%!\P2U4>;FS,MZ?<[>WUKBS\2*]I #ZEQV#CW_, M,=C?#R=5#-47J9%2]3*,%UF2<+@YE;K+]>?
6<=!]IXV="W;M3%K*UEZ8O*=/^ M[_&[X6FT#4:2&B2Y.L D?&H&/'VO("5PZZ&"71/1SHD<'XK+@#C!?2U";L0D2G8H5ZY&H]Z.#H^.
M_W._1S=1(TTBS%ZLE>)C?>K;T]D,*6|*A CQ>-KUM@_AEG^]FZMYW.;WE*H M'MB#I5<"UA.>AX3\0D*JI;Q5O1_KS-I->H)ISVG.^4B*E%W,ˇ_-C(&|OPK:= MRW#W
[,6!E+1:B^NATI[=[_5X.^7>;Y[DKDC\(!>@PKO1='K4W|#4$L#!!0 M (!; 2U]"..>7/0, -0, ; 96$P,C(Y.#$V,#%E>#,R+3%?<&QU MJ?_A%&&E3*Z4A@3)MD"%12#WSWW6/8_AI^&G?
T]_V[0[>,=S,\]/!*$P MZ/BUZH[6VM+LGYSWKV 27@V#]U8BN&Z[YQ8:0I93!6?T%L8B)]RN/M@PH9(E M%D[$]:/5/$WO|)]9]MN0%$EC^.I:'?^D$IRE;HT-.J.Y]=.$,CH
MGHMM0VI[XQ]%N&S9C?YXKS9*%U7G-IZIH[RA*1+FFLEQ7+QB'@!-|KQL.SL]@ M@ M#F=&>F?';/0@C/=[C(C?#>0:\[ATJ]D/@4G0*R%XC;:[K%WFMIU%0<<(L$YC303 M'&Z93D&G%"
[F1"**; %C6@BI 8VG0N;[>YYJ= $B@5$VEPP&/')L$++EYYPI92#B'T?N[\5$4TBII")9 ZBPVC"PX8I<+_#""<+II8PFZ R= M:W9#X3Q)6(1,3(B1I(K%F*$IA|6@2-,BFPHYE+-"8[0
KZS02FG9(*]OZ=3 M@D'1FB_@FHM;7-*,MEZX_|+NR3" 7C <3D;=WN#LPWO+M(>HF?TM)OXT#>&Z]I#,,R1LA 7,#(/6K)+TRYQ)FF.5E2FS6K+=:QR00\,= MKWD0'ZX(L,'!-?^Z4?
I/X2W]3H;7(6S#-2'0-GM-$6ID+&[# M8ZUQ:)]MIFH:.]:6+);T],8X6*7P!RK^LWNMSA,A(0K&5OOW7T5X,),(,%:1 M7"D P3V8ZH9V5]F]3-35F'W4+(%ST*]>@^]C*P:QT5R8(5_(GCSDAX& M(IUC(8)1^,CNM$W6/JE.HE7&K*W*D3I.WEN,M,@.]ZO$%!Z.;6J-!M!T!FG3#J&`(7A0C=OZ]WZ0(PG'(U6Z9S^^`:`B7QO@X$CG]&"VQ"Z[U5R]H=L3TX-*2&%MVQ<5UR]FN4_A!,5=1I;4&&.%/-S@H?[LTYM]?>FNW
?/QR&HZ#CUZHS6FLKLW]\UK^ M:7@Q"HZL1'#= L_--80LHPI.Z15,1$:X7=VP84HE2RQT1-?QVD_3:WU 4C;G M+9!LOM!MR(B<,]QTK8Y_W FN%VS&-

#3J3MVO'2.0\:T0#TV]%1F7NFW8SAU1 MKJFT.B_Y3.7M)TZ"V^H%DW X&/:ZX?#L%,;GD^EY]S2$\.P9]HCIO==P[DR= MG@/3H%="\!I-]V^O[\=";98LK4QCZ-.(M9C,JH>'94'?KAT
4)"Q%TR;ME$8853/<%>$Q!-?1@O!Y&3EC2AF(^,65NSLQ MT1065%*1; !46&T8VC!B1,,'DFHL1V_!: (#Q@F/&$GA+$E8A$!P%S=@XSU3 M%!OR0JJ"< U:P+?^*^64O;?1BV 6-
&;+W9U++JYP$W/:>NI>W6)$V#T>!= + M1J/IN-L;GKXJLERKO!YW^_WU]4\CN6*Q7IBE[@NKE#8_G*RC?#85BDBZAJ9% M;JWDSP_]VID.%/M"JX2;D*Y3;S)N=?:\?13)_@.
<[RQ#N.DT)$6*%(VP@:GA MS(9'DGXJF*09CI(R;58K?GN-/;)OV.(U]^+]-0&V6+=A7#?2QNR]:1RV#1=+
MP'B85"6IE<7O_,_U#M=_^U>,XYZDI&R@:A5FC".FL'XULA#0I@1]UQ297IN M&S-)4RPUJIB9>33D2)EEU[)1@LP8,S*T$9P<%615I01*%YE3G5+)YPGHT)U M=,JZ/8_Z]I[$\
<0L&="91\)?@5=+<_.>4K TS(6,J#R*1IB17R+KUKU\D_BK> M3&@MLA;,4A)=@NX ^GG!J M-] U\\)3O0&9%Z6O4$L#!!0 (!: 2UH+YR%LC@P ,UJ 1 <&QU MJ#6@W4-G<:S9U&%?
2Z;5"OUC?F37[Z..4[W!BA,03(0F-$ MQ*'L=A\-H&.)W=*] RT\P,@L 6D7D;),E,7,1GRWY&$:0-Y_3]FPLGA5D?H_ ME(" ;(C$.1PC;D,#+1HH(VS+8;C? M>K7:J*C7?]!2*[HS
M0DBZ#FS.;?_,OFN% I/%![$DX%.SN=&HUN0FU)'SS-TBY.]C(A##8[ES$1,1 M+K>OH';@J0>N?@J>] AT3"S?O/U8B>J/\>U(=!2DD_L[.L$]YIY(:M/P'(HV
MC)L<;!OA*M+8IZL2XBNVY%Z2R.^7D,EQ&"&!)3;>B]=HFQPTUU^*9O FW'DB M[VOF-I:K^G\S'9&FWK M?V#>/W@C$P%L8/$V@^TUV8G+N WYZ-"B#]KUNQ!(M"?*\
<9S5J[J"JB^UBLW M/YGSY-P*\><_R^-K-R5+^Y@;%N4.0\#/]JW$S7]JDN/B8<$2\\#B6@9!G6(MP&1X*6>V(8/OL--,EY7C$9[F\)QL+U.I"8TA^IP4,D MQEN:7)Z5M1VE+: 02(T@I#
(Y^%SSMN3ME$(R8'0L_;#X]T059%7.=94,TJ. M4@&4#B"5 *EE[0!7#1DS0L52+ B+D%*KQAQ=0,E_O8AO'=NEL=*E XJ[$'S'7]#*2VI?
+)6#Y.GZ-[1YI\,%8[0GCQ M1%]F9E>U>FSM+'2 N9(U(^F,Q(.SO9G[*^S84L0R6-JL5F,>+B%\^UE]9IMK M!& \A^LT:.4"!NQ;T4A<)Y05,$CF8KXO:6\";^8*-:7$-6&9&U4":^F2.:B+
MN<:4;2N5P35]T;+#/A(01VK]D5OO-PM,6:6U_J MM[WNC%M;$^,Q;IV(BNB@D\>MQMVT9IR*ZK?#PWKG2V4RW6O?5"=FAT$Q/6E9 M]R??
OM7AT=G)!]%\]FW_9OMD2A^/;_GEUR]G>W;%:578T2-OWTS;MM/CHSII MC(^X> M[-&].:W" 3+??=ZNDB*#=]N=YN;=87/2KW0VFKW]ZG3O<71IT'/GOG/YH3]K MPNFWN\
<'TMC&^**!S8?*9K5*.W[WSD8G[VJZ^\]UY\8%'7XV?SWNWM]T1>N^ M>S6N]OX!VIVK^4&B%RXG)*V29(GL(&\CL[;F/FQ/C^N2F-)+97*UD(3%;N#)
ML5T*9VO&EHP9(V0Z%J(#=Q0O;/=;]!"!3T'-*T-BVZ PA-](*\]ABV]PR MK"0W7CU/(E<^OI67Z)<$>'!U#]S^@:! (BC]$-:+>/4IT3($GLCQOD(6="GM MD0GB\M=5I^?
SG#8M\K?/=M.Q^GR.B>'W#SP :D[X$(#"L)@LJ9-C/3<2YL;! MU%:?B/F"VYQS(KM=>F%33H78UX <4\'O-C@5\L^]11(F@)IJ;Z&_=0F6<3' MOSBDE0;"_*<6$?XYJI7F]VJ>&HU+
[%C$/ M9%HO9L=$?7]PD/A M*Z)01L_/IZ^&PF_W%!Z.S%)"+A_U278: BaJ;:I($OPA1KWU/J3QB+Q8HP. M3U9+] J_23'J$B^S).3$;^!HF)CV6MN%J+7L?
+1(%L%*%CH"'.0UW2.C/=# M.JEP;.0!$157/T(=K]0]LQ5.O7%U8]G=5KF3O_)'J7\3X57JETWF M_7MM-?U]MP-= +LE/U:[2*HE=%4MX8#(\% M&BNO7
+0D]HM">:H6S6NE(T8IF;7;6,>K8 M?B=8]@^$.D_ G&L$(FES=YDV<\=77\116 EWP/7]QB&2*G9IP>W/A?7I ,)F MMPQ#=FM^A?.UQ=L.8^Y-C:!]8TID_,MF218.H,4339P' L)_U9]?
L=DM&0R9 M6#S=A8- 06"1,K@E@2Z:BCV+&G?^ MN,@H:D?X#Y]X+$*U_PFH=8L]_@4D?RW=RX"]*LLK>S]3]QD2V8X?70<\8,O M95,P*DT8-I5-
F.KO&LAIYX)O.::N'BFYO=E2Y!+.W/3V 3)SWO6%(Y0G5'\Y MX1KAX4BYY0EB<(BN9%0CTT8R5-_ U9 YT.HB-JZ'!]@?KE>>>'^"V6FK]YEP M_*
@Y;:WX&"E6U.BQ.?!X7[6*07D^Y"9D1?H>6@6H'WWA]E<8:CT?BR/!^U M_HH^>F6[=)M;^$19X<8@"9XV&;F4*E0E&"+=/ L(RD6ONKH@[CR5"9B!\$3]C:$" M&:/#])U[B_-
XXA3#/K;<$KT,PFUD")E;NII?)F7X41EB7@NT0W &V1U2*F1V ML>=P3!#G@=S#B+,L>3P:5LL39#T+QTD10C MQ L"TOD<%9W)M$^@4R2##?6_%\"^6'Y/A9Z 2CN5#J9"
[@R%@A^U!M\5]*+ M]X] .X0G;9,-"JK5,7F9I?NB!@1Q]60?B:=L"Q?CI:#43:YY-0?YF5B!'%,R MLA2. MFD6Z]24;P*0 XI.W2(R?#CT7YMT9]$+Y],RD*,I9[\ MAS*!'\,%E+_
5Y9=H'\=R]ZO&8%ZN]%M2T98IJ!4C/GEXP:")E%]B!AG&D6G?DC/F+> M60Y>)*:TR+2[6FLX9&BH@@V'&2,5Y#-L_%!G^$R:-(#UCO&2(67 3)7R/42% M-
2Z.56]7RS3=TZO0*N_H>%*REC8;?;GK[%D6-K# M.H0$PY",77623I@7P[!5H.JW MP*1;XD5>7"OC3:F;IES**\Z1]UPHE&UL[5U;<^*X M$G[?
7^'#>3FGIA@NF5Q();M%R&62R843(#.9K:TI80M08B0BR03RZX]D<,8& MWR/'9FJ>-N,UW>WO:W6W6I]\-=&:I32!DE+'-!4^U@M:#!KQ$!X>%CJ=&UI]K+3*>=2D=2G
;$#H6/L/'_]7*VLC MSB?[EUK@6U4]C7:C6MMK._MU=C?]FJ]:DNK5^O;BY_]<6 B_-@'#&?<&";LP.2RY-LSXU/Q(ZK-2KU:V*?^3%[PW/^\9=]=:S0:%?O_OM[*D-
^-0FRM\NWJLJ./X!B4$68<8%T]8&B? MV1>VLKQ4KM7+6[6/,V:4%KAIV@$E)KR% \VV?)_/ M)_"PQ-!X8D]#[&LC"@>'I8EI42&D_]E67XCXM]SR@_YH$2PXJ\]Q(HI&(;]M[2<^&
<8]CAXN\QQ.F- M794C[%5N:PNPT:E)GE,;^2I HJG$/.FIAF5",N@2#LQ3A 5E")@+.*XA[X*^ M%); X)@B;8>0SZ #4]=,>YA<"HN7=DM1;W(X#R9PQB$VX,_A(O2:1/?<8\]Q
M2JCS0Q/TH7E8LEAY",#D1Y,QR%G+HM3V,C>XTD@FK+1'J0"POCUTES^L2-0K MT.3,N6+S8'/@+_OG2$ELI/2\K:=Y.3)0E-@"H&LR5N TKF(X'? M*!BX^/I M=-
CV\MVDWJ<#5'>L$W^NN8 W+"[O]#!K/+:EE9$8N\[O!Y2,(]CC)@"%RA!]0 MBK18TIXA&HZX_',1*1)S=0PGA"&A(T/'\M?Q:G AF0C 98E\?07YM"(E%C). MD;Z,J=F@[Z^CV.@'X+)$?
TL9^CH48TRD 78J[&M9C(O40)ER @+4+--G<4D(M@F?)PZ2G5BP+8G:7A\P MZ8N/:X+U#.L/E_B4*#2L1RC:#FBC$@@O3)/S8 MRSI++[@#B\5'_[$2L"04]-OB;[\7$,K,D5
MYK_L9IN1^H4H/T <X4K7:9\>=2X*'74C'Q[#/L^T*!&@]3L2.T2((0DM- MF>*HZG"B/XZ(*60RV:?C<\5]^"AXR_X*AS;\,O,9"O%]OA<8W P-YZ-$VN0 M1/8^$E9;AH&DI
M8A&]F2CNK+'$ QIR>41'ZA?Z(A7FV_6.1TX!7EX:C9V26/4P8)R0'@TFI+A)W40:X\09J.&>-V MS::GH1^G3HR6"42JJ!BQA_E?6E+,C<;NV/"L7M7S[SD:13&6Z_,TV-123L"
ME6D%MVVU),4T&L^3,.K'I?UX=F=8$8%UH6OK//B<\IO'S;-,I=N(_=6NQW-(ML_WT*J0M<+ F>T!3Z*;GL^5D'LL^OR-P2O0?M'&)4IY55URG!B=6/ W\\E\' M!WO__O+I]ZO__/M?
[BQY^]^?.O]>#T??UV$=Z?)_8?7^.WKWX[^O+M=D.#U MW/WQ+/@8'\8#]/"ZQ?"?Z]E[Z(E_&W_/CP;_'HYUTY)]>-N$V@AQ M3E'?XG;3ALCX3C 7CRVD#<\QAQ0RU6OJ,BKOR;Y:;-
UNXN=,P;$TC5]<(4RH M;7$F#*^)+UCZ4D74.HPJHZRK3&MB(_'*5)=<:K64#C?]D'? M6XP]SZ]XGMHBC-\,EN*5!T]W[*)@O(+$>G8JI^[SWT(&A:7R],:QD&\2>V/7
MW>W\]_\PCOPXF5WZW%6TR]Y]?OI:;WS MI3*=';7NJU.C0P&?733-IXOOW^O@I.IB&Q,V_7Y\OW/Y].3BRC@_:U5(^^7Z]G.]^[GV;??S M"S$ W3[ZVKOX7_?KP^"AW]Q_V+WL;?
>^[\ O^OWX]M/>#6D^CN9;S_=?=S[A MEUZW.\Y?'2-ZKXB^##WN=QL[C:6/:KW2V&[VG MZNSH9=36R;7RS%&ZL\;8/;]>49;^X&\ .=+.%C.?
3K7^,/[P80(O/MSWC\>C M,X1&3]M#@TQ.]":W.H.G8?/P'ZW5N5T<5LUO^,4:!^+HE$^%Q0&%3NWLT^* M#2A?]R13^?]JQ+P[RII64,K*(B^U7]52T.^O;J09W8G+T]N
M*]RD,>9#1+ABL#.E+'CM=P"80EO3&",&)=&3F$V>3E*VR80%(G8^G2QG+ZE M)*9@Q&M7-LP$ZWG#1C,9!F]\I:H_!"A+.\$\GCVBIN"' *=V&>O/Z+OAQ!V4"[E%/_PY0EQ,
MX6S1TR*PN]LG.'V_=15\Z2O?*A=BW.HSJ'Y=CD^O,MWR.I2@%H>*#-O G] M\W5 0=WG]+XE90OGG2(AZ6C>8[+E_1H&F[JH-='Z-%R%4\55_(:W%OSZZ2PY
M@8F#5LI7E"H(]MZQ>/[1.==R;T)?2]]BC>R=D: PB,@J)&OVA/PLN I1L M-"M!P"D*#BXR$6;FH_AXK_G>.4$A+/Y4)2^M?18;^ M!J
SXVO:ULOI7.!D,H,YO!B(30@#YADEUD3V:!'3]=TBXH&6.(DR4;%'%>'"! M-KNL@" CH?O*"GGUL>:,S5:#C/U#=98*G-MX*L.7WZ0+EG<5=-)6-?9%O6- MQ
P;\G@YO33=]$PTR"2SH;?KG:)!;P2_;W,JE7G$3I+""[7B7X;J6G MG^[-#OT)<5XRW%#4P/?QL\4K"(_A %(*_5]%F/T(CV/$KU6+QL/=Z;E4,^/? MN[:W/.SU'MDZ4/%&-P>2
.R06U.R,N\;6.2\QBD;?L:5]Z W5/DO59:%P^R0 MK&3/:H#IYW@J%.?0C?=3G+X;*P7+[N:>IB7D-AX-L757?KXRLN9FP*X=_3 MS$\
\'JS/]W7.GKE"TXIT2$T['=1=T:$@(7Y]BT9,1M'G\TT+^I<)\6I?_E,D+WRSOZ4%X%V_TQ3U@:9-'3%^ M R#EIYQ^?TTH1\["OSZD)B.^5T2)RDZ_+&VO,D96^ROC?
L_0#;1GQV7],RKO M=<@F0EGZ="PFH8(BO!AU^MS^ABO0)0]G &&YG? (#L0]73!3_$A)-.=>VL4C MVST\$@&K=I=>YT]]IQ,T\]^A6+!Z_?3I<%Y?\!4$L#!!0 (!: 2UJR'^/6MB0 +PN
@ 5 M <&QU&UL]5U;<]LXLG[7^'C\W).37F=-}-K M3RTXVL]4U19&0D E%*@ I6_GU!*\%(B6"N"MB!X_;.TD$=&- MKQL-H-&77]Q_WVY@@W3/PK?]S[_]/12ZD>>'X_?
[=X.X#WN#DXF+_'^W MM_>W7_[KX&X&#O PH1=H+#D0T7R?R1=#9P_;U;[(1D%.'IWO_$T_=.B;Q@_
]YX_WWO^ MZMV+M^]>/-N[NSW9.WIV]#+Y&^&,_![X;>@0M$Y#LG[_1*EAR$>'1 MLV_?/?_J_+^*7:G^?OWWJ]C#\'U^5/B5_W0SKL]-_?H/_[_&6 M+-+^_\&23'F EX?
9/^XSO/;V?L%1@&\[0:"^=XKMX,4/O]XD_G06_\3O)AB- MWN_/@@13:D</_S_*?/TW^*YL_]\G44BBP/>8D(Z=@,UY,$$HWM]C0]_=7%1F MRS[R#X9^%^"-
WPH1I\R'YUR!WD,-4$6$/_N'8P"N,)BGW7"8@1OM?'A\K'!5V- M4S2(Z7]/*3UMWM'H?P:X74PH3A,HL"C-N3L>*+BULZR%&$7RBQVC\,AJQQ M8$\<,CD/HGMM1)
<#')I::9EQ@#90X*KXQ]D]"/HCJM-AW'/=* ECNA5&.2X'R9"@[PG5G;,Y M4R U_-8_-FCS-M?>\2+]+S41-PQCD-F:;< 9!]J&AS>(R17#T2@-=IM',KK* MZ2'52P(4C5*(^C-V5B4?
Z.F=;F=Q=!6%B(X6+1!*B:N!KCBVL?U]2:?GQOZ< M"OL&!4Y*\RZ<(T+_ZV9P5S#29E[RXYM<$$OR9P\S%!)$EN0-34L\KD$CN:3: MI/2:$VD2^^K)1H?A^A% =R8=-OFC
M&+M&K)\EM-CDC+%<10YV91GE^#D*-P5S<+O,^?=\]F_,#W7@H9&3!/2$EY,I M<[T_9PFI1I$;N4G ?-91KCX+G"&*'B_GY"#L>/_E@ZC/JCY=9Z M'9&4ZJZOQ-AQXTWP2('!R"'#%
(A\O$-FL0Y1$)/B;U(;EH*I1#);V\K383Z; M7IBZ;ICYG3L!,V^]^,3!>$&WN,].D-0H0ZOYR-$\7$EHI1<]7)T<5:."N5RC M5)=#_C7;*O6$'$?*:$:8;G?O]Y_1(=+U\]X-
(H*\]_LQ3I"N)$_1C'%(>H2@ MF)PD&*?>4:.2]Z>Q9+@SYI&XX9>B[#OYCY2&-G4T^B>;#A8 MY;(Y I"-B^A*9;Z%$R,&,SND+F-[8&4MVTFLWHY2)[M8]:([FZ2Z10]"-
/YY0KN_HALHTR+#(FFEU<.$)P,LE]M;P(BL==,#L M9CV-[EW".%@5%V2SG@M@F3P",AH)M1 Z4N>ED;D2N$U>""T)06_=R[I)VA'U .$=0MEDNGD]Z&!M@* M034Z&0RR-
/MW@E< =-"K'RO@<&C!)S_0$BOFPM1 M L?B@9?O6VCA]KF,PO$MPM-3-(QAG3\<2EWY9 M1PY6A63,NBM* =^]C90RH^)IHM3%9=2(7"$LP^X*1C,*!W'D?@.)X%L?OGN+
M9Q.A0A1\AX36U]$(B M8H<]!9]Y.*2+D);73)-TO0?]DCL^N:#(X0$,_BN)P-C(<)&)X9>8#9=RFL9 MNT9E5D.@F\NK#]E"+*8C&S]Y880IA8LP1A@1T^MH8_CN;42;"!6RX'LHS*R/
MB] -$B]-8,8IEW&,_6$2IX\]+$'5I6<5.GTZVAA(?H:8ZJ27W91 "G5IBI=H M?1FC)U=P RLDU\73OQC#(F:ZP?'D],.]]E1]VPSD*RIC0I!98B?DJBXMRT* M6Q^GM+ST6G&-
<)KB"G((,HY*RU2L4:1&EV2U&GJHH^)SY.,(35NX($TE(P&$X^EJ!9L_2JTJ\ M\1"])8GU$1^!8#9 DL@NULQKY7-A?"MNHF7QZ49I M-Z7H, YC?XY)@")6BUHT-1@29. YV5?
1;QNHEW>4,2Z>.0C=63RTV$NG!+8+8 MUDCFPC>?(BP@MNM;DBQFPL1@O3MK]BQ3$K"J.# ^+V53\FF"U%!0HU@ 64! MEXE4=,*P>/ATNK)^&I 2YP'KED&@5RB ;:8T<%?
0+V,A3O;56PHH7FU>%A[_ MU>EWXVB@@2M,BG&%$4CA=<;TZ/&&%TE;"+]T<:3 M%\3Z4:/=E9.#(J26<4&Y9IK%1[L"KUCER8E$5R$"&?"ENZH561K824-8R MI(RRB2[H?
YH^|-00:&'VEJ/E#3Y@6VU^H0!;38>YU&\V51C7*M0K#Y1$Q/ MRE0SSH+S^H>"1KG,08&[=22BTP_60?/%$QSM1Y\,!6JI04EIMIN!XUBJ^AD
MK^U0Y>IB/M_M4;2MBXP35:!\X,74%+""+@Y/ M""*9EH6/6;24A&@:)%&3.1\@@B'0Z03BX4'D## 2+7!55 MF.PF#BMIJ])-^38QT)5%K0@KR GIT0>CR,FC)@ZEL4#2%G+.6
^>\R"Z;WI# M;)F57I @\-GHFZ1:/"O\=92V048"]37>=A,CUXDTXO7@7)9]J)&E6#97)4_N)F/I5,@7"7 MSE0]> *U#*TU*DRC"K_FZCRP#;VM\!KV(;4]V *DQST;/1"+F4Y;,'=^*$
M8W1#)]$/V038_YBK>^X$+-ZDVI>86I7J7Y1^N?2,G_ID%A$G^("C9,92OWWB MIB7)Z21S_8U"T\9_!R;4]=/^#N ESK\T8[6*A97OC-NP534DNVRAZA"$BL2L MN9MD 7-
4D5BS'HQB'V?3&0;^&,28Z/'0]2N#%,X2B:*:@J=:Q1B_QM'<]Y!W MO+@C;%-X-"H2[=()4P5.<'*K[6N"D?7;(=1SZ4Z.%3NO&0
M+&G"71*]"IY2F:=MA'H>84K>1<@CYW16@TF$8];(Z2*WCJU_$!G!M?-MQ5@6;[-Y M,VOCV4(,E@.:]N6F>^47V#;@@5]8+0+QJVU&?LK] YV[Z_J;!07?6FQ:^XB[)FJN1
M56CIC^A-,B79'V9)E!=A<;XZCS"G&[KI]=J"DPY%7+0"7-Q^&2ZD/2_JO%\! MM67+E#X>.Z'_(WT/6(7,Y^\&&!$*;_K'4B^:)=Y0L>YF>-*N8=V&.GL;I?J0 M8'1+!7-
,*7W;)+V.Z%QM%OTHHM9^%-2%.? J;%]L>A/_)=]BB0!8:E#8N! M[Y9Z)D/#:W6]#)(A0=\35!S7G]X,%=<>H7 5%4(M'AGM[6)M0+#M%M[M.00&R5O8$/E:% 7B1_E?
#X>>OXRE*NX_>A4]B M^7&>H^5/2QOG"+3U"^85K3F:^G3ZO&L%:57>KPVN.6'2361K,"5&[EW/%Q M&O%3>OFX"E;2>J8]FX5AD0B1]-F(+B:J"0QA*G#B^Y+S.
(HI/_IHA)=6%NH M3+Y+5E$=6ZE"OMOKE5.ID63(5=1L)+Y<[05X2H+QIU4;QJM2/TY^E28]YCL:B MZ837_G[3G]&=]HL9P%O. =!"%>[2K!Q4"E).V;]C6)*;* C.(WSO8&]+>]#'
MS2Y4.Y=3!$VT9]9M-2#L^DLB!8(#1"^>^RZG)FPO2(=+(T)ND!N-0_]'\K(_MB).('T"P/BTWLE#3G&,BT>FW<1V_? @^_+C<,>O]" EP6TAOB4KK<2$Q06F
M[I[7!=IJV%O./[7"74.TDVS.DXRS=0A7(2^64-00*2$W"2HX+1@UO,%\"OX6E,7U9 M>EW-0=^^4Z:B>2O]W$&3B>0:9!)/RXM"/JGU6+@CPMX4A:V MPP19*$P-&F 4%VQ)+:!O?
CRY04%6*VCBSVZCLS"F\Y)OIZD]20%%L VWL;NF M4)>YDA(!:/2)1(,#N>Z; $*TTHP32HZ0;3DWMXS5AE*R'R!MV-1H6WG*;&&V MZBO>2Z%L=-
FF>\?)63\MK(B12W]1VUF2)F@S16EYFAF/=A/>]\UF\0DP:K>,X:*SIN3+<)EC5P M).\?V"Y;-A/;@5P*6Y:K1""+=9-Z09GVZ=W!A:@B!,?GHU'.+8A4&(W30@GU M5U2#E9ZVU8$F19.-
DQK?D))R\OOXMUHD[FO+ST0M9@0@C(] MIVQK6X?N1K)+,Q@Z=-WXPB2@0(LZW5U/ MQ_]^Y'SX]/%E&)'Y[Z=?WWQ\B'Y<_$FN/_VZ7AVF/0.\8'T&6/]T^#]]>_/Q_7ZU/_1)Z#7QY_N?
MS]LO?X[^/;_OGZ\N[EW>^OT&_NU^G-SV_Z4>_;9/'B_NN75S^/^YNCS[' MWO7HS>O;EX/XV_UL]MU[>;_D/?23KV^>A;^-?GHS>OJV_G;^?!P\/+++MW?=G# M[\
<_)M=N=)5]\'US_/%R\]1=1Y^_;C/GSQQO?[++WSQ_O#5LZ_IS_]-$_&7YZ_N>^_LW#0'OAU48:D^F3NTXY8.
M#;WQ&*,QO=KO<20_CR>]EEC&B%NW;F-+-[B%&<:D)]2T]9%&P9W15.*[.J\@4Q^LN@]39<@N0BSFG.%4=LUMI^'K4%+G'&V2V-/8_P"&5-3JF
MM)NDHM+LTN,J_W+T]&RD]6RTI&RZ8/;F$]+NU3)?U7+M]L,3L A;/T+I]&-6 M,WH04RQ_QK[,.95]BU)0]B9*8,A_D=UH9%;#C!3)9!%6_FW=XL3(H9/D'JO9BMOHT MI:#L$]*2?
I8R+RNYERBCTK+R!@4A,-GWIZ>'?/O&4N)1WU"5O*<7_;:<7_M_=UYT2]$S TBB$YOPIZT1P%T8Q9]/S:"E(F6X:BU<<\]5-<>3N4PA#F%#- M ?WK\0<4(DQU+?
1ZWI2BQ=K:Q/Z%3&Y#1_O:J1+M;(E7$%:"BK-$H&\]?H MF@Z&:!@,JM,L]IX=OI!?3;+-<;P$I0D^A@KHLGBO1O]N]H:W9EU 7,;E0%U
MNA/3:U'H\$S"R!^")PG&%*07MU1E"!V22N,#U;K&\]C-** N74>$$]+A;+= MY24M\$I';A5@H8*#+]BUQHC$&=>G:!81/R;,\%>ZA/MQDFX"QETR:M1MACQH MR5@97J"
(FD*C^N&:UBTK_/R*O#%E$/OS]'1E6M(:#%@I6]6P=ED#"4YG:9 MAD4K(-8],8K0$T9BM#*$.94R>2"C6T>ILP:V%C:Y 1SQ]MM'>LZN*;$RXF?
M2P]W.U6'C52.;7M!@(0]U)+8RBM-0XP"7PY MHI"/2# G"^.A"#QI6 P_T)>%W-.8\LZ179!147R'W9G/+HX5'.Z-]CU%S4M M^.5FT0P D OJAMG%$'EG#F:ECTC/=9-ID@;.GE*47-
^T[U*H,T0;(CC MC08-+"<31^ZW2ED*TT7.30*6GST Q%>'HO%8]X+8&?%?LQ\2H9%51K8;M8N M@(3*H(D;.6IY %!\XI]))33WZ17Q>'%'6*E\LOJCAYD5>?.-N5 7"5M,#:2J
M@KE$KI3>X9 RP/['UOW<"5C:5B_T!L(QZPRX$6:T9UFL2J0SH_]B?$]5(OW(3DI]L.OX$8U(OO Y MW] CVVF"*1,@2;E*I/\"DN?#+FR89T]R+D8.0?3(3D?V"HZV(OAZRH_O?*V$
MNTQ;.<#W SI'.K=T\W%"C]W4J5:BT*6'$)@WA1+!WCI!G[#))Q@]RDB-=]MP MZ!C[++.8;?N,5'7W-^Z $)"S>:#2DO=:7+0 3!E'JKKWCIIFEX[OC.E;_F?B
M!/[(1VG&>$B7=+;+1UH[CPA,/8MF/IR>68P,AP-E8;TG?JK,P!]GB!=M&!U0)Y"2Q M\9&]0MOM0-&-E; M?$IXR6B\/*E+7VRQ]T^?]O,6W0U[2;9E?4B<-,<)D3++TR@) MC3^
B@EV<6=1P5/7S+7 ?,G]4?'8;M]C(R;894G^X"EL M>]UN[!@)/Z0GR"5!*9-7\UF7;Y%U*B/$5LIG:7>*S6PU[^Q^MC<#NB-Z8O+
MYU]*X5OYH+O[=W7>,EUXM=)B*A8]]V?:G\@ATDG9B(3MYYMM0+8 M:7FN<(?@?=ME\\]%0]P!%?3IXS)R0C;/>(+.+H]%KQUZ*_84#>-5C=R-=R-# M2Y9'1=?Y78N-?.Y#P^?;
[F8FP'^EI0TSME+KD96D99X0]TD-Y9&?Q^&"R2#6 MLK)QK "ELF04P%)8B.#6G3I9(7:C2L!F^5=(7VB!M/5-C$W&**@@KBDO6Z M5%NOW;!Z*89]'J]&ZH
969N\1&5"/6SEJV3)H+N%9]A5<$-E:G "93.L3:^ MD1J ZXA:]NXG@Z?4ZF]_'@4X?=00L)XRJ7;0]-(?*%O+XPK9XI SAU<,G8+ M//-5D2^-,D9 "60\@L:/)HUBL7I.:2<9,-
O%J0"]KRQVE/N!/5#F*C*I3M M^FIJR\]2W5/J0=QR1[\2$[?WD25)KBAW7I(E$*%*_THP025G:U66:5M]N#$A MS#*,1D/^V-GS$\]5CFDR-W5ZJXUFK"%MS)2M.VVLS-
FW]4A)9JH\Y4"OC[22H MU1F#M!!?AB2IU"Y>^\:J,1 =^S>#KZ"4-*72"\.$57',4E(40*W]L!O(UL\9 M1%W9Y?.<J@0E[E *J!#(-D=7#*[O?&+49*MR:"XWR?H5':K*7Z[X\:]
M.B]Q]HOQ;>5L-$(L*9!I< +<6>IH[_]]2Q-18>]+7K^ HNY5_SYWK3L-O0]&X$FAT1H^_J%(U]E ^&%*XXX.IO)*4 T%_V$VZT*,(5KG*@D; MZ ?
0KET%]XN2SP(@PHU/!TYB7;F8R:Q;VA):46'Q2]T1Z6V<2#1 M;Q$[<:!"?6V(C)^,!"]<7$C0?)24K/:KB<80$"1?XO&QP7YD* N@ M?ESK,;_RMK I'-FCEYH@US1];$6GW96CZ,8G$-
?:1E(= M,IMRT(D+?]0761%=05BTZRFLU7V)+**68@%*M(5@UKS_$4]+K%I[*XH$EA>\;A&1 MNE7O*)SD9G 'DG/83,MBY!.D1:[OQU$+MO$K;>&-.H\PF9T#69N/WABC
M=!TK\)'5?F@U1DW^]7<5;5 [>Y!,R*LH/)O.@FA1G[#.07GS*QLZW_M9OYP;\E,!RX(2:BA*_7"2[CCB)8*8_5BJ9&
MD_A>6F@W"HLN./VPM,3A@@,D;'=$HFIX@M7U*GJA$V+_B%5JDS9+K8C53%I MFUT'-$0J@:4XU;"M0*_I^9W%=Z=,P FO2J9C@EK#""(+\2YTIA&,_1_5*UO: M/X]
(]H02C6$O5THNE%2(@3A7$<3UQ+LK9X=]PLKY((_>EQFC]"Y\&[&_,GM MV/4)\][VQO3$.G9B=$$O$CZUX^YG)TB,KS9K]\AAQ:(/CDQ&IAW%S3H47H39 M,?$+!L<3-L:<)4."OB?
4UI^O=CE$F'&GFRI5(K*!B\%T]5HR6LK'048AZ:YI ,#5 MSLVY$XEAY0AOG+]!I+NGK#N],!T)E3274=O>4=O>4=K>%M#N.B0>* M7N11L1_'J&$@:^$RW;2G@2",3>32VL9R
P4$;*8S&1#X0]PB& &ZJC63-)2*",]>SG06Q,?6,!I[ZXK!G M@KB/;YC7'^!$R:?3M3MW V)PF8"U1$$.EDV4+%E*:5T5B@DX#:6!IO'CI5!.
M5B_4ID0%F.@1I+6/'1PO2O=WD2R9II@CU=7*<)5>@Z<%QN M\E)K"(A8E,:GE.(K2VY%>%?"KI6$O,D_HZV_PI8(FGUU3O!,6SY$?]15, M$,=3FPM XNZ[-$B\F4.I?0/ K=6]1@*
[+@,.+%!OH4T9:V"1?.)T=^:XURA7!1PA M@%/HNDT"LN9H3.U=I"- ^S^\I(P6PVX ;!?A*3V D]NK6V@+Y^E [BSX%# MG-RF+(0/."*DV#"E *]^T1%PUZ9IMOM?
EL)0R2)75&+NQSM"/A;,W'!>4M8_MOLC\O$ZP.W'R;5*9'R]9C X=5R'I=&"!?0Z MFQ58^%"M:]Z87-J)BL1!ZYNT3TOG;X3I#N(@CVO^W#G5;=ASE+-)=0!/O6) MRSI2-E2?
X77#K?URM\UUTY3%$6 KCZ.:3VW7C(H^; M=!EM3C;P+X>,Z)@N!\PP_3]02P,$% @ %H!+6I[YBYDF8 1] $!4 M !P:'5R+3(P,C0Q7VQA8BYX;6SM?8ESY+:UZ/W*_"<5]?
L2BLS&L?Q MDN552V]-V\H&H%2WC.*Y4BB+$CT4V2;9&FE^_<,!P!T P0V@_*T_SXX0&]QB&,GQ1ZZ?4;'TR$R3:*']#GZ<,7Z #=I=I^GNNU>O M/G[\^

>7C$E'Z/!/WWWY M[7=?OD8WU\?HS>LW7[$[_^LQ@1]^N'42C C<8?+7STH[/=W&P1^B^.[5F]>O MOWR5#?R,C?SN"7Y1&?_Q2SKZ\-
MOOWU%_YH/37S10++LX:M_OCN[$N\S1C>$ M_A)' ;[$6T0A_RY]WN&_?I;X#[L **_NX_Q5@Q($,>O8/ZK$-\!Z6&3;V&3 MPS_!)K_CO[XF8H'/G%L#A4,%8A@G0I+O
ES/!3BD,/%S(&*T=N94P A[%V42Z\5_VR<' M=XZS^\|R27":_C&(=IDT0)@89"LG626PH.GTC >O/'5SA(D^PW!_;2B?Q MV@SW#$B H@)F=MI\UH$@:4EVVK'[3W ;T/."C(*C$H<'-
U>?_8V*$7+9&.30 M&7]Y11?Z6O7>95REK!.[V:[DGRT \Q&OW(@<0+OT("B#O8VCAQ:>I)$*K5=_M&\3_SY MIWIOID\#(12:E\$A&^S!4G01Q6#U6*9I[-_N M4^7]9*W
MDIP,Q7.UDY"]C:,DN8BCK3^V%E5>V?1;NK2W1$;H"+2C0^P^F04<*#._CDI_M?7L2)YC =4]DZ 0_XB#:/9 W]^IIA\-$X'L:Q'SU7J-I1%)W6P*2 0EFT//
M$*^8A3";EBQ0B&T_WI186Y:J=DI4#1N=!&VS V\^O0C=Z &?0>6;Q$.XRM M9K<>.@(@)#*4CT0!&63WN%$PIRP@,N0&B 51D]+J]M.M M'Q+MVB?_\NFXG WD6)GUJ_^^W(
M?.619)ZM?:^P0:#.Z7L?6PO3M9 -@5GR01Z/\!$B)T7I/4:W^,X/0[@VHRW] M!$-V03^N-F>YK%9N0FDV1Y2\!R1E>ZQH')I %M%(AE M$9NT2$R ?L[&_=N] 7U4@:E$7HU&PP&?
P])UHWV8TGCWP' MD6K8 X>PPXF?N$&4[&,|D81UVWM]4,E=YU@DZFHQ1I4D:BL(A9$:^ZMSC)0 M]W=U(U;?E]@)ODTGETO)]L;"57R)X9!(FAGD1,R(S4HH:OUT8R$2\VOLA0I
M4.YIV&,>LXFDI+:X266NNK7L(BQGMCODR?)GQ#VB\Q$.,8/*0B% =8#R1&ER MY"3DE1(]0"0N4]_B&(Q%<'X=/1=#+IQG^-7RHQ-[FQT,+/OQS_6;;& MA\^.P6=T/%0RCB(VJ1PQ
F_SBE6' 8Y"NIK=W-BI9+ 2-#) RQ9@"9!1F05 M4HI3P\S3$*;_BE-'#LSC)/\1^W?W*?:6CSAV[O#]"<>NG^"+V'?'3H R!;6] M8%A#&(YU'WSD>R"';8(PWP7M8)O?SK>M(^03??&M?
+14A<,%Z0@4$7ZI=Z MFVKB-][G^]LV,'04\HF^]TX&!]L'.P'N< %RA!W5?7%H(#7XU=S>2-MC3/.LF M/@-TL=,Z!![I8]R,]$,.:D' K^6'PGGU3G^!'WY7P1[SR^_$OREJB+36H#>(
MH.@%N&H(XI; +);%15T8_RN-4S++TBNP'+T/]=^&N#-=DV6?_2]O1/HUA0ADTN?/_FI^/3E MZTYP-8N"YJ0 R.I\PECZ65Q F@_A1:-NB$'9;F4+R)P:1=-W3E:6/TGC/8T) MWI
#)+Z^=T(NVN=1R Z?>3U^.L,]53C4=&ZMKBA*/I&;,+L\E/F33=WR1=T* M?>5XE%N@%Z=>UG.\#X]BYTY=&MO?./^5PDE9U-OA $2FQ6=C0&SA!3 MI06K-S.;P:8&1EGD/D]?
Y?)%#E">KQLG&K:#3VZO?WWMPG^=4_NX=4CG]Z,AG0;HZ5E)4#(SJU\.&+C MYU+VHHUGE0>!"N;DZOT9,)KZS^1A3,J@I%R+\!M08826B M:H6AENFQ$\?/Y-Z:PM.HMZ?Y_O1:
<"E*WE"1+UNF=U^!5VX6R\KID>*GF__M$UZHK2+3(\N9>_3IY(0"]D7.(K3 [+/P]PJDB]Y5:T3(D-V4 ?64OFZ:41% MO(=I41%"(>^P6]Z&:/,"%$+HUC]5@M]6Q7 Q.9]N
YR<$JB.]TE*EKQV$9I MZ3;&55T9)+*+B?\=Q<4\ZWUWU2RKBHP"VP%:|46,=XZ?V1O)54=?[%/>1CH[M6N@&I &61++XS+RE,U5_(FK"<=E$Y-!E;)Y-'?A<[M98)M/+#W0FY#
(JJ9MSM\>7*\NW\WG@29G5O.-)L%SP'E5O3]+]2?5@TK;6+CF MQ)"T]T,RS=FZ9M3DFEPYJB$\0').\-8/L7>$0_*/]()0C_$!U M>LM1)CKLK+AC6XDPI E"\328[!
(5[V';/B6$0NG+#Z+PCMDS:T]!>WY\&:-< M[GLAHOT-56>^<^L"M"$:.=MH UI> 7C24LC:VU]P/>C")GLDKI='Z[/U]7IU MA9;G)^C]^^?EZOO-VKQ,5SP3-3]2H]G0'DV7C/?::
MDCF^W$CVL7#]28&1Q2^Q\;G!W;+8J!E6$QH%HGTO]ZI2GRW^/(W@M&QF07K4 M$&$F^[()LFNT;3(^9\C>=$/^NDK4+]G$FK.\=EN0B/HA@)!62PS=?'E)!4@P3Z%:M/
NJ=J4[KU)O?WJOEZA@TUG!6_>SX;1KA6] +CX?3;S%8*Y%@V')E&=1>'>-XP?H13BMHT6R MDWE%3 &-7KO)/;A4R6_6M!0$K4QPY(0?%BB*H1?E#-PQ:JXVG#(*8O34SQ0-
M4D>6+=5.%K)=Y-#(#-^;=^_6U^]6Y]?,WW*\,;]>G[]=G1*7530;;2[M+-1L M8SN3NH*)VG&I7G]WF)Y&0W@B;TOB.CL_=8+O M[%X*8]]_4!=#."6BD&XP21)D?
7G3GVX= $6C]^A$"8A(LD#_Y_4?7I/_,R0/ MI#BK+HIC]N?OT'*?WD>Q_PE[WZ$OOUY\]?KU@@Q&3@*51$ZPBZ$0%?KR<(&
M'@MJ9_QA'V+TY6OVJS^C=9+L>>G34G^<[]!7BZ_^]-7BCW_\EOZ)_,OU-XLW MAV\X8!VV6" R'LIV^H\X>+9LHI()6?VZ:C![0,9OL=R%$V]B6M;)HRM?X)@>
M!=.)NG1'"PX4#;#TO@G!IX ^]T-T$@6!$R?%;^W>;!T8+Q$_)9GZ&ME+Z]/% MDN(0F4X.&SO9T;\ET.B)G9./GXM8R?@G$2<95EV3TRM03Q76R8G22P MZ,F.3\?.Y_(3\4PI-
25D>UN5EIY':T@[P8?TC>^OPF"G 8[OV)+O8D\ID)+#*K M>#X:03+D ;G2^!O!MF-/S;B*4T^!<6_!N<2I TDQ*R>&RLK)TG7W#_L [D5(MEW']\=/R6C>TD*#7!I/=U7P]+?P'O$#?
^2&Y&*&+V$& M3L86]L;RIE^@=0 D\G(>A0>$BRE9-!OB<^'6XU_D_&F+"%"_(94NGC$X7YT MJW2^K(T+*=MQ&;ZH6?VX\)9FX;_?
M6=9"6MDF=)".4N&81KQ=X@03<*%.UPF1PR"BN9+Y^KQF!7FSIPU7EB1\L=N* M!H6F.W0R]RA.DN_8).2"WK'@AUOGZFO]-SANBZ4U/?3?4K+'R^#_,=W++MV
M'6[!;!CM$W3B)^#H3]@C]7R]7)\LZ*+K)'9PX).A8?3(EN?OV_29CEVOEPOT M/;QWR9^8>[94-V7'@+<8;ME+]/(@S.XL&E/Z/O^F*L5UQT\3;]G,ON&IA$@9
MH[F=9W7E5EXV(@'4Z/>N&8]3MMY9E"3+-(W]VWU*,UTB"#AH; MFI%QZ>[F R0Z0CBBF'OR8WK.0MXF.1IBKB3ND+AHYJ]_V<=DL0O:^9-&$(F[M7XXLZCT
L'"F=X=2U4K^X!9&4YG.AL/CFF6%83!<>GZ,7<*UA,5(PK,[^RN9 M%B;[@/#>=L6N_K+3B!+N3MK>';K$V[&/R];$*R&PDCK0#48C B\|YN'L#H"%\[X[
ME++0ON75]^CT;//C%3]]W+Q#FXO5Y1(2L]#R^'K]GB;0?V?5PM]?(FKVTSX$ MZUW\P_MESU(FD^OH$@.:?H K1MSKR*Z@3P*B^=8 $V AC6C,MX++
(!7D#3^3DFWQGNQS%E*)9#9ZW'O".GSII'@3TBZ2U1:UU2Y* M!);]+THC"3;!'FS;)WZRBQ(G>!M'^QU$+QJ)2VN"$!0V&7O'_N1F@) %FX=] MK"5' ,,G$*8@X;(!*(@T7\G*
KILW#1:.^\R#N-\1-!W)75B@??.K&%P0+6 MH1ID%G]>@5FT'C_^Q@_UMK2M/5>!ZAN"F/1*B:+^,QN7[;:JO)=>CX1HQB3 M;R AWQS+)22O'EKS;'U$UG+"1@NL65S WN"
J"_D^R'<# M]2-CG))W(]A^-K>!?S?))=@/AGD\CC0@[5)L=)[2VD$DU.*K2ZW>CRF)17'*W+&@X(/3(@I\SV'-O@.J0B7W&*>)U3;Q7>2DXM#0 MI>N FG_5[V%)[K0X?
B;7UR25+=6;V:CTIX1(IN& [(&\UH74]CFLQ\Q*]:QV M_/L]+*;4CC;EP7#5DFX:P%ENVBB=;;=.^W$W'EI^^76ZH-NOV;Y'%)Q\D I+ M_EDHV*%WRE+6R\HV6/:"*-E/EM0Z&!SC?
K&A$$MDJW/G"U2^H9"7SX1[G&9K MTY-R/N%18XE2_0@=3-T!#C"^[X86S^_+%WR[26TO-VI_X0]UK";_C;&WN'8 M!HX>$)A647O *!'["P+;/1BIB8SOH$I+G+(B,*
(T*HFU"=$5]A4K[-CZ>@O M&Q531T_B#:AH!CE(F^U-@NFZFUM646]=9F^_TZ@H\U'M+#.V>C$ $O.5%_L# M*RV+5&Y
Y$,]]9BP/;QCK60BN@/\&,/6!]'V8$_&.U08;*LNPV6HHMP,I.V@ MA@,)V9F7E*C'M;G:FL/::]5LFM"&_@_>X4D$IPR M4YQ0+WP\@\)_0GY4BQ+7 M$>IL8]*HFE65A%Z5V\9|
(]7S6P,@J9F(3:(7K5=,$\13S:LN6EDZ=-'O&:SZ M%#?D] D@RLI[(_BG2 I%$LO@L%]17F2>*U;-P MV&BRM7S\Z%!B2'P "SC(Z]I%89X*,WH4@'RG\2+P]25, 8\THH4'K#1DR8H7
MOY5Q55^]&MMIOO#K]H +)5BB+E99X$\1/_3;8\?K$0/7LKC=K"SG)7:Q_TC# M]2>/\U'M;519Z05B6QSYYWY8"FQS]TD:/> 8PL7Y"K,+]-&0!;W,"!FUQA/; MBQA#-
XH3O,5QC#W^H63[.@/%]'%].D",9A@8(L8ZD':3YQU:,3]=2_6+>3M6 M;ADH_:$(]JP;#68A_EUDJB7039?< PPDCR,W"S!>YR8B$26;FQ'<=,%KYO
M%SG@K%%WTPA&)3WOW]V(Y9R'D+<)B4:JCXR48R9>0FQLI@45MX@)859N;OZE MVPW MF!]OZ07%XH(HCW!HCAEAW/3'3T+R=61BE;U1$VY_@_E"^>95TC@;I$+
M]BZZ((Q(RWX(SI *)-0/HUYR3[ZZ;T7.Q^=@!67 M;)RJ]ELMJ!_'D,]VM!Y='=8?7VK_5\9#.K.G:Q@FVVM4LH8 M2;/.$F8]3S!) \=)Q$*]EX7"6 IPVGMV7O">GU/IS6HE-
57%*U9%S^.%SX8 Y:Q+9]"QM7B+* MVTODX#]"<$]Z[]Q'@4=6_)_???/F\.L_(U!-TV?+1FP1;ZK*2@W#GC(@[LTS MB4PHM[*1)*<"2-&M%97[-V6S;
>*Z?"Q'@ZIQ+U_O_XS@G]3S07ZCA/9N+I MT603B+.&'S?;TZQ9VQ7Y#D1V^C"R%(X.GHT&>2/C(LK69VO M+I=G=MOG321-
E89[4Y"S=WEU_R[TB5H"9A+F=82JU@0DU\?)5!^%Y]8V#FD] MT&0U)==OS]>GZ^/E^35:'A]O;LYI$O_%YFQ]O%Y=V:X*V8G5E:1*?:(,LE+X MS-Q!OH-
C6FGH#H=N)0%D*H'LN+GI3(QNX,E,'YMW[];7[VA"/,V2WU#I7)W7 M1=.6*:0[]^MVDHXTZN^F@!Q$L-&=X-MT*ID4[V%:](10R!(?-LMS5L#D^OL5 ME(ZRZU0),JDL.G(<^TL(-
=CQEQYIX9U'*9[^)-/?UTJ+$AW(9)?K]\O+U?>; MLY/5Y57^=O['S?KZ]ZL:8V=&-_]):--D@#2Z]]C:!YBW7FL4?*9P;':T=!1/ MO'R^IMUTIQ+3X0 9E]_![,L$FR\,CBZZ-.*KH+-)4
M^1;&H6_WCX3FF-];^M[+N,8TM1 JSAZ+H9PU]WRHQ-[#*)2=[=:,[A+_,#2 M_4 E@>3EO1/ 9?.F^D5)4I$L@&7,,V,)057]?Q3Q+R]JUD5.BF]QG1_2G$T(MGZ]GJ#'>$B_$.-
N16>S8E@BC>33[G"48XKBWM/C66">)K18C=KZ*1O\2"SSO;6X=". J M"<>NGX#:HPGOV)5+;&#P @^3'FA]'2:X6!<.$SA%QC]07N!Y,N##&/,\Z/'4Q0"-@BX<Q3>D= MRU;?
BYG]]OX-/8TR4)6/X&F^9^G>YC3D*='H]H5J/UI?VK?8)F%C?7-*-@Q(M\1+[Y)M@'4G >D^'!@DSLIQV&]@G]M2SZU_,0V5W:X%#-.U1H?]R9P@ QLN#T[XB7QSUFJEO1$XC&/-Z$?
II<1D%P&L4 OZ' MW'[06#E"AL&L$9:;Q9NBRZ[=K87NKRZR4-UK1KVQQ$D<4QN?\KV_S#Z]BLL MDGX=$DCW-"&(EMN[OG="_NE39B702!F.Y[D\+KJ";:R$BBG,9/G![-;U'UH
M+TR]|RF=HRCR?1@QQ&B0'Q\KGKIPA>-'\A:0(!#0Y2#*=PM-3N]"_Q.!GX(" M]4&FRT>>#$[SW^A4]&CM3"2,XHMS"C8,^"3Y3N3Z%@(R
M3>,3S4UMZ(YZH,FKR>4C1:U/K%0&Z\3@2HDP?5+TK]8"]\TZ=*.'O(PW7]= M*99.>]NHL](%0%F=])A MXB%6$CK3;H &0%[]V+\+CVEW"??YFNAF"?
0;CL*WCA^>14ERA+=DS+7S-+), M=]G9AB[0 3Z) /,5>.L.]QFEL$; % 3/WVXQ_!K7BQ?:$,.>8E"6W:ZTZ]TQ M9+7BV!=QPJL_^BG]_G9 .I9/]W3!^S((MMU=_-1S1TA;&NZYM-EH)-
!5FB; M^CKBW.R';IWP@Z"W@7+1WX&[SBEDV3?7]1:'2L[(?I7KKQ?O; M!/^ZQV&Z>@3;X62]KW0?&YE>,F!D*NS-T=7]'S>K\VNT>@^UUNSF6;6QK**.
M*E$=E.4TB:V:"/T6^S34[84YK#;6KY*,;8F+V_&PG?YZA(L>S M7^Y6'EIV=9/P2('K*/M\DI[RT'E1DP;G7A!*)$D8A@B1%_E2K8)F6LSZ,CR7
MP%ZDZW4@E7Y=N14V^EN"@UQ+)M/:L2V0*U:O8RB]&NY*H MR5ZA$.I0JY?\C7HF=CP+S0G>P".P_\EG0>1Z'WI=#[M^C?P23!"YAU7Q(PXB MVC.7NZ$GZNK7OJ.%5X
&6#)AY#.I['G%W@P^S.X%W(/3U:Z >G3I;2W&M$'8 M6QSBV G(+DOOP0]\C"F#HPLPG2:IVFGO6T\3;L * NB9Y.I=#]5Z2H!M6/* MZ2,+E4=K9WKU%=OC&'M^>NJX?N"GS\LG?
VS7K6"#"=3#0"%\30AD3ULZ$&4C MT<\PUM]=V\ZA2A,A,9*]@U? ;DA*G_[D$2Y@NC\F$$G_)3P5OJVL9X&IE0YE#&YH1$BJYY-)XAQT(
MLZ7]C%W^"LD.G&VBU/=,AVY0A4E^@D]8L('A,[T)@40(8"_]1L[DXY9S]/R- M2Y#LGY:ZOTU\SW?BYRN'=JN!/-@)Q$.^S_BJITI(I'#(#@R'MS*"<3.1E%:> MU>-@Y
AW/4[@0,K;MUZY.'1B/QKILA"O:^@0D0(@#>YG0QHB8?C:4#(CNT+D MB/6TK!1).5%;59=.DG4QP-8N6W:.5B]=UI0'W0#E0+U MKLF4B>X?T2Z&)4@"ANR0R4-!;^$$4!0C.L?F;:7-
O(H)0XEY+^VER&6G M<4KO<'H?>6OJ_J+6W\9O,3YW'L9Z$0_:?O1\'*DF-_!*:?Y"-GF!8*A ES:M M.HT@";F&-91@_4L)\O(4%TZ[A?R#\C^3QR9K97]U'<0]5YHJO
M8_1[6W]C\RF.^L#);GAZ.=] M'T?6:W[V87A9+#O398+GY"..;Z-QV?=:\M9D=D(4W:8.X6"@Y.C_!]Q\/>8Y MDZ5F7Y+K]60?DZTF20WJM/4LSAD9=))SAOS1)?<
U!TF#UPG#*'6L)\E_,=D M$;M9_'UXWR:D2A(-2)T1[^7&V$GPTG7C/6V\0+4RZK#UK'\D.@A_^WB*B=4;YM?4:H7]$2B'-;4Q=$?MRW; MF7\XM('4]EPH53V!EX/-FUR7F:5@S7;T.U[8-
!2YN%$VVW^0V\3?^IB640^) M3.\;/4@EX>CMJQC/@&@%2>N*_36;R4(]^52$_.AY:]VRA&=V"=M1](KLW$ M/_)=CSK]\ARB9R=(G^&Z!J>[G@ U)AE-]ZOO+C.-L6%U/@XD
MY*9ATZVU&M3GF$A>5,3HV;D3FFP0M9V<-V>^<\NU)'*C0:^.ZXCM[6L>%+IK MF14F3:BDM8>SV2C(IA--&7066 #RH.)L":OG3D=&%FG&'.?$'3 .
M0^]HGQ#%/$E*:2V\ZX>NE.FO9O2>T@9+(FCY?*H2W_(5*JE-3KZ&Q5S.SLS, M):T;A8;L:6]91%8= CO?&:OQH"(K$6/U3H: M RR"7
MZNW=H;BY.CJ.'!Y]YWI;4%3"VG:5]0^-6ZG:8)-)2]/N-N8;,W"=V M+=+Z/*V86_2(,,3Z3"ZF*-YD1<+/P&0(SM[--FM)-[;1N7U#\QZ15IAD_E88 M29LLVC8@:[.Q8C?
6P[OO/01+^2'Y$O.%M6XCP33C5KLF#++F&-E % AEP?@M M)2=Z?E=)D.ME95L]I3CTNC&X/L=T;9#;_A+.LE$2MIKFJH3,.4M%*/4QP],5 M>#TV+5Y6)AA6'S-A0XT_$Z&
K$,XW:'H4@R(J!L[%Y1_2Z"<$TQY6$S_DMQ["?G;#4 M6[P/4?Z]N]7F] MU&<9?E$T -"2@2W,D@F ^3M&0OG2_2)"_YHXVULTJ78;>.4&0 M_3"R3&IM:4IC[@*43#MB4W-
G"B2AG$!X,3)%IKL MW*UVI=:G1/Q^X*MZG MCHLG<=Q)MS'N0I%:HOLRFTVV6AOGY(=8#>F^7I.3/3[159BRL8;5)+ZMK-K. M'B//J@Y4(V&A[);@GD3?66VW&$)
[I.^B"54>T=X6*@IW E#S16[76#>([7HZ MCXPT?0M-%]G:FX\A]G@:U$66 C7)7:2WIXUNQAIPR=YY>=+8+<\D$ZL_%]2Q M$XNK[8EUZ=&[+EU5S$VD,NKM:?\1V"5Y,6^@S7,4Q;
(W@X-0.T]1GQI]6TE" M7]3%&X59ILLF M+!4%&EM@.^UM0VJ[-@:"!H1]0K8"$G@KFV[62^^5Z2S,VU&$%'6BI7\0+\! M]FVLS4AH^];&K1U=H&NI:9W0FM;\2)W+V=F#
[(QU2//D,ZSQ5X7\'63HYKN M-9T\5K>Q*7T$L52+3DC!Z \]/[F%WI]2Q^.Q?9$_)](F=4O2UO]V$SD,4I ZG
M:L_EK+6/EEVN;0VC$3,MP$C[+N:SD%N:EO=TLA8BH_6CWAV/43R(#.U1CR0")*3.*I[YU@/ KY9@T/T[XP:YBV MJ]E^-AP]PG@XM=-[3!Y?$=O9;@:3=4D7-P^WP<3^?L&A<+-
B".N0/4A_Q%") MF^!!WNC.':9_! ?']>/'_'49*> M1^E/.+W$;G07@J(S\H<_'9S>^3H=)3C[;YUII<_,I?YK2$'V)!@/?C?11X M1'18BX -4;M&;P4LV<5&84T)+#(+ G"*C_Z?
WWWSYO#K/].:"Y^FS;4N]FG$- MB[X$XWY9%<8'%C1@UZ@3C':;&9$Q]^$M^3OB VPJIQO$#)_N%>!'Z!T]]PY MDWWKZ@W-FPU;89+%0!!0[B%YCCQ"3,>R-7U@CQ]ZA.AG1X#
[I6+.'(Q]I)3 M BUL!&$6>1>EL5W0+9M9<.&I(9*]?7BOK#1"NTSN*D)GUP:BQ]*RF&E0H7>' M>%%;+F[!P-0>7FS$_YH?C@0HS*)^@PYE2>G0+WKT**917W121 M<
,D1+R*53$1@J0E*^7@P)D)C));0]F1DZ&7Z+R-HR3)E$,M,;G.,"X2E>TE M[*=CB#+$!]$$$Y9X>?2=U;)H0GKGC&XBUXNIU6"GCL> =+)ABY$$#)5Q<":U M=]O(7QB65#CV5!1R?
W%F+Z$ZL1;G)5,-)_6)H6@-6LB?Z?786M/<5S,@Y[T" MS2$EU\!@E!65;U1W'UYLK;Z\Z8="0!9E:UBA%5'M(P=E9I](I3Z&YEYOXKB M(9+)U]B&/ND^-FQ\,F#;;,F-
DLQVS'EM/*M8\I2X]M(7+F),]$O\#*$$3C.(MRY@I/;=-&<9OBD: $BS)_$!'4@C5NA(B_>#E-A%RHA7GWCB)>>Y\,B3D#5C [J M@&@BBZ=)8(B!DND ^E
>5V\RR:25]H0C(..Q3[^K$3UPXT10I"+(2#L*91@/$ MA2#(BCOPL=SD#8D%,+IXU/_E?Q\OO_SP=.B>I:__M=7KZYNKOKQZ?
CHY_>OWH7<5.^O3#,OCUAW_]ZXWS]MT/7X51\OBODY^^^>$I M^K3^);EX__=W1[M7^^6K^.VGY/BGI^/=_B:Y?Q-^F^!?GH[>NV].GA]7/[SS MUF^/7T47G\[?79U_?
WA/[_^_E/D.?%71S_>_/"/ZQ]_V?YRN_SIEZ_/;KZZ M=>?\-_=GQXN_/[IC^&GF^LW[U/O8OO-U]=?7:4?/N[N M?_6>7CM;[/W^^]VI>AW_?_OZ;[V_]_'TV\?5;5U=??
7OSZ^NGHT_W%VYTOO_U MZN*/M_?.D_^O#I8_CE-[Z_^=+W/K[ZT^LWOSS_O<[_,/O?[H]^?#+]U>' M7]]_>MQ%=[^D7YT^?#A__:?SM/MWS>?/OSP5;+?XZU_C8ZO+O#\.
[+RDE:)> ME-]0RE1O=T#F75B&'G,OE$PRS=KC@Q6MUNW,9Y.W@=3F5+7?IT"7AV7%2POK M/H?V3>CLR1W 4_]!U:4R(<*FMLH?]'_JP#7H?-?X*3TB"WW0.M%[+&OZ=N\.
MHCRZD2V$^$HH7P]5UK*9*]23Q>7TH3ZTZEG!X,A)_&2S7;KT](2PE"CPW6?V M_R5R,/BHT]S4AMM>#S29<=*_"_VM[\+A5ZR Z.1:#T,+9V$W5I=/Q Y$Z7W;
MWB1XLUTEJ4\D?'1[5FUQX\%PU?UE9QN+>5KTE8=(VLF#H[6E>\]*"2U;KL,C9H<6"L_O1+^9;-99VXG-9W(2)TO,R M/,QL79%<@I75^P <6/.?%?
8KKDCY\4OF+DQ3QP4*9FU'>K(KC&CFO4K*,7>RBM-'UQ\B29!8[SU,R M<_ADC20_1BJYG*54-KC=32JK))E2*HD4VCHQRWO;**37!4"9;,((A7#.4S:;
M/.\HG36Z=+W.DSC]SSL_]!_V#_JB1R:5Q(]\5(A<GQ]CFG[?VU_V9LP&V6=G2I"YPJY"*F.A@ZDD)<2 M;_#8>&B.@O)%:(X,P5[-;B,GA.S;;I:6YBS3S:WK_,A";LDX! /%5A33_)52
MNVAG*T2LJY<,)4"3Y1U1U.^L;YYQV,#!MGQ0,L[LX%SL1_)V-,HP]+ KZ>_\))H"]$/Y3SILC>A MGR:75S>3"(=Z+^,1#4IPI#Z_; YBXD-GH<_)O.2+>=AYM#A:EJ=V.O35-,ZC
M,"MAUT'-;,XRK$ MPDW,ZR!B0.0M\V PRD?/1!M1LZQ:LDN*;A_[PP61AGWH88_'L7>X/"13S:?[M":!0Y/R=TM$HB]NWJTEH]*"^ "C#=,"EHN#[6$D]%CW?.D*1):!8CO%1,D20
M<3+DC4KE*:]%U>&;K\|Q;9*J[2_AZ!$.\=:G8:Q17E/,NDE*0N_\^Q;AUN=(M_WOT(7](O.@L]3IPMCG+\$'> $#"W&P<(@/G\120$CQGK1BW :8^2G0* XO(4
2*2"C47Y8/0S&V(U%;#D4K-8H C3(76E MB9H(&B)-_QK=^%A9?&R#DDHJJEM+#8Y\$/J9&K/[&!1RHFIG;. T]&4 7^W, M#_&;_'/\CL*-#290[K2$((>@71!@**)C[8?
42CDDE(H]DIVU/?!P7/LI="-< MAY[_Z'M]\X"(\$LH 91M!/B =QQUW M">*;0?U[,AG^Z'/^8Y?-&Y;"]KXV))51 N,R9(AUWO?)F*3]0/# 3+XJA@.
MK>R;ZOS=2%22^42L]Y"I4=K="12><:^8I9N2&RY]IG<;?*LWO+,7>) Q04UA:M>+W"8 +#)$9*!5XF[5)*2%]M$T2&V0(HF[A M1TY T]%M/RP[\;4LB^TD&:(&\\]_L]7]W;D,
K[]9EMTYV1MU:!OI^B>'ZX9 M3P+C^$XWI;X\!0X]3> KHGXV81*1]<"K5A;6H!:7HZ=G9]Z :R_0$M:LUGP M +5QLD\IFI7#?C+>C'UR/N+X-C*A*1RV: I<@?*RIM"N(]Q7/:@1>
<]#!?1QC MST]/'1=*VW>P-W^8_M0 73K-L%]8,[X?,FYG^X<.*4A\9,9L(<"HY1#_A 8%M$4^8HM11&/8:4U".N M!U-OP/7W'DIVAG>3W'O5M0WJY"N;2V2,CYG+%2?
D15E8FCCU\KY?@G8U6D9H M>35#/*YMJS!G^(1@+CE%WF$GV<<\],(NMR4=;QZIO>=X-NT]"JZ[CS@ M23YQZ38F;R 9$+*V'&0X*L8O$,RP+16Z?"L?!T]\^Z;N0+QH9&7T:MX"CJ
ME]"X#9II/H?8<7U65AXW>@3H<565RV3;A,@ M(*O,!A,0S+ LW";DJY-_I"^-!UB,3C#-^?8?\W+NL,U$KTO%5L;50CDLTH=F M-J6HX3^'RUR'@U7EL 7UL8+N1XAQ; ;
(VPI<'!2*[(QAGT*48<S M-G"2A&N44SU#Q7L18# D7 J M054YFE.:F9)Y%1>NE ##/"RERC:375GR?0S' M2E-Q3%#$2W%5=7YKL8WJ"T_O(8SWM,>[V,&AY;K9L8.S- MJ89#
(CILH,J4;OCY]<>N[VJ@7/_8X>'=8'G=IK8(L$&AA7C)@32$HHLQ V" M)<^C,.8_PD1:-[]QUEBIH2CC5[5PHA#EWH92?N'Q4C];F+9NGB843;&3D5-& M Q!97!K,
MH5B$IBA&=-8LWE08+!2J.%/T^E79]]U[2_36E6L#0]=(*B*;^ MDLSM":7!G.(!U89_[W9YU86G>D))MS$=ER8"0EN 9A9YIN;0OT5/:!&Y8$7
MN=1!2$V3HJIYZ;KQ'GOO'1;LGOSOXYB,ER72'9,S\1FBLE@;8(>>*>^!4) M2,D]OBGRH' F^4MT&_AW;&'DARZLS52,G?,,WPO:DGMB'^XA3>.1@X!2GZBI MT4<6;Y\E0"=D!Q@%?
R?;85I:@CVGDV+J+:WFE](GU 7ID,9Z'R)/IBL-2 A M=.-X43)D="V@73X\CY8L<0]S;B(?1?+A*,8RY/:=S#:8G2&^/@FP:48CGT@ MMA/[[B[&=U"RE2Q]3^1=3>YL--
KQX8S@R*Z<"W%H4EV!ZLCFO%:R'TH,.2-$3,D>!2EL\(BV&:7&"(%TNLH[V GX]0U MN<,=EH9)U 0W7PP%V6I$7T Q6P\N\CA;T>KAIHFU@(T=]&5##"WHVXA6G2Z] \X6M("(@N1-
/TT?$VCI+D(HY< MC#WIRZ!ZU=$I*)MC4^>H -^@L U\V\R>G]Q.%,9>>D8,+]6%6[SB5,E6!O4 M;")B6E3+$"3DXW]4*]P5]B9P%/,)?[#]UY)@H:1W UOSLN![)!S1KX-
IY]YWM(4=ZP6L-)N^&L>NBRV7#1<4M:V7IF58^3X=7D M@9(-EA2;!";[3_V3D#S:6B%*<\]I['<5%92/39;E$]%Y;GV/H-6M!]LT22$ M^6/G/L8/48B?WSO!@G#Z202
MN]A_E#L8^,P\;B0/!KECG3EC/M\B]UIQ:[),DQPVU]42;) H+C^=.6.HLR?C MCNL$[I['$R?(0;N*]02^U80GT>_BR-N[A('%=YB%'L=$BL,]T3]O:+$O^!4M
MY9#LR9%/YOU"S@/;1WR-2"H.EZAHP=!%!>#;]E]>M_545=:7HN1Z_A%#-"SV MEH^$*7?X$D-8+/E]R14&)M0W,H')YB.^,I70&4O]JQ!3G@61Q3QYAA1 89%
MTX5Y6C;DRA8[;9O$ W@'DV>'BW.P!AAFOPMXH44!"PO2D(U;H(LH\-UG]#/_+V" *]V4X2]")5Y MHD+98%F+99+@-
%G>)E2'DF8N3<_&BEGEEK0Z;$;]+ M!- TSXT7=B"'FN\2N(Z=Y+XE:],8C&#T O'Q-G/RA0B(&*G U##->3(.5#Y2 M?NP\#8D.7" Z=
(%8P7IXB=BA0PFCQ4%63@SVMB0+X#_Q@WT]]IQEPQ$9SZZW!>)3 M;!X_$BQ$'% B;+9P6)8]1K0H[*'&"MW&TWT$T"F1IP?./J#^;'7CR0;V67A<4,M9] MD\&&+FDQD3!37!LC

+RU[LLK49]ZE?GH&Q2\^RW(%H]?$1,;\??K%(T@1!: M/9V8L6P/A7>5K!]91.6C$1V^R*Q^B1TODQH)$==4 MZ)]T\=;,=-4$D%+ TY&3^*YV<%]1"G/5*"]S0'0MNXSJA+:(?
SWH9O2V'6K' MY29Q\&B.$@(VAA&^'/(EL 1V?'E,Y Q:]YAEQA2V_=XR843RV?LP"E>|;F&K M9HFRD8@-M9]A5X>[^?(58V:] 65[GHW(F)#-0DMX(99RC;*),\T::5!?!WV3
MUS9Y[L6@.)Q@]M]U>!'CG>-[6=$>#E]6P,)<^M(\5KX:U!=F_H"ZHCQ)3-F M416] OT*LB/)9E$K#KE%,M5B/JU.#UIYFK3$Z(,F:.&1S\^[9PNZ*@K $&Y:.+ORNV":T
M*610!03C7;+9DB,+RC"0[X)%R+/_WYHN06?3@@SY?*U8>PMLTT-4Q+_B.YJVP'-[MA!]!V:;,;USX@\8D6 =;1/_! G2?Z(]^>E]*/&4UOU1A@7G %%MG@;*5T$>R%,K70N7%;"JB'?$6
MV_)D*YO\T&V2?YXF>A%*]O%!8ER28\C6+L MWX7,W "&R>.2;"C@]4A%PFS&#O3Z>M-TR9YEU_=1W$*#OPUK7>@#%?
M&8W!=$'7.8"%4&DEN^&J^AAKFH*5]#*6^I@5IKN\N@&(+]]H30KL74?:4:/9 M$@C6H*;??!5T'2%54*GYFE?:V#9.M,5A<>?K5@5G?-/@:E) M;TF'-JSBB(F\36T^GQQVB*\
'TZ^AM56IA.W]#6N3!AA/$0 \QG6=04Q(D*5086SI8RVO)M 2\6)(JDMFS$CFYD4&^'!I4;= M:N$592::J.Q*+5UM!E57I%EI"EP-GSW"6B,=2ZW8%GDA#B*R*Y U7P!]ZZ=@
M7H/MWP@M(VD>N$M-D.6Z#A=0P!8R\[(T]F_W*6U+D5+%5I2';_6C*% 5L:1. M"+.E#G *+R "PZ/O8>_H^2:!PK'Y]5C$3K1=^< M^G#,UH)$R<]A.7(]?X&* M&Z-
84GQG6#%G=:6"V*#5CY;FS,7"-F$B13@;B/*1+Z_]V:%)EXLD=(4Z";+[MK9K,]LQ!3GC 3UY<4)AQ7*3#+I"S)0<=.&BVF#;9LWK@=:>&Z'Q]2U-SWY.% MCA>BK[780YZU?
L2SUF^;2>L\9QW=-%]>M&>K'I[<-A,OL=^)Z> >=3)N(]?6 MFG%>;I*WHMN*3Z>F9!Q)RA>\IX*Q#&DRKTO-F?"K4E6#O/M+M7>)B<(6##C] M$LC \4;?EVK>E&T],FA9/>9[>>2-
?X(KSF[PF*^K+4\8+1O".U\(V=%#-<@ M@QX^&6:N/9%.3G+!"=U:PZ;LL(*T=)>%&T4B;#7(N--(5D<_
MTV7G$OO3CQ9")@^@]L$3$DR*3G*_H;V5^0]+EPAE0OTWI_X3N7Y9(QKX;8P] M:8$Q/AMZ5<-B*/NYM-P"T06Y(QAE2]H^4WL006@CZTM+TQ_|_C;!O^[A7GZ$ M_)#V;S]?@-
@,\M7.Y'N5H2+\)-5X=\ZN9P_E_#NGBBS76T61&N*L!%B$IAH< MOOGRD*8;]%W68/1@=^AD6?79;9%%[69/,22+Y]D6M-N-MC?3"P-+/Q(:N!]2
M."70X=")_0ABP\DQUE+E*AMEM2"T'.PR[=N0,VR"8E58\O@4KIF3QY-&+"FO M/=,,VK'V,&G%1?)"T:2!H6L21.2='_H/^P>UV/-!UJ6^ FQ=V 68&&XBR-LQ M-
:K:R%SCU09461IX::+U3H(RC$3BW4X!TRFM]1]+_/!/H@DNL8O]1WB5G&/I MX2,I59F=27G":[8 I'EK'*N&^8B7O:AG8Z5 -6>0;[Y2O9+RG7'
M6>BNZ$@Q8\IP45UDL_W'W@G\K<]+_WLT_%.]#A<3P9Z<3T7EN?8TXE:T&B]4 M)B&,7B]P6D]S] B'Y!_I!:$_#]U&M#LPU4882QX73/*L5(]&+<#+O2*1 ;
M86"'PGK*R+V1!L74;*76."!%3,J/%E(8O:FR;H[7$0^W()H. 2]]AO,6_$OP MF*/AB=+N/7P%B#CC:Z!LD06]EE)6/B1?R2[3]#$6,; KO8SI@T4R.7V4TZJ@ MTHX<1?8\BR>@HZT&"XC
;ZAZ]I=. M9U9[C=::/]I-M["G.B;T"/(BS!9]B/]2WA-;K'4R[:HR,_+-EEV)/VH%LM> M;#?XZLA\<%)%TTH6$ MV:;Y9IF\PNKDMREZQM2CS3=#H\4Q-9;;6X^%?5$,C@Q]^QG-/-
B_$-2FO.N M!?USFN>4U:RBB/"8ZDM8XP4Z:%]183_1E@2AMG:L@DPA*V4Y6A$4O@%TZ6+V M)2=[B"C>V+5W6O69-H,'M@HG,6?::&"X]30S-Z=6/"NZI2)_]P4J
MF5*Z3]%5MC#14+#Z.^=)(UB7#;(?K%L&MLP3"2:FNOV6*C+DT8Q.BHF"0HBN/H(U/59-4EL]H91?0GL>3%1!= F5K6*TNJ8%CPSC3B39& SYIT/PS M
'/E!'+'*!_'&$)'VG.#UF%N4%N,E,GLIF&U3T]'HF:YDS<3%[\I0=2E_LT; MFQ@&(YIG0$$1;D,<7/+HVMRQL:1VNGMQ[D#MRZ>1.-MJ^/B]X+ WK@R4/HNT!692]45&V M+.1L9
O32(S")TG7+BI%VP[ZZT\6$X+MM&)L,N@PZ"8Y)99@E&.#L3F661YEFQ0?G.@]O.VM/+19"WU!) M%#A:]]I>/1TU.D%4;YA%<<6(:T[;K+$NPTT8_])'$#O]2[,XG%(1&MF'D3_>
M^9Q%I7Z/79NI AT12UJQ-^]WKQ8?41NKZ@57YM%&68B"\.:1XVKX;CI*6=2B5:2(H^O"]D,?A%YC50+|B2]T]2$B*95Z[-AC>#)(W' M2 HQ:'Q!*D1-
EA45=S=2'W>UODX'15^GV5P\2KR$WT,[(4SYKU9/*0X]]GQG M@9G"@])T&+=NV8Q*%0'=D'5 N;FXLA#*5H(6W*6U+-=S[8*V4 /N3C>C]_STX:1S+>)>"?WX_ZV(
M>SM_#!H2=87%=I7-84IZUVEMF556GE9SMQ]P]^T5]71-%E\6#L#?6"#+E'N M_FR*AW>G@HB??6YHJX=*UDJRD24W@W&,DWD2>&6'L5<[\^=>FSD/1=7D]! M'L;& AO*0?
W%+(N!:W)4!-%];7B_C&^^M=823YZ 8ZYPA$VD7&I6V5>(K?P&W6(.(4MYF$4X9?)RWR MLQ<$%4 D]"XB\]7@U(\LIO;P+^C.$K?+I(*OL7,!>*KES*"[1,%O[^=1S$;%=)3-%W?
WL',Z M:.$I_.0[4,B@]Z84W,Y;S/0K_P@ENYP 8]XN8C]T_9T3L*QO^;F:349T]@+Q^0N4KS"#Q'$M M',5'I#9Q3.IB)_@V+;3%GWBVH:TP*Q==!%\S5H
MIR:=+KXB)G:EEB67$_7N$EBH:J:I7:)S@$M,&[:MFLBP:7$:"3"WT[5#[=.N MYX$(O=AVLS_DCFL)AD8S/<@71[A,OC:PV\)]]Y'P/Y1WI"XF,%-W:8I=)4V*
MB8CR+6B;-4WE/;CRT*P<.BH;-R%YW5Q&07 :Q? <[-X"LPAR*[C'/A>Z-H+% M$5]=U0O3TNDUC$#"0VX,FL^BU $%CFBK!*'K^QCCEI#>MM@XOA2B:UE-4^^%
M=P>SBXIPG9LP%I5GB.)"U=(M'"RG0?2QX2]C'1>!- FA#:7+UDEN*7'X,]^@ M%>,K'*1)]AO:G)$V9M3:RG0O3P4LLIZ+V10XG^A-0F<)_;%6*A&U,[):8;.R5'SH7K;[;%:M MGH7@
6C:U*+&IV%FT4'?6#%7L!K$R;V_4U^7^: 9-!NK@=R@KQ EDT\)YBQ[MA]/[R*O:9RA8[;8/[MUD*Z!BB04]^" R?%@I>:B+K.A4MF M$E]D@?R\R -672COL#<7LTYKE?763$X)YL?!)
(T>R&]CG'!+5)*"N5LPGY^**$ MLG-=+EFY22-"/*"XF[PRZ4N7_O%8.,77,K: &?;6Y@YFK7XEO*0'U&O=%AU) M6$H!]"K1B*;5K'K"/@)>(J'<0&;.?O^1::B.")B$8:8T\U/_]>IBD9<>?*H[
ME6R]YPVX&PJZ!#/3_7K8Z:36PKDC@]>]GDM=E0;X8C^V$$=CCKFRV3XAG].C MVCM:<44DJ)A@S2LJ04#IGV@@^C)2(YMJK>T:OKW*]-I^]4Y*]0X!4=,PW+#: MI>K\1;/'I&)
(PR'95,3F\M39HIT:7M(S78,H)KN\.WY,G[Z;+3=O M0E.3/,V69DA)2]G#9&9_@-BQ?'XY+7K!TLB>T<_\OR*MU@(#M? 6\; #PKH7\D3,4UC_W:?TA=B&I$+N%H?
VYY"6T%#>OH)D#68;GD6.2'X MRU?K(_7# 08B&(GRH38?90VXFU]L&+.7T)BBM;8#RP&=3U4/GF(K*.GQDM37 MCF0?57_MQ7+3LCS 9)IW/6;E(39;IN*9>'GE6V?E/&@R)-
W>>O+(^!2=PMZM M9)]9E,]".[E8I/]W7+4&@-"'*561L#L U281G9UTQ(G(<[*^QQ*M'\ALA]: M3:\4(";F0BLE#!ZM+0&E,LZTA][:/-U:D!)Q18L.U>>(5@(<:U68^U!XJ-+S
M)0XTH2W(4L;LUOW@T^6&Y>E[FZV63#< M,^+K06N*(IV7+)GWK,@6M1B1/TP BI:7_8EI]K1?.3$XG).L1D*;R2,;7U2&
MF(^50X:+Z!11XVVG1L2%$V]B5CB$&LK;*G94NX>2V2B*L_(JS+@H+-]AMY:$ M#$D1D[1I8]3;Q"Q':GV(C9F)XE,&6$3F)D*E2Z?/W9GEN.1GWO [4VM)4R$*
MW<#2N"+S)*C2%:F^&>W=BUV8*[@/M2EF])MN%BRDAA5>\2[A5=5 YW3=>(^] M4@)+U*0U"Z6+9P7H*/J.5L;E1:W?&X/((OHH!E,95,?
^/%]H]]_C0V6]UN%SEENAM7T;)PY@[58-G\1.[N9DO8 MO)"UQV(8](#MHGOG-#_1 \":)P7!;]'3H70NR";040/"_W/8[R^E^E MW-S6G(WR/JPC8;X3?=*4]Z]&NA7;55*D9U;Q?
6P*BH1G&BX9/1Q]X;.9Y_?$ M#_99>]]R#R.9'#4BG>LN^&KW*+Z\U1N_(^8B_OXU^M[@W2B+OBU\(8T;R\Z=U05UX874G7:6S;39 MI\MMA^=8T5!":(_-CRR^P*1-
>QVE&C'4<^X*].-R6I\5SL"C-=B,]!CK+9Y M:\#:]& T$#';X+5H+UN.9+^.H-P./!0C6G6N]3D&=:HJ/78;M+0?B!XJ"=GH_A3(1T!]N7G&9FK;$7L?](58(# MQZ4,:(D:8*-1/GPN!8[$:
AC"10(FU2I:SY%]LJT% ^O^V1YMF2SWRBJ.-_HQ,JL4;C!<"9Q V+OT*Y*;K-%0ROLC5%>P]VGHO MIB>M#&N%5,B+1+;7?$=^&I8H821:.]MF! MITV=8*LNBAA?
=0D>NS5X^E)'*"PCT=RP<20KUW$:Q1=QY&+LT3+(5_=$P*'2 M5%'+71K7E)^M];3M@+=1INA+-2&(995?73GI+7B;K],-O#5/]_69GT+&TP*3=.UW'VJ1"6[3DK";'LD"I M=0B/]
<1QX;Z4*B/5/]4-#R&O?..']+28Y;;'= 6?E.=R6:0ITV#<_;DS'P' MI68+':WR^5N\|+V4%IM=5+0"<3U3?2OEC#XHEDF"4]VV%&SP_#I2")$0&DKD
MV)K6SJ,D9;6^:=0>#O'63Y.\ZQL\.-4FK.H"#%NAW :O6,2]V5:%"WHU. MIK7"@<7I2A$?;<7I1.:T,6MB5(N?MO5"#6IWL$',0W#3>=FU!OU=.E.9/M% MV0!>^)R4H&B6T*5@-
OO^RI0?+K=N[@5NVY:4H4DAAUZ;.O"Y'-!5K]WY/4W M_9[-F\E[IP6=(W7$T:LP MR+E'=#NHX;_;;K&Z9]RB<<(L4.T<6M"#]'XX568PD)#@NB\[\&,N;VFEQ#
[G2'>P.\II9E@#CQX>?!86 X=U%$(W8$S> M!]A+AG%I%7:IE=>9:R)6-]2%5UP/XAGVL9]$,5:JCNA&R?(NQAKI!W0LR@?/ M(8E7!'Z9["TXFFX[WU-
9U]31+:GHW75S':7RBYF6B&:9%B=QV!*%S$T:/O8>_H^2:! M@*7]\9.1!T:"*M@68%'M!3D*^&VHF,Y(_TP\]VQ7]W)_#QL@/ORA=-\7F\U'L
MIR"]\+$V&>L,&DC$UIM.E8D4%]_6"D76WG[:6.N;O%HJ]%MFK,U78XIAEU7^$ MJL\NSKN,:M:;*MDO%RA?"A5KS2F>MP5M$5M[T,WL!1PX2;+9_NC 6SS=Q)<0 MXE*);,G_F/"_)H?
2BQH6@\^6SX"2YW3*HA:.5!]3Y(L=GSI10CIA=^?HF8_MZ7=^&,4EP[HZ#Z+9I*^U&($5/M:Q$K%(C+F-4CCE=)GV"%(6:UW-$A('C=JA MO0(E$1M:*6#RA=AF?NUFDK;-
B39L^AB@S?.$R.4Z:5, 2[U$1*%UY8GY*\/ M/N<+VSR18B-B1@QJ,S#_][;TPU=.#2OV.UR),=,WYQNNU?#WZ$/T$'G16>JI
MC8790$1&"BR%I@V%#;@;5D()9B^H.:8\3OP2/S@*]#/*C,Q]X ;[\V$5;HU MDP1RT%)-FKHMQSN9IX9TH_>ADR8#=>-GIT@?7Z]=VBC%YR4W5O*/%P^$Q53 MHHPMJT$6P'L;-
))2E1;NQB@U$M!]-N)74! F*SE113P\]D!D'Q,M3->"UF MS,B+(,%%Z E0XFW*0WV)$TP0A("^$_R(@V@'!V#6)BQ+B+YPX]P-E.A5EBV" M:">F8IFBL]HR3R3G2]G45COAW-
!D>U#,Y)-Z:#IDM85[3:NA?X2:;*>.'RL] MZV.JN RDHM6,0,^E0V@=.P2@U<-KYQ1?-A4G]!^U5PN#T0+' Q7XK!WPFBCI M?ICX+L7C4)G@?:L6ZB,NU+=-F:DF,&=?5J MD!GU\FRV-
PFFU[K4OE\/N:/S#]+M 9G)]$C;1DPE7D(C?SLA#+)%2W.7*>PV ME495@+],1[>7'D]UG)SSQ\[.3YV@>_E_IA*6(H,HIM3-4LG*,>VF:1/ A$' MNQ*0*XPZ?C
M.G::INDT]XS\EBIU+!]+3IJ>.=.A2$A"0A$*0]X5F_M_^R?_W=P\(_?_NOP\. M\I!O!<@Y&*\.SLA\,;3QP']R-S@Y.GI^\IC+_RC]\<['T96Q0=,+X]^N99AM+#V'=_M)/[TZ.3Y\Q='Z0>?
Q9_\]8'_(O?Y^Q?1IX]?OWY]%%/UU_5&*BS]](ACT^^O/]_MU=">H;EUB#T:K;|"]5#|*XU^>45L*X*D643Q?NRAZ'/%NXH<]&.?GI
M^"0>XK_Y;_[V_SXC'B4N=KCL3R7V73V4X0RAX=L"'OKOMYR;!OX0/QY@$R)YQ M#(_XIXZ$@QQ%C.KE].\;RT=>.$,!MBV7@C"^/::N>?39(INC8%U.&-
RF!'78::AXFN(@]6(#7)"_!=2K)8,T+-M$GH!L_W;,XV1G(KIWPDV/4RG^. MJS6U/(=AQ"FQW4F6X[)QH.1[12QOXI,YLQP7_5,I]K:^"BG!W>77;+FQ';N6W'Y$8\]Q.0S'%'T-
F>Y<++D"R<2.F0<'-(*YS%%A8 M\BRQ]=4]N4]G-88#I+[O&>CPG#Q"%IW)A4VQ:.'2*V?0DE-@5C2*\B3HHR M6E'@@B+
[QRE9'CD('W'.^0_1%"+V::)$_BZ7.]^,&'2('7+M9(K*OR6/LP1C M%I:FJA,6X2GOBW&T51Z-:>!;=E B MT(E%QU&<*ADOEBIR YK^9B->*9*QUR]G1ZE**!GH<]#-IKX+Z:Q9CB+?,_/
M,V_Y=LH,^W%'&?)1O^031XLH_G1HS[#KI-_F%E -Q(!42HOXS&J]>?:Q8AJ=0$P@G@2Q$S.(V8BM?AY:N&23.@MIP(Y)/@4' M34!F8QO:#9Q(2@EV+QH;2#43>>.CA86=Y,S.#/]
'7A\G0:S#L7L?-H,:RWI M)0C_!(!PP]'"<*R!BUH,V.%$5" M@W)?%-',;]$;!K4Z,1DR+=@/Q:HL]F6R@C)\9IA@#SFGR&,_!#>NY<63NB0^ M_T?R>ZH-6'GZG4<0;1@BUG--R(+Y >
MMC9;7$S#2*2@)GK%$&#(\CD!XNY]]W,Z@)00*X%32 "@M\'3X$]/1'I:*063Z*VR-L.U3]=,\-E$C.:.6"<^2$CMS,= M>"0%= R;7VD@1>"(#,$/'!53#E2X%P@UBE,JP0'=?
Z7!3;1M0]67"17O# % M"7"B]YJ.RM1#1CASTY[,EAV/#]M[V?ERE#]\|^4E!G:JA_%*M7NC'5E^91(R M>^N8X4C[U6,YK4]/>/U:(KP&V(%D=A 9Q=0R?6GJQLMZ/M47?ZM,U>8BLI?]Y
M2XWZX@0[@8!ZKOHBY)7T6F2G52X]RD VDB$9;?M7Q)N.D#_1^- [^V'@%)K M_":)]Q"1T$P=2DIGLX\=N%M&6""F!N<8B%N23%U;Z=3 "B$993,+D=5'ZI4
M=@FN/QLYT.SM9[7\+J5SB-:X.GDE#^@2^6.2,[2]*Y5X$8=:BGNVAS>+7Y7^> M_J#O&1,5F;U"'?2,Z9Q%;ZWIFUP 'O80,;%!0)>VNRB$GE!5*;?A>5[S*33GFV'\S#]!L!S
&T,GPU;2=!PE$$&U3KB W1:839([1MCQY9F MD83@?%45S-YCC_B,C[['5 !1Z#6X,WQW-L!=R9C,"=CEO>_9:NA$G9+\2(A! MX.-Q@$07X+P3CLU\9T:=C3;5A"X04\83A)HM834@
!/YM&2-[3E;K*.GU6HI M)CC_TAAGWMCC:+NSA]Z&'SL=3;-(//7_*#E,,L$-_(B6$YV>;I ?->71=[X4 M4C1N7=7C0)7"!+Q8:8IXQ!'MA<&,>0W?D*,/Z1U*W32=I;(S6N*UPUF?TE_
MH@D5\R<:(#Q3]<&=2D' '(0![Y3.'3;=B&9)/1I8<_*#2QC;DWNST^AT[MK,D4B^D8/G9)P%8B*R/%W+=,6&RBO)'@.5OF+HE:!:3,Y0$4I.=7#&$8FTKE MY.A424%A[&2[*
(&U/6+WL=N1D>'>BF)6P;W!,EI&[V)K MP5I39@H[7WYECD "_$D;>,9DSYEC#_/Y!'B)]&:!;1CB5/%ELM)I<&_;N#E#9.FWN$I4";YA5 6Q#KFD%5(# M]Z11"_+$=[I@I0\0C*:?
@@1XQ);-!?PDL2\6ED- K,*8]2&9YR2D9,(YB.MU9 MDB6R4D,BW;WB5NG'-\&!AFTP,W!W4,I* S+S0'YIH6"S!1M(39*GWQ471T&R MB2:|-G' S+&K$^0N!;&WA)(& %1N&AI]J&E"
<9I5H2E2*B33E74GEE,*GYEL MA6V^3BV*;9B*B8-I9-\%M+RF3@ M]"/BG6^1TULRIWB*KL/YF!U9)SLY$CJ6HQSM[GBODC)-X3>4623@-M%.W)[A;ZLWF3\EN3;E^FK((,W%9#I
MS$9!B;H6_,IIM6/-U86R0FY&[R:V"]2U@"D@TK$5*1*5Z:93<;F?%N!R0W<,_MKKQ83/?(+0[R:P&ME%1K?,^Z,)8+SF1Q_]8,SLFVDGHUX.=.(#&-A(*GOP"^9@XC%L_>"]QW"/R
MM0HJ%5X(CR534-^EP?HX&CROOT^@PYW HCCT;BU6$&Y!CHSI*7%"S8 MB0!0$V*M-:D*I1RTP@=0481RN8)66C]EV:EB5Y!@9^9Y#1@'XN_GK?7A6JX(M!DW?],S,04&VK*+
MEJ"^E0DK+6*C#SI^!YZ0NMI7>$]F4BU[SN>0QF*C,@M8ONPC5V42\(>$;.K M70N+[=A-:UH"/2"93!$]1XRBC7B2 +2 MN#V!@VZ\='"POPAAXB;I+
(V9;]'*0KTJU(M)HRZ%.8TJAY @*U!H&U3\C]P MWNQ12L_TG9QY(]26O,D,DUWV8L7-\]B;WL1/@V?ZVFM7F?]R-!^/OPG660@&O! K=E<;U.KT@VSML^%*>4N,E;*;,;60D> M"LU?
#OX7$PFR X&DXL'>V9Y4W3+1AQX7 S\/WXOM[1<+K-;QKF/[>2R@UG/ M_"\RGUQ?XYUCNB#4IIVL\<3+V87 +2'Z?9K9([E"->^ "%>S8R\'PG!O")H<"[,4'K):Q M-
F&S9D1]U>3+'^O+V=2K!-N\7A*?<6DCY-!+)I+AC/C!"/GS>.K11S0I11W* MIKT36+VH)6O =WI G8Z".1O;.1Z%M9"1,]0;02V)'+4_%&3<\L@Z)5I0,EW!
MWXC]N%9H]]R71)ZR@HJ%!YV^OU_F.^9$[QM:J*,[U]SX"N2FF^IWX?V0);>AHN%&TW:-D#XNGNO/;UV,'"]U=L)XQ*YC48@M31)BIOT0"97?7NYE(C2=1I\W-6>A[\.'
MZXII&%VLBF@*I&7X_LLQ\WH1O/N<2>Y=FY M,[/;7)#;6]'-*8G4Z5P347/E12B6IS0L;U('K<-OE'=&M H[ZEE_@!.7&V) M%"7X!Q#AUL5.#"Y%T MMNU.A]H&*
[1O>5=_P>3.XHBS@:CN$5JWTO#'I=D MD[]ZQ0,C>+S"GJK:<")45.C0Y4:P0+9CUA7'XSDO=]G.8"R3S"H/?Q]3RT/ M?XN8VG3:2/)R,@P/)@DREKO>*2=86%X4GZWN GUC:Z.GC-
*7-@FGB#W3 M[]1#*F#N:5YP'.$V'IV/M^"IAR?8YAD/<25.U.C)Q7;FQKC >"@VK-@AH:OM MA)B0:OO(,D'I6KTUB9J^_;R&-1>BJRG)3]P?WC4+Q\D@EN>
<1Y/ZM#1M=@DB1L]7*GHPG:S-QE! |=3=:W&*V)Y7%+! M#%WT3\&WKW,T#K2O-0$1Y=N&*^)->>=H:'U?7TBFF87*%E$.570H"^4 V]8]O? MRWME*J_^@H.NIY-
&#Z1A[S>2D?[^H3]?H@\(UW]RK+3_86)]N93'B*4#K M4UI<6I(1^8-:&U'I>3PZ3Q:/6Z=H"W*4$U-WN?(#1_]*1M]#<$**MNG(0RVX
MQ*[,;KUNC:TEX$9)3WH*T!M>TY0CK&KXO+ M@#R=;L$NW79?1]$NU6 M%+2N).':@]K@?4?18')! \QT$;R";&MPLUW0I,#;%@M@9I,*2I<6]J/$Q\SE M5-]C[(=1A"^_-
P&!5X^FX78#4]#6E")89S:M>=]9E(^|=B/-LKPI]<22Y/Q MEDV6ER[84TG[#1..+CG8@6VC/DA"Y;Y,6-N*-HV& 1-91)DHI691YK M\R-=M>$Q->\]T]:8P:-Z:- MLHS**,K;9.G
AOF+^<(E*X2&R%]B6_89L^-AHM2BWA+I*F'OR$GKID](U1C M+$D;GT8]>1DM @<(LG'0G]]'-/D$C^.69*,R$8EKYAJFR<$QN836GNR^%!-& M5Z/\K8FJ]#L1.DXG1V)?
*/%ZWO]6QW:V@#^FB1*3-,H^:] PA6S+ \M3C9[P M3 UA\;H41&45AI5?@;N'E_HR/$>!A5TZVGTA0C0C*&+* 3?!%N3]O":!GT1/ M5YN/))VJ>MP#NMI^VU/K6TU2#)DXGJBK/+=%
<$]G[HBZJN6.U_^'N& S[WO M.>PXY826VWO M32#?3FC%>Q?&XT0CVOJ0 %M&SCT)=(S@.7N*DR7V&!9B;U M'LW'R-=F >K0-G3O5]GTQ4^PU9(FE&M-%4QA7SW)?W6+>-
$)BNWNO)#BI/Y1>[]LF>V?/K" M)D"%BFT;-L]-B_L46SKZ+;FC\]'+O[%4]24=@<4UK;>PJ@;<(U>+P,F'] M]E^AP"_OC^P\_^?>?]B\)^.2]?.U\>[6O?MU8LO]H^!V5?^#\KO+D^$?
1\N'T[-/SY?.T>?>"AW<] M]^N[O_XZL=Z^*_?2(W3YU_FG?]X]D&_]S_3FPQ_O3Q='8>_(?_N-GGUZ.%N$ M=W1VXKVFZ//#Z0?]Y'RUO'CWWNF_/3LB-]^NWP^O7_U-.>KW]1Q_)?
GGZ\ M>_>OT'Y,??AF^_OG+Y>OE^&CX\O7=-MU^7U<_8?=^?OGGSGX.SX>WA MX9-K5G?.E]"=K%;1X;?$AH\U6HO*8\:3(]I W[8 -T<&XF5M:,MN:APT85=_S
M#$R?;NE3_'VK@GH3;Y@.H]H\VC.;(*#RN/49W]EW JG\LE\#0_6>NZU4S0Z%YNMR_12.;X2Y^DO4D&?^"!GZ2>?BP/PFZ,[6) M&3O>>)V/?
]@#V9+9AY<^[52W6\6U&GU19$M@F#W8;U]AKDA0TQ1Y6DIZ]6E7-M Y>&#WP1KI:H*$4WU%* K@%%-W=I+H]RU;/] RX)]13!=]O M*X2&,[PKGE]-9UE/,HLT3X]';_>.9]]T
"T;]]FV-)UJ]9^K1SV%M!^3.Z - MGU3A%.[EVG$\2&:5U*].4?E4_Q7;<_%KLWVTZUS \A3[3;Z;]Z>V78S;MQP M,H_'LVB)0-RGO>G4 M1U-VOFYU>KKZ/)[V%4"=2)
<#R*WE7KJ=I'W=;I%K126OZ]Y>P[MU5X;RCB=]M#4^V"(\VA&F8&E9L>B(UM%*G3%*8H*U/I\GNN\IG9Z&:MI=7+6E^H]+^ M50U0Y-4/I"&4PL4V5X#]G9B+VU0Y%X5V-
TL2-J_ARKVR9->U!3$M=IHR(O(MI%>3+)>,]HMA44,F10RKQNL,?)6"@6UN^@B,53N:HX!=VJO.(!9GIEU]U#QQ M-+.\XC2%MCA*TGP_WG2J_<
.VVNE73H>F0G:]^+>O)U1\2VVG^ZC&D.WC>L M+;]]2?P)BI^*ZIAZ]W+^F/(&C""OX*2\CK7U2]2U?K#TUO2L.^)-VJZ,.V8BDG=>9]3ID/F6$[3\C#"+= M<2]7D^F;%.Q
4_TK2=5+R2V2(]+|,K+6D&UYT&CW4K)]CQEMGG%XNLILQ56F MS*+1^MH3W)VFBF+%;^_,F? CU*X29NM>;DIH3!DEPR=XG08I]SNEP@;0 $ % M."
<|>VX_*I#0,NHFU5@'-9!,J9:)BJLNS%LF L;^C-^UHB5RR8(32]R6EH04I6V:K4XR:O)&B0RXH)E%DAE%]\00\?<4A$*7Y'5 M]!!Q-
;T&!=V7Q$=XZIV%#%_/7HV8=E$V),/C+3O,7!%*3]&$?69D/0!/2X:R MZ;58&_+L4L,2+=QZ4PT%L7$0#>+9G:,%H3B@'W$PRZPJ&N @C$+XX+$!.>IF M=W@E;9
6L.'LHU1'!]Z6'[^;]OR.G"F;B(^7T;D*6B<4&#!\3E72"Q4Y@^45 MJRA&^4O]P$I00:R+@%?)3]TE#[@3U SIDV3TW0>#Y*0[!)]4O9.4AM)_"GEH>_1=R=,9^%N-B) M(?
6\U7EAWAH>'"OX" J4-\R>+,VOHBD>RJV+R8&2WW\84D#&_28K44(R6X M=[>3>]R*4=HMB!_++_JG$OG##=*P0M*K H/"SR4(&TZ8T*.#,E)O$' %N7KC
MC/+_N,E96FYT@O2[%5I.!VQ?611Q$XU?A@].1%QOA<5*-;]&(\64I)7?]-V MY\RAZV:)R8'-/IH>+<_AH2.FX\BSF4.EZ[8I0[*W31)3VR4T]'6EX,G1;A+/ M84-
@7A+-71-.*N^A@$=S*LB9=?N4$-\J :H0IXG&E6PKL+DDI\PB_"NT7#S! M*"]%]YAQ"'<>&K(2!#R7&W9&6YP8IOZT.F0O60VOF2R8XG MR]#L3MU(%E]&C1MKQ6/Z R_NVW-+;
(27R)"%1#2,44<5 B:A?$P%/-;3"-;^ M5-]C-IHW 1F1F/-=.)@ P+IC=1/%VI(R%9EX;_E?4!1(\YS3D#+OEM),E:TH M]"D L_YHG32=$L(R$D8Z],M8\H+$=ULP!+&M/CI'?
4@2T4"=H:7;_G#2%E. M40!'U-_$^X6.XU"?--3!6/%P%F^M;T,K*F5%-#NK.0D]\,OV:H+=W-YD)]I@ M#O!:EU+$C)E]X]^OC:YXO(9?#PPF:;H:*"LFF"W,:\CT01SA2>IFF#.N<>
M^8SF=4!6)G[BD*4'EX]2"(-M&$AJRVO)/_>%COH<^4FG@@=XQ$.MR"]G*1.VH /! B(=!;!*="FDS0,@JFN) M'R>6$BB%5@"F+FZ)-X'F@?* MX
N2LB.;B")6+Y#LUI63@[$]I(0++>5'^;%-KY<"O2N 0UAJ!-G6F;=PXKUB M[!D:>'];?T.Y\WAGA-C*]Q>SK#)\3:WP+1#&W# M49+FD&?E..IVFW?"O.6]^8#ZN&[&:]^[LC5GB$)(]9'77T-
UA-Z"1WYW%"DG M[8]N]4K/FK_"DE!F>-?CR#'6F%XMN:L1F'(&(DKB*$WUNO%:*/[C]CLWMS M_MRNX;#90;"4/9$>[>19)1QU+=55WTV)VKJTYTG:(%9(O>MD]UE(Q8ED1-=D?
MUADP,LW*M[YCV*\L%]_.! WE%/<\+^2]/^/J#PEI%WZQU2(OGBK<3B =L;YD MS.OU>=GJEME+LF%\P1ZGC4]6WL.J=9B\+]4N.]],JIC%=6H7?N;1I7YRJD
ML>RV@FC06DHB@;/XFR93H&N (Y@NX.8]77/_^NGMDS,G-'.$T)9WB0STBN&;)635 A1E0P @YQRMNPASU--.[;]K3;Y M3 (KMC-1]%*;Y]?@+%]1UU%'M#R

S\6EA%N/J8HP81^@EG\?*6X-L#ZJQF\# M!#W/N2:>'?\#&/%:)%ON@\B)STPY3_%TF!N+M-22",FTW5FIEA-@NXSZ/DJ(MSNMN?
^EG6V\@UY."JKF!W>HN)A/$2R6%SJ#&W:Z(=ON]2$69@I7?]+U DC9> M&]Q[R#FU7'ZA>/K"FA?FMP63,HE$#]7/J*(1H\&N%:E XF49OD M'-V$ZK152,/D>:-86Z+B] JL8-
+H&SX&PYOU)/+4D.8@IF(.ZJW?HK[_^^(M"@!)? V?/#;_,$D\W2HENR'&@1,TK93H,TY/&M(KUD"?]3_JC?U4?3$76].!O42VQ3,VT1N?
9Y*M7UH:LB.+Y6,"E'%;/*ZIM*WZEJQ$)B!/DTCC MD[!PY_&&55'WOOIFJPHCX=AF?/9*?5P#)!9*HY>+LF/S%V1MJSB)J)&TMP8V MLAE(2WI;&H;RNSA+(QQPV]KW'+S$3LC.X#
6JWC<;E@L@4Q 9,G]LBBNG!)[7 M[K?.;1>5$BV8HJGTF4V<*7U^?!-MNL54QY&RE%3[35L]B<%D(39#,DT#&K%O
M:4JJ+R%ENLZTCD87XUDDMRT73NG4SP]>@P47@9Z2T)WQ34>YY0 HD(\ACVZ= M7A"5H+(/:K'"'^;&[8_;V9**>/]/4S@FJAGV?UZ=%;8=.5YO/)*V((NXW4_"< M&]?
RM!4=;6'1:*"N<$74J.5NB$J3.J>4L\U;$9&AN?-P0&^'=UL,<3FM=B-8 M(2?8F&"K39W@.DP]G4RM"#ZW/_8I#9&3?7(JFA>-_CAY^M!W952#=F>PEY.HZ5-Y MJJHKY/:7_2-
2TUA]^_O!OYJTV8J5"N#7D*:AJM4"9F_8=LSS]R)F]<&<)],Y M2+>D9*B YLZSYL0/\+>\ QP];D5KOI92-8;1-U*JD*D4 -R+-EI.C:+C21R8 MH+R5%?+8$85/B#O)()_=?&
?!M3[DGVIE,?3:T]3WF1[,]QOY@N2'XNC4V MCU9KGWGQ@%44F=#N^"&QOA=[Q!\1GLZX&);2YJBZ(^\?N#2PGX;=5J6^^]" MDZ4AA:]64DK<36J%ALA?LMV\>.
[7)J_1W'B(Y(8+G9OY\1&ER3X!,*F%=/ MIA[?BJ!S@+7QV0VW2R-.<$] J0=9<IH& MO#2"S.OESV\^W>[5EID55,66SM*.<$S1UY"-<,$?>ZCS3+AJXGN6C*8]#R$9 MZ7]/8K%
(5'N4#="P@B S[HX&ZA'D5>X%!:-)T65:%.5$ER)GK&?_]UOY46,E MI;_N R"B^U3ZT;[2CY32392[@FY.]A"$]!E%(IP6%6B5Z6P$>2*V)8'P]Z8]%-$S&Y-0! M,-]N?FC/D!-R>QT?
O]^C8$:<3:.(W=\BQ+=0J,JZ)N3-['=U#69SZ1KHKLZ9 M%C$%5N)20ZTV&EK!Q@]JV0*JB29M]F+ $@<;+H "BMH,D$ M8PI]:=8(;M::U_&"5 M"6K1TU7V+QJV(0G"
[?;3520)4+W4%&PM>U,! =,K4U[!1: V+S'_@WPA<^*0 MJ\"1V)5VOV5V0U*3;.'Q->>$'4]\(4]VM)/R@D:OQ,JNYJN7C=I-$;(0FVZ(:E%'P) M21]J]3DC\SGQLB5D"[E7C$H'Z,)"+9> F4]?
+$^#,*"!Y3G,+6@ 3?$H7<-' M(NX!W!D0'KK$TK3+;X6(/EO=$'X6W,T\PI-OM!5A;\^LQ'VIA8+@J^:SQ*I-$,T9K$9 Q4&+CH17V!KSUT3Q=D5N8S]L9_BN MN%N[<@%
[)4;QW&RM> QGX_JE6@1]9!;2Z=)I62PLR%=@)._F.^!5KRLT-IM M4"&^^MOZ5OOM7,%, =]CD=IE' =S!BPWVO@D]IBB+W9 _XLGG$I_KQ&
R&U4A!@1H,C^<4J61P[",0V'V%&+T:,SLMS#$P+31?<&QU#,R+3%?<&QU&UL4$L! A0#% @ %H!+6I[YBYDF M8 1] $!4 (!U"P! '!L=7(M,C R-#$R,S%?;&%B+GAM M;%!+ 0(4 Q0
(!: 2UK_'[J2U"8 .!E @ 5 " 2V- M 0!P;'5R+3(P,C0Q,C,Q7W!R92YX;6Q02P4& L "P#] @ -+0! end XML 50 ea0229816-10q_pluri_htm.xml IDEA: XBRL DOCUMENT 0001158780 2024-07-012024-12-31 0001158780 2025-02-10 0001158780 2024-12-31 0001158780 2024-06-30 0001158780 2023-07-012023-12-31 0001158780 2024-10-012024-12-31 0001158780 2023-10-012023-12-31 0001158780 us-gaap:CommonStockMember 2023-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001158780 us-gaap:RetainedEarningsMember 2023-06-30 0001158780 us-gaap:ParentMember 2023-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2023-06-30 0001158780 2023-06-30 0001158780 us-gaap:CommonStockMember 2023-07-012023-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-12-31 0001158780 us-gaap:RetainedEarningsMember 2023-07-012023-12-31 0001158780 us-gaap:ParentMember 2023-07-012023-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2023-07-012023-12-31 0001158780 us-gaap:CommonStockMember 2023-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001158780 us-gaap:RetainedEarningsMember 2023-12-31 0001158780 us-gaap:ParentMember 2023-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2023-12-31 0001158780 2023-12-31 0001158780 us-gaap:CommonStockMember 2023-09-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001158780 us-gaap:RetainedEarningsMember 2023-09-30 0001158780 us-gaap:ParentMember 2023-09-30 0001158780 us-gaap:NoncontrollingInterestMember 2023-09-30 0001158780 2023-09-30 0001158780 us-gaap:CommonStockMember 2023-10-012023-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-10-012023-12-31 0001158780 us-gaap:RetainedEarningsMember 2023-10-012023-12-31 0001158780 us-gaap:ParentMember 2023-10-012023-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2023-10-012023-12-31 0001158780 us-gaap:CommonStockMember 2024-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001158780 us-gaap:RetainedEarningsMember 2024-06-30 0001158780 us-gaap:ParentMember 2024-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2024-06-30 0001158780 us-gaap:CommonStockMember 2024-07-012024-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-12-31 0001158780 us-gaap:RetainedEarningsMember 2024-07-012024-12-31 0001158780 us-gaap:ParentMember 2024-07-012024-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2024-07-012024-12-31 0001158780 us-gaap:CommonStockMember 2024-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001158780 us-gaap:RetainedEarningsMember 2024-12-31 0001158780 us-gaap:ParentMember 2024-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2024-12-31 0001158780 us-gaap:CommonStockMember 2024-09-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001158780 us-gaap:RetainedEarningsMember 2024-09-30 0001158780 us-gaap:ParentMember 2024-09-30 0001158780 us-gaap:NoncontrollingInterestMember 2024-09-30 0001158780 2024-09-30 0001158780 us-gaap:CommonStockMember 2024-10-012024-12-31 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-10-012024-12-31 0001158780 us-gaap:RetainedEarningsMember 2024-10-012024-12-31 0001158780 us-gaap:ParentMember 2024-10-012024-12-31 0001158780 us-gaap:NoncontrollingInterestMember 2024-10-012024-12-31 0001158780 plur:FinanceContractWithEIBMember 2020-04-30 0001158780 plur:FinanceContractWithEIBMember 2020-04-302020-04-30 0001158780 plur:FinanceContractWithEIBMember 2024-10-012024-12-31 0001158780 2017-04-302017-04-30 0001158780 2022-08-04 0001158780 2017-09-302017-09-30 0001158780 2017-09-30 0001158780 2024-10-31 0001158780 2024-10-312024-10-31 0001158780 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-04-30 0001158780 2020-04-302020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-07-012024-12-31 0001158780 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-07-012024-12-31 0001158780 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-07-012024-12-31 0001158780 srt:MinimumMemberplur:RoyaltiesMember 2024-12-31 0001158780 srt:MaximumMemberplur:RoyaltiesMember 2024-12-31 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-06-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-06-302021-06-30 0001158780 plur:AnnualInterestMember 2021-06-30 0001158780 plur:LoanFromEIBMember 2024-07-012024-12-31 0001158780 2024-03-012024-03-31 0001158780 2023-02-132023-02-13 0001158780 plur:SalesAgreementMember 2024-07-012024-12-31 0001158780 srt:ScenarioForecastMember 2027-03-312027-03-31 0001158780 us-gaap:StockOptionMember 2024-12-31 0001158780 srt:ScenarioForecastMemberus-gaap:RestrictedStockUnitsRSUMember 2027-09-30 0001158780 plur:NonEmployeeMember 2024-07-012024-12-31 0001158780 2024-11-25 0001158780 2024-11-252024-11-25 0001158780 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-06-30 0001158780 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-07-012024-12-31 0001158780 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-12-31 0001158780 plur:CEOAndDirectorsMember 2024-06-30 0001158780 plur:CEOAndDirectorsMember 2024-07-012024-12-31 0001158780 plur:CEOAndDirectorsMember 2024-12-31 0001158780 plur:UnvestedRSUsGrantedToEmployeesAndDirectorsMember 2024-06-30 0001158780 plur:UnvestedRSUsGrantedToEmployeesAndDirectorsMember 2024-07-012024-12-31 0001158780 plur:UnvestedRSUsGrantedToEmployeesAndDirectorsMember 2024-12-31 0001158780 plur:UnvestedRSUsAndRSGrantedToNonEmployeeMember 2024-06-30 0001158780 plur:UnvestedRSUsAndRSGrantedToNonEmployeeMember 2024-07-012024-12-31 0001158780 plur:UnvestedRSUsAndRSGrantedToNonEmployeeMember 2024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMemberus-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMemberus-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMemberus-gaap:ResearchAndDevelopmentExpenseMember 2024-10-012024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMemberus-gaap:ResearchAndDevelopmentExpenseMember 2023-10-012023-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-012024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012023-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-10-012024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-10-012023-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember 2024-07-012024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember 2023-07-012023-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember 2024-10-012024-12-31 0001158780 plur:RSUsGrantedToEmployeesAndDirectorsMember 2023-10-012023-12-31 0001158780 us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember 2025-01-232025-01-23 0001158780 plur:PrefundedWarrantMemberus-gaap:SubsequentEventMember 2025-01-232025-01-23 0001158780 us-gaap:WarrantMemberus-gaap:SubsequentEventMember 2025-01-232025-01-23 0001158780 us-gaap:SubsequentEventMember 2025-01-23 0001158780 plur:PrefundedWarrantMemberus-gaap:SubsequentEventMember 2025-01-23 0001158780 us-gaap:WarrantMemberus-gaap:SubsequentEventMember 2025-01-23 0001158780 plur:OwnershipMemberus-gaap:SubsequentEventMember 2025-01-23 0001158780 us-gaap:SubsequentEventMember 2025-02-052025-02-05 0001158780 plur:KokomodoLtdMemberus-gaap:SubsequentEventMember 2025-01-232025-01-23 0001158780 plur:KokomodoLtdMember 2024-12-31 0001158780 plur:KokomodoLtdMember 2024-07-012024-12-31 0001158780 us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember 2025-02-032025-02-03 0001158780 us-gaap:WarrantMemberus-gaap:SubsequentEventMember 2025-02-032025-02-03 0001158780 us-gaap:SubsequentEventMember 2025-02-03 0001158780 us-gaap:WarrantMemberus-gaap:SubsequentEventMember 2025-02-03 0001158780 us-gaap:SubsequentEventMember 2025-02-032025-02-03 shares iso4217:USD iso4217:USD shares iso4217:EUR pure iso4217:ILS10-Qtrue2024-12-31false001-31392PLURI INC.NV98-0351734MATAM Advanced Technology ParkBuilding No. 5HaifaIL3508409Common Shares, par value $0.00001PLURNASDAQYesYesNon-accelerated
Filertruefalsefalse6997140722900067830001408400023202000261000254000140000340006560008340002237000031107000800000634000527000470000911000688000623
429310000-420472000-802800096000511100005319000-
29170005415000308610003952700051100015900018500010500020000074000311000159000111000105000656200067040003170000333800074800074700024500037400058
10155000-10590000-4957000-52130001437000928000205800043500042800043000021100021600010090004980001847000219000-9146000-10092000-3110000-4994000-
308000-226000-154000-89000-8838000-9866000-2956000-4905000-1.61-1.61-1.92-1.92-0.53-0.53-0.96-
0.96550591555059155178555517855555293155529315190853519085351556874129390000-39958400013355000194500015300000543169100009100004990001409000-
9866000-9866000-226000-100920005210003413849000-4094500004399000221800066170005181066413446000-
404545000890100021370001103800028937403000403000170000573000-4905000-4905000-89000-49940005210003413849000-
4094500004399000221800066170005408212420568000-4204720009600053190005415000157237714000714000100000814000-8838000-8838000-308000-
91460005565449421282000-429310000-80280005111000-29170005507304421071000-426354000-52830005220000-630005814521100021100045000256000-2956000-
2956000-154000-31100005565449421282000-429310000-80280005111000-2917000-9146000-100920001330001310008140001409000106000-94000-231000393000164000-
713000-251000-410000-2350002500071000-3000-441000-373000-229000869000-25000-6000-8692000-9506000320000224000-9550000-
99450009230000972100081000150006190002300007671000625600082900006486000722900054680002610003730008000006450008290000648600041000800003200078000
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"> NOTE 1: - GENERAL</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pluri Inc. (formally known as Pluristem Therapeutics Inc.), a Nevada corporation, was incorporated on May 11, 2001. Pluri Inc.’s common shares trade on the Nasdaq Capital Market and Tel-Aviv Stock Exchange under the symbol “PLUR”. Pluri Inc. has a wholly owned subsidiary, Pluri-Biotech Ltd. (formerly known as Pluristem Ltd.), or the Subsidiary, which is incorporated under the laws of the State of Israel. In January 2020, the Subsidiary established a wholly owned German Subsidiary, Pluristem GmbH, or the German Subsidiary which is incorporated under the laws of Germany. In January 2022, the Subsidiary established a new subsidiary, Ever After Foods Ltd., or Ever After Foods (formerly known as Plurinuva Ltd.). Ever After Foods is incorporated under the laws of Israel, which followed the execution of the collaboration agreement with Tnuva Food Industries – Agricultural Co-Operative in Israel Ltd., through its fully owned subsidiary, Tnuva Food-Tech Incubator (2019), Limited Partnership, or Tnuva. In March 2024, the Subsidiary established a new wholly owned subsidiary, Coffeesai Ltd., or Coffeesai which is incorporated under the laws of Israel, to develop cultivated coffee. Pluri Inc., the Subsidiary, the German Subsidiary, Ever After Foods and Coffeesai are referred to as the “Company” or “Pluri.” The Subsidiary, the German Subsidiary, Coffeesai and Ever After Foods are referred to as the “Subsidiaries.”</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company is a bio-technology company with an advanced cell-based technology platform, which operates in one operating segment. The Company has developed a unique three-dimensional technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice cell manufacturing facility. Pluri currently uses its technology in the field of regenerative medicine, food technology and agricultural technology and launched a Contract Development and Manufacturing Organization, or CDMO, business and plans to utilize its technology in industries and verticals that have a need for a mass scale and cost-effective cell expansion platform. Pluri is focused on the research, development and manufacturing of cell-based products and the business development of cell therapeutics and cell-based

technologies providing potential solutions for various industries.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">c.</td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has incurred an accumulated deficit of approximately $429,310 and incurred recurring operating losses and negative cash flows from operating activities since inception. As of December 31, 2024, the Company’s total shareholders’ deficit amounted to $8,028. During the six-month period ended December 31, 2024, the Company incurred losses of $9,146 and its negative cash flow from operating activities was $8,692.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the Company’s cash balances (cash and cash equivalents, short-term bank deposits, restricted cash and restricted bank deposits) totaled $22,374.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company plans to continue to finance its operations from its current resources, by entering into licensing or other commercial, partnerships and collaboration agreements, by providing CDMO services to clients, from grants and contracts to support its research and development activities and from sales of its equity securities (see note 7).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s management believes that its current resources together with its existing operating plan are sufficient for the Company to meet its obligations as they come due at least for a period of twelve months from the date of the issuance of these interim unaudited condensed consolidated financial statements. During 2024, the Company also implemented a cost reduction and efficiency plan. There is no assurance, however, that the Company will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of its products. In the case the Company is unable to obtain the required level of financing, operations may need to be scaled down or discontinued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2020, the German Subsidiary entered into a finance contract, or the Finance Contract, with the EIB, pursuant to which the German Subsidiary obtained a loan in an amount of €20 million, or the Loan. The amount received is due on June 1, 2026 and bears an annual interest of 4% to be paid with the principal of the Loan. The Company is currently in discussions with the EIB regarding a potential restructuring of the terms of the loan, however there is no certainty that such restructuring will be achieved. As of December 31, 2024, the linked principal and interest accrued balance was of $23,798 and is presented among long-term liabilities (see note 4).</p></td></tr> </table>-429310000-8028000-9146000-869200022374000200000000.0423798000<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><i> </i></p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><i>a.</i></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Unaudited Interim Financial Information</i></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair statement have been included (consisting only of normal recurring adjustments). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024. The year-end balance sheet data was derived from the audited consolidated financial statements as of June 30, 2024, but not all disclosures required by GAAP are included.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Operating results for the six-month period ended December 31, 2024, are not necessarily indicative of the results that may be expected for the year ending June 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i> </i></p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><i>b.</i></td> <td style="font: 10pt Times New Roman, Times, Serif"><i>Significant Accounting Policies</i></td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The significant accounting policies followed in the preparation of these interim unaudited condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><i>c.</i></td> <td style="font: 10pt Times New Roman, Times, Serif"><i>Use of estimates</i></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -1.35pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments and assumptions that are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><i>d.</i></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Fair value of financial instruments</i></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, restricted cash, short-term bank deposits and restricted bank deposits and other current assets, trade payable and other accounts payable and accrued expenses, approximate their fair value because of their generally short-term maturities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -1.35pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company measures its derivative instruments at fair value under Accounting Standards Codification, or ASC 820, “Fair Value Measurements and Disclosures”, or ASC 820. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -1.35pt"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">Level </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">Level </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">2 - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">Level</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> 3 - Unobservable inputs for the asset or liability.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -1.35pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; ">The Company measures its liability pursuant to the Finance Contract based on the aggregate outstanding amount of the combined principal and accrued interest thereunder. As of December 31, 2024, the Company does not reflect its liability for future royalty payments pursuant to the Finance Contract with the EIB since the royalty payments are to be paid as a percentage of the Company’s future consolidated revenues, pro-rated to the amount disbursed, beginning in fiscal year 2024 and until fiscal year 2030 (see note 4).</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><i>e.</i></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Recently issued accounting pronouncements, not yet adopted</i></td></tr> </table> <p style="font: 10pt Times

New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">ASU No. 2023-07 - “Segment Reporting (Topic 280): Improvements to reportable segment disclosures”, or ASU 2023-07:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">In November 2023, the Financial Accounting Standards Board, or FASB, issued ASU 2023-07. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reported measure of segment profit or loss, an amount and description of its composition of other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The guidance is effective for the fiscal year beginning after December 15, 2023, and interim periods within the fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "> ASU No. 2023-09 - “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”, or ASU 2023-09:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">In December 2023, the FASB issued ASU 2023-09. This guidance is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investors’ requests for enhanced income tax information primarily through changes to the tax rate reconciliation and regarding income tax paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, on a prospective basis. Early adoption and retroactive application are permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">ASU 2024-03 - “Income Statement: Reporting Comprehensive Income - Expense Disaggregation Disclosures”, or ASU 2024-03:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">In November 2024, the FASB issued ASU 2024-03 - which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion), which are included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><i>a.</i></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Unaudited Interim Financial Information</i></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair statement have been included (consisting only of normal recurring adjustments). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024. The year-end balance sheet data was derived from the audited consolidated financial statements as of June 30, 2024, but not all disclosures required by GAAP are included.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Operating results for the six-month period ended December 31, 2024, are not necessarily indicative of the results that may be expected for the year ending June 30, 2025.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <i>b.</i></td> <td style="font: 10pt Times New Roman, Times, Serif"><i>Significant Accounting Policies</i></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The significant accounting policies followed in the preparation of these interim unaudited condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><i>c.</i></td> <td style="font: 10pt Times New Roman, Times, Serif"><i>Use of estimates</i></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments and assumptions that are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. </p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><i>d.</i></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Fair value of financial instruments</i></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, restricted cash, short-term bank deposits and restricted bank deposits and other current assets, trade payable and other accounts payable and accrued expenses, approximate their fair value because of their generally short-term maturities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company measures its derivative instruments at fair value under Accounting Standards Codification, or ASC 820; “Fair Value Measurements and Disclosures”, or ASC 820. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">Level </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">Level</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">2 - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and</td></tr> </table> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">Level</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> 3 - Unobservable inputs for the asset or liability.</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; ">The Company measures its liability pursuant to the Finance Contract based on the aggregate outstanding amount of the combined principal and accrued interest thereunder. As of December 31, 2024, the Company does not reflect its liability for future royalty payments pursuant to the Finance Contract with the EIB since the royalty payments are to be paid as a percentage of the Company’s future consolidated revenues, pro-rated to the amount disbursed, beginning in fiscal year 2024 and until fiscal year 2030 (see note 4).</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><i>e.</i></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Recently issued accounting pronouncements, not yet adopted</i></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">ASU No. 2023-07 - “Segment Reporting (Topic 280): Improvements to reportable segment disclosures”, or ASU 2023-07:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">In November 2023, the Financial Accounting Standards Board, or FASB, issued ASU 2023-07. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reported measure of segment profit or loss, an amount and description of its composition of other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The guidance is effective for the fiscal year beginning after December 15, 2023, and interim periods within the fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">ASU No. 2023-09 - “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”, or ASU 2023-09:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">In December 2023, the FASB issued ASU 2023-09. This guidance is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investors’ requests for enhanced income tax information primarily through changes to the tax rate reconciliation and regarding income tax paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, on a prospective basis. Early adoption and retroactive application are permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">ASU 2024-03 - “Income Statement: Reporting Comprehensive Income - Expense Disaggregation Disclosures”, or ASU 2024-03:</p><p style="font: 10pt Times New Roman, Times,

Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">In November 2024, the FASB issued ASU 2024-03 - which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion), which are included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> NOTE 3: - COMMITMENTS AND CONTINGENCIES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -14.15pt"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of December 31, 2024, an amount of $1,061 of cash and deposits was pledged by the Subsidiary and Ever After Foods to secure its credit line, lease agreement, derivative and hedging and bank guarantees.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b.</td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Law for the Encouragement of Industrial Research and Development, 1984, or the Research Law, research and development programs that meet specified criteria and are approved by the IIA are eligible for grants of up to 50% of the project’s expenditures, as determined by the research committee, in exchange for the payment of royalties from the sale of products developed under the program. Regulations under the Research Law generally provide for the payment of royalties to the IIA of 3% on sales of products and services derived from a technology developed using these grants until 100% of the U.S. dollar-linked grant is repaid. The Company’s obligation to pay these royalties is contingent on its actual sale of such products and services. In the absence of such sales, no payment is required. The outstanding balance of the grants will be subject to interest at a rate equal to the 12-month Secured Overnight Financing Rate, or SOFR (before January 1, 2024, to the 12-month London Interbank Offered Rate, or LIBOR) applicable to U.S. dollar deposits that is published on the first business day of each calendar year. Following the full repayment of the grant, there is no further liability for royalties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the Company’s contingent liability in respect to royalties to the IIA amounted to $27,565, not including LIBOR (from January 1, 2024, SOFR) interest as described above.</p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In April 2017, the Company was awarded a Smart Money grant of approximately $229 from Israel’s Ministry of Economy and Industry to facilitate certain marketing and business development activities with respect to its advanced cell therapy products in the Chinese market, including Hong Kong. The Israeli government granted the Company budget resources that are intended to be used to advance the Company’s product candidate towards marketing in the China-Hong Kong markets. The Company will also receive support from Israel’s trade representatives stationed in China, including Hong Kong, along with experts appointed by the Smart Money program. As part of the program, the Company will repay royalties of 5% from the Company’s revenues in the region for a five-year period, beginning the year in which the Company will not be entitled to reimbursement of expenses under the program and will be spread for a period of up to 5 years or until the amount of the grant is fully paid. As of August 4, 2022, the grant from this Smart Money program received was approximately $180 and the program has ended. To date, no royalties were paid or accrued.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In September 2017, the Company signed an agreement with the Tel-Aviv Sourasky Medical Center, or Ichilov Hospital, to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease, or GVHD. As part of the agreement with Ichilov Hospital, the Company will pay royalties of 1% from its net sales of the PLX-PAD product relating to GVHD, with a maximum aggregate royalty amount of approximately $500.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">e.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In October 2024, Ever After Foods signed a facility operating lease agreement with a lessor. The lease period, which has not yet begun, is expected for a term of five years. In addition, Ever After Foods has the option to terminate the lease after a period of 36 months and to extend the term of the lease for an additional period of five years, or the Extension Option. The average monthly lease payment for the first five years is approximately NIS 50,192 or $14, which is linked to the consumer price index. The monthly lease payments will increase by 5% in the event that Ever After Foods exercises its Extension Option.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">f. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As to potential royalties to the EIB, see note 4.</td></tr> </table>10610000.500.031275650002290000.05P5Y1800000.01500000P5YP36MP5YP5Y50192000140000.05<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 4: - LOAN FROM THE EIB </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On April 30, 2020, the German Subsidiary entered into the Finance Contract with the EIB, pursuant to which the German Subsidiary can obtain a loan in the amount of up to €50 million, subject to certain milestones being reached, receivable in three tranches, with the first tranche consisting of €20 million, second tranche consisting of €18 million and third tranche consisting of €12 million for a period of 36 months from the signing of the Finance Contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The tranches were treated independently, each with its own interest rate and maturity period. The annual interest rate is 4% (consisting of a 4% deferred interest rate payable upon maturity); for the first tranche, 4% (consisting of a 1% fixed interest rate and a 3% deferred interest rate payable upon maturity) for the second tranche and 3% (consisting of a 1% fixed interest rate and a 2% deferred interest rate payable upon maturity) for the third tranche.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition to any interest payable on the loan, the EIB is entitled to receive royalties from future revenues for a period of seven years starting at the beginning of fiscal year 2024 and continuing up to and including its fiscal year 2030 in an amount equal to between 0.2% to 2.3% of the Company’s consolidated revenues, pro-rated to the amount disbursed from the Loan. As of December 31, 2024, Pluri had an accrued royalty in the amount of $5.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During June 2021, Pluri received the first tranche in an amount of €20 million of the Finance Contract. The amount received is due on June 1, 2026, and bears annual interest of 4% to be paid with the principal of the Loan. As of December 31, 2024, the linked principal balance in the amount of $20,819 and the interest accrued in the amount of $2,979 are presented among long-term liabilities. Since the project period ended on December 31, 2022, the Company does not expect to receive additional funds pursuant to the Finance Contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Finance Contract also contains certain limitations such as the use of proceeds received from the EIB, limitations related to disposal of assets, substantive changes in the nature of the Company’s business, changes in holding structure, distributions of future potential dividends and engaging with other banks and financing entities for other loans.</p>5000000020000000180000001200000 0P36M0.040.040.040.010.030.030.010.020.0020.0235000200000002026-06-010.04208190002979000<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 5: - SHAREHOLDERS’ EQUITY</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reverse share split </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2024, the Company’s Board of Directors, or the Board, approved a 1-for-8 reverse share split of the Company’s (a) authorized common shares; and (b) issued and outstanding common shares. The reverse share split became effective on April 1, 2024. All common shares, options, warrants and securities convertible or exercisable into common shares, as well as loss per share, have been adjusted to give retroactive effect to this reverse share split for all periods presented. As a result of rounding-up fractional shares into whole shares as a result of the reverse share split, an additional 67,836 common shares were included in the Company’s issued and outstanding shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> (2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pursuant to a registration statement on Form S-3 (File No. 333-273347), declared effective by the U.S Securities and Exchange Commission on September 21, 2023, on February 13, 2024 the Company entered into an Open Market Sales Agreement, or Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P., which provides that upon the terms and subject to the conditions and limitations in the Sales Agreement, the Company may elect, from time to time, to offer and sell common shares having an aggregate offering price of up to $10,000 through A.G.P. acting as sales agent. As of December 31, 2024, the Company sold 42,729 common shares under the Sales Agreement at an average price of $5.93 per share.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; font-size: 10pt">(3)</td> <td style="font: 10pt Times New Roman, Times,

Serif; text-align: justify">Share options and restricted share units, or RSUs to employees, directors and consultants:</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options to non-employee consultants:</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of the share options granted to non-employee consultants under its equity incentive plans, or the Plans, by Pluri Inc. and its Subsidiary is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate
 intrinsic
 value price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Share options outstanding at the beginning of the period</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">17,475</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">5.80</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">4.87</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share options exercisable at the end of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">19</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Share options unvested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,375</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.05</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share options vested and expected to vest at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Unamortized compensation expenses related to options granted to non-employee consultants by Pluri Inc. and its Subsidiary are approximately $11 to be recognized by the end of March 2027.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options to the Chief Executive Officer, or CEO, and Director:</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of the share options granted to the CEO and director under the Plans by Pluri Inc. and its Subsidiary is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Share options outstanding at the beginning of the period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">240,291</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">14.82</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.42</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">240,291</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14.82</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share options vested and exercisable at the end of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">240,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.91</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2024, the aggregate intrinsic value of these options was $0.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">RSUs to employees and directors:</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and its Subsidiary, for the six-month period ended December 31, 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended
 December 31,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Unvested at the beginning of the period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">353,134</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right">48,653</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(13,938</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(143,243</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Unvested at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">244,606</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Expected to vest after the end of the period</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">223,496</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The fair value of all RSUs was determined based on the closing trading price of the Company’s shares known at the grant date. The weighted average grant date fair value of RSUs granted during the six-month period ended December 31, 2024 granted to employees and directors was $5.20 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Unamortized compensation expenses related to RSUs granted to employees and directors by Pluri Inc. and its Subsidiary are approximately $439 to be recognized by the end of September 2027.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">RSUs and restricted shares, or RS to consultants:</td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following table summarizes the activity related to unvested RSUs and RS granted to non-employee consultants by Pluri Inc. and its Subsidiary for the six-month period ended December 31, 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Six months ended
 December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Unvested at the beginning of the period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,802</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,138</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Unvested at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,946</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The fair value of all RSUs was determined based on the closing trading price of the Company’s shares known at the grant date. The weighted average grant date fair value of RSUs granted during the six-month period ended December 31, 2024 granted to non-employee consultants was $5.47 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Unamortized compensation expenses related to RSUs and RS granted consultants by Pluri Inc. and its Subsidiary are approximately $6 to be recognized by the end of June 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Compensation expenses related to RSUs granted by Pluri Inc. and its Subsidiary were recorded as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended
 December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended
 December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Research and development expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">136</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">634</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">159</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">278</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">696</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">207</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">309</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(4)</td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq Deficiency Letter:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 25, 2024, the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500 in shareholders’ equity for continued listing on The Nasdaq Capital Market, or the Shareholders’ Equity Requirement, nor was it in compliance with either of the alternative listing standards, market value of listed securities of at least $35,000 or net income of $500 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 6, 2025, the Company submitted a plan to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq has determined to grant the Company an extension of time to regain compliance with the Shareholders’ Equity Requirement until May 24, 2025. If the Company fails to evidence compliance by the required deadline, the Company may be subject to delisting. At that time, the Company may appeal Staff’s determination to a Hearings Panel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance the Company will ultimately regain compliance with all applicable requirements for continued listing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither the Nasdaq Letter nor the Company’s noncompliance have an immediate effect on the listing or trading of the Company’s common shares, which will continue to trade on The Nasdaq Capital Market under the symbol “PLUR”.</p></td></tr> </table>6783610000000427295.93<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of the share options granted to non-employee consultants under its equity incentive plans, or the Plans, by Pluri Inc. and its Subsidiary is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate
 intrinsic
 value price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Share options outstanding at the beginning of the period</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">17,475</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">5.80</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">4.87</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align:

left">Share options exercisable at the end of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,100</td><td style="text-align:
left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align:
left"> </td><td style="text-align: right">4.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">19</td><td
style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Share options unvested</td><td style="padding-bottom:
1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,375</td><td
style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td
style="border-bottom: Black 1.5pt solid; text-align: right">4.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td
style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.05</td><td style="padding-bottom: 1.5pt;
text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt
solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align:
bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share options vested and expected to
vest at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom:
Black 1.5pt solid; text-align: right">17,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-
bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.80</td><td style="padding-bottom: 1.5pt; text-align:
left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-
align: right">4.37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-
align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A
summary of the share options granted to the CEO and director under the Plans by Pluri Inc. and its Subsidiary is as follows:</p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0"
style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td
style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended
December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td
style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td
style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align:
center; border-bottom: Black 1.5pt solid">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-
weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted
 average
remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-
color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Share options outstanding at the beginning of the period</td><td style="width: 1%"> </td> <td
style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">240,291</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td
style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">14.82</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td
style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.42</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align:
bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td
style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">240,291</td><td style="padding-bottom: 1.5pt;
text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt
solid; text-align: right">14.82</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt
solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr
style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share options vested and exercisable at the end of the period</td>
<td> </td> <td style="text-align: left"> </td><td style="text-align: right">240,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td
style="text-align: right">14.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.91</td><td style="text-
align: left"> </td></tr>
</table>174755.8P4Y10M13D42000174755.8P4Y4M13D1900081007.41P4Y8M26D1900093754.4P4Y18D174755.8P4Y4M13D19000110002402914.82P2Y5M1D24029114.82P1
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt">The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and its Subsidiary, for the six-
month period ended December 31, 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman,
Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-
weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended
 December 31,
 2024</td><td style="padding-bottom: 1.5pt; font-weight:
bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-
align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom;
background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Unvested at the beginning of the period</td><td style="width: 1%"> </td> <td style="width:
1%; text-align: left"> </td><td style="width: 9%; text-align: right">353,134</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; ">
<td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,653</td><td style="text-align: left"> </td></tr> <tr style="vertical-align:
bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(13,938</td><td style="text-
align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-
bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(143,243</td><td style="padding-bottom: 1.5pt; text-align:
left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Unvested at the end of the
period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-
align: right">244,606</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom:
1.5pt">Expected to vest after the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td
style="border-bottom: Black 1.5pt solid; text-align: right">223,496</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following table
summarizes the activity related to unvested RSUs and RS granted to non-employee consultants by Pluri Inc. and its Subsidiary for the six-month period ended December 31,
2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Six months ended
December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td
colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr
style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-
bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color:
rgb(204,238,255)"> <td style="width: 88%; text-align: left">Unvested at the beginning of the period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align:
left"> </td><td style="width: 9%; text-align: right">4,802</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td>
<td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,138</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-
color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align:
left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-
align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Unvested at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-
bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,946</td><td style="padding-bottom: 1.5pt; text-align:
left"> </td></tr> </table>353134486531393814324324460622349 65.243900048021213813994294 65.476000<p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0 0pt 0.25in; text-align: justify">Compensation expenses related to RSUs granted by Pluri Inc.
and its Subsidiary were recorded as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times
New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom:
1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended
 December 31,</td><td style="padding-
bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-
bottom: Black 1.5pt solid">Three months ended
 December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align:
bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center;
border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td
colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td
style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td
style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align:
center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color:
rgb(204,238,255)"> <td style="width: 52%; text-align: left">Research and development expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align:
left">$</td><td style="width: 9%; text-align: right">136</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align:
left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align:
left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align:
left">$</td><td style="width: 9%; text-align: right">31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align:
left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align:
left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom:
1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">634</td><td
style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td
style="border-bottom: Black 1.5pt solid; text-align: right">159</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td
style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">278</td><td style="padding-bottom: 1.5pt;
text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td
style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align:
right">706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align:
left">$</td><td style="border-bottom: Black 4pt double; text-align: right">696</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom:
2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">207</td><td
style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td
style="border-bottom: Black 4pt double; text-align: right">309</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>136000620004800031000570000634000159000278000706000696000207000309000250000035000000500000<p style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0">NOTE 6: - TOTAL FINANCIAL INCOME, NET</p> <p style="font:
10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table
cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td
style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom:

Black 1.5pt solid">Six months ended
 December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended
 December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Foreign currency translation differences, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">762</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(68</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,754</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(128</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Interest income on deposits and restricted bank deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">572</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">792</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">251</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">356</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Income from hedging derivatives</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">204</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">207</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Other Financial income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,437</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">928</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,058</td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">435</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">EIB loan interest expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(428</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(430</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(211</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(216</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,009</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">498</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,847</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">219</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended
 December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended
 December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Foreign currency translation differences, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">762</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(68</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,754</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(128</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Interest income on deposits and restricted bank deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">572</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">792</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">251</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">356</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Income from hedging derivatives</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">204</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">207</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Other Financial income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,437</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">928</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,058</td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">435</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">EIB loan interest expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(428</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(430</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(211</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(216</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,009</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">498</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,847</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">219</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>762000-680001754000-128000572000792000251000356000103000204000053000207000143700092800020580004350004280004300002110002160001009000498000184700021900 0<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 7: - SUBSEQUENT EVENTS </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On January 23, 2025, the Company entered into a Securities Purchase Agreement, or the Securities Purchase Agreement, with Mr. Alejandro Weinstein, or the Investor, relating to a private placement offering, or the Offering, of: (i) 1,383,948 common shares of the Company, (ii) pre-funded warrants, or the Pre-Funded Warrants, to purchase up to 26,030 common shares, and (iii) warrants, or the Common Warrants, to purchase up to 84,599 common shares. The Offering price per share and accompanying warrant is $4.61. The Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable at any time following the receipt of certain approvals from the Company's shareholders, or the Shareholder Approval, and until exercised in full. The Common Warrants have an exercise price of $5.568 per share, which will not be exercisable until the Company receives Shareholder Approval and will be exercisable for three years following the date of receipt of the Shareholder Approval. The Pre-Funded Warrants and Common Warrants contain customary anti-dilution provisions and are subject to a 19.99% beneficial ownership limitation until the Shareholder Approval is obtained. The Securities Purchase Agreement contains customary representations and warranties and agreements of the Company and the Investor and customary indemnification rights and obligations of the parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the Securities Purchase Agreement, the Company appointed Mr. Weinstein, to the Board of Directors of the Company, or the Board, effective upon the closing of the Offering, and agreed to continue to recommend his election to its shareholders provided the Investor continues to hold at least 10% of the Company's issued and outstanding Common Shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The Offering closed on February 5, 2025, and the gross proceeds to the Company were $6.5 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Concurrently with the Offering, on January 23, 2025, the Company and the Investor entered into a binding term sheet, or the Term Sheet, for the purchase of certain shares representing approximately 71% (on a fully diluted basis) of Kokomodo Ltd., or Kokomodo, for an aggregate purchase price of $4.5 million, payable in common shares, or the Kokomodo Transaction. The Kokomodo Transaction will be subject to, among other conditions, the approval by the Company's shareholders. The Kokomodo Transaction is expected to close during the second quarter of 2025, (calendar year) following the approval of the Company's shareholders. As of the date of this report, there is no guarantee when or if the Kokomodo Transaction will be completed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "> Pursuant to the Term Sheet, in case that the Kokomodo Transaction does not close, for any reason other than due to Investor's failure to perform its material undertakings and/or covenants as agreed under the definitive agreement, or due to any due diligence finding which the we are not currently aware of and that is likely to result in liabilities to us exceeding $0.5 million, then we shall: (a) purchase a certain portion of Investor's shares in Kokomodo for a purchase amount of $1 million (based on a $6 million pre-money valuation of Kokomodo, calculated prior to the investment described in (b)), and (b) invest an additional $0.5 million in Kokomodo under a under a Simple Agreement for Future Equity, or SAFE, providing a 20% discount of the price per share set in connection with

a trigger event for conversion of the SAFE into equity of Kokomodo and a pre-money valuation cap of $5.5 million in connection with such round.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On February 3, 2025, the Company entered into an additional securities purchase agreement, or the Additional Securities Purchase Agreement, with Merchant Adventure Fund L.P., an existing investor, of the Company, relating to a private placement offering, or the Second Offering, of: (i) 759,219 of the Company’s common shares, and (ii) warrants to purchase up to 45,553 common shares. The Second Offering price per share and accompanying warrant is $4.61. The Second Offering warrants have an exercise price of $5.568 per share and a term of three years, commencing on the date of issuance. The gross proceeds to the Company from the Second Offering are expected to be approximately $3.5 million. </p>138394826030845994.610.00015.5680.19990.100.1065000000.714500000500000100000060000005000000.205500000759219455534.615.568P3Y3500000falsefalsefalsefa
74-7108600 0001158780false2025Q2--06-30 Less than $1 See note 5(1) regarding reverse share split Less than $1 See note 5(1) regarding reverse share split